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ABSTRACT  
Since the end of the 20
th
 century, cardiovascular disease has been the major cause of death 
worldwide. Hypercholesterolemia is major risk factor for CVD. Family-based linkage 
analyses in patients with familial hypercholesterolemia (FH) have revealed the major loci that 
are involved in cholesterol hemostasis. These include low density lipoprotein receptor 
(LDLR), proprotein convertase subtilisin/kexin type-9 protein (PCSK9), and apolipoprotein B 
(APOB). However, these discovered genes only explain disease etiology in a proportion of 
patients with the clinical phenotype, and roughly 60% of patients who are diagnosed with FH 
are negative for any FH-causative mutation. This suggests that (1) there are undetected new 
mutations in known genes, (2) that disease-causing mutations might occur in unidentified 
gene(s), (3) disease may occur as a result of an accumulation of common small-effect LDL-C 
raising variants.  
 
My project has three main aims. First, the identification of mutations in patients clinically 
diagnosed with FH in two ethnic groups: UK (n=69) and Iran (n=16). Several novel mutations 
were identified in LDLR [UK: p.(Cys392Tyr), p.(Tyr553Ser) and p.(Tyr553*); Iran: 
p.(Leu479Gln) and p.(Glu668*)] and PCSK9 [p.(Arg357Cys)] using next generation 
sequencing technology. The second aim was to investigate the functional role explaining the 
Genome-Wide Association (GWAS) LDLR “hit” Single Nucleotide Polymorphism (SNP) 
rs6511720. This SNP and one other in strong linkage disequilibrium (LD) (rs57217136) were 
both found to act as a cis-regulatory element, where the sequence around the rare alleles of the 
SNPs is a target for proteins that enhance gene transcription. The third aim was studying the 
Annexin A2 (ANXA2) gene. AnxA2 recently was found to be involved in the LDL-R pathway 
through PCSK9. The study aimed to identify and determine the functional role of common 
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SNPs that are associated with LDL-C. I showed that the ANXA2 common SNP rs17845226 
(V98L) minor allele, was associated with significantly higher levels of LDL-C and a higher 
risk of CHD in a large prospective study of healthy UK men (NPHSII). The SNP shows 
strong LD with SNPs in the intragenic region, and I showed that the minor alleles of 
rs17191344 and rs11633032 are targets for proteins that repress gene transcription and the 
subsequent lower levels of AnxA2 protein means that there will be higher levels of PSCK9-
mediated degradation of the LDL-R and this will lead to an increase in LDL-C levels. Finally, 
I identified that rs116928563 in the 3'UTR of ANXA2 was a potential site for a micro-RNA 
(miRNA-155*) binding, however, the study failed to result in any definite conclusions about 
the influence of miRNA-155 in ANXA2 expression and LDL-C levels. However, it gives 
insight into how a SNP also may affect gene expression at the post-transcription level by 
creating or destroying micro-RNA binding sites.     
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Chapter 1 : Introduction 
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1.1. Cardiovascular disease (CVD) overview 
Cardiovascular disease (CVD) is a disease of the heart and vascular system, comprising 
coronary heart disease (CHD), stroke, peripheral arterial disease and aortic disease. It causes 
30% of mortality world-wide (Figure1-1 A) (1, 2). In 2012, the British Heart Foundation 
published a report that CVD was the main cause of death in the UK, accounting for almost 
180,000 deaths, around one in three of all deaths in that year.  In order to prevent or reduce 
morbidity and mortality as a result of CVD, it is important to diagnose at-risk individuals at an 
early stage by considering CVD risk factors.  
 
Figure  1-1: Main causes of death worldwide  
The pie chart shows that the main causes of mortality globally. Non-communicable diseases 
(NCDs) are the leading causes of death globally 33%, followed by, cardiovascular diseases 
31%, communicable diseases, maternal and parental conditions, and nutritional deficiencies 
27%, and injuries 9%. Adopted from http://www.world-heart-federation.org/ 
fileadmin/user_upload/images/CVD_Health/Global_CVD_Atlas.pdf and http://www.who. int/ 
nmh/publications/ncd_report_full_en.pdf) Prasad et al. (2010).  
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1.1.1. The risk factors of CVD 
Several risk factors are known to influence the likelihood of developing CVD. These factors 
are classified into two types, non-modifiable and modifiable. The non-modifiable risk factors 
are factors that cannot change including age, gender, family history and ethnicity. Age is the 
strongest risk predictor of CVD (3), where there is a positive correlation between age and the 
risk of the disease. Gender is also another strong risk factor; men tend to develop CVD about 
7 to10 years earlier than women (4). Also, both family history (5) and ethnicity (6) are 
important non-modifiable risk factors of CVD, which indicate the role of genetics in the risk 
of CVD.   
 
The modifiable CVD risk factors, also known as “lifestyle” risk factors, include hypertension, 
blood lipid levels, diabetes, obesity and smoking. Prasad et al. (2010) have stated that studies 
by the World Health Organization (2004) showed that a high cholesterol level is a major risk 
factor for CHD (56%) (Figure 1-2). Another important CVD risk factor is hypertension, which 
links to about 50% of CHD and 62% of ischemic stroke (World Health Organization, 2004, 
Prasad et al., 2010). Diabetes mellitus also is a risk factor of CVD; it was reported that 
diabetic patients are at three times higher risk of a heart attack (7). Obesity has been classified 
as a modifiable CVD risk factor, which has influence on known risk factors such as 
dyslipidemia, hypertension and glucose intolerance (8). Smoking is a behavioral lifetime risk 
of many life-threatening diseases. In 2000, 11% of deaths worldwide from CVD were linked 
to smoking (9). It has been reported that smoking promotes CVD through several 
mechanisms: it increases low-density lipoprotein cholesterol (LDL-C) and is involved in the 
oxidative modification of LDL-C (10), it increases the risk of damage of the endothelium 
layer of the blood vessels and plaque rupture (10, 11), it increases the risk of clotting via 
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elevating the levels of clotting factors such as fibrinogen (12), it increases the risk of high 
blood pressure and heart rate through by delivering high arterial plasma levels of nicotine 
(13), and it increases the risk of diabetes mellitus (14).  
 
Figure  1-2: Percentage contribution of modifiable CVD risk factors  
The bar chart shows the percentage contributory risk factors to CHD and ischemic stroke. The 
major risk factor for CHD is high cholesterol levels followed by high blood pressure.  In 
contrast, the major risk factor for ischemic stroke is high blood pressure followed by high 
cholesterol levels. Adapted from Prasad et al. (2010). 
 
 
1.1.2. Managing risk factors 
Lifestyle risk factors can be managed by quitting smoking, and adopting good nutrition and 
regular physical activity. Diet affects CVD in a variety of ways, such as, energy imbalance, 
where more energy is taken in than expended which can result in weight gain and obesity, 
high saturated fat raises cholesterol levels, high salt intake can raise blood pressure, and low 
intake of fiber, fruit and vegetables can lead to a greater susceptibility to CVD. However, 
persuading people to make changes to their lifestyle to reduce risk can be difficult. Therefore, 
49% 
62% 
56% 
18% 
31% 
11% 
22% 
0%
10%
20%
30%
40%
50%
60%
70%
Coronary heart disease Ischaemic stroke
Blood pressure
High Cholesterol
Low fruit & vegetble
intake
Physical inactivity
5 
 
procedures to identify people with high likelihood of developing CVD, and interventions to 
reduce risk are essential to disease prevention. 
 
A number of CVD risk prediction algorithms have been developed to calculate a person’s 
relative risk of cardiovascular events. Currently, two common algorithms are used, the 
Framingham (15) and QRISK (16) risk scores, which include conventional risk factors (age, 
sex, smoking habit, physical activity, blood pressure, cholesterol level, body mass index 
(BMI), presence of diabetes, and family history). These algorithms are used to estimate the 
patient's 10-year risk of developing CVD, in order to identify high-risk individuals (a total 
CVD risk of ≥20%) for primary prevention (16). Although these risk assessment tools help to 
identify high-risk people, they underestimate the true total risk of CVD. Nearly 15% of 
individuals who develop CVD are considered to be low-risk, based on conventional risk 
assessment models (17). Identifying higher-risk patients from the many who are considered 
intermediate-risk or low-risk could help practitioners’ decisions to start primary prevention 
process at an early stage. Recently, there has been debate about the clinical utility of adding a 
genetic risk score (GRS) to risk models to improve predictive performance and risk 
classification. GRS takes advantage of the findings of genome-wide association studies 
(GWASs), which have identified a correlation between single nucleotide polymorphisms 
(SNPs) and clinical phenotypes of complex diseases; adding SNP associated diseases to risk 
assessment models could enhance the predictability of CVD (17).  
 
In order to reduce the risk of CVD, statins are used as primary and secondary prevention 
methods (18). These drugs reduce total cholesterol (TC) and LDL-C levels in circulation via 
inhibiting hydroxymethylglutaryl-CoA reductase
 
(HMG-CoA-R) enzyme synthesis (19). 
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Although statins are effective and convenient  with limited side-effects, patients have variable 
potency statins and the LDL-C reduction outcome range varies from 30% to 60% (20). In 
addition, statins increase proprotein convertase subtilisin/kexin type-9 (PCSK9) levels (21) 
because the PCSK9 promoter also contains a sterol responsive element. The higher levels of 
PCSK9 then bind to the LDL-receptor (LDL-R) and targets it for degradation, thus mitigating 
to some extent the statin induction of LDL-Rs. Statins also have been shown to increase the 
risk of diabetes (22). Mendelian randomization  study suggested a direct consequence between 
inhibition of HMG-CoA-R and type 2 diabetes (T2D ) risk  (23).  However, the benefits of 
statin treatment for CVD prevention heavily outweigh the small increase in T2D risk.  
 
 It is essential to do more intervention studies to determine the best strategies to lower plasma 
LDL-C levels in order to prevent CVD. In the last few years, PCSK9 has become a proposed 
target of intervention to reduce risk of CVD; several approaches are proposed which are 
discussed later. 
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1.2. Lipoproteins and cardiovascular disease (CVD) 
Cholesterol is a lipophilic molecule, which is transported through the blood in lipoproteins. 
The type of lipoprotein is determined by its density, composition, and protein content. 
Lipoproteins are classified into five classes: Chylomicrons, Very low density lipoproteins 
(VLDL), intermediate density lipoproteins (IDL), low density lipoprotein-cholesterol (LDL-
C), and high density lipoproteins-cholesterol (HDL-C).  
 
Lipoprotein trafficking is divided into three pathways: the exogenous pathway, the 
endogenous pathway, and the reverse cholesterol pathway.  
 
1.2.1. Exogenous pathway 
The exogenous pathway provides efficient transport of dietary lipids. Dietary triglycerides 
(TG) hydrolyzed by lipases to fatty acids and monoacylglycerol are readily absorbed by the 
small intestine where they are re-esterified to form triacylglycerol. In the enterocyte, 
cholesterol is esterified to form cholesteryl esters, and then longer-chain fatty acids are 
incorporated into TG and packaged with apolipoprotein B-48 (ApoB-48), cholesteryl esters, 
retinyl esters, phospholipids and cholesterol to form chylomicrons. Nascent chylomicrons 
enter the blood circulation via the lymphatic system, where they acquire apolipoproteins E 
and C (ApoE, ApoC-I, ApoC-II, ApoC-III) from HDL-C. ApoC-II, acts as a co-factor for 
lipoprotein lipase (LPL), which hydrolyzes the TG of chylomicrons, and free fatty acids are 
released. The released free fatty acids are taken up by other tissues such as muscle and 
adipose tissue (Figure  1-3). The chylomicron particle progressively shrinks in size and creates 
a new lipoprotein called a chylomicron remnant. Chylomicron remnants are enriched with 
cholesteryl ester and fat-soluble vitamins and contain apoB-48 and apoE. They are rapidly 
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removed from the circulation by receptors in the liver including the LDL-R, an ApoB/E 
receptor, and the LDL-R related protein (24-27).  
 
1.2.2. Endogenous pathway 
The endogenous pathway refers to the hepatic secretion and metabolism of apoB-containing 
lipoproteins (VLDL, IDL, and LDL-C) (27). To maintain and regulate the energy supply for 
tissues, the liver needs TG, derived predominantly from the esterification of long-chain fatty 
acids in the liver. Hepatic TG are packaged with other components including apoB-100, 
cholesteryl esters, phospholipids, and vitamin E to form VLDL particles. The nascent VLDLs 
enter the circulation, where they acquire multiple copies of apoE and apoC from HDL-C. 
Once nascent VLDLs are loaded with apoC-II and apoE, they are considered mature. As with 
chylomicrons, the TG of VLDL are hydrolyzed by LPL, and free fatty acids are released and 
taken up by peripheral tissues. The cholesteryl ester transfer protein (CETP) controls the 
exchange between TG from VLDLs and cholesteryl esters from mature HDLs, which enriches 
VLDLs in cholesterol esters which then form intermediate density lipoproteins (IDLs). The 
liver removes IDL by LDL-Rs via binding to apoE or remodeling IDL by hepatic lipase to 
form LDL-C. During this process, most of the triglyceride in the particle is hydrolyzed, and 
all apolipoproteins are removed except apoB-100. The apoB-100 in circulating LDL-C is 
capable of being bound to LDL-Rs and internalized (Figure 1-3). The internalized LDL-C 
particles undergo degradation and the cholesterol is metabolized to produce bile (25-27).  
   
1.2.3. Reverse cholesterol transport 
Cholesterol in peripheral cells is transported from the plasma membranes of peripheral cells to 
the liver through a process termed "reverse cholesterol transport” that is facilitated by HDL-C. 
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ApoA-I, synthesized by the liver, rapidly acquires phospholipids and unesterified cholesterol 
from its site of synthesis via the membrane protein ATP-binding cassette protein A1 
(ABCA1) in hepatocytes. This process results in the formation of pre-beta-HDL particles. 
Further free cholesterol is acquired from macrophages and other peripheral cells and esterified 
by lecithin-cholesterol acyltransferase (LCAT). LCAT converts free cholesterol to cholesteryl 
ester, thereby moving the esterified cholesterol inside the HDL-C particle and forming mature 
HDL-C. HDL-C can be selectively taken up by the liver via the scavenger receptor class BI 
(SR-BI). Alternatively, HDL-C cholesteryl ester can be transferred by CETP from HDL-Cs to 
VLDLs, chylomicrons and LDLs, which can then be taken up by the liver (Figure 1-3) (25, 
28). 
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Figure  1-3: Lipoprotein trafficking pathways 
A cartoon showing the three lipoprotein trafficking pathways: the exogenous pathway transports dietary lipids to the periphery and the liver. The 
endogenous pathway transports hepatic lipids to the peripheral tissues. HDL metabolism and reverse cholesterol transport pathway transport 
excess cholesterol from the peripheral tissues back to the liver for excretion in the bile. Adapted from Rader and Hobbs (2005).  
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1.3. Cholesterol homeostasis 
Cholesterol biosynthesis is regulated by the intracellular concentration of free cholesterol in 
hepatic cells. Intercellular cholesterol homeostasis is controlled by steroid response element 
binding protein (SREBP). SREBP is located in the endoplasmic reticulum (ER) in a complex 
with SREBP cleavage-activating protein (SCAP). SCAP has a cholesterol-sensing domain in 
its N-terminal region, when cells are loaded with sterol, SCAP transport SREBP from the ER 
to Golgi bodies. Once in the Golgi, SREBP is cleaved in order to release part of the protein 
from the membrane by two specific proteases (site-1 and site-2 proteases). Site-1 protease 
(S1P), cleaves SREBP in the luminal loop between two membrane-spanning sequences. 
SCAP allows site-1 cleavage to be activated when cells are deprived of sterols. Once the two 
halves of SREBP are separated, a second protease, site-2 protease (S2P), cleaves the NH2-
terminal bHLH-Zip domain of SREBP at a site located within the membrane-spanning region. 
After the second cleavage, the NH2-terminal bHLH-Zip domain leaves the membrane (29, 30). 
This new form of SREBP enters the nucleus where it binds to steroid response elements 
(SREs) in the enhancer/ promoter region of many target genes involved in cholesterol 
hemostasis and activates their transcription, including HMG-CoA-R and LDL-R. HMG-CoA-
R is the rate-limiting enzyme for cholesterol synthesis, whereas LDL-R is responsible for 
LDL-C uptake from plasma (see Figure  1-4). By contrast, an accumulation of free cholesterol 
inactivates the SREBP pathway, where a sterol-sensing domain (SSD) protein SCAP binds to 
the ER retention protein Insig. Insig binding prevents the transport of SCAP-SREBP complex, 
thus the transcription of SRE regulated genes is not turned on. Cholesterol-lowering drugs 
such as statins are used to activate the cholesterol synthesis pathway (31-34).  
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Figure  1-4: The steroid response element binding protein (SREBP) pathway in 
cholesterol regulation 
A diagram showing the SREBP pathway in both high and low levels of cholesterol. At lower 
cellular cholesterol levels, SCAP binds SREBP in the ER. The SCAP-SREBP complex then 
moves to the Golgi, where two specific proteases (site-1 and site-2 proteases) cleave the 
SREBP. The cleaved SREBP then enters the nucleus and activates the transcription of the 
genes coding for LDL-R and for HMG-CoA-R. This in turn stimulates the rate of cholesterol 
uptake and synthesis. Conversely, when cellular cholesterol levels are higher, Insig ER protein 
binds to the SCAP-SREBP complex and prevents SREBP transport, therefore, the enzyme 
required for gene transcription is not produced and uptake and synthesis of cholesterol is not 
enhanced. Adapted (34) with modification.    
 
   
 
  
 
 
LDLR 
HMGCR 
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1.4. Atherosclerosis 
CVD arises from atherosclerosis. Atherosclerosis is a multifactorial disease that has both 
modifiable and non-modifiable risk factors. In the majority of patients, atherosclerosis 
develops through a combination of different factors, including an interaction between genes 
and an interaction between genes and the environment.   
 
An accumulation of cholesterol particles in the walls of arteries is the primary driver of 
atherosclerosis. These particles initiate the inflammatory process, which leads to 
atherosclerotic blood vessels. Atherosclerosis is a progressive disorder marked by several 
stages, with a varying extent of lesions marking each stage. It is initiated by accumulation of 
LDL-C in the sub-endothelium, which leads to remodeling of LDL-C to oxidized LDL 
(oxLDL). ApoB-100 binds to negatively charged extracellular matrix proteoglycans, which 
leads to retention of LDL-C particles in the intima, where they are susceptible to oxidative 
modification by reactive oxygen species, or enzymes such as myeloperoxidase or 
lipoxygenases released from inflammatory cells. An accumulation of oxLDL promotes the 
recruitment of monocytes and lymphocytes and an increase in the production of cytokines and 
growth factors. Monocytes and lymphocytes are  converted to macrophages that take up 
oxLDL and form foam cells (Figure 1-5 (b)). Foam cells form early ‘fatty-streak’ lesions, 
which activate inflammation. The early ‘fatty-streak’ lesion consists of T cells and monocyte-
derived macrophage-like foam cells loaded with lipids. Sequential accumulation of apoptotic 
cells, debris and cholesterol crystals forms a necrotic core, which leads to infiltration and 
proliferation of smooth muscle cells (SMCs) and synthesis of extracellular matrix containing 
collagen, elastin and proteoglycans to form fibrous plaques (Figure  1-5 (c)). Ruptured plaques 
with thin fibrous caps result from degradation of the matrix by proteinases such as 
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collagenases, gelatinases, stromelysin and cathepsins, and by inhibition of matrix secretion 
(Figure  1-5 (d)). Thus, various factors may destabilize plaques and promote thrombosis and 
blocking of the artery, which can lead to myocardial infarction (MI) and sudden death (35-
37). 
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Figure  1-5: Stages in the development of atherosclerotic lesions 
A cartoon showing the atherosclerotic lesions development stages: a) normal blood vessel layers, b) OxLDL accumulation initiates primary 
inflammation response via forming foam cells; c) foam cells activate an inflammatory cascade with forms a  fibrous plaque, and d) fibrous 
plaque and thrombosis formation, which leads to blocking of  the artery. Adapted from Libby et al. (2011).   
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1.5. Hypercholesterolemia 
Elevated plasma cholesterol levels are a major risk factor for atherosclerosis and CVD. They 
are caused by a disturbed balance between cholesterol secretion into the blood and uptake 
resulting in a disease called hypercholesterolemia. Hypercholesterolemia is defined as a 
multifactorial disease due to a combination of environmental and genetic factors. There are 
two types of disease, one is developed from inappropriate life style (smoking, diet, lack of 
physical activity, obesity, and alcohol) and additive small effects of multiple genes “polygenic 
hypercholesterolemia”. The other type is a Mendelian disorder called familial 
hypercholesterolemia (FH) which is caused by a defect in a single gene.   
 
Although hypercholesterolemia is a multifactorial disease, studies of FH have helped unravel 
the pathways that regulate plasma cholesterol metabolism, knowledge of which is important 
for the development of cholesterol-lowering drugs. In the next section general knowledge 
about FH including disease discovery, types, genes, diagnostic criteria and treatment are 
provided in order to understand the genetic power behind hypercholesterolemia.    
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1.6. Familial hypercholesterolemia (FH) 
1.6.1. Overview 
In the early 20
th
 century, Archibald Garrod published his ‘Inborn Errors of Metabolism’ 
theory, where he said that a single defect in one gene could produce a block in a biochemical 
pathway, the so called “one gene-one enzyme” hypothesis (38). Based on Garrod’s 
hypothesis, researchers have focused on understanding biochemical pathways in order to 
uncover the gene causing a particular disorder. One of the studied disorders was the inherited 
metabolic disorder FH, which is an autosomal dominant disease characterized by high 
concentrations of plasma LDL-C. 
 
Between 1972 and 1985, Brown and Goldstein’s laboratory did extensive research focused on 
dissecting the genetic architecture of FH. FH patients have high levels of cholesterol and 
suffer from CHD at an early age. Based on that, they postulated that FH occurs as a result of a 
defect in cholesterol clearance. Two-thirds of cholesterol in human plasma is contained within 
LDL-C particles, which are key players in the progression of atherosclerosis that leads to 
premature CHD. Therefore, they focused on understanding  the regulatory mechanism of 
LDL-C (38). In 1973-74, Goldstein and Brown showed that LDL-C could bind to high affinity 
surface receptor sites on cells and a defect in this process represented the primary genetic 
abnormality in FH (39, 40). Later on in 1979, they discovered that LDL-C uptake from blood 
was caused by a cell surface receptor, called the LDL-R and then described the sequential 
steps of LDL-C uptake (41). Binding of LDL-C to LDL-R initiates internalization of LDL-
C≡LDL-R complexes to lysosomes. In lysosomes, LDL-C is hydrolyzed which leads to 
release of unesterified cholesterol into the lysosome, while the LDL-Rs recycle to the cell 
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surface. In 1985, Brown and Goldstein were jointly awarded the Nobel Prize in physiology 
and medicine for their discoveries concerning the regulation of cholesterol metabolism.  
 
There are two forms of FH – heterozygous and homozygous – heterozygous FH (HeFH) is 
caused by one of the two inherited alleles being affected, which leads to a two-to-three fold 
increase in LDL-C plasma levels than normal. The estimated prevalence of heterozygous FH 
is one in 500 in most European populations (42). However, the prevalence is known to be 
higher in some populations, for example, in Denmark the frequency of FH is 1/137 (43), and 
French Canadians (44). Individuals with heterozygous FH often develop premature CHD after 
the age of 35. Homozygous FH (HoFH) is caused by both inherited alleles being affected, 
which leads to a six-to-eight-fold increase in LDL-C plasma levels than normal. The 
frequency of the homozygous form is 1 in 1,000,000 in most populations. Individuals with 
homozygous FH develop CHD in the early stage of their lives and often die before the age of 
20 (42).  
  
1.6.2. FH genes 
FH is considered a monogenic disorder, which is caused by a defect in one of three genes that 
regulate LDL-C concentration: the LDLR, PCSK9, APOB genes. Rarely is an inheritance 
pattern of FH of autosomal recessive hypercholesterolemia seen, which occurs when an 
individual inherits two recessive variants in the low-density lipoprotein receptor adaptor 
protein 1 (LDLRAP1) gene. UK studies have shown that about 93% of identified mutations 
are found in the LDLR gene, a further 5% are in APOB, and about 2% are in the PCSK9 gene 
(45, 46). All identified FH-causing genes and the involvement of their protein products in the 
LDL-C clearance pathway are summarized in Figure 1-6. More recently, a potential new FH 
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gene called signal-transducing adaptor protein 1 (STAP1) was discovered, which is the fourth 
gene associated with hypercholesterolemia (47, 48), but its role in the LDL-C clearance 
pathway is unknown yet.  
 
Figure  1-6: Molecular pathways of cholesterol regulation  
A cartoon showing the molecular pathway of cholesterol clearance. The cholesterol particles 
are taken-up from the blood by LDL-R protein. The LDL-R is processed through the rough 
endoplasmic reticulum (ER), matured in the Golgi and transported to the cell surface 
membrane. LDL-Rs bind specifically to particles containing ApoE or ApoB-100. A clathrin-
coated pit is then formed and the receptor–ligand complex is internalized to endosomes 
through interactions involving LDLRAP1, which causes internalization of the complex to the 
endosome. Changes in the acidic environment of early endosomes to late endosomes causes 
dissociation of the receptor–ligand complex. The receptor is recycled to the cell membrane 
while the LDL-C particle is degraded in the lysosome. Cholesteryl ester in the core of LDL-C 
is hydrolyzed and becomes free cholesterol in the cell. PCSK9 works as a post-transcriptional 
inhibitor of LDL-R. Some LDL-R is bound to circulating PCSK9 before endocytosis, which 
leads to the degradation of the receptor in the endosome, resulting in a decreased number of 
receptors on the surface of the cells. Adapted from Soutar and Naoumova (2007).  
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1.6.2.1. Low-density lipoprotein receptor (LDLR)  
1.6.2.1.1. LDLR ontogeny and structure  
LDLR is located on chromosome 19 at p13.1-p13.3 and it encodes a cell surface glycoprotein 
predominantly expressed in hepatocytes that mediates the removal of cholesterol carrying 
LDL-C particles via ApoB-100 from blood (Bruno, et al, 2000). The gene’s length of 45 kb 
comprises 18 exons and 17 introns (42). The mRNA transcript is 5.3 kb in length and encodes 
a protein of 860 amino acids. About half of the mRNA constitutes a long 3’ untranslated 
region (3’UTR) that contains two-and-a-half copies of the Arthrobacter luteus (Alu) family of 
middle repetitive DNAs (49, 50).  
 
The mature human LDL-R of 160 kDa is composed of five domains (Figure 1-7), Exon 1 
encodes a short 5’ untranslated region (5’UTR) and 21 hydrophobic amino acids that are not 
present in the mature protein. This sequence functions as a signal peptide to direct the receptor 
synthesizing ribosomes to the ER membrane (50). Exon 2-6 encodes the binding ligands 
region that are composed of seven imperfect 40 amino acid repeats that are characterized by 
six conserved cysteine residues and a cluster of negatively charged amino acids near the 
carboxy terminus of each repeat. Mutations in the ligand-binding domain lead to a LDL-R that 
is defective in its interaction with apoE and apoB and/or in its transport to the cell surface 
(51).  The ligand-binding domain is followed by a domain of about 400 amino acids (Exon 7-
14) that show homology to other proteins such as the C9 component (52), epidermal growth 
factor (EGF) precursor (53), blood coagulation factor IX, factor X (FX) and protein C (54, 
55). Alterations in this domain can lead to reduced transport of the LDL-R to the cell surface 
or an inability of the LDL-R to bind to ligands or be recycled. This domain contains three 40-
amino acid cysteine-rich growth factor repeats (designated A, B, and C). The A and B repeats 
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(encoded by exons 7 and 8) are separated from the C repeat (encoded by exon14) by five 
copies of a 40-60 amino acid repeat (encoded by exons 9-13). Each of  these five repeats 
contains a conserved motif, Tyr-Trp-Thr-Asp (YWTD) (42).  Exon 15 encodes 58 amino 
acids that are the short serine and threonine-rich segment that becomes O-glycosylated during 
maturation of the protein. Exon 16-17 encodes a transmembrane domain of 22 amino acids, 
while exon 18 encodes a 50 amino acids cytoplasmic tail (51). Deletion or substitution of 
conserved residues in the cytoplasmic tail results in a receptor that can neither localize in 
clathrin-coated pits nor mediate the internalization of ligands (51). 
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Figure  1-7: Schematic of the human LDLR gene and LDL-R protein 
A cartoon showing the LDL-R structure. A) LDLR gene 45 kb encodes 18 exons, B) 5.3 kb 
LDLR mRNA transcript encodes 860 amino acids. 2.7 kb of the mRNA encodes 3’ 
untranslated region (3’UTR), and C) LDL-R protein consists of five domains including ligand 
binding domain, epidermal growth factor (EGF) precursor domain, O-glycosylated domain, 
transmembrane domain, and cytoplasmic tail domain. Adapted from Al-Allaf et al. (2010). 
(56) 
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1.6.2.1.2. LDL-R biosynthesis and function 
The LDL-R is processed through the ER, matured in Golgi and transported to the cell surface 
membrane. As illustrated in Figure 1-8, the LDL-C particle binds to the ligand-binding 
domain of LDL-R at the cell surface. A clathrin-coated pit is then formed and the receptor–
ligand complex is internalized to endosomes. The acidity milieu of the endosome leads to 
release of LDL-C from the LDL-R (57), where then LDL-C is confined to the vesicular part of 
the endosome, which is finally degraded in the lysosome (58). Concomitant with the release 
of LDL-C in the endosome, the LDL-R folds back on itself to obtain a closed conformation 
whereby ligand-binding repeats 4 (residues Cys127 to Cys163) and 5  (Cys176 to Cys210) 
interact with the β-propeller  (Ile377 to Gly642), then the LDL-R recycles back to the cell 
surface (59).  
 
Figure  1-8: A cartoon diagram showing catch and release of LDL-C from LDL-R 
The LDL-C particle binds to LDL-R at ligand-binding repeats R4 and R5 at the cell surface. A 
clathrin-coated pit is then formed and the receptor–ligand complex is internalized to 
endosomes. The difference of acidity environment between early endosomes pH 6.5 and late 
endosomes pH 5.3 causes dissociation of the LDL-C and structural change of the extracellular 
domain of the human LDL-R. A new structure of the LDL-R leads to ligand-binding repeats 
R4 and R5 interacting with the β-propeller region of the EGF precursor domain. This 
interaction displaces LDL-C from the receptor in acidic endosomes. Adapted from Innerarity 
(2002) 
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1.6.2.1.3. LDLR promoter 
The LDLR promoter region contains the majority of cis-acting DNA sequences that are 
responsible for gene expression (Hobbs, et al, 1990). Within 200 base-pairs (bp) of the 
initiator methionine codon are two TATA-like sequences of 7bp each, and three imperfect 
direct repeats of 16bp located upstream of a TATA-like sequence (Figure 1-9) (51, 60). 
Repeats 1 and 3 contain binding sites for the transcription factor specificity protein 1 (Sp1) 
and contribute to the basal expression of the gene, while repeat 2 contains the sterol regulatory 
element (SRE-1) (60). At nucleotide position -103 the 5’ end of repeat 1 is located, which is 
considered the major transcription initiation site, while repeats 2 and 3 are located 
immediately adjacent to each other, beginning at nucleotide position -68 (61). Sequence 
variations in any one of these three repeats repress transcription. Sterol-dependent repression 
of transcription is mediated by a 42bp region encompassing repeats 2 and 3 (60). Repeat 3 is a 
positive element that binds Sp1. However, in the presence of sterols, repeat 2 provides strong 
repression of repeat 3 (61). Sp1 and SREBP, which bind to a 10bp sequence within repeat 2, 
cooperate in the repression of repeat 3 (62, 63). 
 
Figure  1-9: Schematic of the LDLR promoter 
The diagram represents the LDLR promoter. The LDLR promoter is within 200bp upstream of 
the  LDLR transcription start site. The promoter contains a TATA-like sequence domain, and 
three imperfect direct repeats located upstream of a TATA-like sequence, where repeats 1 and 
3 contain binding sites for the transcription factor of Sp1 and repeat 2 contains the SREBP.   
 
 
          -103              -88                   -68                -53                  -38        -32              -17       +1 
SP1 SREBP SP1 
TATA 
Repeat 1                                  Repeat 2         Repeat 3                                   Transcription start site  
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1.6.2.1.4. LDLR mutation classes 
LDLR mutations are classified into 5 classes according to the effect they have on LDL-R 
protein function (see Figure 1-10) (51, 64). In class 1 mutations, the LDL-R protein is not 
synthesized which may be due to a mutation in exon 1. In class 2 mutations, the transport of 
LDL-R between ER and the Golgi complex is blocked either partially or completely. In class 
3 mutations, the LDL-R does not properly bind with LDL particles. In class 4 mutations, 
bound surface receptors are not internalized. In class 5 mutations, the internalized LDL-C 
particles are not released in the endosome. Most mutations identified to date are class 2 or 
class 3 mutations occurring in the ligand-binding and epidermal growth factor precursor 
regions of the gene. To date, over 1700 LDLR mutations have been found to cause FH (65). 
 
Figure  1-10: LDLR mutations classification 
a) Illustrates the five different classes for defects of LDL receptor function. b) The 
consequences of the different defects on the cell surface for class I and II defects.  c) Class III 
defects. Adapted from Schaefer et al. (2012).  
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1.6.2.2. Apolipoprotein B-100 (ApoB-100) 
As mentioned before, LDL-C particles are removed from the bloodstream by the liver and 
other tissues via their binding to LDL-R via apoB. The APOB gene lies on human 
chromosome 2 p23-p24 and is 42 kb long consisting of 29 exons and 28 introns (66, 67). 
ApoB mRNA is 14.5 kb long and encodes two main isoforms: apoB-48 and apoB-100. A 
single peptide of apoB-100, found in each VLDL, IDL and LDL-C particle, acts as a 
ligand for the LDL-R on the cell surface and results in receptor-cholesterol homeostasis 
(68). ApoB-48 is a truncated version of apoB and has a different motif to apoB-100; 
therefore apoB48 is not recognized by LDL receptors. Full length apoB-100 mRNA 
encodes five structural domains (Figure 1-11 A): NH3-βα1-β1-α2-β2-α3-COOH (69). The 
β2 domain is the functional region for LDL-R binding that is required for the uptake of 
lipoproteins containing apoB-100 (70). The interaction between apoB-100 and LDL-R 
occurs in residues 3359-3367 (site B) in the β2 domain of apoB-100 (71).  
 
Mutations in apoB-100 cause defective binding of apoB-100 to the LDL-R that leads to 
the failure of hepatic LDL-C clearance and accumulation of LDL-C particles in the 
circulation (72). This form of FH is called familial defective apo-B100 (FDB). A study by 
the Soria group (1989) showed that FDB usually occurs due to transition of G to A at 
nucleotide c.10580, in exon 26 of APOB, which leads to the substitution of arginine 3527 
to glutamine (p. R3527Q, previously p. R3500Q). This substitution alters the affinity 
between apoB-100 and LDL-R (73). The p. R3527Q variant in APOB is most commonly 
associated with FDB in Northern Europeans and US Caucasians (74-79).  A second 
mutation has been reported at the same codon (p.3527) resulting in a substitution of 
tryptophan (W) in place of arginine, which is associated with FDB in East and South 
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Asians (80-82). An additional mutation at p.3527, R3527L, has also been reported in the 
Netherlands but has appeared much less frequently than R3527Q or R3527 W (83). Large-
scale exomic databases, such as that of the Broad Institute Exome Aggregation 
Consortium (ExAC), have reported the prevalence of R3500Q and R3500W across 
populations (see Table 1-1 below). 
Table  1-1: APOB- R3500Q and R3500W minor allele frequencies (MAFs) across 
represented subpopulations  
 
Population  R3527Q MAF (%) R3527W MAF (%) 
African 0 0 
East Asian 0 0.127 
European (Finnish) 0 0 
European (non-Finnish) 0.038 0.006 
Latino 0.009 0 
Other 0.221 0 
South Asian 0 0.030 
Total  0.0321 0.01651 
 
 
APOB p.3527 is known as a mutation “hotspot”, where a mutation at this position alters 
the stabilizing interaction between arginine residue (wild-type) and a tryptophan residue at 
amino acid site 4369 (p. Trp4396) near the carboxyl terminus of the protein (Figure 1-11 
B), resulting in a conformational change that reduces binding affinity with the LDL-R 
(84). The substitution of arginine 3527 to glutamine (p. R3527Q) affects LDL-C protein 
conformation and particle size: the conformational change causes inefficient binding to 
LDL-R. R3527Q has smaller LDL-C particle size than wild-type ApoB-100, which 
consequentially affects LDL-C uptake and concentration. Studies of FDB homozygotes 
have shown that FDB-LDL binding activity is 20% of normal, because the larger LDL-C 
particles and VLDL retaining ApoE moieties can still bind to LDL-R (85, 86).  
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 Figure ‎1-11: Schematic of the human APOB gene 
A) Schematic of the human APOB gene and reported APOB-100 FH ligand-defective 
mutations. Reproduced with modifications from Sundaram and Yao (2012), and Liyanage 
et al. (2008). B) Schematic of the organization of apo-B100 on the LDL-C particle. The C-
terminus folds back over the preceding structure; an arginine (residue 3500) binds to a 
tryptophan (residue 4396), which prevents the C-terminus from sliding over the binding 
site of the LDL receptor between residues 3359 and 3369. Mutation of the arginine (R) 
(residue 3500) results in reduced binding to LDL-R because the arginine–tryptophan 
interaction is broken. Adapted from Boren et al. (1998).  (71) 
(87, 88). 
 
 
Several other variants in APOB associated with FH have been discovered, including 
variants in exon 26 p.(Arg3507Trp (89), p.(Arg3558Cys) (90), in exon 22 p.(Arg1164Thr) 
(89)and in exon 29 p.(Trp4396Tyr), p. (Gln4494del) (89, 91); however, these variants are 
less frequent than R3527Q. Functional studies have shown that these variants have similar 
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but usually a milder effect to R3527Q, where the variants lead to somewhat reduced the 
binding and uptake of LDL-C (89, 91). 
  
1.6.2.3. Proprotein convertase subtilisin/kexin type-9 (PCSK9)   
The third gene causing FH is PCSK9, which works as a post-transcriptional inhibitor of 
LDLR.  
1.6.2.3.1. PCSK9 ontogeny, biosynthesis and structure  
The human PCSK9 gene is located on chromosome 1p32.3, contains 12 exons and encodes a 
692 amino acid glycoprotein belonging to the family of protein convertases (92, 93). It is 
highly expressed in liver hepatocytes and less in small intestine and kidney. PCSK9 is 
comprised of four domains (Figure  1-12). The N-terminal signal peptide (aa 1-30) necessary 
for secretion which is followed by a prosegment domain (pro-domain) (aa 32-152) that 
inhibits the catalytic activity when cleaved. The third domain is a catalytic domain (CAT) (aa 
153-421), which is responsible for autocatalytic intramolecular processing in the ER and is 
followed by a C-terminal domain (CTD) (aa 440-692): A small 18aa hinge region (aa 422-
436) links the catalytic domain to cysteine-histidine-rich domain (CHRD) of CTD. The 
CHRD is composed of three modules: M1 (aa 453-531), M2 (aa 530-605)and M3 (aa 604-
692), and the most histidine residues (9/14 His) are found in the M2 domain (94).  
 
After cleavage of the signal peptide (aa1-30), PCSK9 is synthesized as a ∼75kDa soluble 
zymogen (pro-PCSK9) that undergoes autocatalytic cleavage at position 152 in the ER to 
release the propeptide (14kDa) from the N-terminus resulting in a mature enzyme of about 
60kDa (94, 95).  After intracellular autocatalytic cleavage in the ER, the cleaved prosegment 
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domain is non-covalently bound to the catalytic domain of mature PCSK9 to form a 
prodomain≡PCSK9 complex and the cleaved pro-domain acts as a chaperone to promote 
proper folding and leaving ER (93). Thus, the prodomain≡PCSK9 complex is secreted as an 
enzymatically inactive protein. PCSK9 activity is related to specific target proteins that bind 
to the catalytic domain and/or CHRD. The first PSCK9 target protein identified was the LDL-
R (96-98), where the EGF-A domain of the LDL-R Arg194 and Asp238 bound PSCK9 in the 
catalytic domain at Ser153-Ile-Pro-Trp156 to direct the complex towards intercellular 
degradation (99). The common FH-causing gain-of-function variant Asp374Tyr increases the 
interaction affinity by 25% (100). Also, Annexin A2 (AnxA2) has been identified as a protein 
that binds to the CHRD of PCSK9 and inhibits its action on LDL-R (101, 102). 
Figure  1-12: Schematic of the various domains of human proprotein convertase 
subtilisin/kexin type-9 protein (PCSK9).  
Schematic of the human PCSK9 protein, which is auto-catalytically processed in the ER into a 
540-aa (302-aa catalytic subunit and 238-aa C-terminal domain) that remains tightly bound to 
its 122-aa prosegment (prodomain). The catalytic subunit interacts with the EGF-A,B domain 
of the LDL-R to activate PCSK9 action on LDL-R; while the CHRD binds to AnxA2 to 
prevent PCSK9 activity on LDL-R. Adapted from Seidah (2009) with modification.   
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1.6.2.3.2. PCSK9 and LDL-R degradation  
At the cell surface, PCSK9 binds the EGF-A domain of the LDL-R via its catalytic domain. 
Once the non-covalent complex PCSK9≡LDL-R is formed, it is internalized by endocytosis 
(103, 104). The change of acidity in the sorting endosome environment leads to increased 
interaction affinity between PCSK9 and LDL-R by 120-150 fold, where the C-terminal 
domain of PCSK9 obtains an increased positive charge and electrostatically attracts the 
negatively charged ligand-binding domain of the LDL-R (105). This interaction leads to both 
the catalytic and C-terminal domain of PCSK9 to bind the  LDL-R, which consequently 
prevents the LDL-R from obtaining a closed confirmation in order to recycle to the cell 
surface (Figure  1-13) and direct the receptor to degradation.  
Figure  1-13: PCSK9 mediated LDL-R degradation  
A cartoon showing the function of LDL-R in the presence and absence of PCSK9. A) The 
normal function of the LDL-R. At the cell surface the LDL-R binds LDL-C through its 
ligand-binding domain (left). At the acidic pH of the sorting endosome, LDL-C is released 
from the LDL-R and the LDL-R adopts a closed conformation whereby ligand-binding 
repeats 4 and 5 interact with the β-propeller (right). B) The abnormal function of the LDL-R 
due to PCSK9 binding. PCSK9 binds to the EGF-A repeat of the LDL-R at the cell surface 
through its catalytic domain. In the acidic environment of the sorting endosome, the C-
terminal domain of PCSK9 attracts with ligand-binding domain of the LDL-R. This prevents 
the LDL-R from adopting a closed conformation at acidic pH in the sorting endosome. The 
ligand-binding domain of the LDL-R with its seven ligand-binding repeats is shown in 
yellow. The EGF-A, EGF-B and EGF-C repeats of the EGF precursor homology domain are 
shown in blue and the β-propeller is shown in red. The O-linked sugar domain, the 
transmembrane domain and the cytoplasmic domain are indicated by a solid black line. The 
cell membrane is shown as a horizontal structure. PCSK9 pro-domain (P), PCSK9 catalytic 
domain (CAT) and PCSK9 C-terminal domain (CTD). Adapted from Leren (2014).   
A) B) 
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1.6.2.3.3. PCSK9 mutations  
Both gain and loss of function mutations have been reported for PCSK9 resulting in 
hypercholesterolemia and hypocholesterolemia, respectively (Table 1-2). Gain-of-function 
(GOF) mutations in PCSK9 produce FH and increase the risk of CVD, whereas loss-of-
function (LOF) mutations have been associated with reduced plasma LDL-C concentrations 
from birth and decreased CVD risk (92, 106, 107).  
 
Figure 1-14 illustrates the most reported PCSK9 variants that have been  associated with 
effects on plasma LDL-C levels. The reported LOF mutations, Tyr142X and Cys679X, which 
are two nonsense mutations (108), and Ala443Thr a missense mutation (109) in the PCSK9 
gene are associated with low plasma levels of LDL-C in African-Americans. The functional 
disruption of PCSK9 associated with hypocholesterolemia is supported by the finding of 
reduced cholesterol levels in mice lacking PCSK9 (110). In Caucasians, Arg46Leu is the most 
common PCSK9 variant (108), which reduces LDL-C levels by 14% and CHD by 47% (103). 
It was suggested that Arg46 could affect binding of PCSK9 to the LDL-R in an indirect 
manner and the presence of the variant may affect PCSK9≡LDL-R binding (111, 112). 
Interestingly, when the Arg46Leu mutation is found in patients with a clinical diagnosis of 
FH; the mutation causes mild reduction (non-significant <9%) in LDL-C plasma levels in 
HeFH patients compared to those without Arg46Leu mutation, which suggests that the effect 
of Arg46Leu on cholesterol levels may partially hide the strong impact of FH causing 
mutations in HeFH (112, 113).  Another LOF mutation that has been linked to low levels of 
LDL-C is Q554E in the CHRD domain of PCSK9 which increases the interaction affinity to 
AnxA2 (101). AnxA2 is a protein that binds to PCSK9 and acts on LDL-R (discussed in detail 
later).  
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Figure  1-14: Schematic of some PCSK9 variants associated with plasma LDL-C levels 
Adapted from Soutar and Naoumova (2007). 
 
 
Several PCSK9 GOF mutations have been reported: missense mutations at residues 374 and 
127 (Asp374Try, Ser127Arg) are found in patients with FH. Molecular studies have shown 
that the catalytic domain GOF mutation Asp374Try has a great impact and increases the 
interaction affinity to LDL-R (114), while the pro-domain Ser127Arg is located away from 
the LDL-R–binding site and has weak or no impact on PCSK9’s affinity for the LDL-R, but 
potently reduces LDL-R numbers (115). It is suggested that Ser127Arg could modulate 
interactions with the cellular machinery that sorts LDL-R to lysosomes, because this amino 
acid substitution delays autocatalytic cleavage and secretion (96), and there is only a modest 
increase in affinity for the LDL-R (100, 116). More reported PCSK9 variants are listed in 
Table 1-2.  
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Table  1-2: PCSK9 allelic variants with known functional property. 
Adopted from (117) 
Functional domain DNA allele Mutation Function References 
5′UTR, 2.5-fold increase of 
transcriptional activity 
C−332A   Gain (118) 
Signal peptide G10A Val4Ile Gain (119, 120) 
Prodomain G94A Glu32Lys Gain (120) 
Prodomain A161C Glu54Ala Gain (120) 
Generation of a truncated 
peptide (Ala
68
fsLeu
82
X) 
202del G Ala68ProfsX15 Loss (121) 
Prodomain C230T Thr77Ile Loss (121) 
Prodomain C277T Arg93Cys Loss (120) 
Prodomain del GCC Arg97del Loss (122) 
Prodomain C310T Arg104Cys Gain (120) 
Prodomain G316A Gly106Arg Loss (123) 
Prodomain T341C Val114Ala Loss (121, 124)  
Prodomain T381A Ser127Arg Gain (111, 125, 126) 
Prodomain G385A Asp129Asn Gain (121) 
Prodomain A386G Asp129Gly Gain (111) 
Generation of a truncated 
peptide 
C426G Tyr142X Loss (108) 
Catalytic C503A Ala168Glu No effect (111) 
Catalytic G644A Arg215His Gain (125) 
Catalytic T646C Phe216Leu Gain (126) 
Catalytic A654T Arg218Ser Gain (127) 
Catalytic C655G Gln219Glu Loss (120) 
Catalytic G706A Gly236Ser Loss (125) 
Catalytic C716A Ala239Asp Loss (120) 
Catalytic C757T Leu253Phe Loss (128) 
Catalytic A1061T Asn354Ile Loss (125) 
Catalytic G1070A Arg357His Gain (127)  
Catalytic G1120T Asp374Tyr Gain (114, 129, 130) 
Catalytic G1120C Asp374His Gain (131) 
Catalytic C1171A His391Asn Loss (128) 
Catalytic A1274G Asn425Ser Gain (128, 132) 
Catalytic G1284A Trp428X Loss (120) 
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C-terminal domain C1300T Arg434Trp Loss (133) 
C-terminal domain G1355A Gly452Asp Loss (120) 
Disrupts normal folding of 
the C-terminal domain 
T1384C Ser462Pro Loss (125) 
C-terminal domain C1405T Arg469Trp Gain (120, 127) 
C-terminal domain C1486T Arg496Trp Gain (132) 
C-terminal domain G1540A Ala514Thr Gain (120) 
C-terminal domain G1564A Ala522Thr Gain (121) 
C-terminal domain A1658G His553Arg Gain (128) 
C-terminal domain C1660G Gln554Glu Loss (128) 
C-terminal domain C1847T Pro616Leu Loss (121) 
C-terminal domain G1870A Val624Met Gain (120) 
C-terminal domain C2004A Ser668Arg Loss (120) 
Generation of a truncated 
peptide retained in the ER 
C2037A Cys679X Loss (108) 
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1.6.2.4. Low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) 
LDLRAP1 encodes an adaptor protein, which is necessary for internalization of the LDL-
C≡LDL-R complex and for efficient binding of LDL-C to its receptor (Michaely, Li et al. 
2004). A study by Zuliani and colleagues (134) reported two families of Sardinian origin 
having very similar HoFH characteristics, including severely elevated plasma LDL-C, 
tuberous and tendon xanthomata, and premature atherosclerosis, but they showed a recessive 
inheritance pattern in contrast to the usual dominant pattern. This new disorder is called 
autosomal recessive hypercholesterolaemia (ARH). Mapping the ARH locus revealed that it 
occurs when two defective copies of LDLRAP1 are inherited, which leads to failure in the 
internalization of the LDL-C≡LDL-R complex and in LDL-C clearance (135).  
 
The LDLRAP1 gene, located on human chromosome 1p35–36.1, consists of 9 exons and 8 
introns (136). It contains a phosphotyrosine binding (PTB) domain (Figure 1-15), which binds 
to NPXY motifs in the cytoplasmic tails of cell surface receptors, including the LDL-R, which 
promotes LDL-R endocytosis through the clathrin-coated pits on the cell surface (135, 137). 
Usually functional LDLRAP1 mutations introduce a premature stop codon and results in a 
truncated non-functional protein.  
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Figure  1-15: Schematic of LDLRAP1 structure and function. 
A) LDLRAP1 functions to engage the LDL-R using clathrin-coated pits for endocytosis. B) 
Diagram of the LDLRAP1 gene. Exons are shown as vertical bars numbered above, with the 
position of known point mutations shown below and two large gene rearrangements. All 
mutations are 'null' and would result in a truncated protein, as indicated in the protein 
diagram. The different domains of the LDLRAP1 protein and their proposed function on the 
basis of studies in vitro are shown. Adapted from Soutar and Naoumova (2007). 
 
 
 
 
 
 
A) 
B) 
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The Garcia group (2001) studied six families of Sardinian, Lebanese, American and Iranian 
origin with ARH and described six different mutations (Figure 1-16). Two different mutations 
were identified in the Sardinian families that caused premature termination of translation. One 
family was homozygous for a single base-pair insertion in exon 4 (c.432insA, p. (170Stop)) 
that introduces a premature termination codon at amino acid 170, truncating the protein in the 
terminal portion of the PTB domain, while the other family was homozygous for a nonsense 
mutation at codon 22 (c.65G>A, p. (W22X)). In Lebanese families, one family was 
homozygous for a nonsense mutation in codon 136 (c.406C>T, p. (Q136X)), which stops 
translation in the terminal region of the PTB binding domain. The second family was 
homozygous for a missense mutation substituting a histidine for proline at amino acid 202 
(c.605C>A, p.(P202H)), which is outside the PTB domain. Two other families from USA, and 
Iran were homozygous for different frameshift mutations located in a string of seven guanine 
residues in exon 1 (c.72insG. p.(33Stop) and c.71delG, p.(55Stop) respectively). Both 
mutations predicted truncation of the protein near the NH2-terminus. 
 
Figure  1-16: Schematic representation of ARH showing the location of the mutations 
identified by the Garcia group (2001) study 
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1.5.2.5. Signal-transducing adaptor protein 1 (STAP1) 
More recently, a new gene, STAP1, was identified as the fourth gene associated with 
autosomal dominant hypercholesterolemia (ADH). Fouchier and his group (2014) identified a 
Dutch family who had FH phenotype but were mutation-negative for LDLR/APOB/PCSK9. 
Exome sequencing of chromosome 4 resulted in identification of the mutation p. Glu97Asp in 
exon 3 of STAP1. Co-segregation analysis of the mutation was carried out by screening three 
generations of the family. Results showed that 11 members were affected (TC or LDL-C 
levels > 95
th
 percentile), 4 members were possibly affected (75
th
 <TC or LDL-C levels <95
th
 
percentile), and one member was unaffected (TC or LDL-C levels <75
th
 percentile (Figure 1-
17). Further analysis of 400 unrelated FH subjects resulted in the identification of four rare 
variants in STAP1 (Glu97Asp, Leu69Ser, Ile71Thr, and Asp207Asn) in ADH patients with no 
FH mutations (47). It was observed that patients with rare variants of STAP1 have 
significantly higher TC and LDL-C plasma levels compared to those who are STAP1 mutation 
negative. Although the lipid phenotype of STAP1 patients is less severe than LDLR mutation 
patients, it is similar to FDB patients. The identified mutations are located in exon 3 and 6, the 
affected amino acids are highly conserved and were predicted to be pathogenic.   
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Figure  1-17:  Co-segregation analysis of the STAP1 mutation p. Glu97Asp 
Half-blackened symbols indicate affected members (>95th percentile), quarter-blackened 
symbols indicate possibly affected members (between 75th and 95th percentile), and white 
symbols indicate unaffected members (<75th percentile). A dot indicates carriers of the 
p.Glu97Asp variant. The triangle represents the proband. Age (in years), lipid measurement[ 
total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), triglycerides (TG)] in mmol/L, and history and age onset of coronary 
vascular disease are given. Percentiles matched for age and sex, pTC, pLDL, pHDL, and pTG 
are given in brackets, a percentile indicated by 99 resembles a >95th percentile. Individuals 
with mapping data are marked with +. For individuals with exome data, symbols are marked 
with brackets. AMI indicates acute myocardial infarction; CABG, coronary artery bypass 
graft; CVD, coronary vascular disease; and UPN, unique personal number. Adapted from 
Fouchier et al. (2014). 
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The STAP1 gene, located on human chromosome 4p13.2, consists of 9 exons and 8 introns 
and contains a Pleckstrin homology domain, a Src homology 2 domain, and several tyrosine 
phosphorylation sites (Figure 1-18) (138). Fouchier et al. (2014) briefly described STAP1 as 
having three variants – Glu97Asp, Leu69Ser, and Ile71Thr – located in the Pleckstrin 
homology domain. This is believed to be a phosphoinositide-binding domain that facilitates 
the association of STAP1 with membranes, thus alterations in this domain may affect the 
interaction of STAP1 with membrane or membrane proteins. The fourth variant, Asp207Asn, 
is located in the Src homology 2 domain, which is the domain responsible for signal 
transduction emanating from upstream receptor tyrosine kinase which includes c-kit and c-
fms. The STAP1 functioning downstream of c-kit controls cholesterol levels. An in vivo study 
showed that a LOF mutation in c-kit leads to increased plasma cholesterol levels (139, 140). 
Fouchier et al. (2014) suggested that STAP1 might be involved in cholesterol homeostasis.  
  
Figure  1-18: STAP1 gene structure  
PH: Pleckstrin homology domain, SH2: Src homology 2 domain. The tyrosine residue 
positions are indicated by arrowheads. 
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1.6.3. Diagnosis of FH 
1.6.3.1. Clinical diagnosis of FH 
Clinical signs and family history are important in diagnosing FH. Currently, there are two 
clinical diagnostic criteria that are widely used. First, the Simon Broome Register Criteria in 
the UK distinguishes two types of the disease: definite FH (DFH), and possible FH (PFH). 
Both DFH and PFH patients should have a total cholesterol greater than 7.5 mmol/l, and/or a 
LDL-C greater than 4.9 mmol/l (Table 1-3). A positive family history of MI is also a criterion. 
In addition, DFH patients have observable tendon xanthoma around their joints and/or arcus 
cornealis (Figure  1-19). Presence of a mutation in one of the known FH genes also classifies a 
patient as DFH (141). In 2008, the National Institute for Clinical Health and Excellence 
(NICE) guidelines for FH identification and management recommended that all patients with 
clinical and biomarkers of hypercholesterolemia should be offered molecular diagnosis to 
confirm their diagnosis(142).  
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Table  1-3: Simon Broome Register Criteria to diagnose familial hypercholesterolemia in 
adults and children. 
Adapted from Marks et al. (2003).  
 Simon Broome Register Criteria 
1 TC >7.5 mmol/L or LDL-C>4.9 mmol/l in adult 
TC >6.7 mmol/L or LDL-C>4 mmol/l in children  
2 Tendon xanthomas are present in the patient, first-degree relative or second-degree 
relative 
3 DNA-based evidence of a mutation in LDLR, APOB or PCSK9 
4 Family history of premature myocardial infarction (<50 years in second-degree 
relative or <60 years in first-degree relative 
5 Family history of elevated TC (>7.5 mmol/l in first-degree relative or second-
degree relative 
 Definite FH = 1+2 or 3  
Possible FH = 1+4 or 5  
 
Figure  1-19: Physical signs of heterozygous familial hypercholesterolemia. 
Tendon xanthoma can occur in several places, they are shown with arrows. A: lateral borders 
of thickened Achilles, B: in hand, C: in eyelids, D: in arcus corneal. Adapted from Yuan et al. 
(2006). (143).  
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The Dutch Lipid Clinic Network Criteria (DLCNC) is the second diagnostic tool used to 
diagnose FH. It has similar features to the Simon Broome criteria. In addition to family history 
of premature CHD, LDL-C levels, presence of tendon xanthoma, and DNA analysis, DLCNC 
diagnosis adds to the calculation of a numeric score (WHO-Human Genetic, 1999) to 
distinguish between three classes of patients: definite, probable, and possible. A diagnosis is 
considered definite if the score is greater than 8, considered probable if the score is between 6 
and 7 points, and considered possible when the score is between 3 and 5 points. If the score is 
below 3 points, a diagnosis of FH is not made (144).  The DLCNC criteria for FH are shown 
in Table 1-4. 
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Table  1-4: Dutch Lipid Clinic Network diagnosis score of FH 
Adapted from Marks et al. (2003).  
 
Criteria Score 
A- Family history  
First-degree relative with known premature (>/55 years men; >/60 years women) 
coronary and vascular disease. 
1 
First-degree relative with known LDL-C _/95th percentile  
First degree relative with tendon xanthomata and/or arcus cornealis 2 
Children below 18 years with LDL-C_/95th percentile 
B- Clinical history 
Patient has premature (>/55 years men; >/60 years women) coronary artery disease 2 
Patient has premature (>/55 years men; >/60 years women) cerebral or peripheral 
vascular disease 
1 
C- Physical examination  
Tendon xanthomata 6 
Arcus cornealis below 45 years 4 
D- Laboratory analysis 
                                                       mmol/l                                mg/dl  
LDL-C >8.5        >330 8 
LDL-C 6.5-8.4 250-329 5 
LDL-C 5.0-6.4 190-249 3 
LDL-C 4.0-4.9 155-198 1 
E- DNA analysis  
Functional mutation in the low-density lipoprotein receptor present 8 
 Total Score 
Definite FH >8 
Probable FH 6-8 
Possible FH 3-5 
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1.6.3.2. Genetic diagnostic of FH 
A DNA-based test can provide a definite diagnosis of FH and is a useful tool to identify 
affected relatives of a patient. Different screening methods have been adopted due to mutation 
variety among populations. First, the amplification-refractory mutation system (ARMS) 
commercial kit (Elucigene FH20) used in the UK, was designed to detect the most common 
UK FH mutations including 18 LDLR mutations, APOB p.Arg3527Gln and PCSK9 
p.Asp374Tyr (145) . It was reported that the ARMS assay detected over 44% of the UK 
mutations, with a prevalence of 12% for APOB and 1.7% for PCSK9. Because of the wide FH 
mutation spectrum in the UK another method was developed, high-resolution melting (HRM) 
of the coding region of LDLR followed by Sanger sequencing. It is an effective method for 
detecting mutation involving single base changes or small deletions, however, its sensitivity 
decreases in some regions of the gene depending on the nucleotide composition of the 
fragment (146). The third method is the multiplex ligation-dependent probe amplification 
(MLPA) assay (SALSA P062 from MRC-Holland), which was developed to detect large 
deletions, and duplication (147). Although the technique is highly reliable, and allows 
detection of large rearrangements, which account for up 10% of UK FH mutations (148), it is 
time-consuming and a costly addition to sequencing. LIPOchip (Progenika Biopharma, Spain) 
is another commercially available kit to diagnose FH, which is designed to detect 251 FH 
mutations and can detect point mutations and copy number changes (149). It was reported that 
LIPOchip detected 66% of FH mutations in Spanish FH diagnosed patients. Although 
Elucigene FH20 and LIPOchip have been widely used as simple diagnostic tools, in 2012, the 
National Institute for Health Technology Assessment reported that the tests certainty and 
sensitivity to detecting FH-causing mutations in patients with a clinical diagnosis of FH were 
variable between studies. It found that Elucigene FH20 sensitivity ranged from 44% to 52% 
while LIPOchip ranged from 33.3% to 94.5%. In addition, these tools as targeted tests are 
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designed to detect a limited number of genetic mutations, thus they cannot detect all FH 
mutations, where over 1700 LDLR FH mutations have been reported (65, 150) and 
Elucigene FH20 and LIPOchip can only detect 20% of FH mutations. It became important for 
a new method to emerge to diagnose FH that considers cost-effectiveness, specificity and 
sensitivity.  Next Generation Sequencing (NGS) technology has revolutionized the genomic 
field. Implementing NGS into molecular diagnostic labs has become essential due to time 
efficiency, cost-effectiveness, and specificity. NGS and targeted NGS (exome sequencing) 
have been used as diagnostic tools of  FH (151-154), with 100% specificity and 98-100% 
sensitivity (155).  
 
1.7. Polygenic hypercholesterolemia  
Hypercholesterolemia is a quantitative phenotype, and is complex in etiology, with multiple 
environmental and genetic causes. The genetic contribution is usually considered as a single 
gene-familial disorder, and in FH patients, mutations can be detected in 60-80% of those with 
a  clinical  diagnosis of DFH and 20-30% with clinical PFH in the three key genes, LDLR, 
APOB, and PCSK9 (46, 145, 148). These data show that roughly 60% of patients who are 
diagnosed with FH are negative for any FH-causative mutation. Failing to identify a new FH 
causing mutation in clinical FH patients suggests that FH could be also a polygenic disease. 
Polygenic hypercholesterolemia is a condition of uncertain etiology. It may occur when 
individuals have a negative family history of disease as a result of an unclear mode of 
inheritance, or relatives may be undiagnosed, or it could be the result of a new autosomal 
dominant mutation, autosomal recessive inheritance, and incomplete penetrance in autosomal 
dominant inheritance. In addition, it may occur in a presence of multiple gene variants with 
mild affect, where accumulations of these common variants lead to an observed phenotype. 
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Also, it may occur as a result of the interaction between variants with mild affect and 
environmental factors which together cause the disease or trait (40).  
 
There are several possible explanations for the clinical finding of a patient with a diagnosis of 
FH without any FH causative mutation. First, it may occur due to misinterpretation of clinical 
diagnosis, where patients with ‘phenocopy’ caused disease are included (156). Secondly, it is 
possible there are undetected new mutations in known genes, which may be due to low 
sensitivity levels of current FH-screening methods in some region of the gene(s) or may be 
due to classical genetic diagnostic methods not covering non-coding regions (introns or 
upstream or downstream transcription regulatory regions), where causal mutation could be 
present. The third possible explanation is that the disease-causing mutations might occur in 
unidentified gene(s). The classical FH mutation screening methods (HRM, MLPA and Sanger 
sequencing) that were used in clinics until recently only focus on the three known FH genes: 
LDLR, APOB, and PCSK9. However, identifying FH causative mutations in known genes and 
new genes becomes possible, faster and cost-effective by using the high-throughput NGS  
technology (155, 157). The fourth possibly explanation of no detected mutation in some 
clinical FH patients is the presence of multiple gene common variants with small effect, 
together leading to the FH phenotype. It has been hypothesized that common complex 
diseases (such as hypercholesterolemia) are caused by common genetic variants (158), each 
with small effect, through additive and interactive effects of these variants in conjunction with 
environment stress (159). Figure 1-20 shows the genetic variations and susceptibility to 
polygenic diseases. In the last 10 years a new genetic approach called the GWAS has become 
a major contributor to genetic knowledge, where the GWAS examines the association 
between variant genotypes and phenotypes in large populations. In 2010 and 2013, large 
GWAS meta-analysis identified many novel loci associated with lipid traits (160, 161). These 
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studies reported that SNPs in LDLR, APOB, PCSK9 and LDLRAP1 have significant 
association with LDL-C, therefore, it was suggested that other genes, within which common 
variants are associated with moderate effect on LDL-C, may also contain rare FH causing 
variants. However, to date no new rare variants in GWAS hit loci for LDL-C have been 
reported.   
Figure  1-20: Genetic variations and susceptibility to polygenic diseases 
A schematic showing several genetic variants (SNPs) and possible involvement of 
environmental factors in defining susceptibility to multifactorial diseases. A strong correlation 
to disease susceptibility can be explained by taking into account the various factors affecting 
susceptibility to diseases such as environment factors, different types of genomic variants 
(SNP, CNVs, small insertions and deletions (indels), etc). Adapted from Almal and Padh 
(2012) (162).  
 
 
 
It has been reported that a proportion of individuals carrying several LDL-C-raising SNPs 
have LDL-C levels that exceed the FH LDL-C diagnostic cut-off 4.9mmol/l (163). In 2013, 
the same group were used to gene-score in a case/control study to test whether adding a LDL-
C associated SNP could help to improve the FH diagnostic. They selected 12 common LDL-
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C-raising SNPs identified by Teslovich et al., (2012) to construct a weighted LDL-C-raising 
gene score, and compared the gene-score distribution among patients with FH and with 
mutation positive, mutation negative, and controls from the Whitehall II study (WHII). The 
major finding of the study was that the SNP score for both mutation negative and mutation 
positive patients with a clinical diagnosisof FH had significantly higher SNP scores than the 
control population, and the difference between mutation negative and mutation positive also 
was significant (156, 161, 164). High SNP scores explained hypercholesterolemia in at least 
13-20% of patients with no identified mutation; however, ~12% of FH patients who were 
mutation negative remained with unexplained disease (Figure 1-21).  Those patients may 
carry very rare mutations in known genes or in new gene(s) affecting LDL-C plasma 
homeostasis.          
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Figure  1-21: Genetic causes of definite familial hypercholesterolaemia (DFH) in a 
genetically heterogeneous population. 
A familial hypercholesterolaemia-causing mutation can be found in roughly 75% of DFH 
patients (68% in LDLR, 6% in APOB, and 1%in PCSK9). Approximately half of the patients 
with no mutation in known FH genes are thought to have a polygenic cause due to common 
variants in LDL-C-modifying genes, while the other half remained with an unexplained cause. 
Adapted from Talmud et al. (2014).  
  
 
52 
 
1.8. Annexin A2 (AnxA2) a new protein links to LDL-C levels  
PCSK9 is the third gene involved in cholesterol homeostasis. It binds to LDL-Rs thus 
promoting receptor degradation, and thereby modulating LDL-C plasma levels. Several 
PCSK9 mutations have been reported; the reported GOF variants have been associated with 
increased risk of high LDL-C and of CVD. This suggests that PCSK9 is an attractive 
therapeutic target for lowering circulating LDL-C, especially for hypercholesterolemia 
patients who under the standard care of statins, fail to reduce their LDL-C levels to intended 
target levels. One reason could be because statins increase both LDLR and PCSK9 mRNA 
expression (21). It has been reported that high-dose atorvastatin (80 mg) leads to increased 
PCSK9 levels in serum over time (165). These findings have shown that PCSK9 is a viable 
target to reduce LDL-C and thereby reduce the risk of CVD (166, 167). 
  
Pharmaceutical companies have become interested in the introduction of a drug that would 
target the PCSK9 molecule. PCSK9 monoclonal antibodies have been shown effective in 
reducing LDL-C levels (168), although their widespread use may be limited by practical 
issues such as subcutaneous administration and high costs (169). Other drugs that target 
PCSK9 mRNAs (ASO, siRNAs, and LNA) are developing. So far, it is unknown whether 
injection of these compounds is safe for humans, and/or can be produced at a reasonable cost 
(168). However, Mayer (2008) and his group have identified a small molecule called Annexin 
A2 (AnxA2), which binds to PCSK9 and inhibits PCSK9 mediated LDL-R degradation. 
AnxA2, as an endogenous inhibitor for PCSK9, has an advantage as a therapeutic target. An 
overview of AnxA2 is given below. 
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1.8.1. ANXA2 ontogeny, biosynthesis and structure 
The ANXA2 gene is located on chromosome 15q22.2 and consists of 13 exons (170). AnxA2 
belongs to the Annexin family of phospholipid and calcium-binding proteins, it is a 36kDa 
protein produced by endothelial cells, monocytes, macrophages, trophoblasts, and some tumor 
cells, which is found free in the cytoplasm and in association with intracellular and plasma 
membrane surfaces (171, 172). It exists as a monomer and as a heterotetrameric complex with 
the plasminogen receptor protein p11 (also known as S100A10) (173, 174). AnxA2 as a 
member of the Annexins binds to anionic phospholipids in a calcium (Ca
2+
)–dependent 
manner. It has three distinct functional regions (Figure 1-22): first, a N-terminal region 
containing tissue plasminogen activator (tPA) (175) and a p11-binding site (176); second, a C-
terminal region containing F-actin (177), heparin (178) and plasminogen-binding sites (179); 
and third, in the core region of AnxA2 has calcium and phospholipid-binding sites. The core 
domain contains four repeat sequences of 70 amino acid residues composed of five alpha-
helices (A–E). The AB and DE helices are connected by loops. Also, it contains several Ca2+ 
binding sites which are present in the AB loops (180, 181). 
 
To combine two molecules of AnxA2 (Figure 1-20), the first 10 amino acids of the N-terminal 
of AnxA2 form an alpha-helix, the hydrophobic surface of which binds to p11. Four 
hydrophobic amino acids of the amino terminus of AnxA2 (V3, I6, L7 and L10) form seven 
points of contact with helix HI of one p11 monomer. Two points of contact with the hinge 
region of p11 and nine points of contact with helix HIV of the other p11 monomer form a 
total of 19 contact points between AnxA2 and p11 (182-185).  The AnxA2 heterotetramer is a 
planar, curved molecule with opposing convex and concave sides. The convex side of AnxA2 
faces the cellular membrane and contains the Ca
2+
 and phospholipid binding sites, while, the 
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concave side is oriented away from the membrane and contains both the N- and C-terminal 
regions (183, 186). 
  
Figure  1-22: Schematic of the cell surface of AnxA2 heterotetramer 
AnxA2 complex, the predominant form of AnxA2 and p11 on the cell surface, is composed of 
two molecules of AnxA2 linked together by a dimer of p11, which is located at the center, 
with an AnxA2 molecule on each side. The first 10 amino acids of AnxA2 form a helix, which 
lies in a hydrophobic cleft formed by loop L2 and helix HIV of one molecule of p11 and helix 
HI of the other p11. The binding of tPA and plasminogen to the complex occurs on the C-
terminal lysine of the p11 subunit. Adapted from Madureira (2011). (187) 
 
 
 
1.8.2. ANXA2 Functions 
AnxA2 has been reported to play a key role in many processes including exocytosis, 
endocytosis, membrane organization, ion channel conductance, membrane reorganization, 
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vesicular trafficking and redox regulation. Anxa2 impacts over 60 genes as well as control of 
the cellular levels of other proteins such as an p11 (188). AnxA2 functions are summarized in 
Figure 1-23.  
 
Figure  1-23: Schematic summary of the functions of AnxA2 heterotetramer. 
Adapted from Bharadwaj et al. (2013) with modification.  
 
 
1.8.3. The relationship between ANXA2, PCSK9 and LDL-R 
Studies have shown that PCSK9 activity is related to specific target proteins that bind to the 
catalytic domain and/or the CHRD. It is known that the catalytic domain of PCSK9 is bound 
to LDL-R and degrades the receptor. In addition, it has been reported that the CHRD of 
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PCSK9 is important for intracellular and extracellular LDL-R degradation induced by PCSK9 
(101, 189-191). Interestingly in 2008, the Mayer group identified AnxA2 as a protein that 
binds to the CHRD of PSCK9, where the N-terminal repeat one (R1) of AnxA2 (102) binds to 
M1 and M2 domains of PCSK9 CHRD (192). An in vitro study has shown that AnxA2-
derived peptides prevent the PCSK9≡LDL-R interaction while in vivo adenoviral AnxA2 
overexpression increased hepatic LDL-R levels (102). In addition, it was found that AnxA2 
has a role in PCSK9 translation, where cytosolic AnxA2 inhibits PCSK9 mRNA translation 
and enhanced the sorting of the endocytosed Dil-LDL≡LDL-R complex to lysosomes (192). 
From these findings AnxA2 is proposed as an endogenous regulator of LDL-R degradation, 
mostly in extra-hepatic tissue (102).  
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1.9. Clinical management of FH and hypercholesterolemia 
1.9.1. Lifestyle intervention  
Healthcare professionals provide lifestyle advice to hypercholesterolemia and FH patients as 
part of the clinical management of the disease. They ask their patients to improve their 
lifestyle by having a low-fat diet, increasing physical activity, quitting smoking, losing weight 
(for overweight patients), and controlling alcohol consumption.    
 
1.9.2. Treatments 
1.9.2.1. Statins 
The main target of physicians is to reduce LDL-C levels in their hypercholesterolemia and FH 
patients. The most common cholesterol-lowering drugs are statins, which are used as the 
primary intervention method to prevent CVD. Statins stimulate expression of the LDLR gene 
by inhibiting HMG-CoA-Reductase activity. Statin therapy reduces LDL-C by 30% to 60%; 
this variation is caused by the variable potency of the statin used, the type of statin used, the 
dose, and the type of LDLR mutation (20). Table 1-5 shows statin types, dose and reduction 
levels of LDL-C. 
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Table  1-5: Statin types, doses and reduction of LDL-C 
Adapted with modification from Sharma et al. (2009) and Robinson (2013). (193) 
Statins Low Dose, mg/d High  Dose, mg/d 
Reduction levels 
of LDL-C 
Atrovastatin 5, 10, and/or 20 40 and/or 80 30-50% 
Simvastatin* 5, 10, and/or 20 40 and/or 80 30-40% 
Rousuvastatin 5 and/or 10 20, 40 and/or 80 30-60% 
Pravastatin 5, 10, 20 and/or 40 80 30-40% 
Fluvastatin 5, 10, 20 and/or 40 80 30-40% 
Lovastatin 5, 10, 20 and/or 40 80 30-40% 
mg/d = milligram/ day  
*Simvastatin has a better result when combined with ezetimibe > 50%  
 
 
Despite the powerful effect of statins, often the target LDL-C concentrations cannot be 
achieved with monotherapy in many patients with FH and hypercholesterolemia. In such cases 
the goal of treatment should be the maximum LDL-C reduction attainable with an appropriate 
combination of treatment at tolerated doses, for example, use of a statin combined with a 
cholesterol absorption inhibitor (ezetimibe), a bile acid–binding agent (bile acid sequestrants), 
nicotinic acid, and fibrates, which are fibric acid derivatives. Ezetimibe combined with 
simvastatin decreases LDL-C levels by a further 16.5% compared with statin monotherapy 
(194). The bile acid sequestrants also upregulate the expression of LDLR and increase the 
uptake of LDLs from the circulation, by upregulating Cytochrome P450 Family 7 Subfamily 
A Member 1 (CYP7A1), an enzyme that is involved in the bile acid synthesis pathway (195). 
Nicotinic acid decreases LDL-C and triglyceride levels while increasing HDL-C levels in 
plasma (196). Fibrates decrease triglyceride, increase HDL-C levels in plasma, but have no 
effect on LDL-C levels directly (197). However, in patients with combined dyslipidemia, 
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combination therapy of a statin with fenofibric acid show a huge reduction in triglyceride and 
LDL-C levels and an increase in HDL-C levels than with any monotherapy medication (198).  
 
Ezetimibe, bile acid sequestrants or nicotinic acid can be used as monotherapeutic agents 
inHypercholesterolemia and FH patients who show intolerance to statins. Young adults and 
women of childbearing age should not take statins because they comprise molecules that may 
alter the signaling pathway of the Sonic Hedgehog gene, which could affect embryogenesis 
and development. Bile acids (e.g., colesevelam) are the alternative treatment recommended 
during pregnancy (199).  
 
1.9.2.2. Other treatment options  
One of challenges that face these conventional and combination therapies is that sometimes 
they are unable to reduce LDL-C levels to recommended targets in patients with HoFH. The 
severity of HoFH is based on LDL-C levels (LDL-C >13 mmol/L) (200), which results from 
the mutation types, heterogeneity [true homozygous (have two identical mutations of the 
LDLR gene), compound heterozygous patients (have different mutations on each copy of the 
LDLR), and double heterozygous (have mutations on two different genes)] and their effects on 
LDL-C metabolism (200-204). Some mutations in the LDLR gene completely eliminate LDL-
R function (<2% of normal activity; receptor-negative or null mutations), and others reduce 
function by up to 75% (2–25% of normal activity; receptor-defective mutations) (205).  
Patients with receptor-negative HoFH generally have higher levels of LDL-C, respond poorly 
to conventional therapy, and have more accelerated disease than patients with receptor-
defective HoFH (206, 207). Conventional therapies generally are not effective in HoFH 
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because they predominantly upregulate LDL-R, and HoFH patients lack fully functioning 
LDLR.  
 
Several new drugs that target different mechanisms of action in addition to LDL-R 
upregulation are being developed. They effectively reduce LDL-C levels and reduce the risk 
of CVD events in HoFH patients. These treatment options are discussed below.  
  
1.9.2.2.1. LDL-apheresis 
LDL-apheresis (LDL-A) is a blood purification therapy that removes LDL-C from the 
circulating blood and rapidly reduces the plasma cholesterol level. There are various LDL-A 
techniques used to reduce LDL-C levels by up to 76%, including dextran sulphate cellulose 
adsorption (DSA), heparin-induced extracorporeal LDL-C precipitation (HELP), 
immunoadsorption, double filtration plasmapheresis (DFPP, lipid filtration), and direct 
adsorption of lipoproteins (DALI) (208, 209). Although the DFPP and DSA systems are 
highly selective and effective because they eliminate all ApoB-containing lipoproteins, they 
are obsolete technology. The simple technology of the DALI method effectively adsorbs TC, 
LDL-C, Lp(a), and TG,  is available in different sizes and has good selectivity. Clinical trials 
have shown that different LDL-A methods are in agreement with the findings of reducing 
serum lipid concentrations (210-216) and all systems are safe and show equivalent clinical 
efficacy even during long-term treatment (209). 
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1.9.2.2.2. Mipomersen 
Mipomersen is an antisense oligonucleotide directed against the messenger RNA (mRNA) of 
apoB, which blocks the hepatic synthesis of apoB protein, thereby reducing secretion of LDL-
C (217-219). In a placebo-controlled double-blind trial in 51 patients with HoFH, mipomersen 
200 mg administered once/week by subcutaneous injection was added to standard lipid 
lowering therapies (excluding lipoprotein apheresis) (217). When compared to a placebo, 
mean reductions of plasma LDL-C, apoB, and lipoprotein(a) (Lp(a)) levels [24.7% (p = 
0.0003), 26.8% (p < 0.0001), and 32% (p = 0.0013) respectively] were observed at 26 weeks. 
An open-label study in 2015 enrolled 141 patients (including 38 with HoFH), who were 
treated with mipomersen in three different trials.   It showed that long-term treatment with 
mipomersen for up to 104 weeks provided sustained reductions in all atherosclerotic 
lipoproteins measured, including plasma LDL-C, apoB, and lipoprotein(a) levels [28% , 31%  
(p < 0.001), and 14% (p < 0.001) respectively] (218).  Both studies (217, 218) showed 
common adverse events included injection site reactions, flu-like symptoms and elevations in 
alanine aminotransaminase levels. The second study measured median liver fat and found an 
incremental increase in the initial 6–12 months that appeared to diminish with continued 
mipomersen exposure beyond 1 year and returned towards baseline 24 weeks after last drug 
dose, which was suggestive of adaptation (217).  
 
1.9.2.2.3. Lomitapide 
Lomitapide is an oral inhibitor of the microsomal triglyceride transport protein (MTP), which 
transfers triglycerides and phospholipids onto apoB, thereby playing an important role in the 
assembly and secretion of apoB-containing lipoproteins (such as VLDL and chylomicrons) in 
the liver and intestine (220, 221). By inhibiting MTP, lomitapide induces post-translational 
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degradation of apoB, thereby reducing the secretion of lipoproteins into the blood, resulting in 
lower serum cholesterol and triglyceride levels (220, 222).  
 
In 2013, lomitapide (5 to 60 mg/day) was added to standard care, including LDL-A, in an 
open-label, dose-escalation study of 29 patients with HoFH (202) . Of the 23 patients who 
completed the 26 week treatment (median lomitapide dose, 40 mg/day), mean LDL-C, apoB, 
and Lp(a) levels were reduced by 50% (p<0.0001), 49% (p<0.0001), and 15% (p = 0.0003), 
respectively. A similar observation was reported for LDL-C and apoB at weeks 52 and 78, but 
Lp(a) reduction was not sustained, returning to baseline at 78 weeks. The most common 
adverse events, reported in 93% of patients, were gastrointestinal in nature, accumulation of 
liver fat, and elevations in alanine aminotransaminase levels.  
 
1.9.2.2.4. Inhibition of PCSK9   
Although statins are the most effective LDL-C lowering drug, they increase PCSK9 levels and 
are in some patients, are unable to reduce LDL-C levels to recommended levels in patients 
with severe FH and HoFH (21). As a result, PCSK9 has emerged as a major target for 
intervention to lower plasma LDL-C levels and prevent or treat atherosclerosis and CVD. In 
the last few years, several pharmacologic approaches to PCSK9 inhibition have been 
proposed. Table 1-6 summarizes the proposed therapeutic approaches and their present stage 
of development. 
63 
 
Table  1-6: Approach and mechanism of PCSK9 inhibition  
Adapted from Pitts, R. and Eckle, R. (2014). 
 Approach Mechanism Example 
Gene 
Silencing 
 Antisense oligonucleotide  
 Small interfering RNA (siRNA) 
 ISIS pharmaceutical (223) 
 Santaris pharma (224) 
 Alnylam pharmaceutical (225) 
Mimetic 
Peptides 
 Peptide that mimics EGFA domain of 
LDLR and binds PCSK9 (226, 227) 
 Peptide that mimics PCSK9 and binds 
LDLR (228) 
 Genentech 
Monoclonal 
antibodies 
 Targeting catalytic domain of PCSK9  Amgen AMG145 (evolocumab)  
 Regeneron SAR236553/REGN727  
 Pfizer RN316 (bococizumab) 
 Novartis LGT209 
 Genentech MPSK3169A 
Small 
molecule 
inhibitor  
 Target binds to PCSK9  Natural inhibitor Annexin (101, 
102) 
 Berberine (229, 230) 
 BMS-962476 (231) 
 
 
The most clinically advanced mechanism to inhibit PCSK9 is the use of monoclonal 
antibodies, which prevent the binding of PCSK9 to LDL-R. The first successful development 
of a monoclonal antibody against PCSK9 was reported in 2009 by Chan et al., when a human 
monoclonal antibody (mAB) bound to both the catalytic and prodomain sites prevented 
PCSK9 binding to LDL-R.  The mAB was shown to increase LDL-R levels by 1.7 to 2.2-
fold. Phase I studies showed significant efficacy in reducing LDL-C levels with minimal side-
effects (232, 233). With time, multiple monoclonal antibodies have been developed with 
completion of phase II trials and ongoing and completed phase III clinical trials (234-236). In 
2015, Evolocumab, an anti-PCSK9 human monoclonal antibody, was approved by European 
Medicine Agency for the treatment of adults and adolescents aged 12 years and over with 
HoFH, in combination with other lipid-lowering therapies. The combination of Evolocumab 
and statins lowered LDL-C levels by 59% [(0.78 mmol/l) (p<0.001)] and reduced the risk of 
cardiovascular events 15-20% compared to the “usual care” group who only received statin 
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therapy (237). Also, another study suggested that combination of Evolocumab with other 
agents such as Mipomersen and Lomitapide have the potential to further lower LDL-C levels 
in HoFH patients (207). A recent study in an atherosclerotic mouse model 
(APOE*3Leiden.CETP mouse model) (238) showed that active immunization against PCSK9 
with the so-called AT04A peptide-based vaccine elicited antibodies that effectively bind and 
remove PCSK9 from the circulation and reduce circulating TC, LDL-C, TG, and biomarkers 
of inflammation.  
 
Other PCSK9 therapeutic approaches are also proposed, but many are still in the preclinical 
development stage such as mimetic peptides which bind either to the PCSK9 or LDL-R 
binding domains, where both reduce or prevent LDL-R degradation. Furthermore, several 
antisense RNA inhibitors have been used to prevent the action of PCSK9 on LDL-R including 
antisense oligonucleotides (ASO) (226), small interference RNA (siRNA) (228), and locked 
nucleic acid antisense oligonucleotide (LNA) (227). In addition, small molecules such as 
AnxA2 and berberine have been identified, which inhibit PCSK9 action on LDL-R. 
Berberine, a naturally occurring plant alkaloid, has been shown to decrease PCSK9 mRNA 
expression and increase LDL-R in both in vitro and in vivo studies (229, 230).  AnxA2, a 
natural inhibitor, is expressed in many tissues and inhibits PCSK9 degradation of LDL-R 
(101, 102).  
 
A recently developed small interfering RNA (siRNA) molecule, Inclisiran (ALN-PCSsc) is a 
long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of PCSK9 
(239). The siRNAs bind intracellularly to the RNA-induced silencing complex (RISC), 
enabling it to cleave mRNA encoding PCSK9 specifically. The cleaved mRNA is degraded 
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and thus unavailable for protein translation, which results in decreased levels of the PCSK9 
protein. In 2016, a study in patients at high risk of CVD due to high LDL-C levels showed 
that a single subcutaneous injection of inclisiran 300 mg led to a 50% reduction in LDL-C 
after 90 days. And with a further injection of the same dose at 90 days after the first injection, 
LDL-C had decreased by 57% after 180 days. Inclisiran is considered to have good overall 
tolerability and safety (240).  
 
Genome-editing technology has also been used in PCSK9 drug development. A study showed 
the efficacy and safety of CRISPR-Cas9 therapy targeting the human PCSK9 gene in human 
hepatocytes in mice using adenovirus or adeno-associated virus (AAV) for delivery. The data 
showed that post-treatment blood levels of human PCSK9 protein were reduced on average by 
52% compared with pretreatment levels (p=0.007). This study supports further development 
of the therapy, with the goal of eventual clinical use for long-term protection against CVD 
(241).  
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1.10. Gene regulation 
Only 2% of the human genome is coding DNA, while 98% is non-coding DNA. Some 
non-coding DNA is transcribed into functional non-coding RNA molecules, while others 
are involved in gene expression regulation. Expression of a gene can be controlled at 
many levels, including transcription, post-transcription, translation and post-translation. 
Figure 1-24 shows gene regulation targets in eukaryotes.   
 
Figure  1-24: Gene regulation targets in eukaryotes 
A cartoon showing the five different targets of gene regulation: chromatin-remodeling, 
transcription, post-transcription (RNA processing), translation, and post-translation. 
Adapted from http://www.uic.edu/classes/bios/bios100/lectures/genetic_control.htm 
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1.10.1. Transcriptional regulation  
Gene transcription is a process that converts DNA to RNA in order to produce a protein that is 
involved in biological pathways. The transcriptional machinery is regulated by a combination 
of three elements including chromatin regulators, Cis-regulatory elements, and transcription 
factors (TFs). These elements together are the components of the “gene regulation network” 
(242). 
 
1.10.1.1. Chromatin regulation 
In eukaryotic cells, DNA is tightly wound into a complex called chromatin in order to be 
enfolded and packaged inside the nucleus. Chromatin comprised of octamers of histone 
proteins, and chromatin structure regulates gene expression through control of the 
accessibility of RNA polymerase II (RNA pol II) and TFs to the gene. A condensed form of 
chromatin prevents the transcriptional machinery from accessing the DNA, and consequently, 
the gene is repressed (243). Therefore, chromatin must have an "open structure" in order 
for gene expression to take place and this process is called chromatin remodeling (Figure 1-
25). Chromatin remodeling occurs as a result of enzymatic modifications of the amino 
terminal tails of histones which leads to an opening up of the structure. For example, histone 
acetylation correlates with gene expression and silencing, where certain lysine residues in 
histones are acetylated leading to open chromatin. In contrast, histone deacetylases close 
chromatin structure and prevent transcriptional machinery from operating (244).  
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Figure  1-25: Cartoon of chromatin remodeling.  
Chromatin consists of octamers of histone proteins around which DNA is wrapped and 
packaged inside the nucleus. Enzymatic modifications of histones, e.g. acetylation (Ac) result 
in remodeling of the chromatin and the opening up of the structure, which is now called 
euchromatin.  The euchromatin allows the transcription machinery to access the DNA and 
regulate transcription. Adapted from http://www.lerner.ccf.org/pathobio/labs/ stylianou/  
     
 
 
1.10.1.2. Transcription factor (TFs) 
TFs play a key role in gene expression regulation, but it is important to distinguish between 
two types of TFs: the basal transcription apparatus and the regulatory factors. The basal 
transcription apparatus requires that the initiating transcription machinery including RNA pol 
II and other general TFs are directed to the promoter region, while regulatory factors interact 
either directly or indirectly with cis-regulatory elements and control the efficiency of 
transcription via links to promoters (245). Regulatory transcription factors can be divided into 
two categories; sequence-specific regulators and co-regulators. The sequence-specific 
regulators interact directly with cis-regulatory elements in a sequence-specific manner. They 
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comprise two types of regulators – activator and repressor – depending on their role in 
promoter utilization (246, 247). In contrast, the co-regulators do not interact with DNA 
directly; they interact with regulatory elements via protein-protein interactions with sequence-
specific regulators. Similar to the sequence-specific regulators, co-regulators can be 
subdivided into co-activator and co-repressor, depending on their role in gene regulation (245, 
248). Regulatory transcription factor binding sites are usually clustered and form regulatory 
modules. Regulatory modules are directed to regulatory elements and are either enhancer or 
silencer, based on their role in transcription regulation. Many genes have multiple enhancer 
and/or silencer elements distributed over large regions (100kb or more). The interaction 
between these elements and regulatory modules are affected by time (development stage), 
tissue type and environment (245).    
 
1.10.1.3. Cis-regulatory element 
The cis-regulatory elements are located in non-coding DNA regions. They are recognized by 
sequence-specific DNA binding motifs and are located in the 3’UTR, 5’UTR, and within the 
introns, and control the transcription of genes (249, 250). The cis-regulatory elements 
including promoter and enhancer sequences have a role in the transcription levels of genes.  
 
The promoter region of a gene contains sequence-specific DNA binding transcription 
elements that work in the complex to initiate DNA transcription. Promoter regions provide a 
platform for the assembly of a basal transcription apparatus complex that includes TFIIA, 
TFIIB, TFIID, TFIIE, TFIIF, TFIIH, and RNA pol II, which work together to specify the 
transcription start site. Transcription complex formation usually begins with a TATA-binding 
protein (TBP), a subunit of transcription factor TFIID binding to the TATA box. This recruits 
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other TFs and RNA pol II holoenzyme (including a variety of distinct complexes that contain 
the core RNA pol II, SRB/Mediator complex, the chromatin remodeling SWI/SNF complex, 
and general initiation factors TFIIB, TFIIE, TFIIF, and TFIIH) which together form a 
promoter-bound complex (251)  (Figure 1-25).  
 
Figure  1-26: Promoter regions of a gene and transcription machinery 
There are two stages of assembly of the RNA polymerase II transcription complex. 
Transactional activators bind to the activator sequence of the promoter and recruits 
transcription factors TFIID and TFIIA to the TATA box. The combined action of this 
complex recruits the RNA polymerase II holoenzyme, which includes a variety of distinct 
complexes that contain the core RNA pol II, SRB/Mediator complex, the chromatin 
remodeling SWI/SNF complex, and general initiation factors TFIIB, TFIIE, TFIIF, and 
TFIIH. Adapted from Locker (2001). 
  
 
However, a promoter-bound complex alone is not enough to initiate transcription, as another 
cis-regulatory element is required, which is called the enhancer element (245). 
Enhancer elements can be bound with  "enhancer-binding proteins" to activate gene 
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transcription (252). Enhancers can be located upstream, downstream, or within genes they 
control, and they can function in the normal or inverted orientation (249, 250). Enhancer DNA 
sequences bind to regulatory transcription factors, which also have sites that bind to a basal 
transcription apparatus located in the promoter of the gene, and they together 
activate transcription.  
 
1.10.1.4. Landscape regulatory  
Transcription regulation is mediated by “DNA looping”, which is generated by a protein or 
complex of proteins that simultaneously binds to two different sites on the DNA (253). When 
loops form in the DNA structure, proteins that are bound a distance away from the genes they 
control can be brought to the promoter. DNA looping brings promoters, enhancers, 
transcription factors and RNA processing factors together to regulate gene expression, and the 
DNA loop is stabilized by a complex of TFs (Figure 1-27). For example, the bovine 
papillomavirus type 1 (BPV-1) gene requires an enhancer protein E2 to initiate gene 
transcription. However, the BPV-1 promoter has no binding site for this protein, but the 
promoter has a binding site for Spl which interacts with the distance enhancer protein E2 
through DNA looping; this complex in turn initiates gene expression (254). 
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Figure  1-27: Landscape transcriptional regulation 
Schematic showing the transduction of regulatory information from a gene activator protein 
bound to DNA enhancer element to the pol II transcription machinery at a promoter by 
mediator proteins. Adapted from http://bio1151.nicerweb.com/Locked/media/ch18/activat 
or.html   
 
 
 
TFs and chromatin regulators coordinate the regulation of complex transcriptional networks, 
and a selective recruitment of these factors to enhancer elements has an essential role in 
transcription activation (255). Thus, TFs and chromatin regulators are useful tools in 
identifying enhancer elements. Gene expression patterns can be disrupted by perturbation of 
TFs. Variants or mutation in the regulatory DNA element including the promoter and 
enhancer can contribute to disease and changes in trait and then phenotype. GWAS have 
identified trait-associated SNPs, and has been suggested that a genetic variant can contribute 
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to disease and/or traits by affecting gene expression activity. For example, the presence of a 
SNP in an enhancer element may create or disrupt a TF binding site; consequently, enhancer 
activity and target gene expression are changed. For example, GWAS identified a new locus 
Sortilin 1 (SORT1) that is associated with LDL-C and MI. It was found that the rs12740374 
SNP creates enhancer-binding protein for C/EBP transcription factors, which leads to 
increased SORT1 expression levels and reduced LDL-C and VLDL levels (256). The C/EBPα 
is a liver-enriched transcriptional factor that regulates the expression of several hepatic genes 
involved in metabolic processes (257).    
     
1.10.2. Post-transcription: micro-RNA mediated regulation 
In eukaryotes, gene regulation has complex machinery whereby transcription and translation 
are processed in separate compartments, the nucleus and the cytoplasm, respectively. This 
additional level of regulation is called post-transcription regulation, where pre-mRNA is 
processed to produce a mature mRNA. The post-transcriptional process includes capping, 
splicing, addition of a poly (A) tail, RNA editing, export and mRNA stability. Then, when the 
mature mRNA is in the cytoplasm, it is translated into protein. In the post-transcriptional 
stage, a member of a class of non-coding RNAs, termed micro-RNAs (miRNAs), are involved 
in regulating gene expression. 
  
1.10.2.1. Micro-RNA biogenesis 
MiRNAs are small non-coding single strands of RNAs about 22 nucleotides in length. In 
eukaryotes, miRNA biogenesis begins inside the nucleus (Figure 1-28), and then processing 
and maturation take place in the cytoplasm. MiRNAs are transcribed by RNA polymerase II 
as a long primary transcript (pri-miRNAs) characterized by multiple hairpin loop structures. 
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Pri-miRNAs are processed by the enzyme Drosha complex to produce smaller precursor 
molecules of nearly 70-nucleotides (pre-miRNAs). These precursors are then exported to the 
cytoplasm by the Exportin 5/Ran-GTP complex (258). In the cytoplasm, the pre-miRNAs are 
processed by RNAse III Dicer, which generates double-stranded-RNAs called duplex 
miRNA/miRNA of 22-24 nucleotides. The duplex miRNAs are converted to mature single-
stranded miRNAs by the RNA-Induced Silencing Complex (RISC) that creates a large protein 
complex; the complex then interacts with the 3’UTR of the targeted mRNA. Mature miRNAs 
target specific mRNA by Watson-Crick pairing (259, 260), where a complementary level 
between the miRNA ‘seeding region’ and the sequence of 3’UTR of mRNA controls the 
expression. If the complementarity between the 2-7 nucleotide of the miRNA seeding region 
and the 3’UTR is perfect, the mRNA is cleaved by RISC and the mRNA is degraded, whereas 
if the matching is imperfect then translational repression occurs (261). 
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Figure  1-28: miRNA biogenesis 
The synthesis of miRNA begins within the nucleus, where is transcribed by polymerase II to 
pri-miRNA. Then, Drosha enzyme converts the pri-miRNA to pre-miRNA through cleavage. 
Once pre-miRNA is formed, the molecule is exported into the cytoplasm by 5/Ran-GTP 
complex. Through cleavage and the splitting of phosphodiester bonds, a second RNAase III, 
Dicer, converts pre-miRNA to miRNA duplex, which then is processed by RISC to generate 
RISC that is bound to 3’ UTR of the targeted mRNA. Adapted with modification from He and 
Hannon (2004).   
 
 
 
1.10.2.2. Micro-RNA and cholesterol metabolism regulation 
MiRNAs have been identified as post-transcriptional regulators of lipid metabolism related 
genes. MiR-122, for instance, was the first identified miRNA to regulate lipid metabolism. It 
is highly expressed in liver (262) and is associated with plasma cholesterol levels (263, 264), 
where in vivo studies have shown that miR-122 antisense oligonucleotides (ASO) treated mice 
have 25-35% lower levels of LDL-C and HDL (265). Studies showed that the miR-122 
downregulated several genes, some of which, such as Fatty acid synthetase (FASN),  and 
Acetyl-CoA Carboxylase 1 and 2  (ACC1 and ACC2), are involved in fatty acid synthesis and 
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oxidation (265, 266). In addition, miR-122 has indirect impact on targeted gene expression by 
interacting with other miRNAs such as miR-370, where the miR-370 upregulates the 
expression of miR-122 leading to an increased expression of lipogenic genes including Cpt1α 
,SREBP1c and DGAT2 (267).  
   
A variant such as a SNP in either the target gene seeding region or in the miRNA itself could 
disrupt mRNA/miRNA binding, which may affect gene expression and disease phenotype 
(268). Identifying functional miRNA-associated SNPs is challenging because miRNAs 
usually have imperfect complementarity with the target gene (263). The presence of SNPs in 
the target gene seeding region have direct and indirect impact of miRNAs in gene regulation.  
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1.11. Human genome sequence projects 
In time, and with genetic technology improvement, it has become easier, faster and cheaper to 
study the human genome. From the end of last century to date, several projects have been 
published to analyze the human genome, which are having a great influence on human health. 
Here, I highlight some of the human genome related projects.       
  
1.11.1. The Human Genome Project (HGP) 
The human genome project (HGP) is an international, collaborative research program. The HGP 
ran between 1990 and 2003, and had two goals: the mapping of the human genome to help in the 
study of inherited disease and provide scaffold for genome assembly; and the sequencing of the 
human genome to serve as a foundation for future genomic studies. In 2003, the final phase of 
the project reported that the human genome sequence comprises about 2.85 billion nucleotides 
and covered ~ 99% of the euchromatic genome with an error rate of ~1 event per 100,000 bases 
(269). The HGP has had, and continues to have, a great impact on biomedical research. It 
provides the essential foundation data for follow-up genome studies such as HapMap and 
ENCODE. 
 
1.11.2. The HapMap project 
The HapMap project is an international organization aimed to develop a haplotype map 
(HapMap) that describes the common patterns of DNA sequence variation in the human genome 
(https://hapmap.ncbi.nlm.nih.gov/index.html.en) (270). Individuals share approximately 99.5% 
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of their DNA sequence; however, their genome differs at specific nucleotide sites; these sites are 
known SNPs. The HapMap project was interested only in common SNPs that occur in >1% of 
the population. To determine the common patterns of DNA sequence in the human genome, the 
HapMap project used genotype technology to characterize sequence variants, their frequencies, 
and correlations between them, in DNA samples from populations with different ancestry from 
Japan, the United Kingdom, Canada, China, Nigeria, and the United States. HapMap has three 
phases: the complete data obtained in Phase I was published in 2005 (271), the Phase II dataset 
analysis was published in 2007 (272), and the Phase III dataset was released in 2010 (273).  
 
1.11.3. The 1000 genome project 
The 1000 Genomes project was set up in 2008 and final phase data were published in 2015. The 
1000 Genomes project extended the data from the international HapMap project. The goal of the 
1000 Genomes project was to provide the largest public catalogue of human variation and 
genotype and their haplotype contexts. By the end of the project, the genomes of 2,504 
individuals from 26 populations were reconstructed using a combination of low-coverage whole-
genome sequencing, deep exome sequencing, and dense microarray genotyping. It characterized 
over 88 million variants (84.7 million SNPs, 3.6 million short insertions/deletions (indels), and 
60,000 structural variants) (274). The 1000 Genomes Project data can be viewed in Ensembl 
(http://www.ensembl.org/ index.html). 
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1.11.4. The Encyclopedia of DNA Elements (ENCODE) 
In 2003, the ENCODE project was launched as a follow-up project of the HGP to interpret the 
human genome sequence. The human genome has approximately 20,000 genes that encode 
protein, but these genes represent only 1% of genome, while 99% of genome encodes non-gene 
sequences of unknown function. The ENCODE project aimed to identify and locate all of the 
genome's protein-coding genes, non-protein coding genes, and other sequence-based functional 
elements (275). ENCODE has developed methods and performed a large number of sequence-
based studies to map functional elements across the human genome including RNA transcribed 
regions (RNA-seq, CAGE, RNA-PET, and manual annotation), protein-coding regions (mass 
spectrometry), transcriptional factor-binding sites (ChIP-seq and DNase-seq), chromatin 
structure (DNase-seq, formaldehyde assisted isolation of regulatory elements (FAIRE-seq), 
histone ChIP-seq and MNase-seq), and DNA methylation sites (RRBS assay. These have led to 
systematically mapped regions of transcription, transcription factor association, chromatin 
structure, and histone modification (276). ENCODE has reported that 80% of the non-coding 
region of the genome has biochemical functions and the majority of GWAS identified SNPs are 
residing in or near these ENCODE-defined functional regions (277). In fact, the ENCODE 
project has provided a comprehensive catalogue of the structural and functional components 
encoded in the human genome sequence, which has had a great impact in identifying biological 
pathways influenced by variants which led to disease phenotypes.  
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1.11.5. The Genome-Wide Association Study (GWAS) 
To study a Mendelian disorder, family-based linkage analyses are used, where a large family 
with a penetrant phenotype is required (278). Linkage studies are well-powered to detect variants 
with large effects and high penetrance. However, by contrast, a common complex disease is 
caused by a combination of multivariants with small effects as well as environment. Therefore, 
identifying trait or disease associated variants requires a new  experimental regime and a new 
statistical method (279). GWAS is a statistical method that used the success of the international 
HapMap project to annotate the location of millions of the common SNPs and apply an 
association approach in large phenotyped cohorts (case-control study genotype them all with 
SNP-Chip) (279). This method has had a great impact on identifying common disease-associated 
variants that have minor allele frequency (MAF) of more than 5% with small genetic effects 
(278). Figure 1-29 shows the feasibility of identifying genetic variants by risk-allele frequency 
and strength of genetic effect. Since 2007, GWAS has been successful in identifying a huge 
number of genetic variations that contribute to the risk of common and complex diseases such as 
cancer, diabetes, blood pressure, heart disease and mental disorders. In 2012, the Genome-Wide 
Associations published at p≤5X10-8 for 17-trait categories 
http://image.sciencenet.cn/home/093802b 2f182 zmjuuzap84.jpg. 
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Figure  1-29: Feasibility of identifying genetic variants by risk-allele frequency and strength 
of genetic effect  
Schematic showing the relationship between the frequency of susceptible alleles and the strength 
of their phenotypic effect (effect size). Here variants are categorized as common (MAF > 5%), 
low frequency (5% > MAF > 0.05%), and rare (MAF < 0.05%). The severity of the mutation 
(penetrance) can be expressed as the phenotypic effect (effect size) to minor allele carriers and 
can be distributed as high (effect size > 3.0), or low (effect size < 1.1). The causative variants of 
Mendelian inheritance disorders confer a high risk of disease (e.g. FH), most of which are caused 
by rare mutations. By contrast, genetic variants identified by GWASs are mainly common alleles 
that are associated with a low risk of disease. Currently, low-frequency alleles that are associated 
with intermediate levels of risk and rare variants that are associated with a low risk of disease 
can only be identified (whole-genome or targeted) by the resequencing of large cohorts of 
patients. Adapted from Manolio et al. (2009). (280)  
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GWAS have examined the correlation between phenotype and variant genotype in large 
samples of the general population, assuming that individuals of similar phenotype share 
the same risk variant (279). GWAS statistical power is a function of sample size, effect 
size, and causal/marker allele frequency. Thus, large population samples are required to 
detect variants of small effects. In the past few years, GWAS has moved along very 
rapidly. Combined data from different GWASs of large-scale meta-analyses have 
resulted in an impressive number of robustly-replicated associations between common 
variants and specific traits. An example of a large-scale GWAS consortia is the Global 
Lipid Genetic Consortium’s (GLGC) (http://csg.sph.umich.edu/) meta-analysis which has 
identified over 150 human loci associated with lipid levels (161, 281), and 
CARDIoGRAMplusC4D (http://www. cardiogramplusc4d.org/) whose GWAS meta-
analysis has identified >50 risk loci for CVDs (282) 
 
Although GWAS has been a major success in biomedical discovery, there is some 
skepticism regarding its small effect size and the problem of “missing” heritability, 
signals in non-coding regions and linkage disequilibrium (LD). Herein, I discussed some 
of these issues. First, small effect size and missing heritability, the effect sizes (odds 
ratios) of GWAS “hit” SNPs that are small, often less than 1.3, and even in combination 
they explain less than 10% of complex trait heritability (283). Some of this ‘missing 
heritability’ may result from the number of variants that are responsible for the phenotype 
being significantly underestimated, thus there are likely to be many more variants with 
even smaller effect size that need to be discovered. Another possible explanation is that 
GWAS arrays lack the ability to detect structural variants such as insertions, deletions, 
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inversions and copy number variants, which commonly occur in the human genome and 
have strong association with several diseases and/or the arrays miss some loci. There is 
also a possibility that missing heritability arises from rare variants with a large effect size, 
which are undetectable by GWAS SNP arrays (278, 283).  
 
One of the major issues associated with GWAS findings is that the majority of common 
variants (80% or more) have been discovered in non-coding regions, and their functional 
implications are unknown (278, 283). It then became clear that non-coding regions are 
involved in gene regulation, and a variant in these regions could turn the gene OFF or 
ON; however, interpretation of the molecular mechanisms of non-coding variants is a 
huge challenge because of the diversity of non-coding functions, including transcription, 
mRNA splicing and translation (284). Extensive functional studies are needed to identify 
the precise molecular mechanisms of SNPs that associate with a trait or disease. LD is 
another obstacle of the GWAS findings (278, 283). LD is the nonrandom association 
between alleles at different loci because of recombination events at meiosis. On GWAS 
arrays, marker SNPs serve as proxies for much of the surrounding genetic variation with 
which it is inherited. The problem is identifying the true “causal” variant, and how do we 
prove that a particular variant causes the observed phenotype, when all SNPs in the LD 
with the functional SNP may carry some or all of the association with the trait of interest, 
although they have no relevant function?. This requires substantial biological research.   
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1.11.6. The Genotype-Tissue Expression (GTEx) project  
GWASs have identified common SNPs in thousands of loci that are associated with 
common diseases, however, the majority of common variants have been discovered in 
non-coding regions, and the mechanism underlying disease susceptibility remains 
unknown (278, 283). It is suggested that such common variants can influence gene 
expression through alterations in splicing, non-coding RNA expression and RNA 
stability. The Genotype-Tissue Expression (GTEx) project aimed to create a reference 
catalogue for genetic variant and gene expression association in multiple reference 
human tissues (285, 286). The GTEx project is a powerful tool for interpreting GWAS 
findings, and provides data and resources about expression quantitative trait loci (eQTL) 
in a wide range of tissues of relevance to many diseases. 
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Chapter 2 : Materials and Methods 
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2.1. Materials 
2.1.1. Reagent/stock/kit: 
Table  2-1: Reagent/stock/kit list 
 
Reagent/stock/kit suppliers Contents 
ABI PRISM ® 384 well clear optical 
reaction plate with barcode  
Applied Biosystems/ Life 
Technologies 
Cat No 4309849 
50 plates 
ACC65I 
New England BioLab Inc 
Cat No R0599L 
10,000 units 
 
AccuMelt HRM SuperMix (2x)  Quanta Biosciences  
AccuStain kit 
NanoEnTek Inc 
 Cat No: ADR-1000 
12.5 ml AccuStain solution T,  
and 4 12.5 ml AccuStain solution N  
Acrylamide to Bisacrylamide 
Stabilized Solution40% (W/V)19:1 
National diagnostic , USA 
Cat No EC-850 
1L 
Agarose gel (1.2% (w/v)) In house  
1.2g agarose, 10ml 10X Tris-Borate-
EDTA (TBE) buffer with 0.01μl 
ethidium-bromide dye (EtBr); 90 ml 
dH2O 
Agarose gel loading buffer (6X) In house 
10mM Tris-HCL(PH7.6),0.03% 
Bromophenol Blue, 0.03% Xylene 
Cyanol CFF, 60% glycerol 
(C3H8O3), 60mM 
Ethylenediaminetetraacetic acid 
(EDTA) 
Ammonium Persulphate (APS)  
Sigma-Aldrich 
Cat No A3678   
100g 
Ampicillin D-(−)-α-
Aminobenzylpenicillin sodium salt 
Sigma-Aldrich 
Cat No A9518-25G 
25 g 
Annealing buffer (10X) In house  
200 mM Tris pH 7.6, 100mM 
MgCl2, 500mM NaCl 
ANXA2 rs17191344 TaqMan® SNP 
Genotyping Assay (40X) 
Applied Biosystems 
Cat No  4351379 
188ul 
ANXA2 rs17845226 TaqMan® SNP 
Genotyping Assay (40X) 
Applied Biosystems 
Cat No 4351379  
625ul 
Bacto Agar 
 
BD Diagnostics, Maryland, USA 
Cat NO 214010  
454g 
BamH I 
New England BioLab Inc Cat No 
R0136S 
10,000 units 
 
Biotin-11-dUTP 
 
Ferments Life Science 
 Cat No R0081-50 nmol 
To get a 5μM stock (=5pmol/μl) 
dilute 1:200 in 10mM Tris-HCl pH 
7.6, 1mM EDTA 
Bovine Serum Albumin (BSA) 
Sigma 
Cat No B4287-1G 
Heat shock fraction, protease free, 
suitable for hybridization, pH 7, 
≥98%  
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Bromophenol Blue 0.04% 
Sigma-Aldrich 
Cat No 318744 
500ml 
calf intestinal alkaline phosphatase 
(CIAP)  
Invitrogen, Life Technologies,  
Cat No 18009-027 
1 U/µL 
Chloroform 
AnalaR NORMAPUR® ACS 
analytical reagent 
VWR, UK 
Cat No 22711.324 
2.5 L 
CL-XPosure Film, 7 x 9.5in. (18 x 
24cm) 
Thermo Scientific 
Cat No 34089 
100 films 
DH5α‎cell 
New England BioLab Inc Cat No 
C2988J 
Lot No 0291305 
NEB 5-alpha Competent E. coli 
(Subcloning Efficiency) 
Dulbecco's Modified Eagle medium 
Code:E15-810 
LotE81013-1793 
DMEM with 4.5g/L glucose and L-
Glutamine (500ml) 
Eagle's Minimum Essential Medium 
(EMEM) 
Sigma 
Cat No M4655 
500ml 
EMSA Annealing Buffer  (10X)  In house 
200 mM Tris pH 7.6 
100 mM MgCl2 
500 mM NaCl 
EMSA Pre-loading dye In house 
200 µl of 2X Binding buffer, 8 µl 
BSA, 66.6 µl 6X dye, 125.4 µl 
dH2O 
EMSA, 2X Binding buffer  In house 
16% ficol, 40mM HEPES, 100mM 
KCl, 2mM EDTA, and 1mM DTT 
Ethidium-bromide dye (EtBr) 
10mg/ml 
Invitrogen, Life Technologies, 
Carisbad, California, USA 
Cat No 15585011  
10ml 
Ethylenediaminetetraacetic acid 
(EDTA) 
Cat No AM9262 1L 
Ficol 
Pharmacia Biotech 
Cat No 237655 
Ficol®400 
Foetal bovin serum (FBS) 
Gibco, Life Technologies  
Cat No 10499044 
500ml 
GenElute™‎HP‎Plasmid‎Maxiprep‎
Kit 
Sigma  
Cat No NA0310-1kt 
25 preps 
Glucose 
D(+)-Glucose anhydrous, Certified 
AR for analysis, meets analytical 
specification of Ph.Eur., BP, USP 
Fisher Scientific 
Cat No 10141520 
500g  
glycerol (C3H8O3)  
Glycerol, 99.5%, for molecular 
biology, DNAse, RNAse and 
Protease free 
Fisher Scientific 
Cat No 10692372 
 
1 L 
HepG2 cell line 
European Collection of 
Cell Cultures  
Cat No: 85011430. 
1 tube 
High Capacity RNA to cDNA Kit 
Applied Biosystems 
Cat No 4387406 
50 rxn 
HindIII 
New England BioLab Inc Cat 
R0104S 
10,000 units 
 
Huh7 cell line  
Health Protection Agency culture 
collections  
Cat No: 01042712 
1 tube  
Hybond-N+ membrane   
VWR, UK 
Cat No RPN203B 
20Cmx3M 
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Illustrs GFX PCR DNA and gel 
band purification kit 
GE Healthcare  
Cat No 28-9034-70 
100 purifications 
In-Fusion® HD Cloning Kit 
Clontech Laboratories, Inc 
Calfornia, USA 
Cat No 638918 
100 rxns 
Isoamyl alcohol 
Fisher Scientific 
Cat No 10680311 
500 ml 
KAPA 2Xmastermix 
KAPA Bioscience 
Cat No KK4604 
5ml 
Klear Kall 2x mastermix 
K Bioscience 
Cat No KBS-1002-003 
2.5ml 
LightShift™‎Chemiluminescent‎
EMSA Kit EMSA Kit 
Thermo Scientific  
Cat No PI-20148 
- 
Lipofectamine™‎2000 
Invitrogen, Life Technologies, 
Carisbad, Calfornia, USA 
Cat No: 11668-019 
1.5ml 
Luciferase Reporter Assay System 
Promega 
Lot No 0000078853 
- 
Luria Broth (LB) In house 
2.5g of Tryptone powder, 1.25g of 
Yeast, 2.5g of NaCl, 0.5g of 
Glucose, 2.50μl of 5mol NaOH, and 
250ml dH2O 
Luria Broth (LB) /ampicillin agar In house 
2.5g of Tryptone powder, 1.25g of 
Yeast, 2.5g of NaCl, 0.5g of 
Glucose, 2.50μl of 5mol NaOH, 
3.75g of Agar , 250ml dH2O, and 
250μl of 100mg/ml ampicillin) 
MgCl2 
BDH- Biochemical  
Lot No TA753889 
50µm/µl 
mirVanaª miRNA Mimic miR-1 
Positive Control 
Applied Biosystems 
Cat No 4464062 
5nmol 
mirVana™‎miRNA‎mimic‎(hsa-
miR-155-3p) 
Life Technologies 
Cat No 4464066 (MC12634) 
5nmol 
mirVana™‎miRNA‎Mimic‎Negative‎
Control #1 
Applied Biosystems 
Cat No 4464058 
5nmol 
N,N,N′,N′-
Tetramethylethylenediamine 
(TEMED) 
BOH Electron 
Cat No 54824214.742 
100ml 
Nuclei extract buffer A In house 
10mM HEPES (pH 7.9), 1.5mM 
MgCl2, and  10mM KCl 
Nuclei extract buffer C In house  
20mM HEPES (pH 7.9), 25% v/v 
glycerol, 0.42M NaCl, 1.5mM 
MgCl2, and  0.2mM EDTA   
Opti-MEM® Medium 
Gibco, Life Technologies, 
Carisbad, Calfornia, USA 
 Cat No: 31985-062 
100ml  
Oragene•DNA‎(OG-500) kit  DNAgenoTek, Ottawa, ON, 
Canada 
Cat No: (OG-500) 
2ml 
Paraffin  
BDH 
Cat No 29436511 
20 L 
pGL3- Basic Vector  
Promega, Madison, Wisconsin, 
USA,  
Cat No E1751 
20µg 
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pGL3- Promoter Vector  
Promega, Madison, Wisconsin, 
USA,  
Cat No E1761 
20µg 
pGL3-Control Vector  
Promega, Madison, Wisconsin, 
USA,  
Cat No E1741 
20µg 
pGL3-Enhancer Vector 
Promega, Madison, Wisconsin, 
USA,  
Cat No E1771 
20µg 
Phosphate-buffered saline  (PBS) 
Gibco 
Cat No: 18912014 
100 tablets 
Phusion®High-Fidelity PCR Kit 
New England BioLab Inc  
Cat No E0553L 
- 
Plus DNA ladder (1Kb) 
Thermo Fisher Scientific 
Cat No 10787-026 
- 
Poly(deoxyinosinic-deoxycytidylic) 
acid sodium salt 
Qiagen 
 Cat No 338162 
1µg/µl 
Poly(deoxyinosinic-deoxycytidylic) 
acid sodium salt (poly dI.dC) 
Sigma Aldrich 
Cat No 118578-37-3  
1µg/µl 
Potassium chloride (KCl) 
AnalaR BDH Limited 
Poole England  
Cat No 1019 
Lot No 512542H 
- 
prepIT®•L2P‎reagent‎ DNAgenoTek, Ottawa, ON, 
Canada 
Cat No: PT-L2P-5 
0.5mL 
pRL-TK 
Promega, Madison, Wisconsin, 
USA 
Cat No:E2241 
20µg 
Protease inhibitor cocktail (100X) Sigma Cat No P8340 1ml 
puc 18 plasmid 
New England Biolabs, Ipswich, 
Ma, USA 
 Cat No: 78410 
20µg 
QIAamp DNA Mini Kits 
QIAGEN 
Cat No 51306 
50 QIAamp 
QIAprep Spin Miniprep Ki 
QIAGEN 
Cat No 27104 
50 QIAprep  
QuikChange Lighting Site-Directed 
Mutagenesis Kit 
Agilent Technologies 
Cat No 210519 
30 reactions 
Rabbit monoclonal [EPR17362] to 
GATA1 
Abcam , Cambridge, UK 
Cat No:  ab181544 
10µl 
Rabbit monoclonal [EPR17874] to 
GATA2 + GATA3 
Abcam , Cambridge, UK 
Cat No: ab182747  
10µl 
Rabbit monoclonal [EPR5014(2)] to 
Egr1 
Abcam , Cambridge, UK 
Cat No:  ab133695 
10µl 
Rabbit monoclonal [EPR7313] to 
CTCF 
Abcam , Cambridge, UK 
Cat No: ab128909  
100µl 
SalI 
New England BioLab Inc 
Cat No R0138L 
10,000 units 
 
siPORT™‎NeoFX™‎Transfection‎
Agent with Manual 
Applied Biosystems 
Cat No AM4510Μ 
400ul 
Sodium  chloride (NaCl) 
Fisher Scientific  
Cat No 117128 
- 
 90 
Sodium Acetate (NaAc)  
AnalaR BDH Limited 
Cat No 100192-416 
3 M-pH5.2 
100ml 
 Sodium Hydroxide (NaOH) 
Sigma-ALDRICH  
Cat No BCBH 9037V 
- 
SSC 20X In house 
175.32g NaCl + 88.23g Na3Citrate 
 → in 1L dH2O 
T4 DNA ligation 
New England BioLab Inc  
Cat No M0202S 
20,000 units 
TaqMan Expression assay: UBC  
Applied Biosystems 
Cat No 4331182 
250 rxn 
TaqMan Gene Expression assay 
ANXA2 (50RXN/150PCR runs) 
Hs00743063_s1  
Applied Biosystems 
Cat No 4331182 
250 rxn 
TaqMan miRNA Expression assay : 
GAPDH 
Applied Biosystems 
Cat No 4331182 
250 rxn 
TaqMan miRNA Expression assay : 
hsa-miR-155-3p or miR-155* 
Applied Biosystems 
Cat No 4427975  
50RXN/150PCR runs 
TaqMan miRNA Expression assay : 
hsa-miR-155-5p  
Applied Biosystems  
Cat No 4427975 
50RXN/150PCR runs 
TaqMan Universal Master Mix II-
no UNG 
Applied Biosystems 
 Cat No 4440040 
5ml 
TaqMan® MicroRNA Assays: 
RNU6B   
Applied Biosystems 
Cat No 4427975 (001093) 
50RXN/150PCR runs 
TaqMan® MicroRNA Reverse 
Transcription Kit, 200 rxn 
Applied Biosystems 
Cat No PN 4366596 
200 rxn 
TaqMan® Universal PCR Master 
Mix, No AmpErase® UNG, 1-Pack 
(1 x 5 mL) 
Applied Biosystems 
Cat No PN 4324018 
200 rxn 
Tris Base 
Fisher Scientific  
Cat No 117128 
- 
Tris- Borate -EDTA (TBE) 1X 
Fisher BioReagents 
Cat No BP2430-4 
5L 
Tris-HCL 
Fisher Scientific  
Cat No BP153-1 
1Kg 
TRIzol reagent  
Thermo Fisher scientific 
(Ambion™) 
Cat No 15596026 
100ml 
Tropix TF microplate 
96 well Assay plate, no lid,flat 
bottom,non-treated,non-sterile, 
white polystyrene 
Appleton Woods 
Cat No CC704 
25/pack 
TruSeq Custom Amplicon (TSCA) 
v1.5 kit  
Illumina, San Diego, CA 
Cat No:  FC-130-1001 
96 samples 
Trypsin-EDTA solution 
Sigma 
Cat No T4049-100ML 
0.25% Trypsin-EDTA 
100mL 
Tryptone powder 
Oxoid 
 Cat No LP043B 
500g 
Ultra pure agarose  
Invitrogen, Life Technologies,  
Cat No 16500-500 
500g 
Whatman paper 
GE Healthcare life Sciences  
 Cat No: 3030-700 
Grade 3MM Chr Blotting Paper, roll, 
23 cm × 100 m 
3MM Chr cellulose blotting sheets 
X-gal 
Fisher Scientific  
Cat No 10234923 
- 
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Yeast Extract Powder 
Oxoid 
Cat No LP0021B 
500g 
β-Gal fixation solution In house 
100 µl 10XPBS, 50 µl Formalin 
(40%formaldehyde Sol), 2 µl 
Glutaraldehyde, 850 µl dH2O 
β-Gal staining solution In house 
100 µl 10XPBS, 2µl MgCl2 1M, 100 
µl potassium Ferricyanide 
(50mM),100 µl potassium 
Ferrocyanide (50mM), 
 700 µl dH2O 
β-Galactosidase‎‎(β-Gal) 
Promega, Madison, Wisconsin, 
USA,  
Cat No:E1081 
20µg 
  
 
Figure ‎2-1: pGL3 Vectors circle maps 
 
A) The pGL3-Basic Vector lacks eukaryotic promoter and enhancer sequences, allowing 
maximum flexibility in cloning putative regulatory sequences. Expression of luciferase activity 
in cells transfected with this plasmid depends on insertion of a functional promoter upstream 
from luc+. Potential enhancer elements can also be inserted upstream of the promoter or in the 
BamHI or SalI sites downstream of the luc+ gene. B) The pGL3-Enhancer Vector contains an 
SV40 enhancer located downstream of luc+ and a poly (A) signal. This aids in the verification of 
functional promoter elements because the presence of an enhancer will often result in 
transcription of luc+ at higher levels. C) The pGL3-Promoter Vector contains an SV40 
promoter upstream of the luciferase gene. DNA fragments containing putative enhancer elements 
can be inserted either upstream or downstream of the promoter-luc+ transcriptional unit. D) The 
pGL3-Control Vector contains SV40 promoter and enhancer sequences, resulting in strong 
expression of luc+ in many types of mammalian cells. This plasmid is useful in monitoring 
transfection efficiency, in general, and is a convenient internal standard for promoter and 
enhancer activities expressed by pGL3 recombinants. luc+ = cDNA encoding the modified 
firefly luciferase; Ampr = gene conferring ampicillin resistance in E. coli; f1 ori = origin of 
replication derived from filamentous phage; ori = origin of plasmid replication in E. coli. Arrows 
within luc+ and the Ampr gene indicate the direction of transcription; the arrow in f1 ori 
indicates the direction of ssDNA strand synthesis. Adopted from 
https://www.promega.co.uk/resources/vector-sequences/reporter-vectors/pgl3-luciferase-
reporter-vectors/ 
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A) pGL3-Basic‎Vector 
B)‎pGL3-Enhancer‎Vector 
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C)‎pGL3-Promoter‎Vector 
D)‎pGL3-Control‎Vector 
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2.1.2. Equipment:  
Table  2-2: Equipment 
 
Equipment Company  
BioRad C1000
Tm 
Thermocycler  
7900HT fast Real-Time PCR System Applied Biosystems 
Syngene Gel Documentation system and Genesnap 
software version 6.04   
Syngene 
Syngene G:BOX Documentation system  Syngene 
NanoDrop 8000  
Thermo Scientific, ThermoFisher Scientific, 
USA 
Advanced Detection and Accurate Measurement 
(ADAM) cell counter  
Digital Bio 
Maxi Electrophoresis Modular Systems (code CS2221) Appleton Woods 
UV Stratalinker 2400  Stratagene 
X-ray film developer  Photon imaging system 
Rotor-Gene6000  Qiagen Ltd, Crawley, West Sussex, UK 
2.1.3. Websites: 
Table  2-3: Websites 
 
Database URL 
International HapMap 
project 
http://www.hapmap.org 
UCSC Genome Browser http://genome.ucsc.edu/ 
Ensembl http://www.ensembl.org/ 
HaploReg http://www.broadinstitute.org/mammals/haploreg/haploreg.php 
MatInspector http://www.genomatix.de/matinspector.html 
miRWalk http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/ 
MirSNP http://cmbi.bjmu.edu.cn/mirsnp 
miRanda http://www.microrna.org/ 
PolyPhen 2 http://genetics.bwh. harvard.edu/pph2/ 
SIFT http://sift.jcvi.org/ 
STRING http://string-db.org/ 
Applied-Biosystems http://www.thermofisher.com/uk/en/home/brands/applied-biosystems.html 
R version 3.2.0 http://www.R-project.org/. 
GTEx portal  http://www.gtexportal.org/home/ 
Gene network  http://genenetwork.nl/bloodeqtlbrowser/ 
GE Healthcare/ Life Sciences https://www.gelifesciences.com 
Source Bioscience Life 
Sciences  
http:// www.lifesciences. sourcebioscience.com/genomic-services/saner-
sequencing-service.aspx 
CLUSTALW sequence 
alignments   
http://www.genome.jp/tools/clustalw/ 
In-Fusion primers convert http://bioinfo.clontech.com/infusion/convertPcrPrimersInit.do 
Primer3 design program 
version 4.0  
http://primer3.ut.ee/  
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2.2. Bioinformatics tools  
I used several bioinformatics databases that helped me to annotate genes and SNPs of interest as 
well as annotating protein interaction. 
  
2.2.1. Genomic annotations 
International HapMap project: HapMap Genome Browser release #28 
( http://www.hapmap.org) was chosen to identify gene FASTA sequence (287). The gene name 
or SNP ID number was typed into the search box and the standard search parameters were kept 
and the ‘Download Decorated FASTA File’ Report & Analysis function was selected to view 
results.  
 
 University of California Santa Cruz (UCSC) Genome Browser: The UCSC Human Genome 
Browser (http://genome.ucsc.edu/) was chosen to annotate genes and SNPs, regulatory domains 
and regulatory features, including transcribed regions and sequences that interact with protein, 
RNA and other regions of the genome to affect gene activation and chromatin structure (288). 
The gene name or SNP rs number was typed into the search box. The regulation track was 
regulated by specifying the cell line in all sub-tracks including regulation from ENCODE tracks 
where transcription factor criteria were selected, ENCODE open chromatin by DNaseI HS and 
FAIRE tracks, ENCODE transcription factor binding tracks, and HMR conserved transcription 
factor binding sites (CTFBS). When all tracks were optimized, the data were submitted to view 
the results. This bioinformatics tool also was used to identify the transcription factor binding 
sites (TFBS) domain within the gene sequence by selecting the view option from the main menu, 
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then DNA and extended DNA, and case/color options were configured to enable discrimination 
of TFBS from the whole sequence.  
 
Ensembl: The Ensembl project (http://www.ensembl.org/) was chosen because it facilitates 
genome annotation by providing links to gene view, transcript view, protein view, and variation 
view. These pages contain additional information about the gene or a region of the gene (289).   
The gene name or SNP rs number was typed into the search box and then the annotation of 
interest was selected. Menus provided the ability to select specific annotations for display. 
 
2.2.2. Tools for annotating the non-coding genome 
HaploReg: HaploReg (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) is a tool 
that was used for annotations of the non-coding genome at variants on haplotype blocks, such as 
candidate regulatory SNPs at disease-associated loci. This tool uses LD information from the 
1000 Genomes project, LD SNPs along with their predicted chromatin state, their sequence 
conservation across mammals, and their effect on gene regulation such as promoter and enhancer 
related histone marks, DNase hypersensitivity, binding proteins and altered transcription factor 
motifs (290). The SNP rs number was typed into the search box and the standard parameters 
were kept to view the results. 
 
MatInspector: MatInspector software (http://www.genomatix.de/matinspector.html) was 
utilized to predict transcription factor binding sites in specific DNA sequences in silico (291). 
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Consensus FASTA sequences were selected from the Ensembl Human Genome Browser and 
manually copied into the MatInspector tool. The software uses a large library of matrix 
descriptions for transcription factor binding sites, locating matches within the FASTA sequence 
and assigns a quality rating to each match. I selected each FASTA sequence to include either the 
common or the rare variant of a SNP of interest, to assess whether there is a possibility of 
differential TFBs between alleles. The parameters selected for tests were as follows: sequence 
added manually using ‘your sequence’ function, Homo sapiens option selected for ‘search 
corresponding promoters’ and ‘Transcription Factor Binding (weight matrices)’ selected for the 
library option.  
   
2.2.3. Tools for annotating‎3’UTR‎and‎miRNAs predicting binding sites 
Several miRSearch tools are available online, which are designed to identify miRNAs that target 
specific gene transcripts. In my thesis I used computational prediction methods to predicate 
miRNA target. Several predication algorithms were used for this purpose.  
 
miRWalk  
miRWalk is an algorithm search for seeds based on Watson–Crick complementarity. It is 
walking on the complete sequence of a gene searching for a heptamer (seven nucleotides) seed, 
and as soon as it identifies a heptamer with perfect base-pairing, it immediately extends the 
length of the miRNA seed until a mismatch arises (292). The miRWalk database provides 
predicted and validated information on miRNA-target interaction (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/). 
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For predicted miRNA-target interaction, the “gene miRNA target” option was selected, human 
gene Ensembl ID was entered (ANXA2: ENSG00000182718). In addition, a compression tool 
was used, two other popular miRSearch databases, miRanda and Targetscan, were selected, then 
the search was run. MiRWalk provided a table of putative miRNA binding site predictions 
within the 3’UTR region. The table showed information on miRNA-target interaction including 
the starting position of miRNA seeding, seeding length, seed start, end position, and p-value. 
Also, miRWalk provided a table of a comparative platform of miRNA binding site predictions 
with the 3’UTR region resulting from different algorithms (miRWalk, miRanda and Targetscan). 
These algorithms are used for seeding the complementarity method. 
 
Moreover, miRWalk provides experimentally verified miRNA-target interactions. For this the 
“validated target module” option was selected from the main menu, then the “gene miRNA 
target” option was selected, and human gene Ensembl ID was entered (ANXA2: 
ENSG00000182718), and then the search was run. The output data showed validated gene-
miRNA interactions.  
 
 MirSNP  
MirSNP is a collection of human SNPs at predicted miRNA-mRNA binding sites (293) and is 
publicly available online (http://cmbi.bjmu.edu.cn/mirsnp). The MirSNP algorithm was used to 
predict miRNA: ANXA2 3’UTR SNP seed match. The gene name was typed in the single search 
box and the search was run. The output data showed the gene name, the miRNA name, the SNP 
ID, the mirSVR score of a binding site, the considered alleles for each SNP, the predicted score 
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of miRNA-mRNA binding by miRanda software (the higher the score, the more stable the 
binding), the free energy of the miRNA-mRNA duplex, and the conservation (phastCons score). 
An example of a miRNA-related SNP search results is shown in Figure (2-2).  
 
Figure  2-2: An example of miRNA-related SNP search results using the MirSNP algorithm 
The figure shows the MirSNP output data.  The G-allele of the ANXA2 SNP rs184828726 may 
promote the binding of the ANXA2 gene and hsa-mir-4305, and where the interaction is stable 
(mirSVR= -0.249), leads to produce free energy (-12.52), and is conserved. However, the C-
allele of the SNP prevents the interaction between the mature miRNA and the ANXA2 gene.  
 
 
 
MiRanda  
MiRanda software is freely available and facilitates evaluation of predicted targets and design of 
experiments. It provides both high-scoring targets as strong candidates for validation 
experiments, and lower-scoring targets which may have a role in gene regulation. In addition to 
expression information for miRNAs and mRNAs, target sites are ranking by complementarity 
and evolutionary conservation (294).   
 
At the home page (http://www.microrna.org/) the target mRNA was typed (ANXA2) in the 
search box, species type was selected (Homo sapiens), and the search was run. For miRNA-
ANXA2 alignment, all miRNA target sites with all mirSVR score options were selected. The 
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output data showed a road map of ANXA2-3’URT with both validated and predicted miRNA 
target sites. Simply click on the miRNA mature name to visualize the miRNA-ANXA2 
complementary alignment.   
   
2.2.4. Tools for annotating the coding genome 
PolyPhen 2: The Polymorphism Phenotyping V2 (PolyPhen 2) software (http://genetics.bwh. 
harvard.edu/pph2/) was used to predict the possible impact of missense mutations on the stability 
and function of human proteins using eight sequence-based and three structure-based predictive 
features (295). A protein sequence in FASTA format was entered and amino acid substitutions 
were specified.   
 
SIFT: The Sorting Intolerant From Tolerant (SIFT) algorithm (http://sift.jcvi.org/) was used to 
predict whether an amino acid substitution affects protein function (296). The SIFT/PROVEAN 
Human SNP database was selected and input format was used as recommended. 
 
Mutation Taster2: This is the other in silico tool (http://www.mutationtaster.org/) (297) that 
was used to estimate the impact of the variant on the gene product / protein. Ensembl transcript 
ID of gene of interest was used as input format (starting with ENST). 
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2.2.5. Protein annotation 
STRING: The STRING database (http://string-db.org/ ) version 9.1 was used to identify protein-
protein networks (298). A protein name was typed into the search box, then the Homo sapiens 
option selected. 
 
2.3. Population background 
Genotype-phenotype analysis was performed on several studies. A general overview of these 
studies is given below.  
The Second-Northwick-Park Heart Study (NPHSII)  
The NPHSII consists of 3,052 healthy middle-aged men (50–61 years) who were recruited in 
1989 from nine general medical practices in the UK (299). Information on lifestyle habits, 
height, weight, blood pressure, and family history of CHD was recorded at baseline and on 
subsequent prospective follow-up (300). Exclusion criteria were as follows: participants with 
unstable angina, history of MI, evidence of silent infarcts, coronary surgery, anti-coagulant 
drugs (including aspirin), cerebrovascular disease, malignancy and any other condition or 
disease preventing the attainment of written, informed consent or long-term follow-up. 
Participants did not fast for the study, but they had been instructed to avoid heavy meals to 
ensure that triglyceride concentration and clotting factors influenced by plasma lipids would be 
neither atypically low (fasting) nor high (heavy lipemia) at examination.  
 
DNA was obtained from 2,778 of the men at the time of recruitment. Interviews and repeat 
measurements were conducted annually for surviving participants. CHD end points up to 15 
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years follow-up were as follows: (1) acute CHD events: sudden coronary death, fatal acute MI, 
and nonfatal acute MI, the clinical history, ECGs, cardiac enzymes, and pathology were 
assessed by independent review according to the World Health Organization criteria (1976) (71) 
and normal limits for cardiac enzymes were those for the reporting laboratory; (2) a new major 
Q wave on an ECG after 5 years of follow-up (87); and (3) surgery for angina pectoris with 
CHD angiographically demonstrated (301). Further details about recruitment, measurement, 
follow-up and incident disease definition have been described elsewhere (5, 299, 302, 303).  
 
Whitehall II study (WHII) 
The WHII is a cohort study of 10,308 UK participants (3,413 women and 6,895 men) recruited 
between 1985 and 1989 from 20 London-based Civil service departments for consideration to 
participate in a study that investigated the effect of socioeconomic differences in health and 
mortality. The participants were invited to the research clinic at 5-year intervals (1985-2009). 
The study has 9 phases; only phases 1, 3, 5 and 7 included both medical and non-medical 
examinations. Details of the WH-II cohort profile have been described elsewhere (304). Blood 
samples for DNA were collected from more than 6,000 participants. They attended the clinics in 
a fasting state, had blood drawn, drank a standard glucose load, and had blood drawn again 
precisely two hours later—a mammoth undertaking. This blood sample collection method was 
performed at the Phase 3 (5-year examination), repeated at Phase 5 (10-year examination), and 
again at Phase 7 (15 years) (305). Standard assays for plasma lipids were carried out as 
described (306). LDL-C concentration was calculated with the Friedewald formula (LDL-C 
(mmol/L) = TC – HDL-C – TG/2.2). Details of the design, participants, and lipid measurements 
have been described in Talmud et al. (2009).  
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The UCL-LSHTM-Edinburgh-Bristol (UCLEB) consortium  
The UCLEB consortium was established to allow interrogation of genetic associations of risk 
factors for CVD through Metabochip-wide association analyses, as well as associations with 
measures of subclinical disease such as carotid intima media thickness (cIMT), and with clinical 
events (307). The consortium consists of 30,000 participants from 12 well-established UK 
studies (participants are almost exclusively of European ancestry): NPHS II, WHII, British 
Regional Heart Study (BRHS), English Longitudinal Study of Ageing (ELSA), MRC National 
Survey of Health and Development (MRC NSHD), 1958 Birth Cohort (1958BC), Edinburgh 
Artery Study (EAS), Edinburgh Type 2 Diabetes Study (ET2DS), Edinburgh Heart Disease 
Prevention Study (EHDPS), Aspirin for Asymptomatic Atherosclerosis Trial (AAAT), 
Caerphilly Prospective Study (CaPS) and the British Women’s Heart and Health Study 
(BWHHS).  
 
Around 21,000 individuals across the cohorts have been typed using Metabochip, a genotyping 
platform consisting of 200,000 SNPs, which cover loci identified by GWAS in cardiometabolic 
diseases, and rare variants from the 1000 Genomes project (307).  Also, the study extended 
coverage from 200,000 SNPs to approximately 1 million SNPs by imputation of data from 1000 
Genomes project when the r
2
 is >0.8. The principle of imputation is that by exploiting patterns of 
LD within populations, the genotypes of unobserved sites can be inferred. Details of the 
consortium have been described in Shah et al. (2013).  
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2.4. TaqMan Genotyping 
Each Applied Biosystems® TaqMan® SNP Genotyping Assay (40X) contains sequence-
specific forward and reverse primers to amplify a polymorphic sequence of interest, and two 
TaqMan minor groove binder (MGB) probes. The TaqMan® MGB Probes consist of target-
specific oligonucleotides with a fluorescence reporter dye at the 5´ end of each probe; one 
probe labeled with VIC® dye detects the allele 1 sequence, and the other probe labeled with 
FAM™ dye detects the allele 2 sequences. The presence of VIC dye fluorescence indicates 
homozygosity for allele 1, while the presence of FAM dye fluorescence indicates 
homozygosity for allele 2. The presence of both dyes in a reaction allows genotyping of the 
two possible variant alleles (heterozygosity) at the SNP site. The 3´ end of the MGB probe 
has a non-fluorescent quencher (NFQ). 
 
For a TaqMan genotyping reaction, 5ng of genomic DNA was pipetted into a barcoded 384 
well polymerase chain reaction (PCR) plate (Applied Biosystems/ Life Technology) using 
Biomek 2000 laboratory automation workstation. Then the plate was centrifuged at 3000rpm 
for 1 minute, followed by air-drying for 24 hours at room temperature. Each plate contained 
at least two no template control (NTC) wells. 
 
The genotyping reaction was carried out as per the genotyping mastermix manufacturer’s 
instructions. Two genotyping mastermixes were used; Klear Kall 2x mastermix and KAPA 
mastermix (Fast qPCR kits 2x Master mix), the ROX passive reference was supplemented 
with the Klear Kall 2x mastermix kit; while the ROX passive reference was added to the 
KAPA mix as recommended by the manufacturers. Components of both mastermix reactions 
are shown in Table 2-4. In both cases, 2µl of the reaction mix was added to each well. The 
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plate was then centrifuged at 3000rpm for 1 minute and the PCR reaction carried out using 
the BioRad C1000
Tm 
Thermocycler. The standard PCR reaction conditions were as follows; 
started at 50
0
C for 2 minutes, then 95
0
C for 10 minutes to activate DNA polymerase followed 
by 40 cycles of denaturing at 92
0
C for 15 seconds and annealing/extending at 60
0
C for 1 
minute.  
 
 
Table  2-4: Master Mix reaction for TaqMan genotyping (384 well PCR plate) 
 
 KAPA Klear Kall 
Sigma Water 
(Molecular Biology Reagent) 
384 389.5 
2x Master mix 410 410 
ROX 426.4 - 
X40 SNP 20.5 20.5 
 
 
Each PCR reaction had several phases: when genomic DNA is introduced into a reaction 
mixture consisting of TaqMan genotyping mastermix, forward and reverse primers and two 
TaqMan MGB probes, each TaqMan MGB probe anneals specifically to a complementary 
sequence between the forward and reverse primer sites. When the probe is intact, cleavage 
separates the reporter dye from the quencher dye, increasing fluorescence by the reporter, 
while the proximity of the quencher dye to the reporter dye suppresses the reporter 
fluorescence. The increase in fluorescence occurs only if the amplified target sequence is 
complementary to the probe. Thus, the fluorescence signal generated by PCR amplification 
indicates which alleles are in the sample (Figure 2-3). 
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Figure  2-3: A cartoon of the process of TaqMan assay genotyping during PCR. 
Adapted from http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/ 
general documents/cms_042998.pdf  
 
 
 
TaqMan signal detection 
Fluorescence was detected using 7900HT fast Real-Time PCR System with Sequence 
Detection System (SDS) V2.4 software (http://tools.lifetechnologies.com/content/ 
sfs/manuals/cms042114. pdf). Standard allelic discrimination was carried out using SDS 
software which induced an automatic cutoff signal detector. When the PCR plate was inserted 
into the 7900HT fast Real-Time PCR system, the standard allelic discrimination program 
assigned genotypes automatically to a plate coordinate in a text output file and in the form of 
an allelic discrimination plot based on the fluorescence signal detection. The light source 
from the cycler excites the reporter dyes by fluorescence resonance energy transfer. VIC and 
FAM have significantly different excitation and mission wavelengths, which allows them to 
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be differentially detected. Each dot on the scatter plot from results is shown in Figure 2-4. 
Undefined samples are represented by ‘X’. These samples did not reach the cut-off 
fluorescence signal level (95%) to be defined as a particular genotype. 
 
 
Figure  2-4: Allelic discrimination plot 
This plot represents the results of genotyping ANXA2 SNP rs17845226 C>A. Samples with 
significant VIC signal are called homozygous for common allele C (red cluster). Samples 
with significant FAM signal are called homozygous for common allele A (blue cluster). A 
sample with an even distribution of VIC and FAM signals is called heterozygous (green 
cluster). Any sample that has not reached the cut-off signal level for any group is indicated by 
‘X’.  
 
 
 
 
 
 
 
 
 
 
CC 
A
A
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2.4. 1. Genotype - phenotype association statistical analyses  
Using an in-house spreadsheet template, the MAF [MAF= (2XN11) + N12)/N total], the Hardy–
Weinberg equilibrium (HWE) (Chi-square test [ 𝑥2 = ∑
(𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑣𝑎𝑙𝑢𝑒−𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒)2
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒
 ], 
frequency = p
2
+ 2pq + q
2
 = 1). P-value significance cut-off of 0.05 was used to determine 
whether the genotypes were in HWE.  
Table  2-5: Two-allele polymorphism genotype statistical analysis: Hardy–Weinberg 
equilibrium  
The table shows an example of Hardy–Weinberg equilibrium assessment output in the NPHS-II 
study for the ANXA2 SNP rs17845226. Observed genotype (O), Expected genotype (E), major 
allele homozygote (11), heterozygote (12), minor allele homozygote (22). 
 
 
Stats for a 2-allele polymorphism: rs17845226 
  Observed 
 
  
  rs17845226 rs17845226 rs17845226     
Genotypes 11 12 22 Total   
Frequency 1889 570 31 2490   
  
    
  
  p q p+q 
 
  
  0.873 0.127 1 
 
  
  
    
  
  Expected 
 
  
  rs17845226 rs17845226 rs17845226     
Genotypes 11 12 22 Total   
Frequency 1898.1 551.8 40.1 2490   
  
    
  
  Chi^2 test and level of significance 
  O E (O-E)^2/e Chi^2 Sig level 
 
1889 1898.1 0.0 
 
  
  570 551.8 0.6 
 
  
  31 40.1 2.1 
 
  
  
   
2.711 0.0997 
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To assess the association between SNP genotype and lipid trait and CHD risk, statistical analyses 
were performed on several studies, which were conducted using R version 3.2.0 (Dr. Jon White) 
and STATA data analysis and statistical software (Ms. Jackie Cooper).  
 
The LDLR SNP rs6511720 was genotyped in the UCLEB consortium  (307), meta-analyses and 
statistical analyses was carried out by Dr. Jon White. Patient levels of LDL-C and TC were first 
adjusted to take account of the individual’s cholesterol lowering drug status (LDL-C * 1.352; TC 
* 1.271). The adjusted values were further adjusted to take account of the fixed effect of the 
study. Patient adjusted lipid measurements were then partitioned according to patient gender and 
genotype. The patient genotype was represented as number of copies of the minor allele (0, 1, 
and 2 (additive model)). The levels of LDL-C and TC data were normally disrupted and mean 
and standard deviation (SD) were determined. The per allele effect was estimated using a linear 
model in terms of effect size (ES) and 95% confidence intervals (95% CI). The per allele effect 
of the SNP on CHD risk was estimated in a logistic regression in terms of Odds Ratio (OR) and 
95% CI.  
 
The ANXA2 SNPs rs17845226 and rs17191344 were genotyped in NPHSII, and statistical 
analysis was carried out by Ms. Jackie Cooper. To determine the relationships between SNP 
genotype and the continuous variables (plasma lipid levels) under selected genotypic models, a 
summary measure for each group was generated based on data distributions. For normal 
distributed data, mean and SD was calculated. For skewed data, the median and inter-quartile 
range (IQR) was calculated. In highly skewed distribution data, a log transformation was 
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performed in order to make data normally distributed. To test the hypothesis a one-way ANOVA 
was used for either an additive or recessive model. To determine whether a patient’s risk of 
having CHD as a health outcome is increased or decreased by the presence of exposure (SNP 
genotype), the Cox proportional hazards models or the logistic regression models were used. In 
cohort studies, the Cox proportional hazards models were used to estimate hazard ratios (HR) 
and 95% CI to determine how many times more likely the exposed group (specific SNP 
genotype) was to develop CHD than the unexposed group. Stepwise models were used to 
determine which of the combined genotype groups (1-9) of the rs17191344 and rs17845226 
SNPs were having an effect on lipids and CHD. The groups were fitted using 8 dummy 
variables.  Models used forward selection with a significance level of 5%. 
 
Meta-analyses and statistical analyses were carried out on the ANXA2 SNPs rs11633032, 
rs12900101, and 116255697 by Dr. Jon White, using the R statistical software. The ANXA2 
SNPs rs11633032, rs12900101, were inputted into the UCLEB consortium (307) r
2
= 0.60 to 
0.65. Studies included in this analysis were: MRC1946, WH-II, ET2DS, ELSA, EAS, CAPS, 
BRHS, and BWHHS. The genotypes were phased using MACH1 http://csg.sph.umich. 
edu//abecasis/MaCH/tour/imputation.html, and missing SNPs were imputed using the 1000G 
Europeans as a reference haplotype population (308) (Minimac software was used: 
http://genome.sph.umich.edu/wiki/Minimac): the imputation strategy has been described in 
Howiw et al. (2012). For imputed genotypes, a probabilistic model is used which can be 
expressed either in terms of the probabilities of the three genotypes: P (homozygous minor 
allele), P (heterozygous), P (homozygous major allele) or as the “dose” of a stated allele. “Dose” 
is given by 2*P (homozygous for allele) + P (Heterozygous), when the probabilities are 1 or 0; it 
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gives three possible genotypes 0, 1, 2 which correspond to the additive model. In the case of 
imputed genotypes, the genotypes include non-integer values in the range 0-2.  A recessive 
genotypic model was used in the ANXA2 SNPs statistical analyses, thus imputed genotype data 
were converted to the recessive model. The patient genotype was represented as a binary 
character, the imputed dose <= 1.5 was called the genotype 0 (heterozygotes+homozygous major 
allele) otherwise, the genotype was set to 1 (homozygous minor allele genotype). Patients’ lipid 
levels were first adjusted to take account of age, sex, the fixed effect of the study and genotype, 
then lipid measurements were partitioned according to patient genotype. The per-allele effect on 
the continuous variable was estimated using a linear model, where the variables were log-
transformed before analysis due to skewed distribution. A p-value ≤0.05 was considered as 
significant.   
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2.5. Gene expression: the expression quantitative trait loci (eQTL) 
The eQTL applies a direct association between genetic variation and gene expression levels of 
mRNA. Genetic studies of gene expression have identified thousands of eQTLs in different 
tissue types for the majority of human genes. The eQTL catalogue provides an important 
resource for identifying the functional impact of human genetic variation. In my project, I used 
three data sets as shown below.   
 
GTEx portal  
The Genotype-Tissue Expression (GTEx) project is a public resource database.  It provides data 
and resources on eQTLs in a wide range of tissues of relevance to many diseases (309). On the 
home page (http://www.gtexportal.org/home/) under the gene association section, the Test your 
own SNP option was selected in order to find the association between SNPs and the tissue of 
interest. In the text entry box, the SNP ID, gene name, and tissue name were typed; the data 
output showed eQTL box plot, effect size, standard error, and p-value. In addition, Dr. Claudia 
Giambartolomei provided further analysis for ANXA2 intergenic SNPs in tissues of interest from 
unpublished data.   
      
The Advanced Study of Aortic Pathology (ASAP)  
The ASAP uses the gene expression level quantification method to identify cardiovascular and 
metabolic associated-SNPs in relevant tissues including liver, aorta (medial and adventitial 
portions), mammary artery, and carotid plaque. Full description of the study is found in 
Folkersen et al. (2010). The ASAP study’s statistical analyses of microarray expression data was 
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carried out by Dr. Per Eriksson and Dr. Lasse Folkersen (the Karolinska Institute, Stockholm, 
Sweden) using R version 2.2.3. (310). Genotypes for relevant SNPs were extracted and re-coded 
according to a linear additive model encoding genotypes numerically (0, 1, 2). Association with 
gene expression levels was then calculated with linear regression and the log2 transformed gene 
expression levels, using the lm function in R. Calculations were performed with or without 
gender as covariate on all samples or gender-specific samples as indicated. 
  
 
eQTL meta-analysis in blood for lipid-regulatory and immune-mediated disease variants 
Westra et al. (2013) established a data set, which is a large blood eQTL meta-analysis for lipid-
regulatory and immune-mediated disease variants. This data set is available online 
(http://genenetwork.nl/bloodeqtlbrowser/). On the home page, the SNP ID was typed in the 
search box.   
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2.6. DNA amplification and purification 
The Phusion
®
High-Fidelity PCR Kit was used to amplify DNA fragments of interest. DNA 
fragment primers were designed using Primer3 design program version 4.0 (http:// 
primer3.ut.ee/) and are listed in Table 2-6. The PCR reaction and conditions are shown in Tables 
2-7 and 2-8, respectively.  
 
To amplify the ANXA2 rs12900101 DNA fragment, the nested PCR approach was used. Nested 
PCR involves two sets of primers, used in two sequential runs of PCR, the second set intended to 
amplify a secondary target within the first run product.   
 
Table  2-6: DNA fragment primers 
DNA Fragment primer Sequence 
Fragment 
size 
WT LDLR promoter 
Forward 5’-TTTGGAATAACAATGTAAAAACAATAT3’ 
594 bp 
Reverse 5’-CAGCCGCTGCAGGCAGTGTC3’ 
LDLR rs6511720 
Forward 5’- GCCACTCAGTTTTACAAAAGAAA -3’ 
883bp 
Reverse 5’- TTGA TCAGTGCTTCTTTCCAA -3’ 
LDLR rs141787760 + 
rs60173709  
Forward 5’- TGACTGGATGGAGAGCTTTGA -3’ 
643bp 
Reverse 5’- GCTTGCGGTTCAGATTCCAA -3’ 
LDLR rs57217136 
Forward 5’-TGATCTGCCCAAAAGTGCTG -3’ 
814bp 
Reverse 5’-TGAAGATCTCGGCTGCAGAC -3’ 
ANXA2 Promoter 
Forward 5’-TTTTCGCTCTTGTTGCCCAG-3’ 
1323 bp 
Reverse 5’-GTTGGTCTCAGCAACTAGGC-3’ 
ANXA2 rs11633032 
Forward 5’-TGTGTGCTCTTTGGTTCAAGG-3’ 
585 bp 
Reverse 5’-CTACTTGGGAGGCTGAGGTG 
ANXA2 rs12900101 
Nested PCR 
Forward 5’-GGAGACCTCAGGATCATGGC-3’ 
2012 bp 
Reverse 5’-CCGCTTTTCCTTTGCTCTCA-3’ 
ANXA2 rs12900101 
target 
Forward 5’- CCATGGTCTTAGGCAGCTCT -3’ 
369 bp 
Reverse 5’- GTGGGTGCACAGAAGTCAAG -3’ 
ANXA2 rs17191344 
Forward 5’-AACCACTTCAGAGGCGATCA3’ 
767bp 
Reverse 5’-AGGCACTCACCCAAAGAAGT3’ 
ANXA2 rs116928563 
Forward 5’- GCTGCCCCTGATGCTTATTT3’ 
409bp 
Reverse 5’- GTACTTTGTGGCCCTGCTTT3’ 
ANXA2 rs17845226 
Forward 5’- AAGCGTCATACTGAGCAGGT3’ 
253bp 
Reverse 5’- GGGTCTGTTGAAGGGAATGC3’ 
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Table  2-7: The Phusion
®
High-Fidelity PCR reaction 
 
 Component 20 μl‎reaction Final concentration 
Nuclease –free water  10.5 μl - 
5X Phusion GC buffer 4 μl 1X 
10mM dNTPs 0.4 μl 200 mM 
10 𝛍𝐌 Forward primer 1 μl 0.5 mM 
10 𝛍𝐌 Reverse primer 1 μl 0.5 mM 
70ng Template DNA  2 μl <250ng 
DMSO 0.6 μl 3% 
Phusion DNA polymerase 0.2 μl 0.4 units/20 μl  PCR 
 
 
Table  2-8: The Phusion
®
High-Fidelity PCR conditions 
 
Cycle step Cycle Temperature Time 
Initial Denaturation  1 98
o
C 30 seconds 
Denaturation 
Annealing 
Extension 
30 98
o
C 
45-72
o
C 
72
o
C 
10 seconds 
30 seconds 
30 seconds  
Final Extension 1 72
o
C 10 minutes 
Hold 1 4
o
C 10 minutes 
 
 
Agarose gel was commonly used either to confirm DNA size or to purify the PCR product. A 
standard 1.2% (w/v) agarose gel (Table 2-1) was used for showing products in the range of 500 
bp-1kb. The agarose and water were added together and heated in a microwave on medium 
power for 3 minutes. Then, the TBE/EtBr was added to the agarose mix, which was poured into a 
pre-assembled module after it had cooled for a few minutes. A comb was used to form wells and 
it was left at room temperature for 30 minutes to solidify.  
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Usually, 3μl of 6X agarose gel loading buffer (Table 2-1) was added to 10μl of PCR product. 
Five microliters of 1Kb Plus DNA ladder was loaded into the well of each gel in order to 
determine fragment size. Gel electrophoresis was carried out in 1X TBE buffer at 120V for 45-
60 minutes or longer until loading buffer had moved down two-thirds of the gel. Gels were 
analysed and photographed under UV illumination using the Syngene Gel Documentation 
system and Genesnap software version 6.04 or Syngene G:BOX Documentation system. For 
optimal gel image viewing, the standard parameters were maintained with brightness and zoom 
for each gel.    
 
To purify a DNA fragment from the gel, the DNA bands were visualized in darkness using a UV 
light transilluminator and then were cut out of the gel and kept in individual micro-centrifuge 
tubes. The DNA gel bands were purified using the Illustra GFX PCR DNA and gel band 
purification kit 
(https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/13147744436 
72/litdoc28951562AA_20110831111511.pdf). Five-hundred microliters of capture buffer type 3 
was added to the gel slice, mixed by inversion and incubated at 60°C for 15–30 minutes until the 
agarose was completely dissolved. Once the agarose had completely dissolved and the capture 
buffer sample mix was yellow or pale orange in color, the mix was centrifuged briefly to collect 
the supernatant. Then, the supernatant was transferred into the assembled GFX MicroSpin 
column and collection tube, incubated at room temperature for 1 minute, spun at 16000×g for 1 
minute and the flow through discarded. Then 500µl of wash buffer type 1 was added to the GFX 
MicroSpin column, spun at 16000×g for 1 minute, and the GFX MicroSpin column was 
transferred to a fresh DNase-free 1.5ml micro-centrifuge tube. Finally, 10–50µl of Nuclease–free 
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water was added to the center of the membrane in the assembled GFX MicroSpin column and 
sample collection tube, incubated at room temperature for 1 minute, and spun at 16000×g for 1 
minute to recover the purified DNA. The DNA concentration was measured using a NanoDrop 
8000. The purified DNA was kept at 4°C for short-term storage and -20°C for long-term storage  
 
The standard Sanger sequencing (in the forward and reverse direction) was used as the 
confirmational method. The service is provided by Source Bioscience Life Sciences. The primers 
used in sequencing are listed in Table 2-2 in addition to pGL3 3’UTR and pGL3 3’UTR primers 
(listed in Table 2-9)  
Table  2-9: Sanger sequencing primers  
 
pGL3 3’UTR 
sense primer 5’-TCAGGTTCAGGGGGAGGT-3’ 
antisense primer 5 ́-GACGATAGTCATGCCCCGCG-3 ́ 
pGL3  
Forward 5´-CTAGCAAAATAGGCTGTCCC-3´ 
Reverse  5´-CTTTATGTTTTTGGCGTCTTCCA-3´ 
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2.7. Cell culture 
Two human liver hepatocellular carcinoma cell lines, Huh7and HepG2 were used. The Huh7 cell 
line was cultured in Dulbecco's Modified Eagle’s Medium (DMEM with 4.5g/L glucose and L-
Glutamine) supplemented with 10% fetal bovine serum (FBS), while the HepG2 cell line was 
cultured in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% FBS and 
0.5% essential amino acids. The cells were cultured and maintained in a 5% CO2 humidified 
atmosphere at 37°C. The cells were grown to a confluence of about 80-90%.  
 
To passage cells, the monolayer was briefly rinsed with warm 1x phosphate-buffered saline 
(PBS), and then pre-warmed (37°C) 0.05% Trypsin-EDTA solution was added and the mix 
incubated for 2-3 minutes in a 5% CO2 humidified atmosphere at 37°C. When the cells detached 
from the flask surface, 12ml of complete growth medium with 10% FBS was added, and 
transferred to 15ml Falcon tubes.  
 
Cell viability was estimated on an Advanced Detection and Accurate Measurement (ADAM) cell 
counter. Twenty microliters of cells were added to each of two micro-centrifuge tubes, followed 
by adding an equal volume of AccuStain Solution T to the first tube for total cell counting, and 
20μl AccuStain Solution N to the second tube for non-viable cell counting. Both tubes were 
incubated at room temperature for 2 minutes, then 15μl of each mix was added to a designated 
place in a chip, which was then inserted in the ADAM cell counter.   
 
 119 
DNA purification from cell cultured cells 
QIAamp DNA Mini Kits was used to purify DNA from the cultured cells.  In a 175T flask, cells 
were grown in a monolayer to 90-95% confluence, detached from the culture flask by 
trypsinization. A quantity of 5x10
6 
cells was transferred to a 1.5ml micro-centrifuge tube, 
centrifuged for 5 minutes at 300xg, and the supernatant removed completely without disturbing 
the cell pellet. Then, the cell pellet was re-suspended in PBS to a final volume of 200µl. Twenty 
microliters of QIAGEN Proteinase K and 200µl Buffer Al were added to the sample and mixed 
by pulse-vortexing, incubated at 56°C for 10 minutes, and briefly centrifuged. Then 200µl 100% 
ethanol was added to the sample, vortexed for 15 seconds, and briefly centrifuged. Then, the 
mixture was applied to the QIAamp Spin Column, centrifuged at 6000xg for 1 min. The QIAamp 
Spin Column was placed in a clean 2ml collection tube, 500µl Buffer AW1 was added, and 
centrifuged at 6000 x g for 1 minute.  The QIAamp Spin Column was placed in a new clean 2 ml 
collection tube, 500µl Buffer AW2 was added and centrifuged at 6000xg for 3 minutes. Finally, 
The QIAamp Spin Column was placed in a clean 1.5 ml micro-centrifuge, 200µl dH2O was 
added, incubated at room temperature for 1 minute, and then centrifuged at 6000xg for 1 minute. 
 
The DNA was ready for downstream experiments including PCR amplification and sequencing. 
This method was used to confirm ANXA2 rs116928563 genotype in the Huh7 cell line (Chapter 
6), where DNA was purified from Huh7 cells and then sequenced.  
                                                      .
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2.8. Reporter gene expression assay 
A Dual Luciferase assay was used to study eukaryotic gene expression by determining whether 
different genotypes affect luciferase expression (https://www.promega. co.uk/~/media/Files/ 
Resources/Protocols/Technical%20Manuals/0/Dual%20Luciferase%20Reporter%20Assay% 
20System%20Protocol.pdf). A DNA fragment that contained the SNP of interest was inserted 
into a pGL3-basic vector or pGL3-promoter vector (vector construct is shown in Figure 2-1). 
Dual reporter refers to using two reporter enzymes: experimental and co-transfected reporters, 
the latter of which is used as an internal control. This system helps to normalize the activity of 
the experimental reporter to the activity of the internal control, which minimizes experimental 
variability caused by differences in cell viability or transfection efficiency. The pRL-TK vector 
was used as the co-transfected reporter. The pRL-TK vector contains a cDNA (Rluc) encoding 
Renilla luciferase and a herpes simplex virus thymidine kinase (HSV-TK) promoter to provide 
low to moderate levels of firefly luciferase expression in co-transfected mammalian cells.  
 
2.8.1 Cloning 
2.8.1.1.  Preparation of pGL3-basic vector and DNA fragments for cloning 
For cloning, the In-Fusion® HD Cloning Kit was used. This system requires 15bp overlap 
between DNA fragment and vector. To achieve this, DNA fragment primers were modified to 
have a 15bp overlap with the vector.  
 
Primer modification 
The DNA fragments end was modified using synthetic linkers, by a PCR amplification using 
primers containing sites for appropriate restriction enzymes and vector. To convert PCR Primers 
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into In-Fusion® primers, the bioinformatics website was used to design the fusion primers 
(http://bioinfo.clontech.com/infusion/convertPcrPrimersInit.do). The following criteria were 
considered for designing the In-Fusion PCR primers: A) the 5’ end of the primer must contain 15 
bases that are homologous to 15 bases at one end of the vector; and B) the 3’ end of the primer 
must contain a sequence that is specific to the target gene, between 18–25 bases in length, and 
have a Guanine-Cytosine content between 40–60%, and a melting temperature (Tm) between 58 
and 65°C. The Tm difference between the forward and reverse primers should be ≤ 4°C, and the 
last five nucleotides at the 3’ end of each primer should not contain more than two guanines (G) 
or cytosines (C).  
 
When In-Fusion® primers were designed, the pGL3-basic vector or pGL3-promoter vector and 
appropriate restriction enzymes were selected from the primer designing program menu. The 
primers that were used to amplify DNA fragments of interest are listed in Table  2-10. DNA 
fragments were amplified using the Phusion
®
High-Fidelity PCR kit and were followed by DNA 
purification as described previously. 
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Table  2-10: In-fusion primers sequence to amplify a target from human genome DNA 
The restriction enzymes site is highlighted in yellow and the vector site highlighted in green.  
 
 
polymorphism Enzyme Vector type Orientation Primer sequence PCR 
product size 
WT LDLR promoter ACC65I 
HindIII 
pGL3-basic Forward 5’- TCTATCGATAGGTACCTTTGGAATAACAATGTAAAAACAATAT -3’ 594bp 
Reverse 5’- CCGGAATGCCAAGCTTCAGCCGCTGCAGGCAGTGTC -3’ 
LDLR rs6511720 
T allele 
BamH I 
and Sal I 
pGL3-basic + 
LDLR 
promoter 
Forward 5’- AAATCGATAAGGATCCTGCCACTCAGTTTTACAAAAGAAA -3’ 883bp 
Reverse 5’- AAGGGCATCGGTCGACTTGA TCAGTGCTTCTTTCCAA -3’ 
LDLR rs141787760 C 
allele + rs60173709 T 
allele 
BamH I 
and Sal I 
pGL3-basic + 
LDLR 
promoter 
Forward 5’- AAATCGATAAGGATCCTGACTGGATGGAGAGCTTTGA -3’ 643bp 
Reverse 5’- AAGGGCATCGGTCGACGCTTGCGGTTCAGATTCCAA -3’ 
LDLR rs57217136 T 
allele 
 
BamH I 
and Sal I 
pGL3-basic + 
LDLR 
promoter 
Forward 5’-AAATCGATAAGGATCCTGATCTGCCCAAAAGTGCTG -3’ 814bp 
Reverse 5’-AAGGGCATCGGTCGACTGAAGATCTCGGCTGCAGAC -3’ 
ANXA2 rs11633032 G 
allele 
BamH I 
and Sal I 
pGL3-
promoter 
Forward 5’-AAATCGATAAGGATCCTGTGTGCTCTTTGGTTCAAGG-3’ 585bp 
Reverse 5’-AAGGGCATCGGTCGACCACCTCAGCCTCCCAAGTAG-3’ 
ANXA2 rs12900101 C 
allele 
BamH I 
and Sal I 
pGL3-
promoter 
Forward 5’-AAATCGATAAGGATCCCCATGGTCTTAGGCAGCTCT-3’ 369bp 
Reverse 5’-AAGGGCATCGGTCGACGTGGGTGCACAGAAGTCAAG-3’ 
ANXA2 rs17191344  A 
allele 
Sal I pGL3-
promoter 
Forward 5’-ATAAGGATCCGTCGACAACCACTTCAGAGGCGATCA-3’ 767bp 
Reverse 5’-AAGGGCATCGGTCGACAGGCACTCACCCAAAGAAGT-3’ 
ANXA2 rs116928563 
T allele  
BamH I 
and Sal I 
pGL3-basic Forward 5’- AAATCGATAAGGATCCGCTGCCCCTGATGCTTATTT-3’ 409bp 
Reverse 5’- AAGGGCATCGGTCGACGTACTTTGTGGCCCTGCTTT-3’ 
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PGL3 vector digestion  
The pGL3-basic vector or the pGL3-promoter was digested with restriction enzymes that will 
generate compatible ends for cloning. One microgram of plasmid DNA, 2.5μl of restriction 
enzyme A, 2.5μl of restriction enzyme B, and 5μl of 10X buffer 3 were added in a 50μl total 
reaction volume. The reaction was incubated in a water bath for 3 hours at 37
0
C. Then, the 
vector digestion confirmation was performed using gel electrophoresis and followed by DNA 
purification as described previously. 
 
2.8.1.2. Ligation  
To ligate the compatible ‘Sticky’ ends of the linearized vector polylinker site and amplified 
DNA fragment, the In-fusion® HD cloning kit was used.  For each fragment, the reaction was 
set up according to Table 2-11; volumes of vector and inserted DNA were varied according to 
their concentration after gel band purification. Each 10μl total reaction mix was set up and 
gently pipetted up and down, briefly centrifuged and incubated at 50
0
C for 15 minutes and 
then the ligation mixture was placed on ice. 
 
Table  2-11: In-fusion ligation reaction 
 
Reagent Volume‎(μl) 
5× In-Fusion HD Enzyme Premix  2μl 
Linearized vector   To 50-100 ng 
DNA fragment  To 10-50 ng 
dH2O  To 10μl 
Total  10μl 
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2.8.1.3. Transforming vector/insert complex into NEB 5-alpha competent 
cells 
The ligation mix was transformed into NEB 5-alpha competent E.coli cells (DH5α) to 
maintain the vector/insert complex. An amount of 2.5µl of ligation product was transformed 
to 50µl of DH5α using the heat shock method. This was achieved by incubating the 
transformation mixture on ice for 30 minutes, then in a water bath at 42
0
C for 1 minute, and 
immediately incubated for 2 minutes on ice.  
 
To grow the transformed cells, 500µl of warmed Luria Broth (LB) bacterial culture medium 
(Table 2-1) was added to the transformed cells and incubated at 37
0
C for 1 hour on a 220rpm 
shaker. After an hour, the cells were plated onto an LB/ampicillin agar plate (Table 2-1) and 
incubated at 37
0
C overnight. Since homologous recombination is restored on the second day, 
only corrected cells survive in a medium containing ampicillin. 
  
2.8.1.4. Plasmid DNA purification  
2.8.1.4.1. Mini-prep plasmid purification 
One colony was picked from the agar plate and grown in 5ml LB/ampicillin medium (Table 2-
1) at 37
0
C overnight on a 220rpm shaker. The plasmid DNA was purified using QIAprep Spin 
Miniprep Kit (http://www.qiagen.com/Products/ Catalog/Sample-technologies/DNA-Sample-
Technologies/Plasmid-DNA/QIAprep-Spin-Miniprep-kit#resources).Fifteen-hundred 
microliters of bacterial cells were transferred to 2ml micro-centrifuge and centrifuged for 2 
minutes at 13,000rpm. Then, the bacterial cell pellet was re-suspended in 250μl Buffer P1, 
vortexed briefly. Two-hundred and fifty microliters of Buffer P2 was added and mixed by 
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inverting the tube 4–6 times. Three-hundred and fifty microliters of Buffer N3 was added and 
mixed immediately by inverting the tube 4–6 times, centrifuged for 10 minutes at 13,000rpm. 
Then the supernatant was applied to the QIAprep spin column, centrifuged for 30–60 seconds, 
and the flow-through discarded. Next the QIAprep spin column was washed by adding 500μl 
Buffer PB, centrifuged for 30–60 seconds, and the flow-through discarded. The QIAprep spin 
column was washed again using 750μl Buffer PE, centrifuged for 30–60 seconds, the flow-
through discarded, and the spin column centrifuged for an additional 1 minute to remove 
residual wash buffer. Finally, the QIAprep column was transferred into a clean 1.5ml micro-
centrifuge tube, and 20-30μl dH2O was added to the centre of each QIAprep spin column to 
elute DNA, incubated at room temperature for 1 min, and centrifuged for 1 minute. Then, the 
sample underwent plasmid DNA screening in order to confirm the generated pDNA construct 
had the fragment of interest.  
 
2.8.1.4.2. Plasmid DNA screening 
For clone screening, the purified plasmid DNA construct was digested to confirm DNA 
fragment size for vector and fragments. The diagnostic digestion reaction required 2µl of 
DNA, 0.5µl of each restriction enzyme that was used in the In-fusion protocol, 1µl of 10X 
buffer 3, and dH2O  to a total volume of 10µl. The diagnostic digest reaction was incubated in 
a water bath for 2 hours at 37
0
C. After that, the digested product underwent gel 
electrophoresis as described earlier.  
 
In addition, standard Sanger sequencing (in the forward and reverse direction) was used as the 
second confirmational method. The pDNA samples were prepared for sequencing as 
recommended by the service provider. The sequencing primers used pGL3 3’UTR (Table 2-
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5).  All sequencing results were analyzed manually on FinchTV (Geospiza Inc), and aligned 
with a reference sequence using multiple sequence alignment by CLUSTALW 
(http://www.genome.jp/tools/clustalw/). After the fragment sequence had been confirmed, the 
bacterial glycerol stock was made to store the plasmid for long-term by adding 0.5 ml of 
culture to 0.5 ml of glycerol (50%) and stored at -80
0
C for future experiments. 
 
2.8.1.4.3. Maxi-prep plasmid purification 
When the cloned sequence was confirmed, 15-20μl of mini-prep bacterial cell product was 
plated onto a LB/ampicillin agar plate and incubated at 37
0
C overnight, then one colony was 
picked from the agar plate and inoculated into 150ml LB/ampicillin medium and incubated at 
37
0
C overnight on a 220rpm shaker. Then, bacterial cells were harvested and DNA purified 
using the GenElute™ HP Plasmid Maxiprep Kit. The bench protocol was performed as 
recommended by the manufacturer (http://www.sigmaaldrich.com/content/dam/sigma-aldrich 
/docs/Sigma/Bulletin/2/na0200bul.pdf). First, the column was prepared by adding 12ml of 
column preparation solution to the column and allowing it to pass through. Second, a filter 
syringe was prepared by removing the plunger and placing the barrel in an upright position. 
Third, the pDNA purification process was performed using 150ml of an overnight culture 
pelleted at 5740rpm for 10 minutes and the supernatant discarded. Then, the cells were re-
suspended in 12 ml of Resuspension/RNase Solution and vortexed. Twelve milliliters of lysis 
solution was added, the tube was gently inverted 6–8 times to mix, and incubated at room 
temperature for 3-5 minutes. Twelve milliliters of neutralization solution was added to the 
lysed cells that were gently inverted 6–8 times to mix. Then 9ml of binding solution was 
added and gently inverted 1–2 times to mix. Immediately, the mix was added to the barrel of 
the filter syringe and was let to sit for 5 minutes. The filter syringe was held over the column 
and the mix gently inserted to expel the cleared lysate, then centrifuged at 15000rpm for 2 
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minutes, and the flow-through discarded. Twelve milliliters of wash solution 1 was added to 
the column, centrifuged at 15000rpm for 2 minutes, the flow-through discarded. Then, 12 ml 
of wash solution 2 was added to the column, centrifuged at 15000rpm for 5 minutes, and the 
flow-through discarded.  Finally, the column was transferred to a new collection tube, where 3 
ml of Elution Solution was added to the binding column, and then the column/collection tube 
unit was centrifuged in a swinging bucket rotor at 15000rpm for 5 minutes.  
 
For pDNA precipitation, 300µl of 3M NaAc (pH=6.5) and 2.2ml of isopropanol were added 
in a tube, mixed, and incubated at -20
0
C for overnight. The mix was centrifuged at 15000 rpm 
for 45 minutes, and the isopropanol mix discarded. Then, 2ml of 70% ethanol was added to 
the pellet, centrifuged at 15000rpm for 20 minutes, the ethanol discarded, and the pellet air-
dried for 15 minutes. The pDNA pellet was re-suspended in 150-200µl dH2O. The pDNA 
construct was saved at 4
0
C for short-term storage and at -20
0
C for long-term storage.   
   
2.8.2. Site-Directed Mutagenesis   
To create variants, a site-directed mutagenesis (SDM) was performed using QuikChange 
Lightning Site-Directed Mutagenesis Kit. The SDM primers were designed (Table 2-12) and 
bench protocol was performed as recommended by the manufacturer (http://pef.aibn. 
uq.edu.au/wordpress/wp-content/blogs.dir/1/files/Support/MolecularCloning/Manuals/Quik 
Change_Lightning_SDM.pdf). The SDM reaction was prepared as shown in Table 2-13, and 
the reaction mix overlaid with paraffin. The SDM reaction underwent PCR according to the 
conditions shown in Table 2-14. When the PCR was completed, 2μl of the Dpn I restriction 
enzyme was directly added to amplification reaction, the reaction mixture was mixed by 
pipetting the solution up and down several times, spun down briefly and immediately 
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incubated at 37°C for 5 minutes to digest the parental supercoiled pDNA (the non-mutated). 
At the same time, 2μl of β-mercaptoethanol was added to 45μl of XL10-Gold ultracompetent 
cells, spun briefly, and the cells were incubated on ice for 10 minutes. Next, 2μl of the Dpn I-
treated DNA was transferred to the ultracompetent cells, spun briefly, and the reaction was 
incubated on ice for 30 minutes, placed in a water-bath at 42
o
C for 30 seconds, and on ice for 
2 minutes. Finally, the SDM mixture was added to 500μl of warmed LB medium and was left 
for 1 hour at 37
o
C on a shaker; then the total cell mixture was plated onto LB/Ampicillin agar. 
On the next day, a colony was collected and plasmid purification was performed as described 
previously.    
Table  2-12: The QuikChange Lightning Site-Directed Mutagenesis (SDM) primer 
sequences  
 
SNP ID Primer Sequence 
LDLR rs6511720 
 G allele 
Forward 5'-CCAATCAACCTCTTAAGAGAAAATGTTAAGGAAGTCCTTAGG-3' 
Reverse   5'- CCTAAGACTTCCTTAACATTTTCTCTTAAGAGGTTGATTGG-3' 
LDLR 
rs141787760 
C allele deletion 
Forward 5'-GAGCCACCGCGCCCACCGGGGA-3'  
Reverse   5'-TCCCCGGTGGGCGCGGTGGCTC-3'  
LDLR 
rs60173709   
T allele deletion  
Forward 5'-GTAACTAACACACCAGTTCCTCTGGGAGGCCA-3'  
Reverse   5'-TGGCCTCCCAGAGGAACTGGTGTGTTAGTTAC-3'  
LDLR 
rs57217136 
 T allele  
Forward 5'-CATTGGGTGTAGTCCAACAGGCCACCCTCG-3'  
Reverse   5'-CGAGGGTGGCCTGTTGGACTACACCCAATG-3'  
LDLR 
rs57217136 
 G allele deletion  
Forward 5'-CATTGGGTGTAGTCCAACAGGCCACCCTCG-3'  
Reverse   5'-CGAGGGTGGCCTGTTGGACTACACCCAATG-3'  
ANXA2 
rs11633032  
 A allele 
Forward 5'-TGCCCTTCGCTTGCTGTCTGAGCTGCTTC-3' 
Reverse   5'-GAAGCAGCTCAGACAGCAAGCGAAGGGCA-3' 
ANXA2 
rs12900101  
G allele 
Forward 5'-CACAGTGCCCCTCCTGGGGCACTGC-3' 
Reverse   5'-GCAGTGCCCCAGGAGGGGCACTGTG-3' 
ANXA2 
rs17191344   
G allele 
Forward 5'-GACTCCTCCACGACGGCCCTGCTCTCA-3' 
Reverse   5'-TGAGAGCAGGGCCGTCGTGGAGGAGTC-3' 
ANXA2 
rs116928563  
A allele  
Forward 5'-TGAGGCTGTCCCTGTTGGAAGAAAGCTCTGG-3' 
Reverse   5'-CCAGAGCTTTCTTCCAACAGGGACAGCCTCA-3' 
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Table  2-13: The QuikChange Lightning SDM reaction 
 
Reagent Volume 
10x reaction buffer 2.5 μl 
400ng of template pDNA 1.5 μl 
100ng For SDM primer 1.5 μl 
100ng Rev SDM primer 1.5 μl 
dNTP mix 0.5 μl 
QuikSolution 0.75 μl 
dH2O 16.25 μl 
QuikChange Lightning Enzyme 0.5 μl 
Total 25 μl 
 
Table  2-14: The QuikChange Lightning SDM PCR conditions 
 
Segment Cycles Temperature Time 
Initial Denaturation  1 95
o
C 2 minutes 
Denaturation 
Annealing 
Extension 
18 95
o
C 
60
o
C 
68
o
C 
20 seconds 
10 seconds 
30 seconds/kb 
Final Extension 1 68
o
C 5 minutes 
 
For experimental efficiency purposes, the SDM pDNA products were re-cloned into a fresh 
vector in order to avoid any change within the vector that could have occurred during the 
SDM procedure. The digestion reaction for re-cloning is shown in Table  2-15. The digestion 
reaction was incubated in a water bath at 37
o
C overnight, the digestion process and gel 
electrophoresis were carried out and the DNA was purified as described earlier. 
   
 Table  2-15: Re-cloned SDM pDNA reaction 
 
SDM plasmid construct Vector 
SDM miniprep, up to 1μg xμl Vector, up to 1μg 5μl (400ng/ul) 
Enzyme A 2.5μl Enzyme A 2.5μl 
Enzyme B 2.5μl Enzyme B 2.5μl 
10x buffer 5μl 10x buffer 5μl 
dH2O xμl dH2O 35μl 
Total 50μl Total 50μl 
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T4 DNA ligation was used in re-cloning. The T4 ligation reaction component was the vector 
with an insert ratio of 3:1; 1μl of T4 ligase buffer, 1μl of T4 ligase and dH2O to a total volume 
of 10μl was mixed gently, centrifuged briefly, and then incubated in a thermo-cycler block 
overnight via the program shown in Table  2-16. The next day, 2μl of the ligation reaction was 
transformed to 50μl of DHα5 competent cells. The transformed product was plated on 
LB/Ampicillin agar and after 24 hours, a colony was collected and plasmid purification was 
performed as described earlier. 
 
Table  2-16: T4 ligation program 
 
Stage Temperature Time 
1 22
0
C 10 minutes 
2 16
0
C 10 minutes 
3 Go to 1 X5 
4 4
0
C 30 seconds 
5 27
0
C 30 seconds 
6 13
0
C 30 seconds 
7 Go to 4 X50 
8 4
0
C 30 30 seconds 
 
 
2.8.3. Transfection to mammalian cell 
The original and mutated plasmid DNA was transfected into Huh7 cells. When the Huh7 cells 
were 85-95% confluent, they were plated into a 96-well plate (2X10
4 cells/ 100μl) and 
incubated in a humidified CO2 atmosphere at 37°C for 24 hours. For each luciferase assay 
carried out in this study the plate included one row containing the puc18 plasmid as a negative 
control, one containing pGL3 promoter as a positive control, and one containing β-Gal as a 
transfection efficiency detector. Detection of β-Gal was by X-gal, when X-gal was cleaved by 
active β-Gal enzymes. This reaction leads to color the transfected cells blue, which was easily 
identified by light microscopy.   
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Transfection was carried out with Opti-MEM® reduced serum medium and Lipofectamine 
2000. Two mastermixes: pRL-TK mastermix and lipid mastermix were prepared for 96-well 
plates. The first was pRL-TK mastermix (0.1μl of pRL-TK vector (10ng/μl), and 2,928μl of 
Opti-MEM® Medium). The pRL-TK activated the firefly luciferase gene in the pDNA and 
this measurement represented the co-transfected control reporter enzyme activity.  The second 
was Lipid mastermix (66μl of Lipofectamine™ 2000 (1mg/ml) and 3,243μl of Opti-MEM® 
medium). Lipofectamine™ 2000 is a transfection reagent that contains lipid subunits capable 
of forming liposomes in an aqueous environment. In the presence of free DNA, liposomes 
encapsulate the nucleic acids to create an efficient delivery system. The liposome-nucleic acid 
complex is able to interact with the cell membrane of the Huh7 cells because of charge 
differences and then endocytosis subsequently releases the nucleic acids into the Huh7 cells 
cytoplasm.  
 
The transfection procedure was performed as follows. In a micro-centrifuge tube 343μl of the 
pRL-TK mix was added to 7μl pDNA (400ng/µl), except in the case of puc18 and β-Gal. The 
samples were incubated at room temperature for 5 minutes. Then, lipid mastermix was 
prepared and incubated for 5 minutes at room temperature before adding 350µl of the mix to 
each reaction tube. After all mixes were added to pDNA constructs, the samples were 
incubated at room temperature for 20 minutes. To each well of the 96-well plate of Huh7 
cells, 50μl of transfection mix was added and the plate was incubated in a humidified 5% CO2 
atmosphere at 37°C for 48 hours. 
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2.8.4. Assay of luciferase activity 
2.8.4.1. Cell‎lysate‎and‎β-Gal 
For the β-Gal assay, the medium was removed from the cells and the cells washed with 150µl 
of 1X PBS. Then 50µl of fixation solution (Table 2-1) was added per well and incubated at 
room temperature for 5 minutes. The fixation solution was removed and cells were washed 
twice with 150µl of 1X PBS. Next, 50µl of staining solution (Table 2-1) per well was added, 
incubated for 20 minutes at room temperature and then examined for transfection efficiency 
under the microscope. When transfection efficiency ≥30%, the transfected cells were eligible 
for the luciferase activity assay. 
 
To perform the luciferase activity assay, cells were lysed by washing them twice with 150μl 
of 1xPBS. Then, 20μl of 1x lysis buffer (Luciferase Reporter Assay System kit) was added to 
each well and the plate was incubated for 20 minutes at room temperature on a shaker.  
 
2.8.4.2. Dual-Luciferase Reporter  
The activity of firefly luciferase and renilla luciferase in cell lysate was measured using the 
Dual Luciferase Reporter Assay System. The firefly luciferase was measured by the addition 
of Luciferase Assay Reagent II (LAR II) to generate a stabilized luminescent signal. After 
quantitation of the firefly luminescence, this reaction was quenched, and the renilla luciferase 
reaction was initiated by adding Stop & Glo reagent to the same well. The Stop & Glo reagent 
also produced a stabilized signal from renilla luciferase, which decays slowly over the course 
of the measurement. 
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The Dual Luciferase Reporter Assays were performed using the Tropix TF microplate 
luminometer (Applied Biosystems/ Life Technologyies) and WinGlow software. The 
equipment injectors were set to dispense 50 μl of LAR II and Stop & Glo. All measurements 
were set for 2 second delay and 10 second read time. A 10μl aliquot of lysed cells from each 
well was transferred to the white Tropix TF microplate and placed in the luminometer. LAR II 
was dispensed to each well in the plate and the firefly luciferase activity was measured and 
recorded. Then Stop & Glo was dispensed and the renilla luciferase activity was measured and 
recorded. The results were recorded using WinGlow software. The ratio of firefly luciferase to 
renilla luciferase activity was used to compare the different expression between samples and 
plates. Twelve wells were assayed for each construct and transfection experiments were 
repeated at least 4 times. 
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2.9. Electrophoretic mobility shift assay (EMSA) 
EMSA, also known as band shift assay, is a technique that is used to characterize nuclear 
protein-DNA binding interactions (311). The conventional EMSA protocol was performed to 
determine whether different alleles of a SNP of interest cause differential protein binding. The 
assay concept is that when protein is added to a SNP oligonucleotide sequence, and protein 
complex generates, the fragment becomes heavier and runs more slowly on the gel and is 
'shifted' up the gel (Figure 2-5 (lane 2)).  In my thesis, labeled and unlabeled (specific 
competitor) oligonucleotides were used to determine a SNP specific band. The specific 
competitor had identical sequence as labeled oligonucleotide, thus, the competitor competed 
out any specific interactions with labeled oligonucleotide, eliminating or reducing any 
positive shift result (Figure 2-5 (lane 3)). 
 
Once DNA-protein binding is determined, the search will narrow to identify the transcription 
factor that could regulate the transcription of the gene of interest. To achieve this multiplexed-
competitor-EMSA (MC-EMSA) was perform, seven sets of cocktails were used with each set 
having 10 consensus sequence oligonucleotides of known transcription factors. When one set 
competed out binding, the individual consensus sequences from this set were run in a further 
reaction (312).  
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Figure ‎2-5: Overview of the electrophoretic mobility shift assay (EMSA) method. 
Adapted from http://www.licor.com/bio/applications/emsa/ 
 
 
 
 
2.9.1. Nuclear extraction 
Mammalian eukaryotic cell nuclear extract containing proteins was isolated from a Huh7 cell 
line that had grown to 95% confluency in a T175 flask. First, the Huh7 cells were washed 
with 25ml 1XPBS, then 5 ml of Trypsin-EDTA solution (0.05%) was added to detach 
growing cells from the flask surface by incubation at 37
0
C for 3 minutes. Second, 25ml of 
DMEM supplemented with 10% FBS was added to the cells, which were transferred to falcon 
tubes and centrifuged at 4
0
C for 5 minutes at 1500rpm. Third, the cell pellet was re-suspended 
in 5ml ice-cold nuclear extract Buffer A (Table 2-1) with 50µl of 100X protease inhibitor 
cocktail, vortexed, then incubated for 10 minutes on ice, and centrifuged at 4
0
C for 5 minutes 
at 1500rpm. The cell pellet was re-suspended in 2ml ice-cold nuclear extract Buffer A with 
20µl of 100X protease inhibitor cocktail, vortexed and incubated in ice for 10 minutes, and 
then centrifuged at 4
0
C for 5 minutes at 13000rpm. Finally, the cell pellet was re-suspended in 
800µl ice-cold nuclear extract Buffer C (Table 2-1) with 16µl of 100X protease inhibitor 
cocktail, vortexed, then incubated on ice for 10 minutes (the vortex/incubation process was 
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repeated 4 times in total), and then centrifuged at 4
0
C for 45 minutes at 13000rpm. The 
nuclear product (supernatant) was aliquoted into 50 µl volumes and stored at -80
0
C.    
       
2.9.2. Designing probes, biotin labeling and annealing probes 
Forward and reverse probes were designed to be between 27-31bp. When the probe was 
designed the following criteria were considered; the forward and reverse probes were 100% 
complementary, and the probes length was between 27-31 nucleotides with SNP in the 
middle. EMSA probes that were used in this thesis are shown in Table  2-17. 
 
Table  2-17: Electrophoretic mobility shift assay (EMSA) probes 
 
LDLR rs6511720 (G>T) 
Forward wild type ACCTCTTCCTTAAGAGAAAATGTTAAGGAAG 
Reverse wild type CTTCCTTAACATTTTCTCTTAAGGAAGAGGT 
Forward rare variant ACCTCTTCCTTAAGATAAAATGTTAAGGAAG 
Reverse rare variant CTTCCTTAACATTTTATCTTAAGGAAGAGGT 
LDLR rs57217136 (T>C) 
Forward wild type GAATTGAATTCCATTGGGTGTAGTCCAACAGGCCAC 
Reverse wild type GTGGCCTGTTGGACTACACCCAATGGAATTC 
Forward rare variant GAATTCCATTGGGTGCAGTCCAACAGGCCAC 
Reverse rare variant GTGGCCTGTTGGACTGCACCCAATGGAATTC 
LDLR rs60173709 (T>-) 
Forward wild type TAACTAACACACCAGTTTCCTCTGGGAGGCC 
Reverse wild type GGCCTCCCAGAGGAAACTGGTGTGTTAGTTA 
Forward rare variant TAACTAACACACCAG*TTCCTCTGGGAGGCC 
Reverse rare variant GGCCTCCCAGAGGAA*CTGGTGTGTTAGTTA 
LDLR rs141787760 (C>-) 
Forward wild type GAGTGAGCCACCGCGCCCCACCGGGGATGAT 
Reverse wild type ATCATCCCCGGTGGGGCGCGGTGGCTCACTC 
Forward rare variant GAGTGAGCCACCGCG*CCCACCGGGGATGAT 
Reverse rare variant ATCATCCCCGGTGGG*CGCGGTGGCTCACTC 
ANXA2 rs12900101 (C>G) 
Forward wild type TAGGCAGTGCCCCAGCAGGGGCACTGTGCGG 
Reverse wild type CCGCACAGTGCCCCTGCTGGGGCACTGCCTA 
Forward rare variant TAGGCAGTGCCCCAGGAGGGGCACTGTGCGG 
Reverse rare variant CCGCACAGTGCCCCTCCTGGGGCACTGCCTA 
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ANXA2 rs11633032 (G>A) 
Forward wild type TGAAGCAGCTCAGACGGCAAGCGAAGGGCAA 
Reverse wild type TTGCCCTTCGCTTGCCGTCTGAGCTGCTTCA 
Forward rare variant TGAAGCAGCTCAGACAGCAAGCGAAGGGCAA 
Reverse rare variant TTGCCCTTCGCTTGCTGTCTGAGCTGCTTCA 
ANXA2 rs116255697 (A>G) 
Forward wild type GTTCAAAGTACCACAAATCTCTAAGGCAGGG 
Reverse wild type CCCTGCCTTAGAGATTTGTGGTACTTTGAAC 
Forward rare variant GTTCAAAGTACCACAGATCTCTAAGGCAGGG 
Reverse rare variant CCCTGCCTTAGAGATCTGTGGTACTTTGAAC 
ANXA2 rs17191344 (A>G) 
Forward wild type TGAGAGCAGGGCCATCGTGGAGGAGTC 
Reverse wild type GACTCCTCCACGATGGCCCTGCTCTCA 
Forward rare variant TGAGAGCAGGGCCGTCGTGGAGGAGTC 
Reverse rare variant GACTCCTCCACGACGGCCCTGCTCTCA 
*Nucleotide deletion  
 
2.8.2.1. Biotin labeling  
EMSA probes were labeled with biotin using the Thermo Scientific Biotin 3´ End DNA 
Labeling Kit. This kit uses terminal deoxynucleotidyl transferase (TdT) enzyme to incorporate 
1-3 biotinylated ribonucleotides onto the 3´-OH end of DNA (https://www.piercenet.com/ 
instructions/2161290.pdf). 
 
A standard 50µl biotin labeling reaction used 10µl of 5X TdT Buffer, 5µl of Biotin-11 DUTP, 
0.5 µl TdT, and 5µl of primer. Biotin labeling mixes were incubated at 37
0
C for 90 minutes 
then at 70
0
C for 10 minutes to stop the reaction. Then, an equal volume of chloroform: 
isoamyl alcohol (24:1) was added to extract TdT; this mix was vortexed briefly and 
centrifuged for 2 minutes at 13000rpm. The labeled primer layer (top layer) was kept for the 
annealing step.   
  
2.8.2.2. Annealing primers 
Both labeled and unlabeled forward and reverse probes were annealed to create double 
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stranded probes. Equal amounts of labeled (5pmol/μl) or unlabeled (undiluted, at 100pmol/μl) 
complementary probes were mixed with 1/10
th
 total volume 10X annealing buffer (Table 2-1). 
The annealing mix was vortexed briefly and underwent an annealing action on the BioRad 
thermocycler: 95
0
C for 5 minutes, then the temperature was gradually reduced per cycle 95-
35
0
C (-5
0
C/cycle) for 3 minutes and then held at 4
0
C. Probes were measured into 50µl 
aliquots and stored at -80
0
C.  
 
2.9.3. Polyacrylamide gel preparation 
EMSA reactions were run on a 5% polyacrylamide gel (1.5 mm thickness). A 5% 
polyacrylamide gel was prepared using 6.25ml acrylamide 40% (w/v) (19:1), 2.5ml TBE 10X, 
250µl ammonium persulphate 10%, 50µl TEMD, and dH2O to a total volume of 50ml. A gel 
glass was placed on a frame holder of the Electrophoresis Modular System. In the 1.5 mm gap 
between the glass plates, the polyacrylamide mix was poured immediately and a comb was 
placed into the top of the glass through the polyacrylamide mix to create wells. The 
polyacrylamide mix was left overnight at room temperature to polymerize. When the 
polyacrylamide gel had set, the comb was removed and the gel wells were washed with 0.5X 
TBE. Then the glass holder was placed into a running tank containing 5L pre-cooled 0.5X 
TBE. The middle bay between glass plates was filled with 0.5X TBE to a height several 
millimeters above the top of the wells. The outside of the tank was filled with 0.5X TBE to 
above the wells, which reduced heat during electrophoresis. A 5µl EMSA pre-loading dye 
(Table 2-1) was used and the gel was pre-electrophoresed at 120V for 1 hour at 4
0
C.  
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2.9.4. EMSA binding reaction and electrophoresis 
Two EMSA reactions were performed, one has competitor probes while the other did not. The 
following mix was used for both reactions: 10 µl of 2X binding buffer (Table 2-1), 0.8 µl of 
poly dI.dC (1µg/ µl), 2µl of MgCl2 (50mM), 0.8µl of BSA and 3µl of Huh7 cells nuclear 
extract and dH2O to 20μl. For the competitor reactions 1µl of unlabeled probe was added and 
incubated at 4
0
C for 30 minutes. For both reactions 1.5µl of biotin labeled primers were 
added, and then reaction tubes were incubated at 25
0
C for 30 minutes, followed by adding 4µl 
of 6X gel loading dye to each reaction, then the reactions were loaded to pre-prepared 
polyacrylamide gel and run at 120V at 4
0
C for 4 hours. The samples were electrophoresed 
until the bromophenol blue dye had migrated approximately 2/3 to 3/4 down the length of the 
gel. The free biotin-DNA duplex migrated just behind the bromophenol blue in the 
polyacrylamide gel.  
 
2.9.5. EMSA blotting membrane 
Once the gel electrophoresis was completed, the protein-DNA was blotted onto a nucleic acid 
nylon membrane in order to visualize the binding bands. Four pieces of Whatman paper and a 
piece of Hybond-N+ membrane were cut to about 15X10 cm and soaked for 10 minutes in 
10X SSC buffer. 
 
The blotting tank contained 20X SSC buffer (Table 2-1) with a perspex block in the middle. 
Over the perspex block, a piece of Whatman paper was laid with the ends submerged in the 
buffer. Over the prepared perspex block the blotting membrane assembly included two pieces 
of 10X SSC soaked Whatman paper, then on top of these the gel was placed with its edges 
covered with clingfilm. The Hybond-N+ membrane was placed on top of the gel and finally 
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the remaining two pieces of Whatman paper were placed on top of the membrane, and were 
flattened with a roller to ensure no air bubbles were trapped. The Whatman paper was 
essential for keeping all layers of the blotting membrane assembly moist. To create pressure 
on the blotting apparatus, a large stack of paper hand-towel and weights were added. This was 
left to blot overnight. After 18 hours, the membrane was retrieved from the blotting assembly 
and cross-linked using a UV Stratalinker 2400. The autocross link program (254nm bulbs for 
60 seconds’ exposure) was chosen to fix the protein-DNA complexes to the membrane.   
 
2.9.6. Lightshift chemiluminescent EMSA detection system 
The Thermo Scientific LightShift Chemiluminescent EMSA Kit was used to detect binding 
bands of protein-DNA complexes (https://www.piercenet.com/instructions/2160919.pdf). 
First, the Blocking Buffer and the 4X wash buffer were gently warmed to 37-50°C in a water 
bath until all particulates were dissolved.  Then, 1X wash solution was prepared by adding 
40mL of 4X wash buffer to 120mL of dH2O. Second, the membrane was blocked by adding 
20mL of Blocking Buffer and incubated for 20 minutes with gentle shaking. Next, 66.7μL 
Stabilized Streptavidin-Horseradish Peroxidase Conjugate was added to 20mL Blocking 
Buffer (1:300 dilution), and incubated for 20 minutes with gentle shaking. The membrane was 
transferred into a new container and washed with 20mL of 1X wash solution for 10 minutes 
with gentle shaking (the washing process was repeated 4 times in total). Then, 30mL of 
Substrate Equilibration Buffer was added to the membrane, and incubated for 10 minutes with 
gentle shaking. The membrane then was removed and the edge of membrane was carefully 
blotted on a paper towel to removed excess buffer. The membrane was placed on a clean glass 
plate. Substrate Working Solution (6mL Luminol/Enhancer Solution and 6mL Stable Peroxide 
Solution) was poured onto the membrane, incubated for 7 minutes, the membrane removed 
from the Working Solution and the edge of the membrane blotted on a paper towel for 2-5 
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seconds to remove excess buffer, and wrapped in plastic wrap, avoiding bubbles and wrinkles. 
Finally, to visualize the protein-DNA complex, the membrane was exposed to X-ray film or 
Syngene G:BOX Documentation system at various time points. The film was developed 
according to the manufacturer’s instructions.  
 
2.9.7. Multiplexed Competitor Electrophoretic Mobility Shift Assay (MC-EMSA) 
The MC-EMSA concept uses seven cocktails (Table  2-18), each cocktail containing 10 
competitors. These 70 competitors are consensus sequences for known transcription factor 
binding sites. When these unlabeled competitor sequences are incubated with the nuclear 
extract, a protein which binds to the SNP of interest instead binds to the relevant competitor 
probe, which causes band elimination (312). 
 
The SNPs that showed a band shift in conventional EMSA were subjected to MC-EMSA 
analysis in order to identify the transcription factors. The cocktail of DNA competitors were 
made by mixing 50μl of forward and reverse primer sets (100pmol/μl), adding 1/10th total 
volume of 10X annealing buffer, then vortexing the tubes gently. The multiplex competitor 
sequences used and their corresponding transcription factors are listed in Table 2-19. The 
primers were run on the ‘anneal’ program as described earlier. For the MC-EMSA, the 
reaction conditions were identical, except that the DNA competitor is a cocktail. If a particular 
set of competitor sequences is able to compete out the SNP of interest, then an individual 
competitor of this set undergoing EMSA separately will identify the precise competitor(s). 
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Table  2-18: MC-EMSA Cocktails 
Unlabeled Multiplexed DNA-based competitors to commonly studied DNA-binding protein 
Cocktail 0 Cocktail 1 Cocktail 2 Cocktail 3 Cocktail 4 Cocktail 5 Cocktail 6 
AP1 E2F1 HIF1a NFATc RAR Stat4 VDR 
AP2 Egr ISRE NFkB RXR Stat5 YY1 
AR ER HNF4 NR5A2 SIE Stat56 ZEB 
Brn3 Ets IRF1 Oct-01 Smad Tbet HNF1 
CBP Ets1 MEF1 p53 Smad34 TFE3 ARP1 
CDP FAST1 MEF2 Pax5 Smuc TFEB NFY 
CEBP GAS MIBP1 Pbx1 Sp1 TFIID HNF3 
cMyb GATA MycMax Pit1 SRE TGIF BARP 
CREB Gfi1 NF1 PPAR Stat1 TR SREBP1 
CTCF GR NFE2 PR Stat3 USF1 HSF1 
 
 
Table  2-19: Consensus sequence for competitor cocktails 
 
Oligo name  consensus sequence 
AP1 
Forward CGCTTGATGACTCAGCCGGAA 
Reverse TTCCGGCTGAGTCATCAAGCG 
AP2a 
Forward GATCGAACTGACCGCCCGCGGCCCGT 
Reverse ACGGGCCGCGGGCGGTCAGTTCGATC 
AR 
Forward GAAGTCTGGTACAGGGTGTTCTTTTTG 
Reverse CAAAAAGAACACCCTGTACCAGACTTC 
Brn3 
Forward CACAGCTCATTAACGCGC 
Reverse GCGCGTTAATGAGCTGTG 
CBP 
Forward AGACCGTACGTGATTGGTTAATCTCTT 
Reverse AAGAGATTAACCAATCACGTACGGTCT 
CDP 
Forward ACCCAATGATTATTAGCCAATTTCTGA 
Reverse TCAGAAATTGGCTAATAATCATTGGGT 
CEBP_F_R 
Forward/ 
Reverse 
TGCAGATTGCGCAATCTGCA 
cMyb 
Forward TACAGGCATAACGGTTCCGTAGTGA 
Reverse TCACTACGGAACCGTTATGCCTGTA 
CREB 
Forward AGAGATTGCCTGACGTCAGAGAGCTAG 
Reverse CTAGCTCTCTGACGTCAGGCAATCTCT 
CTCF 
Forward GGCGGCGCCGCTAGGGGTCTCTCT 
Reverse AGAGAGACCCCTAGCGGCGCCGCC 
E2F1 
Forward ATTTAAGTTTCGCGCCCTTTCTCAA 
Reverse TTGAGAAAGGGCGCGAAACTTAAAT 
Egr 
Forward GGATCCAGCGGGGGCGAGCGGGGGCGA 
Reverse TCGCCCCCGCTCGCCCCCGCTGGATCC 
ER 
Forward GGATCTAGGTCACTGTGACCCCGGATC 
Reverse GATCCGGGGTCACAGTGACCTAGATCC 
Ets 
Forward GGGCTGCTTGAGGAAGTATAAGAAT 
Reverse ATTCTTATACTTCCTCAAGCAGCCC 
Ets1 
Forward GATCTCGAGCAGGAAGTTCGA 
Reverse TCGAACTTCCTGCTCGAGATC 
FAST1 
Forward TGTGTATTCA 
Reverse TGAATACACA 
GAS 
Forward AAGTACTTTCAGTTTCATATTACTCTA 
Reverse TAGAGTAATATGAAACTGAAAGTACTT 
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GATA 
Forward CACTTGATAACAGAAAGTGATAACTCT 
Reverse AGAGTTATCACTTTCTGTTATCAAGTG 
Gfi1 
Forward TAAATCACTGC 
Reverse GCAGTGATTTA 
GR 
Forward AGAGGATCTGTACAGGATGTTCTAGAT 
Reverse ATCTAGAACATCCTGTACAGATCCTCT 
HIF1a 
Forward TCTGTACGTGACCACACTCACCTC 
Reverse GAGGTGAGTGTGGTCACGTACAGA 
ISRE 
Forward AAGTACTTTCAGTTTCATATTACTCTA 
Reverse TAGAGTAATATGAAACTGAAAGTACTT 
HNF4 
Forward CTCAGCTTGTACTTTGGTACAACTA 
Reverse TAGTTGTACCAAAGTACAAGCTGAG 
IRF1 
Forward GGAAGCGAAAATGAAATTGACT 
Reverse AGTCAATTTCATTTTCGCTTCC 
MEF1 
Forward GATCCCCCCAACACCTGCTGCCTGA 
Reverse TCAGGCAGCAGGTGTTGGGGGGATC 
MEF2 
Forward GATCGCTCTAAAAATAACCCTGTCG 
Reverse CGACAGGGTTATTTTTAGAGCGATC 
MIBP1 
Forward TCTTTTCCCA 
Reverse TGGGAAAAGA 
MycMax 
Forward/ 
Reverse 
GGAAGCAGACCACGTGGTCTGCTTCC 
NF1 
Forward TTTTGGATTGAAGCCAATATGATAA 
Reverse TTATCATATTGGCTTCAATCCAAAA 
NFE2 
Forward TGGGGAACCTGTGCTGAGTCACTGGAG 
Reverse CTCCAGTGACTCAGCACAGGTTCCCCA 
NFATc 
Forward CGCCCAAAGAGGAAAATTTGTTTCATA 
Reverse TATGAAACAAATTTTCCTCTTTGGGCG 
NFkB 
Forward AGTTGAGGGGACTTTCCCAGGC 
Reverse GCCTGGGAAAGTCCCCTCAACT 
NR5A2 
Forward GATCAACGACCGACCTTGAG 
Reverse CTCAAGGTCGGTCGTTGATC 
OCT1 
Forward TGTCGAATGCAAATCACTAGAA 
Reverse TTCTAGTGATTTGCATTCGACA 
p53 
Forward TACAGAACATGTCTAAGCATGCTGGGG 
Reverse CCCCAGCATGCTTAGACATGTTCTGTA 
Pax5 
Forward GAATGGGGCACTGAGGCGTGACCACCG 
Reverse CGGTGGTCACGCCTCAGTGCCCCATTC 
Pbx1 
Forward CTCCAATTAGTGCATCAATCAATTCG 
Reverse CGAATTGATTGATGCACTAATTGGAG 
Pit1 
Forward TGTCTTCCTGAATATGAATAAGAAATA 
Reverse TATTTCTTATTCATATTCAGGAAGACA 
PPAR 
Forward AGGTCAAAGGTCA 
Reverse TGACCTTTGACCT 
PR 
Forward GATCCTGTACAGGATGTTCTAGCTACA 
Reverse TGTAGCTAGAACATCCTGTACAGGATC 
RAR 
Forward AGGGTAGGGTTCACCGAAAGTTCACTC 
Reverse GAGTGAACTTTCGGTGAACCCTACCCT 
RXR 
Forward AGCTTCAGGTCAGAGGTCAGAGAGCT 
Reverse AGCTCTCTGACCTCTGACCTGAAGCT 
SIE 
Forward GTGCATTTCCCGTAAATCTTGTCTACA 
Reverse TGTAGACAAGATTTACGGGAAATGCAC 
Smad 
Forward GTCTAGACCA 
Reverse TGGTCTAGAC 
Smad34 
Forward TCGAGAGCCAGACAAAAAGCCAGACATTTAGCCAGACAC 
Reverse GTGTCTGGCTAAATGTCTGGCTTTTTGTCTGGCTCTCGA 
Smuc 
Forward GGATCCCCCAACACCTGCTGCCTGA 
Reverse TCAGGCAGCAGGTGTTGGGGGATCC 
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Sp1 
Forward ATTCGATCGGGGCGGGGCGAGC 
Reverse GCTCGCCCCGCCCCGATCGAAT 
SRE 
Forward GGATGTCCATATTAGGACATCT 
Reverse AGATGTCCTAATATGGACATCC 
Stat1 
Forward CATGTTATGCATATTCCTGTAAGTG 
Reverse CACTTACAGGAATATGCATAACATG 
Stat3 
Forward GATCCTTCTGGGAATTCCTAGATC 
Reverse GATCTAGGAATTCCCAGAAGGATC 
Stat4 
Forward GAGCCTGATTTCCCCGAAATGATGAGC 
Reverse GCTCATCATTTCGGGGAAATCAGGCTC 
Stat5 
Forward AGATTTCTAGGAATTCAATCC 
Reverse GGATTGAATTCCTAGAAATCT 
Stat56 
Forward GTATTTCCCAGAAAAGGAAC 
Reverse GTTCCTTTTCTGGGAAATAC 
Tbet_F_R 
Forward/ 
Reverse 
AATTTCACACCTAGGTGTGAAATT 
TFE3 
Forward GATCTGGTCATGTGGCAAGGC 
Reverse GCCTTGCCACATGACCAGATC 
TFEB 
Forward CACGTG 
Reverse CACGTG 
TFIID 
Forward GCAGAGCATATAAAATGAGGTAGGA 
Reverse TCCTACCTCATTTTATATGCTCTGC 
TGIF 
Forward ACTCTGCCTGTCAAGCGAGG 
Reverse CCTCGCTTGACAGGCAGAGT 
TR 
Forward AGCTTCAGGTCACAGGAGGTCAGAGAG 
Reverse CTCTCTGACCTCCTGTGACCTGAAGCT 
USF1 
Forward CACCCGGTCACGTGGCCTACACC 
Reverse GGTGTAGGCCACGTGACCGGGTG 
VDR 
Forward AGCTTCAGGTCAAGGAGGTCAGAGAGC 
Reverse GCTCTCTGACCTCCTTGACCTGAAGCT 
YY1 
Forward CGCTCCCCGGCCATCTTGGCGGCTGGT 
Reverse ACCAGCCGCCAAGATGGCCGGGGAGCG 
ZEB 
ZEB 
Forward GATCTGGCCAAAGGTGCAGGATC 
Reverse GATCCTGCACCTTTGGCCAGATC 
HNF1 
Forward GTTAATGATTAAC 
Reverse GTTAATCATTAAC 
ARP1 
Forward AGGTGACCTTTGCCCA 
Reverse TGGGCAAAGGTCACCT 
NFY 
Forward ATCAGCCAATCAGAGC 
Reverse GCTCTGATTGGCTGAT 
HNF3 
Forward GCCCATTGTTTGTTTTAAGCC 
Reverse GGCTTAAAACAAACAATGGGC 
BARP 
Forward TCACTCAAGTTCAAGTTATT 
Reverse AATAACTTGAACTTGAGTGA 
SREBP1 
Forward TTTGAAAATCACCCCATGCAAACTC 
Reverse GAGTTTGCATGGGGTGATTTTCAAA 
HSF1_F 
Forward GATCTCGGCTGGAATATTCCCGACCTGGCAGCCGA 
 TCGGCTGCCAGGTCGGGAATATTCCAGCCGAGATC 
CTCF motifs consensus sequence 
CTCF1 
Forward CCAGCCTTCAGCAGGTGGCACTGTTG 
Reverse CAACAGTGCCACCTGCTGAAGGCTGG 
CTCF2 
Forward TGTTTCAGCCACCTGCTGGGCAGCAG  
Reverse CTGCTGCCCAGCAGGTGGCTGAAACA 
CTCF3 
Forward CAGCCCTGCCCCCTGCCGGGCCCTGTG  
Reverse CACAGGGCCCGGCAGGGGGCAGGGCTG 
CTCF4 
Forward ATGATGGCCAGCAGAGGGCGCATGGC 
Reverse ATGATGGCCAGCAGAGGGCGCATGGC 
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CTCF5 
Forward AGACAGCGCCCTCTGTTGGAATTAGCC  
Reverse GGCTAATTCCAACAGAGGGCGCTGTCT 
CTCF6 
Forward CTGATTTCCACTAGGGGGCCGTGGTG  
Reverse CACCACGGCCCCCTAGTGGAAATCAG 
CTCF7 
Forward CAACGGCGCCCCTTCGTGGTGATAAT  
Reverse ATTATCACCACGAAGGGGCGCCGTTG 
CTCF8 
Forward TCCTGGCCCCCTCTGCTGGACATCCT  
Reverse AGGATGTCCAGCAGAGGGGGCCAGGA 
CTCF10 
Forward CCAAGGCTGCCCCTGCTGGCAAAGGC  
Reverse GCCTTTGCCAGCAGGGGCAGCCTTGG 
CTCF11 
Forward AGCTACACCGACAGGGGGCGCCAGCC  
Reverse GGCTGGCGCCCCCTGTCGGTGTAGCT 
CTCF12 
Forward CTTGAGTGCCCTCTGGTGGGCAATAG  
Reverse CTATTGCCCACCAGAGGGCACTCAAG 
 
2.9.8. Supershift EMSA 
To verify protein specificity, a supershift assay is often carried out using a specific 
monoclonal antibody to a putative transcription factor. For the supershift assay, the reaction 
conditions were identical to conventional EMSA, except that the DNA competitor was 
replaced with 1.5µl of monoclonal antibody to the transcription factor of interest. Anti-CTCF 
was added to rs17191344 reaction mix and anti-GATA1, anti-GATA2+3 and Egr1 (Table 2-1) 
were added to rs11633032 reaction mix individually. 
  
Antibodies and binding partners may require a specific order of addition. Some antibodies 
may block binding of a protein to DNA if added before the complex is formed, thus adding 
the antibody after labeled probe is required. Thus, two antibody addition protocols were used, 
before and after addition of labeled probed to the nuclear extract. If the antibody recognizes 
the target protein two results are possible. First, when the antibody binds to the protein which 
then binds to the labelled probe, this creates a larger molecular weight complex antibody-
protein-DNA, and this will move slower through the gel which will be observed as supershift 
on the gel (Figure 2-6). Alternatively, the antibody may prevent DNA/ protein interaction, 
where the antibody binds to essential site on the protein required for DNA binding, resulting 
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in a loss of the specific complex and absence on the gel. The disappearance of specific band is 
a negative result, but it can support the identification of the protein of interest.   
 
Figure  2-6: Overview of the Supershift EMSA Method. 
Adapted from http://www.piercenet.com/method/gel-shift-assays-emsa 
 
 
 
2.10. TaqMan Gene Expression 
TaqMan Gene Expression was used to perform real-time reverse transcription-PCR (real-
time RT-PCR), to measure the amount of mRNA expression associated with the target 
sequence and allele of interest in the presence and absence of treatment (miRNA).    
   
The Real-Time PCR was performed with two-step RT-PCR, using two separate reactions. 
In the first reaction, total RNA is reverse transcribed into complementary DNA (cDNA), 
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and in the second reaction, the cDNA is amplified by PCR.  Gene expression was 
quantified using the Relative Quantitation (RQ) method. The workflow of mRNA 
quantification using real-time RT-PCR is summarized in Figure 2-7. 
 
Figure ‎2-7: The work flow of mRNA quantification using real-time RT-PCR 
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2.10.1. RNA isolation and DNase I treatment 
Total RNAs were isolated from culture cells by TRIzol. First, the growth medium was 
removed from the culture dish, then 1ml of TRIzol was added to the culture dish per 10 
cm
2
 of dish surface, incubated for 5 minutes at room temperature. The cells were lysed in 
a culture dish by pipetting the cells up and down several times, and then the cell lysate 
was transferred to a 2ml micro-centrifuge tube, incubated at -80
o
C for between 1 hour and 
overnight. To separate phases, 200µl of chloroform was added and incubated for 3 
minutes at room temperature, and centrifuged at 4°C for 15 minutes at 12000xg, to 
separate the solution into an aqueous phase and an organic phase (RNA remains 
exclusively in the aqueous phase). The aqueous phase was transferred into a fresh tube; 
the RNA was recovered by precipitation with 500µl of 100% isopropyl alcohol, incubated 
at room temperature for 10 minutes, and centrifuged at 4°C for 15 minutes at 12000xg. 
The RNA pellet then was washed with 1ml of 75% ethanol and centrifuged at 4°C for 10 
minutes at 7500xg. The washing step was repeated twice, and then the sample was stored 
at -80°C overnight. On the next day, the washing step was repeated once and the 
supernatant discarded. The RNA pellet then was re-suspended with 50µl of DEPC-H2O 
and 5µl of NaAc RNase-free (3M), mixed, 150µl of 100% ethanol was added, incubated at 
-80°C for at least 60 minutes, centrifuged at 4°C for 10 minutes at 12000xg, and the 
supernatant was discarded. The RNA pellet was washed with 1ml of 75% ethanol and 
centrifuged at 4°C for 10 minutes at 12000xg. Residual ethanol was removed and the 
RNA pellet air-dried and then dissolved in 20µl of Nuclease-free water. RNA 
concentration and quality were examined using a Nanodrop spectrophotometer device and 
absorbance was measured at 260 nm and 280 nm.  
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To remove the genomic DNA from the RNA sample, it was treated with DNase I 
amplification grade. One microgram of RNA sample was added to 1µl 10XMgCl2, 1µl 
DNase I to a total volume of 10µl. followed by incubation at 37°C for 30 minutes. Then 
2µl of 250M EDTA was added to the mixture and incubated at 65°C for 10 minutes. The 
prepared RNA was stored at -80°C, to use as a template for reverse transcriptase. 
   
2.10.2. Reverse transcription (RT) 
In the first step of a two-step RT-PCR protocol, total RNA is reverse transcribed into 
cDNA. Two different protocols were performed: High Capacity cDNA and TaqMan® 
MicroRNA Reverse Transcription.   
 
High Capacity RNA-to-cDNA KIT was used to synthesize single-stranded complementary 
DNA (cDNA) from total RNA. For a 20µl reaction: 10µl 2XRT buffers, 1µl RT Enzyme 
Mix, and 9µl RNA template (1µg) was added to a thin micro-tube followed by gentle 
mixing, briefly centrifuged and incubated on ice for 5 minutes. The RT thermal cycler 
condition was 60 minutes at 37°C, 5 minutes at 95°C, and 10 minutes at 4°C.  
 
To synthesize single-stranded cDNA of Mir-155, Mir-155* and a small nuclear RNA U6 
(used as endogenous control for miRNAs) from total RNA, the TaqMan® MicroRNA 
Reverse Transcription kit was used with specific miRNA primers. For TaqMan® 
MicroRNA Reverse Transcription the RNA sample was first diluted 1:50 as recommended 
by the manufacturer. The miRNA RT reaction consisted of 5µl of diluted RNA, 0.15µl 
dNTP mix, 1µl Multiscribe
TM
 RT enzyme,1.5 µl 10XRT buffer, 0.19 RNase inhibitor, 3µl 
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5XRT specific primers (mir155, mir155*, and U6), and 4.16 µl nuclease-free water. Then, 
the reaction tube was gently mixed, briefly centrifuged, and incubated on ice for 5 
minutes. The RT thermal cycler condition was 30 minutes at 16°C, 30 minutes at 42°C, 5 
minutes at 85°C, and 10 minutes at 4°C.  
 
2.10.2.1. TaqMan Gene Expression Assays (20X) 
TaqMan Gene Expression Assays (20X) (Table 2.1) are targeting protein-coding 
transcripts. All assays used in this thesis were of human species. The assays used for the 
work were either Inventoried assays or Made-to-Order assays, which were predesigned 
real-time PCR assays previously manufactured and either stored as stock or manufactured 
at the time of order. 
   
TaqMan endogenous controls are a collection of predesigned assays for candidate 
controlled genes used to normalize for differences in RNA samples. TaqMan Gene 
Expression Assays and Endogenous Controls (20X) contain two unlabeled primers (18 
μM per primer) and one 6-FAM dye-labeled TaqMan MGB probe (5 μM). A FAM dye 
reporter dye is linked to the 5’ end of the probe and a MGB at the 3’ end of the probe, 
while a nonfluorescent quencher (NFQ) is linked at the 3’ end of the probe.  
 
2.10.2.2. The real-time PCR reaction and conditions 
In the second step of a two-step RT-PCR protocol, the TaqMan® Universal Master Mix II 
was used. In 384-well TaqMan PCR reaction plate, the 20µl PCR reaction comprising 
10µl of master mix II, 1µl TaqMan Gene Expression Assays (20X) (ANXA2, GAPDH, 
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UBC, MiR155*, MiR155, U6), and cDNA product 2µl or 3µl (ANXA2, MiRNAs, 
respectively) was placed. The plate was covered by a TaqMan PCR adhesive cover and 
inverted several times to mix the reaction components and centrifuged briefly. Each 
sample had three replicates per experiment. A Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and ubiquitin C (UBC) were used to normalize the mRNA 
levels of the target gene (ANXA2).  
 
The Real-Time PCR was performed in The TaqMan 7900HT fast Real-Time PCR System. 
The standard PCR reaction conditions were as follows: the reaction was incubated at 50°C 
for 2 minutes, then DNA polymerase was activated at 95°C for 10 minutes, followed by 
40 cycles of denaturing at 95°C for 15 seconds for each and annealing/extension at 60°C 
for 1 minute.   
 
TaqMan Gene Expression Assays are similar to TaqMan genotyping; there are several 
phases that occur during the PCR reaction. The TaqMan MGB probe anneals to a specific 
complementary sequence between the forward and reverse primer sites. When the probe is 
intact, the proximity of the reporter dye to the non-fluorescent quencher leads to 
suppression of the reporter fluorescence (Figure 2-8). Next, the DNA polymerase 5’ to 3’ 
activity along the DNA template specifically cleaves the probes that were hybridized to 
their target. When the cleavage occurred, the reporter dye separates from the non-
fluorescent quencher which leads to increased fluorescence by the reporter dye and the 
probe fragment becomes displaced from the target. Polymerization of the strand 
continues.. During PCR process, ROX dye was the passive reference that acted as an 
internal reference to normalize the reporter dye signal.  
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Figure  2-8:  TaqMan Gene Expression PCR stages. 
The schematic shows the stages of the cycle of the TaqMan Gene Expression PCR. The 
TaqMan MGB probe is hybridized to the complementary sequence of the target between the 
forward and reverse primer sites. The primers bind to the DNA template followed by 
extension by DNA polymerase. When the probe hits with the primer, the reporter dye 
separates from the quencher dye, thus fluorescence is increased by the reporter. The increase 
in fluorescence occurs only if the target sequence is complementary to the probe and has been 
amplified during PCR, thus nonspecific amplification is not detected. NFQ= Non-fluorescent 
quencher, MGB = Minor groove binder, R=Reporter, and P= DNA polymerase. Adapted from 
https://tools.thermofisher.com/content/sfs/manuals/cms04128 0.pdf 
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2.10.2.3. TaqMan Gene Expression signal detection   
Fluorescence was detected using the 7900HT fast Real-Time PCR System with Sequence 
Detection System (SDS) V2.4 software (http://tools.lifetechnologies.com/content/sfs 
/manuals/cms042114. pdf). Standard relative quantification (RQ) ∆∆CT was carried out 
using the SDS software which induced an automatic threshold signal detector. When the 
PCR plate was inserted into the 7900HT fast Real-Time PCR System, the ∆∆CT (RQ) 
program assigned real-time PCR to a plate coordinate in a text output file and in the form 
of real-time CT plot based on the fluorescence signal detection.  
 
In Real-Time PCR, reactions are characterized by the point in time during cycling when 
amplification of a target is first detected. The quantitative endpoint for real-time PCR is 
the threshold cycle (CT). The CT is defined as the fractional cycle number at which the 
fluorescence signal of the reporter dye passes the threshold. The relative quantification 
method compares the CT of the target gene related to the passive reference (ROX).  
 
Normalized reporter (Rn) was automatically calculated using the SDS relative 
quantification function. Rn is the ratio of the fluorescence emission intensity of the 
reporter dye to the fluorescence emission intensity of the passive reference dye (ROX) at 
two time points (baseline and Rn). The baseline is determined from the initial cycles of 
PCR in which there is little change in fluorescence signal, while Rn is fluorescence signal 
at the endpoint of PCR (40 cycles). Delta Rn (∆Rn) is the magnitude of the signal 
generated by the specified set of PCR conditions (∆Rn = Rn - baseline). The threshold is a 
level of ΔRn used for CT determination in real-time assays; this level is set to be above the 
baseline and sufficiently low to be within the exponential growth region of the 
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amplification curve (Figure 2-9) (https://www3.appliedbiosystems.com/cms/groups/ 
mcb_support/documents/generaldocuments/cms_042115.pdf). Table 2-10 shows an 
example of a TaqMan gene expression output plot.  
 
Figure  2-9: The schematic shows how TaqMan gene expression amplification plot is 
interpreted and the calculation of CT.  
The graph represents how ∆Rn is calculated and indicates the point of significant exponential 
growth that determines CT based on the increase in fluorescence signal detected with PCR 
amplification.   
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Figure ‎2-10: TaqMan gene expression output plot (amplification plot) 
The figure is an example of a typical results plot for ANXA2 TaqMan gene expression using 
SDS software. The plot allows interpretation of whether the assay has worked. The PCR was 
run for 40 cycles. The point at which the curve intersects the threshold (horizontal green line) 
is the CT.  In this example, the samples reached the threshold between 13-18 cycles, while the 
No template control (NTC) samples did not reach the threshold before 40 cycles. a) plateau 
phase, b) linear phase, c) exponential phase, d) background, and e) baseline.   
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2.10.3. Transfection to mammalian cells: ANXA2 rs116928563 (T>A) and 
mir-155-3p 
To determine the effect of miR-155 on both alleles of the ANXA2 rs116928563 SNP, 
constructs that have the common allele (T) and the rare allele (A) were created using a cloning 
method and transfected to mammalian cells using two-step transfection: plasmid DNA 
transfection and MiRNA transfection. 
 
2.10.3.1. Cloning 
The 409bp of 3’UTR of human ANXA2 was amplified using Phusion®High-Fidelity PCR Kit 
as described earlier, and inserted into the enhancer site of pGL3-basic luciferase reporter 
vector after the SV40 polyadenylation signal at Sal I and BamH I. The ANXA2 rs116928563 
variant was generated using a QuikChange Site-Directed Mutagenesis kit as described earlier. 
All constructs were confirmed by sequencing.  
 
2.10.3.2. Plasmid DNA transfection 
The original and mutated plasmid DNA were transfected into Huh7 cells. When the Huh7 
cells were 90-95% confluent, they were plated into a 20 cm
2
 cell culture dish (3X10
6 
cells/ 
5ml) and incubated in a humidified CO2 atmosphere at 37°C for 24 hours. For each TaqMan 
expression carried out in this study, three dishes were prepared; one contained the ANXA2 
rs116928563 common allele plasmid, another contained the ANXA2 rs116928563 rare allele 
plasmid, and the third contained the β-Gal as transfection efficiency detector.  
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Transfection was carried out with Opti-MEM® reduced serum medium and Lipofectamine 
2000. The transfection procedure was performed as follows; in micro-centrifuge tube 500μl of 
Opti-MEM® was added to 20μl of pDNA (400ng/µl). Then, lipid mastermix was prepared 
(60μl of Lipofectamine™ 2000 (1mg/ml) and 1440μl of Opti-MEM® medium) and incubated 
for 5 minutes at room temperature before adding 500µl of the mix to each reaction tube, 
which was incubated at room temperature for 20 minutes. To each dish of the Huh7 cells, 
1000μl of transfection mix was added and the plate was incubated in a humidified 5% CO2 
atmosphere for 24 hours at 37°C. 
 
For the β-Gal assay, the medium was removed from the cells and washed with 5 ml of 
1XPBS. Then 500µl of fixation solution was added to the cells and incubated for 5 minutes at 
room temperature. The fixation solution was removed and the cells were washed twice with 
150µl of 1XPBS. Next, 500µl of staining solution was added, incubated for 20 minutes at 
room temperature and then examined for transfection efficiency under the microscope. When 
the transfection efficiency of the cell was ≥30%, the transfected cells were eligible for the 
second transfection. 
 
2.10.3.3. MiRNA-155* transfection 
Human mir-155* (mir-155-3p) was delivered to Huh7 cells that contained ANXA2 
rs116928563 SNP constructs using has-mir-155-3p mimic. Transfection was performed using 
siPORT NeoFX Transfection Agent. This Transfection Agent adopts the reverse transfection 
method, which involves simultaneous transfection and plating. For each TaqMan expression 
carried out in this study, two 12 well plates (6 column) would include one column containing 
the rs116928563 T allele transfected with negative control miRNA mimic (NC), one 
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containing the rs116928563 T allele transfected with mir-155* mimic, one containing the 
rs116928563 A allele transfected with NC, one containing the rs116928563 A allele 
transfected with mir-155* mimic, columns five and six contained Opti-MEM® medium, and 
Opti-MEM and siPORT NeoFX Transfection Agent, respectively, which are used as negative 
controls. Plate design is shown in Figure 2-11.  
 
Figure ‎2-11:  MiRNA-155* transfection plate design 
 
 
The transfection procedure was performed as follows (the volume stated is per well); first, 
adherent cells of the first transfection was trypsinized and diluted in normal growth medium 
(1.6X10
5
 per well/1ml growth medium), and incubated at room temperature for 10 minutes.  
Second, 3µL of siPORT™ NeoFX™ Transfection Agent was diluted in 50µL of Opti-MEM 
medium, and incubated 10 minutes at room temperature. Three microlitres of miRNA (10 
µM) was diluted in 50µL of Opti-MEM medium. Third, diluted siPORT™ NeoFX™ 
Transfection Agent and diluted RNA were combined, mixed by pipetting up and down and 
incubated for 10 minutes at room temperature. Next RNA/siPORT™ NeoFX™ Transfection 
Agent transfection complexes were dispensed into wells of a culture plate. Finally, 1ml of cell 
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suspension was overlaid onto the transfection complexes and the plate gently tilted to mix, 
then incubated in normal cell culture conditions for 24 hours. 
 
Total RNAs were isolated from culture cells by TRIzol as previously described, and TaqMan 
expression assay was performed.      
 
2.10.4. TaqMan gene expression analysis for ANXA2 and MiR-155 isoforms  
To assess whether the ANXA2, the MiR-155* and MiR-155 (MiR155-5p) are expressed in two 
of the human liver hepatocellular carcinoma cell lines (Huh7 and HepG2), TaqMan gene 
expression was carried out.  
 
Into 6 well plates, 2X10
5
 cells were added per well (one plate for Huh7, another for HepG2). 
When the cells were 90% confluent, RNA was isolated and the expression assay performed as 
described above. They were compared and normalized to housekeeping genes: GAPDH for 
ANXA2, and U6 for MiR-155* and MiR155.  Each sample was run in triplicate for each assay 
on an ABI 7900HT fast Real-Time PCR System.  
 
2.10.5. TaqMan gene expression analysis for ANXA2 rs116928563 (T>A)  
To determine the effect of miR-155 on both alleles of the ANXA2 rs116928563 SNP, human 
mir-155* was delivered to Huh7 cells that contained ANXA2 rs116928563 SNP as described 
above. Each allele of SNP was transfected with both mir-negative control (mir-NC) and mir-
155* mimic. Each sample was run in triplicate for each assay, and each assay had two 
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negative controls: the SNP common allele (T allele) and Opti-MEM medium, and the SNP 
common allele and siPORT NeoFX Transfection Agent.   
 
Huh7 cells were first transfected with ANXA2 rs116928563 SNP constructs (WT and mutant). 
After 24 hours the constructs were transfected with either mir-155* mimic or mir-NC and 
incubated for another 24 hours. RNA was isolated and the expression assay performed as 
described above. The samples expression were compared and normalized to housekeeping 
genes: GAPDH or UBC for ANXA2, and U6 for MiR-155* and MiR155.  Each sample was 
run in triplicate for each assay on an ABI 7900HT fast Real-Time PCR System.  
 
2.10.6. Quantitative real-time PCR data analysis 
To analyze quantitative real time PCR data, the relative quantification method was used which 
describes the change in expression of the target gene relative to a reference group or control. 
∆Ct and ∆∆Ct were calculated using the following mathematical formula: ∆CT= CT target- CT 
reference; ∆∆Ct= ∆CT target- ∆CT control.  ∆CT was calculated separately for each well. These ∆Ct 
values were then averaged before proceeding with the 2^ΔΔCT calculation. The mean relative 
expression difference between variant genotype was determined by a two-sample t-test. 
Results were analyzed using a spreadsheet. 
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2.11. Familial hypercholesterolemia (FH) mutation screening 
2.11.1. FH subjects 
2.11.1.1. UK- FH 
Sixty-nine samples were collected from several UK clinics. Participants’ information about 
lifestyle habits, ethnicity, height, weight, blood pressure, treatment and family history of CHD 
were recorded. Standard assays for plasma lipids were carried out on samples providerd. In this 
study there was no clinical data for 18 subjects, however the FH mutation screening was 
performed based on physicians requests.         
2.1.1.1. Iran- FH  
Ninety-five samples were collected from 16 probands with clinical FH and their families 
from different pediatric and endocrinology clinics in five different cities (Ahvaz, Bandar 
Abbas, Esfarayen, Mashhad and Torbat Heydariye), which represent three regions of Iran 
(Figure 2-12). Clinical diagnosis was made according to the Dutch Lipid Clinic Network 
Criteria (DLCNC) as previously described (144).The probands were diagnosed with clinical 
definite FH (DFH) if they had a total cholesterol >6.7 mmol/l or LDL-C >4.0 mmol/l if <16 
years and/or TX in a first or second degree relative. They were diagnosed with clinical 
probable FH (PFH) if they had a high TC and LDL-C as for DFH and a family history of 
myocardial infarction (MI) in a first degree relative<60 years or a family history of total 
cholesterol >7.5 mmol/l in a first or second degree relative. Dr Amir Hossein Sahebkar 
provided the DNA samples and participants’ clinical information on lipid plasma levels and 
family history of CHD.  
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Figure  2-12: Map of the Islamic Republic of Iran 
The map shows the five regions of Iran and their capital cities (Tehran, Isfahan, Tabriz, 
Kermanshah, and Mashhad). The investigated samples were collected from five cities shown 
by a red dot and these cities occur in three regions of Iran. Provided by Dr Amir Hossein   
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2.11.2. DNA sample collection, purification and quantification 
The Oragene•DNA (OG-500) kit (http://www.dnagenotek.com/ROW/pdf/PD-BR-
017.pdf) was used to collect saliva samples from the UK participants as recommended by 
the manufacturer, and prepIT®•L2P (PT-L2P ) reagent was used for the purification of 
genomic DNA. Each sample was mixed in the DNA Genotek kit by inversion and gentle 
shaking for a few seconds and incubated at 50°C in a water bath for 1 hour or in an air 
incubator for a minimum of 2 hours. Five-hundred microliters of the mixed sample was 
transferred to a 1.5mL micro-centrifuge tube. Then, 20µL of PT-L2P was added and the 
sample was mixed by vortexing for a few seconds and incubated on ice for 10 minutes 
followed by centrifugation at room temperature for 5 minutes at 15000xg. The clear 
supernatant was transferred into a fresh micro-centrifuge tube. To 500μL of supernatant, 
600μL of 100% ethanol was added and mixed gently by inversion 10 times. The sample 
was left at room temperature for 10 minutes to allow the DNA to fully precipitate and 
then centrifuged at room temperature for 2 minutes at 15000xg. The supernatant was 
discarded and the DNA pellet was washed with 250µL of 70% ethanol, the sample left 
at room temperature for 1 minute, and the supernatant discarded. One-hundred 
microliters of TE solution was added to dissolve the DNA pellet and vortexed for at 
least 5 seconds and incubated at 50°C for 1 hour with occasional vortexing. The sample 
was stored at -20°C for long-term storage and in TE at 4°C for up to 2 months 
(http://www.dnagenotek.com/US/pdf/PD-PR-006.pdf).  
 
For Iranian participants, blood samples (3 mL) was obtained from all patients and their 
available parents and were collected in EDTA tubes. Genomic DNA was extracted from 
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peripheral blood samples using the standard salting-out method (313) with the High Pure 
PCR Template Preparation Kit (version 20). 
 
Genomic DNA was quantified using a Nanodrop spectrophotometer device. To assess 
DNA quality, the absorbance ratio was measured at 260 nm and 280 nm. The optimized 
DNA absorbance ratio values A260/A280 = 1.8-2.0. The DNA concentration was 
optimized to be 50ng/ul for targeting sequencing and 30ng/ul for high resolution melting 
(HRM) using dH2O and TE buffer. 
 
2.11.3. Targeted Sequencing 
Targeted sequencing was performed by Dr. Marta Futema and she provided sequencing 
data as a BAM file. Primers to amplify coding regions (±25 base pairs (bp)) of the three 
autosomal dominant FH genes (LDLR, APOB, PCSK9), and the autosomal recessive FH 
gene (LDLRAP1), and six LDL-C-associated SNPs [SNPs ID (nearby gene): rs629301 
(CELSR2), rs1367117 (APOB), rs6544713 (proxy of rs4299376, ABCG5/8), rs6511720 
(LDLR), rs429358 (APOE), and rs7412 (APOE)] for targeted sequencing were designed 
using the Illumina DesignStudio. The length of amplicons was set to 250bp. The library 
preparation was performed using the TruSeq Custom Amplicon (TSCA) v1.5 kit 
(http://support.illumina.com/content/dam/illumina-support/documents/documentation/ 
chemistrydocumentation/sampleprepstruseq/truseqcustomamplicon/truseq-custom-
amplicon-15-reference-guide-15027983-02.pdf) and sequencing (in both directions) was 
done using the Illumina MiSeq platform.  
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The criteria for standard variant calling pipeline were: coverage ≥30×, minimum of five 
reads for an altered allele, Phred quality ≥20, and a strand bias filter. To ensure that 
variants were not missed a sensitive pipeline was used (coverage ≥15×, minimum of two 
reads for an altered allele, Phred quality ≥ zero, no strand bias filter.  
 
2.11.4. Filtering of the variants 
The BAM file provide all variants in different target genes transcripts, thus only variants 
that were reported in reference gene transcripts (LDLR: ENTS00000558518, APOB: 
ENTS00000233242, PCSK9: ENTS00000302118, and LDLRAP1: ENTS 00000374338) 
were nominated. The nominated variant also was filtered based on its frequency and 
functional affects. Variants were flagged as rare (frequency<0.005) and novel 
(frequency=0) according to their frequency in publicly available databases including the 
1000 Genomes project. Also, variants were flagged as functional, when they were most 
likely to affect a protein's function, that is, non-synonymous, stop gain, stop loss, frame-
shift deletions and insertions, and splice site variants. 
 
2.11.5. Analysis of the variants 
2.11.5.1. Bioinformatics 
Variants within FH known genes (LDLR, APOB, PCSK9, LDLRAP1) were assessed on 
the basis of their frequency and functionality using in-silico prediction tools (SIFT, 
PolyPhen 2 and mutation Taster), Also, the variants were described as causing FH if they 
were reported on the UCL-FH mutation database (http://www.ucl.ac.uk/ldlr/Current/) 
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(65, 314), which is supported by evidence in the literature. Variants were described as 
possible FH-causing if they were unreported in the database but were predicted to be 
pathogenic in-silico and highly conserved (the UCSC genome browser used to analyze 
the conservation level of the variant position). 
 
2.11.5.2. Sanger sequencing 
Sanger sequencing was used to confirm all identified mutations by NGS. Oligonucleotide 
primers for PCR were designed to cover, where appropriate, intron–exon junctions and 
up to 60bp of the introns (146). Primers were designed to amplify the promoter and 
LDLR exons, a part of exon 26 of APOB that included the p.R3527Q mutation and 
p.D374Y (exon 7) of the PCSK9 gene for screening (Table 2-20). PCR was carried out in 
the Rotor-Gene6000. Exon 4 of the LDLR was screened by four overlapping PCR 
fragments (4.1, 4.2, 4.3and 4.4) and exon 10 by two overlapping fragments (10.1 and 
10.2).  
 
 
 
167 
 
Table  2-20: PCR primers used to amplify DNA fragments of LDLR, APOB, and 
PCSK9 
Target Orientation Sequences 
LDLR promoter  Forward  CAGCTCTTCACCGGAGACCC 
 Reverse  ACCTGCTGTGTCCTAGCTGG 
LDLR- Exon 1 Forward  ACTCCTCCCCCTGCTAGAAACCTCA 
 Reverse  CTATTCTGGCGCCTGGAGCAAGCC 
LDLR- Exon 2 Forward  TTGAGAGACCCTTTCTCCTTTTCC 
 Reverse  GCATATCATGCCCAAAGGGG 
LDLR- Exon 3 Forward  TCAGTGGGTCTTTCCTTTGAG 
 Reverse  CAGGACCCCGTAGAGACAAA 
LDLR- Exon 4.1 Forward  TGGTGTTGGGAGACTTCACA 
 Reverse  CACTCATCCGAGCCATCTTC 
LDLR- Exon 4.2 Forward  AAGTGCATCTCTCGGCAGTT 
 Reverse  CCCCTTGGAACACGTAAAGA 
LDLR- Exon 4.3 Forward  AGCTTCCAGTGCAACAGCTC 
 Reverse  CATACCGCAGTTTTCCTCGT 
LDLR- Exon 4.4 Forward  TGTTCCAAGGGGACAGTAGC 
 Reverse  AAATCACTGCATGTCCCACA 
LDLR- Exon 5 Forward  AGAAAATCAACACACTCTGTCCTG 
 Reverse  GGAAAACCAGATGGCCAGCG 
LDLR- Exon 6 Forward  TCCTCCTTCCTCTCTCTGGC 
 Reverse  TCTGCAAGCCGCCTGCACCG 
LDLR- Exon 7 Forward  GGCGAAGGGATGGGTAGGGG 
 Reverse  GTTGCCATGTCAGGAAGCGC 
LDLR- Exon 8 Forward  CATTGGGGAAGAGCCTCCCC 
 Reverse  GCCTGCAAGGGGTGAGGCCG 
LDLR- Exon 9 Forward  TCCATCGACGGGTCCCCTCTGACCC 
 Reverse  AGCCCTCATCTCACCTGCGGGCCAA 
LDLR- Exon 10.1 Forward  AGATGAGGGCTCCTGGTGCGATGCC 
 Reverse  GCCCTTGGTATCCGCAACAGAGACA 
LDLR- Exon 10.2 Forward  GATCCACAGCAACATCTACTGGACC 
 Reverse  AGCCCTCAGCGTCGTGGATA 
LDLR- Exon 11 Forward  TCCTCCCCCGCCCTCCAGCC 
 Reverse  GCTGGGACGGCTGTCCTGCG 
LDLR- Exon 12 Forward  GCACGTGACCTCTCCTTATCCACTT 
 Reverse  CACCTAAGTGCTTCGATCTCGTACG 
LDLR- Exon 13 Forward  GTCATCTTCCTTGCTGCCTG 
 Reverse  GTTTCCACAAGGAGGTTTCAAGGTT 
LDLR- Exon 14 Forward  GAATCTTCTGGTATAGCTGAT 
 Reverse  GCAGAGAGAGGCTCAGGAGG 
LDLR- Exon 15 Forward  GAAGGGCCTGCAGGCACGTGGCACT 
 Reverse  GTGTGGTGGCGGGCCCAGTCTTT 
LDLR- Exon 16 Forward  CCTTCCTTTAGACCTGGGCC 
 Reverse  CATAGCGGGAGGCTGTGACC 
LDLR- Exon 17 Forward  GGGTCTCTGGTCTCGGGCGC 
 Reverse  GGCTCTGGCTTTCTAGAGAGGG 
LDLR- Exon 18 Forward  GCCTGTTTCCTGAGTGCTGG 
 Reverse  TCTCAGGAAGGGTTCTGGGC 
APOB- Exon 26 Forward  TGTCAAGGGTTCGGTTCTTT 
 Reverse  GGGTGGCTTTGCTTGTATGT 
PCSK9- Exon7 Forward  CCCTCTCTTGGGCTCCTTTCT 
 Reverse  AAAGGGGCTGTTAGCATCACG 
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The PCR reaction mix is comprised of 1.5ng of DNA, 0.05µl of each primer, 5µl 
AccuMelt HRM SuperMix (2x), and dH2O to a total volume 10µl. The PCR conditions 
were as follows; started at 95
0
C for 5 minutes, followed by 40-45 cycles of denaturing at 
95
0
C for 5 seconds, annealing at 60
0
C for 10 seconds, and extending at 70
0
C for 20 
seconds. Negative and positive controls with defined mutations were used for each run to 
compare with samples and evaluate run performance. The amplified fragment was 
sequenced using Sanger sequencing. The DNA sequence was assessed manually. 
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Chapter 3 : Mutation detection and spectrum of familial 
hypercholesterolemia of UK patients  
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3.1. Introduction  
FH is an autosomal dominant disorder resulting in elevated plasma LDL-C levels. The 
inherited form of heterozygous FH (HeFH) is the most common, with an estimated 
prevalence of 1/500 (42). This is even higher in some populations such as those of 
Denmark (43) and the Netherlands (201), the Afrikaners in South Africa (315) and 
French Canadians (44). The plasma LDL-C levels in HeFH are two-to-three fold higher 
than normal. Individuals with this form of FH are more likely to develop premature CHD 
in the second or third decade of their lives (42). If an individual inherits two defective 
genes they have homozygous FH (HoFH), which has an estimated prevalence of 1 in 
1,000,000 in most populations. Individuals with homozygous FH have six-to-eight-fold 
higher levels of  LDL-C plasma than normal and  develop CHD in the first decade  of  
life and often die of CHD before the age of 20 (42). FH can be diagnosed using well-
established clinical criteria such as The Simon Broome Register Criteria (141) in the UK, 
and The Dutch Lipid Clinic Network (DLCNC) (144) in other European countries. FH 
patients are treated with statins, however the treatment outcome ranges from 30% to 60% 
reduction in LDL-C, because it depends on  statin potency, type and dose, and the FH 
mutation type (20). Identifying and treating FH patients in childhood through to early 
adulthood is critical in order to prevent or reduce morbidity and mortality from premature 
CHD (316). 
 
FH is considered a monogenic disorder, which is caused by a defect in one of three 
known genes LDLR, APOB, and PCSK9. Inheritance of FH as an  autosomal recessive 
hypercholesterolemia (ARH) has rarely been reported (134); it occurs when an individual 
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inherits two variants in the LDLRAP1 gene. In the UK, the vast majority (93%) of 
identified mutations are found in the LDLR gene, a further 5% in APOB, and about 2% in 
the PCSK9 gene (45, 46). To date 1,700 different LDLR mutations have been reported 
(65), but only one common APOB mutation  p.(Arg3527Gln) and one common PCSK9 
mutation p.(Asp374Tyr) are found in the UK. The FH mutation spectrum varies between 
European countries. In Greece, for instance, six mutations have been reported in 60% of 
FH patients in that country (317), while in the Netherlands two mutations are common 
(318). On the other hand, the UK has a wide FH mutation spectrum, where over 200 
common FH mutations have been reported (150). The majority of LDLR mutations (76%) 
are single nucleotide substitutions (missense, nonsenses, and splice site), 21% small 
insertions or deletions, and 5-6% large insertions or deletions.  
 
The different types of FH mutations have led to the development of different FH 
screening methods such as ARMS, HRM, MLPA and commercial chips (LIPOchip,  
Elucigene FH20) (46, 146, 147, 149). However, these methods are labor-intensive and 
costly. Recently, next-generation sequencing (NGS) has been used to identify FH causing 
mutations (153, 157); the improved specificity and sensitivity of the method has led to 
the identification of new mutations in well-known FH genes and potential new FH genes 
(153, 155, 157, 319). In this study, a NGS-based method and Sanger sequencing were 
used to screen FH mutations in 69 subjects from the UK either with a clinical diagnosis 
of definite FH (DFH) or possible FH (PFH). Also, a family segregation analysis was 
performed in this study on a reported case of familial defective apo-B100 (FDB), which 
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provided an early diagnosis of disease in members of the family and led to appropriate 
treatment.  
 
3.2. Results  
3.1.1. Patient characteristics 
Sixty-nine samples were collected from suspected FH subjects from several UK clinics. 
The subjects participating were clinically diagnosed with HeFH. Participants’ clinical 
information and family history of FH and CHD were provided. Baseline characteristics 
are shown in Table 3-1. Forty-four subjects were children and young adults (≤20 years 
old), and 25 subjects were adults (>20 years old). The Simon Broome Register Criteria 
used for the diagnosis of FH in the UK are: (a) total cholesterol  >7.5 mmol/l or LDL-C 
>4.9 mmol/l if  >16 years and total cholesterol >6.7 mmol/l or LDL-C >4.0 mmol/l if <16 
years; (b) tendon xanthoma (TX) in the patient or in a first or second degree relative; (c) 
family history of MI <60 years in a  first degree relative or family history of MI <50 
years in a second degree relative; and (d) family history of total cholesterol >7.5 mmol/l 
in first or second degree relative. Diagnosis is classified into two classes – DFH  where 
both a+b must be present, or PFH where both a+c or a+d must be observed (141). In this 
study, 3 subjects were diagnosed with DFH, and 19 subjects were diagnosed with PFH. 
However, 49 subjects had suspected FH because they had high levels of TC and LDL-C, 
but no TX or a reported family history of MI (60% children). Indeed, pediatric subjects 
diagnosed with HeFH may initially present with lipid levels within the normal range, or 
borderline, but they are highly likely to develop hypercholesterolemia in adulthood (320). 
It is common that parents with hypercholesterolemia follow a low-fat family diet, which 
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leads to borderline lipid measurements in their children. In many of these cases a family 
history of MI may not be evident due to the parents' young age. Also, children with 
HeFH rarely present with TX in childhood and this also may be the case for their young 
parents. Therefore, elevated lipid levels in a family member with a positive history of 
premature CAD are suggestive of HeFH in children (317). Table 3-1 shows that the TC, 
LDL-C and TG plasma levels were significantly different between adult and children, 
which is expected.    
  
Table  3-1:  Familial hypercholesterolemia (FH) patient characteristics in UK study  
 
 Adult Children p-value 
Sample size 25 (36.2%) 44 (63.8%) - 
Age (years) 46.26 (±12.0) 11.43 (±3.5) 0.0001 
Male (%) 12 (48%) 22 (50%) 0.017 
TC (mmol/l) 9.8 (±2.77) 7.12 (±0.91) 0.0001 
LDL-C (mmol/l) 7.66 (±2.0) 5.16 (±0.94) 0.0001 
HDL-C (mmol/l) 1.27 (±0.29) 1.4 (±0.33) 0.120 
TG (mmol/l) 2.27 (±1.17) 1.08 (±0.44) 0.0001 
Tendon xanthomata (%) 2 (8.0. %) 1 (2.2%) 0.24 
Family history of MI (%) 7 (28%) 11 (25%) 0.79 
Mean and standard deviation, where appropriate, are shown. P-value was determined using ANOVA test 
for numeric variables and chi-squared test for categorical variables.   
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3.1.1. Identified mutations in this study  
An FH-causing variant was found in 29 out of 69 patients (42.1%) examined, the 
detection rate in the children was not different (21/44 = 48%) compared to the adult 
samples (8/25 = 32%), p= 0.41. As shown in Table 3-2, there was no significant 
difference in cholesterol plasma levels between mutation positive and mutation negative 
groups (TC: p= 0.23, and LDL-C: p= 0.16) in adult groups. However, in the children’s 
group cholesterol plasma levels were significantly different between mutation positive 
and mutation negative groups (TC: p= 0.002, and LDL-C: p= 0.001). Seven children with 
FH mutation had a family history of MI.   
 
Table  3-2:  Familial hypercholesterolemia (FH) patient characteristics: mutation 
positive and negative groups in the UK study 
 
 Adult (25) Children (44) 
Variable 
Mutation 
positive 
Mutation 
negative 
p-value 
Mutation 
positive 
Mutation 
negative 
p-value 
Sample size 8 17 - 21 23 - 
TC (mmol/l) 
10.1 
(±2.7) 
8.5 (±2.8) 0.23 
7.6 
(±0.99) 
6.7 (±0.6) 0.002 
LDL-C (mmol/l) 8.7 (±2.7) 7.2 (±1.4) 0.16 5.7 (±1.0) 4.7 (±0.6) 0.001 
HDL-C (mmol/l) 1.1 (±0.2) 1.4 (±0.3) 0.89 1.4 (±0.3) 1.5 (±0.3) 0.55 
TG (mmol/l) 2.9 (±1.5) 1.9 (±0.9) 0.12 1.0 (±0.3) 1.1 (±0.5) 0.63 
Tendon xanthomata  2 0 0.06 1 0 0.3 
Family history of MI  3 0 0.02 7 0 0.001 
Mean and standard deviation, where appropriate, are shown. P-value was determined using ANOVA test 
for numeric variables and chi-squared test for categorical variables.   
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3.1.2. FH mutation positive in UK study 
Mutations were found in all three FH causing genes (Table 3-3); 18 
different LDLR mutations (3 novel) were found in 23 patients and accounted for 79% of 
all observed mutations, 2 different mutations were reported in the APOB gene in 5 
subjects (3 probands) (18%), one novel mutation in PSCK9 gene (3%), and no mutations 
was detected in LDLRAP1. 
 
3.1.2.1. LDLR mutations  
Twenty-three patients clinically diagnosed with FH carried LDLR causing variants; the 
19 different mutations identified have been reported in the literature, and three were 
novel (Figure 3-1). The identified mutations are located in 10 different exons of LDLR (2, 
3, 4, 8, 9, 10, 11, 12, 13, and 14) (Table 3-3).  Of the identified mutations that have been 
reported in the UCL-FH mutation database, three mutations were most common: the 
nonsense mutations in exon 3 [c.226 G>A, p.(Cys89*)] was detected in two patients, the 
missense mutation in exon 4 [c.136 T>G, p.(Cys197Tyr)] was identified in two patients, 
another a common missense mutation was identified in exon 14 [c.2054 C>T, 
p.(Pro685Leu)] in three patients.  
 
Other reported missense mutations were identified in exon 2 [c.136 T>G, p.(Cys46Gly)], 
in exon 4 [c.434 T>A, p.(Val145Glu); c.463 T>A, p.(Cys155Ser)], in exon 8 [c.1073 
G>A, p.(Cys358Tyr), c.1133 A>C, p.(Gln378Pro)], in exon 9 [c.1246 C>T, 
p.(Arg416Trp)], in exon 10 [c.1436 T>C, p.(Leu479Pro)], in exon 12 [c.1745 T>C, 
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p.(Leu582Pro)], in exon 13 [c.1860 G>T , p.(Trp620Cys)],  and in exon 14 [c.2042 G>C , 
p.(Cys681Ser)]. Furthermore, two previously reported nonsense mutations were 
identified in exon 8 [c.1150 C>T, p.(Gln384*)] and in exon 11 [c.1686 G>A, 
p.(Trp562*)].  
 
Figure  3-1: Diagram of LDLR gene showing the mutations identified in this study.  
Of 19 mutations identified in UK subjects in this study, three are novel mutations 
(indicated in red).  Exons are shown as vertical boxes and introns as the lines connecting 
them. 
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Table  3-3: Identified LDLR mutations in UK familial hypercholesterolemia (FH) patients 
Gene  
Location Base pair change Amino acid change PolyPhen SIFT 
Mutation 
Assessor  
Reported  
FH caussing 
Number of 
carriers 
(number of 
probands) 
LDLR 
Exon 10 19:c.1436 T>C p.(Leu479Pro) D D D Yes 1 (1) 
Exon 11 19:c.1659 C>G p.(Tyr553*) N/A N/A N/A No 1 (1) 
Exon 11 19:c.1686 G>A p.(Trp562*) N/A N/A N/A Yes 1 (1) 
Exon 11 19.c.1658 A>C p.(Tyr553Ser) D D P No 1 (1) 
Exon 12 19:c.1745 T>C p.(Leu582Pro) D D D Yes 1 (1) 
Exon 13 19:c.1860 G>T p.(Trp620Cys) D D D Yes 1 (1) 
Exon 14 2:c.2042 G>C p.(Cys681Ser) D D D Yes 1 (1) 
Exon 14 19:c.2054 C>T p.(Pro685Leu) D D D Yes 3 (3) 
Exon 2 19:c.136 T>G p.(Cys46Gly) D D D Yes 1 (1) 
Exon 3 19:c.226 G>A p.(Cys89*) N/A N/A N/A Yes 2 (2) 
Exon 4 19:c.590 G>A p.(Cys197Tyr) D D D Yes 2 (2) 
Exon 4 19:c.434 T>A p.(Val145Glu) N/A N/A N/A Yes 1 (1) 
Exon 4 19:c.463 T>A p.(Cys155Ser) N/A N/A N/A Yes 1 (1) 
Exon 8 19:c.1150 C>T p.(Gln384*) N/A N/A N/A Yes 1 (1) 
Exon 8 19:c.1073 G>A p.(Cys358Tyr) D D D Yes 1 (1) 
Exon 8 19:c.1133 A>C p.(Gln378Pro) D P P Yes 1 (1) 
Exon 8 19:c.1175 G>A p.(Cys392Tyr) D D D No 1 (1) 
Exon 9 19:c.1246 C>T p.(Arg416Trp) D D D Yes 1 (1) 
APOB 
Exon 26 2:c.10580 G>A p.(Arg3527Gln) D D D Yes 2 (2) 
Exon 26 2:c.10579 C>T p.(Arg3527Trp) D D D Yes 3(1) 
PCSK9 Exon 7 1:c.1070 C>T p.(Arg357Cys) P P P No 1 (1) 
D: Deleterious (PolyPhen2, SIFT), portion function (Mutation Assessor), P: Possibly damaging, B: benign, N/A: not applicable 
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3.1.2.2. APOB mutations 
Five patients (3 probands) carried the two different APOB missense mutations at position 
p.3527, two patients carried p.(Arg3527Gln) and three patients carried the 
p.(Arg3527Trp) variant. 
 
Family segregation analysis of the APOB Arg3527Trp affected subjects’   
 The APOB p.(Arg3527Trp) was identified in a proband patient (TM) who had suspected 
FH.  A 9 year-old South Asian girl (Pakistan) with a family history of MI had a TC = 6.6 
mmol/l, LDL-C = 4.2 mmol/l is heterozygotes for the p.(Arg3527Trp) mutation. To 
analyze mutation heritability, family members were genetically screened. Figure 3-2 
shows family segregation analysis; there is a consanguineous marriage of the parents, 
where the parents’ mothers are sisters (cholesterol levels unknown) and they share the 
same grandparents. The parents are heterozygotes for the mutation, and the mother has a 
raised TC level (7.5 mmol/l) and LDL-C level (5.5 mmol/l). Of their five children, not 
only is the proband affected but also two boys, aged 11 and 15 years are homozygous for 
the mutation [TC = 9.2 mmol/l, and LDL-C = 7.0 mmol/l; TC = 7.7 mmol/l, and LDL-C 
= 6.2 mmol/ respectively], while the other two girls aged 8 and 19 years are mutation 
negative and have normal cholesterol levels.    
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Figure  3-2: Family segregation of the c.10579 C>T, p.(Arg3527Trp) APOB mutation.  
(A) A family pedigree of the proband patient (TM) with the mutation including age 
(years), TC level (mmol/l) and LDL-C level (mmol/l). Six members of the family (WM, 
CB, IM, HM, IM and AM) were screened and sequenced for the mutation. Four members 
of the family were found to carry the variant. (B) APOB exon 26 sequencing for wild 
type and base change in patients (appropriate base highlighted).  
 
 
Full-filled shape= Homozygote for the APOB p.(Arg3527Trp) mutation (HoFH) 
Half-filled shape= Heterozygote for the APOB p.(Arg3527Trp) mutation (HeFH)  
No filled shape = no mutation  
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3.1.2.3. Novel mutations in the UK-FH study  
Three novel mutations were found in the LDLR gene and they were predicted to be 
pathogenic, however, family members of these patients were not available for segregation 
analysis. Missense mutations were found in exon 8 [c.1175 G>A, p.(Cys392Tyr) and in 
exon 11 [c.1658 A>C, p.(Tyr553Ser)] and one nonsense mutations was found in exon 11 
[c.1659 C>G, p.(Tyr553*)]. The three mutations are highly conserved a cross species 
(Figure 3-3) and are encoded in the epidermal growth factor-like domain (EGF-like 
domain), where a variant in this domain blocks receptor dissociation in endocytosis and 
receptor recycle to the cell surface machinery, both of which are highly likely to cause a 
disease phenotype. A 35 year-old White Caucasian woman was found to be heterozygous 
for Cys392Tyr (Figure 3-4 (A)); she had raised levels of TC=9.1 mmol/l, and LDL-C= 
6.5 mmol/l, but no TX or MI family history. Tyr553Ser (Figure 3-4 (B)) was identified in 
a 38 year-old White Caucasian man, who had raised levels of TC=8.5 mmol/l, and LDL-
C= 7.2 mmol/l, but no TX or MI family history. Peptide truncated mutation Tyr553* 
((Figure 3-4 (C)) was identified in a 12 year-old White Caucasian girl, but unfortunately 
no clinical data were available.    
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Figure  3-3: Sequence conservation of the two LDLR novel mutations in the UK 
study across-species 
 
 
 
Another novel variant p. Arg357Cys was identified in the PCSK9 gene in a 38 year-old 
white Caucasian man who was homozygous for the variant (Figure 3-3 (D)); the Arg 357 
is conserved, and substitution at this position is predicted to be pathogenic. He had raised 
levels of TC=8 mmol/l and LDL-C= 10.1 mmol/l and a family history of MI in a first 
degree relative (father). The variant is within the catalytic domain of PCSK9 (which is 
the domain that interacts with LDL-R to mediate receptor degradation). Also, it is located 
close to the oxyanion hole (Asn317), which has functional importance in catalysis 
(Russel et al., 1987; Carter et al., 1988). Replacement of an arginine by cysteine 
(p.(Arg357Cys)) may disturb hydrogen bond formation between residues (Betzel et al., 
2001). In addition, arginine 357 is located next to cytosine 358 which is predicted to be 
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involved in a disulfide bond in the rat Narc-1 protein (Naureckiene et al., 2003). 
Interestingly, another variant has been identified in a French FH patient at the same 
codon (p.357) resulting in a substitution of histidine (H) in place of arginine. The patient 
has a strong family history of hypercholesterolemia through five generations in both sides 
of his family and history of CVD in the paternal side (127).  
 
Figure  3-4: Novel mutations identified in the UK familial hypercholesterolemia 
study  
 
The figures show the DNA sequence of novel identified mutations. A) LDLR mutation in 
exon 8 c.1175 G>A, p.(Cys392Tyr). B) LDLR mutation in exon 11 c.1658 A>C, 
p.(Tyr553Ser). C) LDLR mutation in exon 11 [c.1659 C>G, p.(Tyr553*). D) PCSK9 
mutation in exon 7 c.1068 C>T p.(Arg357Cys).  
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3.3. Discussion 
This study has identified a number of previously reported and novel mutations among 
patients with FH attending various UK clinics. Amongst 69 patients clinically diagnosed 
with HeFH, mutations were found in 29 patients (42%).  Different mutations were 
identified using a target NGS method and were confirmed by Sanger sequencing: 18 
mutations in LDLR (3 novel mutations: p.(Cys392Tyr), p.(Tyr553Ser), and p.(Tyr553*)), 
one novel mutation in PCSK9 p.(Arg357Cys), and two mutations in APOB 
(p.(Arg3527Gln) and p.(Arg3527Trp)).   
 
The overall mutation detection rate in this study is 42% which is higher than that  
reported in previous UK studies: 35.53% (145), and 20% (148). This may be due to an 
increase in the sensitivity and specificity of the NGS mutation detection method. The 
Taylor (2010b) and Futema (2013) groups used ARMS, MLPA and HRM screening 
methods, which may include false negative results due to human error in data and sample 
handling (157). Also the ARMS kit was designed to detect only the 18 most common 
LDLR mutations in the UK (44% of UK mutations), APOB p.(Arg3527Gln) and PCSK9 
p.(Asp374Tyr) (145), while  the MLPA kit was developed to detect large deletions, and 
duplications which account for 10% of UK mutations (147). The HRM method has low 
coverage in some regions which may affect method sensitivity (146). In contrast, the 
NGS method has been used recently as a diagnostic tool for FH in studies of different FH 
populations  (151-154), and has shown 100% specificity and 98-100% sensitivity (155).  
All of these factors in addition to time efficiency and cost-effectiveness, have led to 
identification of novel mutations either in the three related FH genes (155, 157) or in new 
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genes that are suggested to be associated with polygenic FH  (151, 157). It is also 
possible that the detection rate is higher because a large proportion of the subjects here 
are children with a clinical diagnosis of HeFH and as such it would be expected that 
fewer have a polygenic etiology than a cohort of adults with a clinical diagnosis of HeFH 
 
In this study, the mutation spectrum was similar to the results of previous UK studies 
overall, where 80% of identified mutations were reported in LDLR, 17% in APOB, and 
3% in PCSK9. The LDLR identified mutations are located in 10 out of 18 exons of LDLR; 
there is a correlation between exons and the functional domain of the LDL-R protein. The 
identified mutations are encoded in two domains: the ligand binding domain and the 
EGF-like domain. The reported mutations could be classified into three classes of LDLR 
according to the  5 proposed LDLR mutation classes (51). Class 1 mutations are usually 
caused by nonsense mutations where the variants create stop codons and hence truncated 
proteins which prevent LDL-R protein synthesis. Class 3 mutations result in defective 
LDL binding to the receptor. Class 5 mutations occur due to a mutation in the EGF-like 
domain, where a mutation in this domain leads to blocking receptor dissociation in 
endocytosis and machinery for receptor recycling to the cell surface. Both LDLR 
mutation type and heterogeneity have an influence on FH phenotype. Studies have shown 
that the LDLR mutation types have an influence on the lipid profile and the response to 
lipid-lowering therapy (321, 322). Also, pharmacogenomic studies have reported that FH 
patients harboring a ‘null mutation’ (including classes 1 and 2, and large rearrangements 
or deletions leading to a frameshift and a premature stop coding) are at higher risk of 
premature CHD than patients with a defective mutation (322). This raises the importance 
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of identifying FH mutations and their type in order to establish lipid-lowering treatments 
at an early stage of the disease.  
 
In addition to 15 LDLR identified mutations that have been previously reported and 
linked to FH, there were three novel mutations all reported in the EGF-like domain. The 
first LDLR novel mutation reported was the substitution of cysteine 392 to tyrosine. 
Indeed, the 392 position looks like a hotspot for a FH causing mutations. It has been reported 
previously as a site for defective and null mutations: p.(Cys392Arg) (323) and p.(Cys392*) 
respectively (324-327). The other two novel mutations were reported at position 553; one 
defective mutation p.(Tyr553Ser) and one null mutation p.(Tyr553*). The literature has 
reported that the substitution of  tyrosine 533 to cysteine  is  an FH causing mutation (83). 
The three novel mutations are encoded positions that have been reported for FH causing 
mutations, and are predicted to be pathogenic, which suggests that the new identified 
mutations are highly likely to be functional.  
 
Also, a novel mutation in PCSK9 p.(Arg357Cys) was identified. The identified mutation 
is encoded in the catalytic domain, which is the part of PCSK9 the binds to LDL-R and 
mediates receptor degradation. Thus, mutation in this domain is highly likely to be 
functional. Indeed, patient clinical data, in silico functional prediction tools and mutation 
screening together have demonstrated that the identified mutation is highly likely to be an 
FH causing mutation. Usually, family segregation analysis would provide a definitive 
conclusion; however, family members were not available. Interestingly, Allard et al. 
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(2005) reported an FH case with p.(Arg357His) (high TC and LDL-C levels, and family 
history of hyperlipidemia and CHD, but no data was available for variant heterogeneity). 
They suggested that substitution of  arginine 357 to histidine may disturb the hydrogen 
bond formation between residues Asp, His and Ser of the catalytic triad, and 
consequently the structure of PCSK9  (127).      
 
Five patients (3 probands) were found with familial defective apoB-100 (FDB), which 
accounted for 17% of the identified mutations in this sample. Two unrelated white 
Caucasian children carried the most common APOB mutation p.(Arg3527Gln). The 
substitution of arginine to glutamine at position 3527 reduces the affinity between apoB-
100 and LDL-R, where the highly conserved receptor binding-site is stabilized by the 
interaction of Arg3527 with Trp4396, thus replacement of arginine 3527 by a glutamine 
impairs receptor recognition, affects hepatic LDL-C clearance and accumulation of LDL-
C particles in the circulation (73, 328). The affected probands are heterozygote for the 
variant which reflects the FH phenotype (TC > 7mmol/l, LDL-C > 5mmol/l, family 
history of MI in a first degree relative and no TX reported).  
 
The substitution of arginine 3527 with tryptophan p.(Arg3527Trp) was identified in a 
South Asian proband and another four members of the family. The novel finding here 
was that two patients were homozygous for the APOB variant p.(Arg3527Trp) and have 
milder phenotype than those homozygous for LDLR. There are three possible 
explanations of the lower plasma lipid levels found in FDB patients.  First, studies in 
187 
 
FDB homozygotes showed that the binding affinity of LDL to receptors in homozygous 
FDB was 10-20 % of normal affinity (329), which reduce clearance of LDL via the 
receptor. Secondly, lower plasma lipoprotein levels in FDB can partially be caused by an 
increased uptake of VLDL remnants via LDL-Rs  (85). Thirdly, the increased uptake of 
apoE containing particles from the plasma results in a decrease of apoB-100 production 
rate as well as of LDL-C particles (85).  It has been reported that the p.(Arg3527Trp) 
mutation has arisen independently in Asians (75, 80-82), while the p.(Arg3527Gln) 
mutation is inherited from a common ancestor in several Western populations (74-79, 
330).  
 
Fifty-eight percent of subjects examined in this study were FH-mutation negative. It has 
been demonstrated that the elevated LDL-C levels in mutation negative subjects with a 
clinical diagnosis of FH can be explained by the “polygenic” contribution of 12 common 
LDL-C raising variants in genes that were identified by GWAS (164). Although 6 of 
these LDL-C associated variants were included in the NGS amplicon design, they were 
excluded in data analyses due to the filtration criteria, where the common variants with 
MAF > 0.05% are excluded. Thus, it is possible that the elevated levels of LDL-C seen in 
the FH-mutation negative patients have a polygenic and not a monogenic explanation. 
For future work, it is worth examining whether FH is caused by an accumulation of 
common small-effect LDL-C raising variants in the mutation negative group. Such 
examination may help to explain the FH phenotype seen in the FH-mutation negative 
group.          
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3.4. Limitations 
There were limitations in this study. One was the small sample size and another, the 
unavailability of lipid measurements for 18 (26%) of the 69 participants, due to loss of 
participant communication after they had submitted FH mutation screening applications. 
The samples were sent for screening because the patients had met the FH criteria and it 
would not have been ethical to stop screening. For the same reason it was impossible to 
perform segregation analysis for all patients with novel variants. Another limitation was 
that polygenic FH was not examined in the mutation negative group due to time 
constraints.  
    
3.5. Conclusion   
NGS is a powerful technology that has the potential to address clinically relevant 
phenotypes related to genetic conditions of FH. FH monogenic mutations were identified 
in 42% of FH clinically diagnosed subjects. The mutations were identified in autosomal 
dominant hypercholesterolemia (ADH) genes including LDLR, APOB, and PCSK9; 
among 21 mutations identified in this study, four mutations were novel. It is 
recommended that FH-mutation negative subjects with a clinical diagnosis of FH are 
examined for 12 common “polygenic” LDL-C raising variants.  
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Chapter 4 : Mutation spectrum of familial 
hypercholesterolemia in Iranian patients 
190 
 
4.1. Introduction  
CHD is a leading cause of mortality, morbidity, and disability in the Iranian population, 
which  accounts for nearly 50% of  total deaths per year, and elevated LDL-C levels is the 
major risk factor, being present in ~45% of subjects (331). The prevalence of 
hypercholesterolemia (defined as having TC>90th percentile, 170mg/dl) in  Iranian children 
and adolescents varies between 3% and 48%  across the country (332). The causes of this are 
likely to be due to differences in both environmental factors and genetic background, for 
example due to the difference in frequency of common cholesterol-raising variants in 
different regions. The prevalence of the monogenic disorder FH may also contribute to this, 
and the frequency and spectrum of FH-causing mutations in the Iranian population is 
essentially unknown, with only a handful of studies reporting FH patient characteristics in 
Iran. Cases of homozygote FH (HoFH) have been reported in children with severe septum 
symptoms (TC≥ 440 mg/dl, LDL-≥ 390 mg/dl, HDL≥ 76 mg/dl) corneal arcus in both eyes 
and tendon xanthomas in the dorsum of both hands, both elbows, both knees, and Achilles 
tendons, and with early CHD (coronary artery stenosis and treated with coronary artery 
bypass graft surgery)  (333, 334). Genetic studies by the Fard-Esfahani group in 2005, who 
examined 30 patients with clinical possible FH, identified one novel mutation in exon 4 of the 
LDLR (p.(Gly445Cys0 G>T) using the PCR-single-strand conformation polymorphism 
(PCR-SSCP) method (335), but no carriers of the common mutation in the  APOB gene (exon 
26) were found (336). In another study in 2011, 30 Iranian subjects who had been clinically 
diagnosed with FH, were screened for FH mutations using PCR-Restriction Fragment Length 
Polymorphism (PCR-RFLP) and PCR-SSCP methods. No mutations were reported either in a 
promoter or coding region of LDLR or in exon 26 of APOB, but four common LDLR 
polymorphisms were reported in 17% of Iranians with possible FH, sensitivity of the method 
demonstrated by the identification of common LDLR polymorphisms (337, 338). Targeted 
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PCR methods are designed to detect a limited number of genetic mutations, thus they cannot 
detect all FH mutations; in addition, specificity and sensitivity issues are associated with the 
methods. Recently, NGS methods have been used as diagnostic tools for FH (151-154), and 
have shown 100% specificity and 98-100% sensitivity (155).  
 
In 2015, clinical practice guidelines for the diagnosis and treatment of FH in the Middle 
East were published. These guidelines noted some factors that are not applicable in Western 
countries such as the high prevalence of consanguineous marriage, limited treatment 
accessibility and the difficulties of cascade testing (339), which make FH management and 
CHD prevention difficult.  Historically, HeFH prevalence in most Western populations is 
thought to be 1:500 (42). By contrast,  HoFH has a much lower frequency of 1:1,000,000 in 
most Western countries  (42) and  1:300,000 in the Netherlands (201). HoFH may have a 
higher prevalence in Iran than in Western countries due to consanguineous marriage, which is 
more common in Iranian culture (35-54%) (340). To be given a clinical diagnosis of  HoFH 
patients should have LDL-C >13 mmol/L (500 mg/dL) if untreated or LDL-C >8 mmol/L 
(300 mg/dL) if treated, and the presence of tendon xanthomas (TX) before the age of 10 
years, or both the patients’ parents should  have been diagnosed with HeFH (200). However, 
the range of LDL-C levels reported in patients with HoFH is broad and can overlap with 
ranges found in other types of hypercholesterolemia (200, 339).  In Iran, it is essential to 
determine the type of FH patient in order to reduce morbidity and mortality due to CHD. 
Also, identifying the mutation spectrum and frequency of this region with help to improve 
disease management in the country.   
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As mentioned earlier, some countries in the Middle East have limited access to the new 
technology that is now used in FH mutation screening. In this study, my lab collaborated with 
Dr. Amirhossein Sahebkar from Iran, who provided samples from patients clinically 
diagnosed with HoFH, which were collected across several pediatric clinics in Iran. This 
study aimed to assess the FH mutation spectrum and frequency in Iran using the NGS-based 
screening method followed by Sanger sequencing to confirm identified mutations.  
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4.2. Results 
Fifty-seven samples were received from 16 unrelated families, and 16 children probands were 
selected to undergo mutation screening; of these, 14 probands were diagnosed with clinical 
HoFH, with an LDL-C >13 mmol/L (untreated) or LDL-C >8 mmol/L (treated), TX, and a 
positive family history of hyperlipidemia or MI. Two probands (FH9-P1 and FH10-P2) were 
suspected of having HeFH, although their cholesterol levels (LDL-C = 3.3 and 4.9 mmol/l, 
respectively) did not exceed the FH diagnostic cut-off, but they reported a strong family 
history of hyperlipidemia and/or MI. Thus, these probands also underwent analysis for LDLR, 
APOB and PCSK9 mutations because if the child was from a family with PFH, there is a high 
probability that he/she has FH. For this reason, samples were collected from the proband and 
any first degree relatives.  Baseline characteristics of the 16 selected cases are shown in Table 
4.1 and Figure 4-1shows LDL-C level distribution in Iranian FH probends.     
 
Table  4-1: Baseline characteristics (mean ± SD) used in the Iranian FH study 
 
Variable Probands 
Sample size  16 
Age (in years) 7.1 (±4.8) 
Total Cholesterol (mmol/l) 16.3 (±5.7) 
LDL-Cholesterol (mmol/l) 12.0 (±4.6) 
Tendon xanthomata 14 (87.5%) 
Family history of CHD 6.0 (37.5%) 
Family history of hyperlipidemia 16 (100%) 
Taking lipid-lowering medication  16 (100%) 
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Figure  4-1: The distribution LDL-C levels in Iranian FH probands 
 
 
4.1.1. Identified mutations in this study  
Out of the 16 patients examined, a FH-causing variant was found in 9 patients (56%), while 
no mutation was detected in 7 individuals (44%), 5 clinically diagnosed with FH and 2 
suspected of FH. All identified mutations were found in LDLR, and no mutation was found in 
APOB or PCSK9. As shown in Table 4-2, although TC and LDL-C levels were higher in the 
mutation positive group compared to the mutation negative groups, in this small sample these 
differences were not statistically significant (TC p= 0.10 and LDL-C p= 0.09).  
Table  4-2: Familial hypercholesterolemia (FH) patient characteristics: mutation positive 
and negative groups in the Iran study 
 
Variable Mutation positive Mutation negative p-value 
Sample size  9 7  
Age (in years) 7.8 (±5.6) 6.3 (±3.8) 0.56 
Total Cholesterol (mmol/l) 18.4 (±4.6) 13.7 (±6.7) 0.10 
LDL-Cholesterol (mmol/l) 13.6 (±3.8) 9.6 (±5.0) 0.09 
Tendon xanthomata 9 (100%) 5(71.4%) 0.16 
Family history of CHD 5 (55.5%) 1 (14.3%) 0.12 
Family history of hyperlipidemia 9 (100%) 7 (100%) 
- 
Taking lipid-lowering medication  9 (100%) 7 (100%) 
- 
Mean and standard deviation (SD), where appropriate, are shown. P-value was determined using ANOVA for 
numeric variables and chi-squared test for categorical variables.   
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Nine patients clinically diagnosed with HoFH carried LDLR causing variants; five different 
mutations were identified that have been previously reported in the literature, and two were 
novel  (Table 4.3, Figure 4.2). The identified mutations are located in six different exons of 
LDLR (4, 10, 11, 12, 14, and 17). Of the identified mutations reported in the UCL-FH 
mutation database, two were nonsense mutations [c.389C>G, p.(Ser130*) in exon 4, and 
c.1599G>A, p. (Trp533*) in exon 11], and two were missense mutations [c.1729T>C 
p.(Trp577Arg) and c. 2001T>G p.(Cys667Trp) in exon 12 and 14, respectively]. The fifth 
mutation was a frame-shift mutation in exon 17, c.2416_2417insG p.(Val806GlyfsTer11), 
where an insertion of guanine leads to a change in the amino acid from valine to glycine, 
which shifted the reading frame and created a stop codon downstream. Of the five identified 
mutations, two were common in this study: the missense mutation p.(Trp577Arg) was 
detected in three patients and the frame-shift mutation p.(Val806GlyfsTer11) was identified 
in two patients. 
 
The missense mutation’s functionality was assessed by in-silico mutation prediction tools, 
including PolyPhen2, SIFT, and Mutation Taster, and were predicted to be functional (Table 
4.3). As the nonsense mutations and insertion frame-shift mutation led to peptide truncation, 
they were predicted to be functional.  
 
Also, Lipoprotein(a) (Lp(a)) levels was screened in two FH suspected probands (FH mutation 
negative), and found that  they  had high levels of (Lp(a)  [Lp(a) > 100 mg/dL but with  LDL-
C levels  within the normal range (~3.3 mmol/l) when undergoing lipid-lowering drug 
therapy] 
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Table  4-3: Identified LDLR mutation in Iranian patients with familial hypercholesterolemia (FH)  
 
ID 
TC 
mmol/l 
LDL-C 
mmol/l 
Exon 
Base pair 
change 
Amino acid 
change 
PolyPhen SIFT 
Mutation 
Assessor  
Reported  FH causing 
 
Country report 
FH15-P 18.6 13.0 Exon 4  c.389C>G p.(Ser130*) N/A N/A N/A (341) Denmark 
FH14-P 16.5 15.0 Exon 10 c.1436 T>A p. (Leu479Gln) D D D Novel Iran 
FH8-P 21.7 19.4 Exon 11  c.1599G>A p.(Trp533*) D D D (342) 
Subject origin 
unknown   
FH1-P 11.4 10.0 
Exon 12 c.1729T>C p.(Trp577Arg) D D D (343, 344) Turkey FH2-P 18.6 14.2 
FH7-P 22.5 17.5 
FH17-P 15.3 13.6 Exon 14 
 c.2001T>G p.(Cys667Trp) D D D (345) France 
c.2002G>T p.(Glu668*) N/A N/A N/A Novel Iran 
FH3-P 21.5 16.1 
Exon 17 
 c.2416_241
7insG 
p.(Val806Glyfs
Ter11) 
N/A N/A N/A 
(346), 
(347), 
(348), 
(325) and 
(349). 
US 
South-Sweden 
Czech 
Netherlands 
Japan FH5-P 15.5 7.8 
D: Deleterious (PolyPhen2, SIFT), portion function (Mutation Assessor), P: Possibly damaging, B: benign, N/A: not applicable 
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Figure  4-2: Diagram of LDLR gene showing the mutations identified in the Iranian 
study. 
 
Seven mutations were identified in this study: two novel mutations are indicated in red.  
Exons are shown as vertical boxes and introns as the lines connecting them. 
 
 
 
 
4.1.1. Novel mutations 
Two novel mutations in LDLR were found in two probands with HoFH, which were not 
reported in the UCL-FH mutation database, one in exon 10 c.1436T>A p.(Leu479Gln) and 
another in exon 14 c.2002G>T p.(Glu668*). Both mutations are highly conserved a cross 
species  (Figure 4-3) and are encoded in the epidermal growth factor-like domain (EGF-like 
domain), where a variant in this domain blocks receptor dissociation in endocytosis and the 
receptor recycle to the cell surface machinery, both of which are highly likely to cause a 
disease phenotype.  
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Figure  4-3: Sequence conservation of the two LDLR novel mutations in the Iranian 
study a cross-species 
 
      
 
 
The homozygous p.(Leu479Gln) variant was found in a 10 year-old boy (FH14-P) who had 
high levels of TC (16.5 mmol/l) and LDL-C (15 mmol/l). Co-segregation analyses showed 
that this mutation is an FH-causing mutation and was present in all members of the family 
including both parents and a sibling (Figure 4-4). They were all heterozygous for this 
mutation; both parents had raised cholesterol levels [father (FH14-F): TC = 9.8mmol/l, LDL-
C = 6.6mmol/l; mother (FH14-M): TC = 8.5mmol/l, LDL-C = 6.8mmol/l], but not the 
sibling.    
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Figure  4-4: Co-segregation analysis of a family with novel mutation at exon 10 of LDLR 
A) NGS sequencing output for proband FH14-P reports a variant at exon 10  of the LDLR 
gene [c.1436T>A, p.(Leu479Gln)], the call rate A allele of the variant is 95% which indicates 
the proband is a homozygous for the variant. B) Co-segregation analysis of the FH14 family 
shows the 3 other family members are heterozygous for the variant. C) Sanger sequencing 
shows a base change between homozygote and heterozygote inherited modes.   
 
  
 
The second novel mutation, p.(Glu668*), was found in a 4 year-old girl ((FH17-P), Figure 4-
5) who had high levels of TC (15.0mmol/l) and LDL-C (13.6mmol/l), but no family history 
of either hyperlipidemia or MI. It was also found that the proband was homozygous for 
another mutation p.(Cys667Trp).  Family members of the proband were not available for 
segregation analysis.  
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Figure  4-5: a novel mutation at exon 14 of LDLR sequence data 
A) NGS sequencing output for proband FH17-P reports two variants at exon 14  of the LDLR 
gene [c. 2001T>G, p.(Cys667Trp) and c.2002G>T, p.(Glu668*)], the call rate of minor 
alleles of the variants are ≥94% which indicate the proband is a homozygous for  the variant. 
B) Sanger sequencing shows a base change between wild type and mutant homozygote 
inherited mode.   
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4.2. Discussion 
This study has identified a number of previously reported as well as novel mutations 
among patients with a clinical diagnosis of HoFH and HeFH attending various Iranian 
clinics. Amongst the 16 child probands clinically diagnosed with HoFH, mutations were 
found in 9 patients (57%).  Different mutations were identified using the targeted NGS 
method and were confirmed by Sanger sequencing, all in LDLR, where five had been 
previously reported as FH-causing mutations, but were not previously reported in the 
Iranian population, and two, p.(Leu479Gln) and p.(Glu668*) that were first reported in 
this study.  
 
This study has found two common mutations in people of Persian descent. The most 
common mutation was p.(Trp577Arg), which was seen in three patients with HoFH, 
explaining 37.5% of HoFH LDLR identified mutations. This was previously reported as 
very common in the Turkish population explaining 21.4% of the predicted defective 
LDLR alleles (343, 344). For populations that are geographically close, genetic and 
geographic distances are often highly correlated (350). Since there is close geographical 
and cultural links between Turkey and Iran they may share some common founder 
mutations. The three probands were from Esfarayen (FH1-P, FH2-P) and Guchan (Fh7-P) 
which are in the north-east of Iran on the border with Turkmenistan (Figure 4-6) and 74% 
of the Turkmenistan population are Turkmen (Turkish background).      
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Figure  4-6: Map of Iran representing the region of LDLR p.(Trp577Arg) affected 
probands 
  
 
 
The second common mutation was a frame-shift mutation p.(Val806GlyfsTer11) in exon 
17, which was found in two patients with HoFH. This mutation has been reported in 
different populations in the USA (346), South Sweden (347), Czech (348), Netherlands 
(325) and Japan (349). There are two possible explanations for the presence of the same 
mutation in different populations. First, there may be an ancestral mutation occurring in 
an individual living somewhere in the European continent, which has then spread 
throughout the world due to human migration. The FDB mutation (R3527Q), for 
example, is an ancestral mutation found in western Europe 6000-7000 years ago, and 
distributed to the East and West via human migration in the past 2000-3000 years (330). 
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This possibility could be tested by determining if the mutation occurs on the same SNP 
haplotype, but data are not available to carry this out.   
 
The second possible explanation is that the mutation may be located in a CpG (5'—C—
phosphate—G—3') mutation hotspot (351). Cytosine in the CpG dinucleotide carries a 
methyl group which is added via methyltransferase to form 5-methylcytosine, which 
causes DNA methylation and affects gene transcription via preventing transcription 
factors and other proteins from binding (352). However, by looking for the sequence 
around the point mutation and the CpG island map of the LDLR gene,  the insertion of 
guanine (G) nucleotide (c.2416_2417insG) does not create a CpG sequence (Figure 4-7).   
 
Figure  4-7: Electropherogram for DNA sequence analysis of 19: c.2416_2417insG 
(LDLR, p.(Val806GlyfsTer11) 
 
 
Inserted G nucleotide between 2416 and 2417 positions 
Stop codon 
(TAA) 
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 As shown in the LDLR CpG island map, exon 17 was not included in any CpG island 
(figure 4-8). The literature reported 12 CpG in the  LDLR promoter in atherosclerosis 
patients (353). Thus at the present time it is not possible to distinguish between these two 
possibilities. 
 
Figure  4-8: The CpG island map of LDLR gene by ENCODE, displayed using UCSC 
genome Browser 
 
 
Green boxes are indicating CpG islands. CpG island map shows that LDLR gene has three CpG islands, in 
the promoter and 5’UTR (CpG: 116), in exon 4 (CpG: 29), and in intron 10 (CpG: 24). 
 
 
Five of the identified mutations in this study have been reported in the UCL-FH mutation 
database, and are predicted to be pathogenic. Two identified mutations are nonsense 
mutations: p.(Ser130*) (exon 4) is located in repeat three of the ligand binding domain of 
the receptor and p.(Trp533*) (exon 11) encodes the EGF-like domain. Both mutations 
create a premature stop codon resulting in peptide truncation and nonfunctional protein 
products.  Also two missense mutations p.(Trp577Arg) and p.(Cys667Trp,) were 
identified that encode the EGF-like domain. A variant in this domain blocks both receptor 
dissociation in endocytosis and this influences the machinery responsible for recycling 
Exon 17 
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receptors to the cell surface, which causes the disease phenotype. The exon 12 mutation 
p.(Trp577Arg) is located  in the third Y-repeat (five repeats containing a YWTD motif ) 
of the EGF-like domain of the LDL-R, where other missense mutations have been 
functionally characterized to be class 2 mutations (transport-defective alleles) (42, 354). 
Thus we propose that the p.(Trp577Arg) mutation reported here would cause the same 
class of deficiency due to its location. The exon 14 mutation p. (Cys667Trp) encodes the 
third cysteine-rich EGF-like growth factor repeat of the LDL-R, which is a region that 
interacts with other proteins (42)., Six other mutations affecting this codon have been 
described in the UCL-FH mutation database, one of which, p.(Cys667Tyr) (FH French 
Canadian-2) (355), results in a transport defective protein (mutation class 2). It was 
postulated that the p.(Cys667Tyr) mutation identified here would have a similar impact; 
however, due to the presence of the sequence change creating the nonsense mutation at 
position 668, we designate the pathogenic mutation in this subject as p.(Glu668*). The 
fifth mutation was identified in Exon 17 p.(Val806GlyfsTer11) which encodes 
membrane-anchoring and cytoplasmic tail domains which are vital for locating the 
receptor correctly in the cell membrane, thus the truncated peptide at this position affects 
this machinery and leads to the disease phenotype. 
 
Two novel mutations have been identified in LDLR that were not reported in the UCL-FH 
mutation database: a missense mutation in exon 10 p.(Leu479Gln) and truncated peptide 
in exon 14 p.(Glu668*).  Both mutations are located in the EGF-like domain of LDLR, 
which is known to be important for receptor dissociation in endocytosis and receptor 
recycling to the cell surface, and are thus pathogenic. Analysis of the proband family 
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members carrying p.(Leu479Gln) showed that the mutation is inheritable and confirms 
that it is pathogenic and causing FH.  
  
Forty-three percent of subjects examined in this study were FH-mutation negative. It has 
been demonstrated that the elevated LDL-C levels in mutation negative subjects with a 
clinical diagnosis of FH  may be due to accumulation of  LDL-C raising “polygenic FH” 
(164). There are 12 common “polygenic” LDL-C raising variants described in the 
European population (MAF > 0.05%), however, the frequency of these variants in the 
Iranian population has not yet been studied.  However, based on data from other 
countries, it is likely that the elevated levels of LDL-C seen in patients who are FH-
mutation negative have a polygenic and not a monogenic explanation, and this could be 
examined in the future. The other possible explanation for the lack of a mutation in the 
three known FH genes would be that the hypercholesterolaemia is due to a mutation in an 
undiscovered gene(s). 
 
Two probands (7 and 12 years) suspected of having FH were included in this study, 
although their cholesterol levels did not exceed the FH cut-off, but they reported a strong 
family history of hyperlipidemia and MI. No mutations were found in the three FH genes. 
In both patients the presence of TX, a family history of CHD and hyperlipidaemia led to 
testing with a further lipoprotein screen: high levels of Lp(a) were found in both probands 
(Lp(a) > 100 mg/dL but with  LDL-C levels  within the normal range (~3.3 mmol/l) when 
undergoing lipid-lowering drug therapy). An elevated plasma concentration of Lp(a) has 
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been reported as  an independent risk factor for CVD (356-358). The clinical phenotype 
of Lp(a) hyperlipidemia (Lp(a)-HLP) shows great variability, as does FH, however the 
diagnosis of Lp(a)-HLP can be determined by the plasma concentration of Lp(a)  (359). 
Currently there is no effective and approved therapeutic drug for Lp(a)-lowering. A 
cohort study in 2009 showed that the long-time use of Lp(a) apheresis with maximal 
tolerated doses of lipid-lowering drugs reduced the plasma concentrations of Lp(a) by 
over 70%, and decreased the risk of CHD events (360). The HEART-UK working group 
has recommended that patients with progressive CVD, plasma concentrations of Lp(a) 
above 60 mg/dL, and plasma LDL cholesterol above 3.2 mmol/l (despite maximal lipid-
lowering drug therapy) should be considered for LDL apheresis (361). However, other 
clinicians have disputed whether Lp(a)-HLP should be treated by Lp(a) apheresis (359). 
There is no clear guidance for the indication of Lp(a) apheresis treatment, however most 
apheresis centers use the criteria of (a) plasma Lp(a) of 60 mg/dL as the cut-off, and (b) 
history of advanced and/or progressive CVD, or alternatively (c) presence of additional 
risk factors for CVD that accelerate the course of the disease (362). Further clinical and 
experimental studies are required in order to establish diagnoses, screening and 
therapeutic guidelines for Lp(a)-HLP and combined Lp(a)-HLP/ FH. Several genetic 
variants have been reported in the Apo(a) gene including a coding variant in the kringle 
domains (e.g. R560S), and a SNP in the promoter region of the gene (362). Indeed, the 
development of genetics and the availability of high throughput screening technology 
provide a great opportunity to identify gene variants that may explain disease phenotypes.   
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4.3. Limitations 
There were limitations in this study. One was the small sample size and another was that 
only patients with HoFH were included in this study.  It was not possible to perform 
segregation analysis for all patients with novel variants due to communication 
difficulties. Another limitation was that polygenic FH was not examined in the mutation 
negative group due to lack of reports about polymorphism frequency in the Iranian 
population, and Apo(a) was not screened because of grant and time limitations.  
 
4.4. Conclusion  
Although more than 1,700 variants have been reported in LDLR (65), there are still novel 
variants being found, proving the heterogeneity of FH. This is the first study in an Iranian 
population integrating both clinical and molecular-based techniques in order to elucidate 
FH heterogeneity and mutation spectrum. FH monogenic mutations occurred in LDLR 
and were identified in 57% of patients with FH clinically diagnosed with HoFH. Among 
the seven mutations identified in this study, two mutations were novel. It is recommended 
that FH-mutation negative subjects with a clinical diagnosis of FH are examined for 12 
common “polygenic” LDL-C raising variants Also, a genetic screening for the Apo(a) 
gene in patients with Lp(a)-HLP is recommended. Further and larger studies are needed 
to elucidate FH frequency in Iran and to identify common variants and/ or unique variants 
in subjects of Persian ancestry. 
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Chapter 5 : Identification of functional variant(s) behind the 
GWAS LDLR SNP (rs6511720) 
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5.1. Introduction 
Elevated levels of LDL-C is a major risk factor for CHD. LDL-C is mainly cleared by LDL-
R, and mutations in LDLR are the most common cause of FH (93%), with more than 1,700 
variants identified within the gene (65, 314, 363). Most of these mutations are located in the 
exonic regions, and thus affect protein structure and function. Ten percent of mutations are in 
the intronic region (exon boundary) and are predicted to affect splicing, while 2% are found in 
the promoter region. Thirty-six SNPs have been identified within the LDLR promoter region, 
which are predicted to prevent gene transcription via altering transcription factors that have an 
essential role in LDLR expression: they include SREBP, SP1 and CREB (311, 364-366). This 
finding encourages researchers to identify SNPs in regulatory regions of the gene and 
determine their pathogenicity and functionality.      
 
GWAS have revealed new genes and variants that are associated with traits and/or disease 
phenotypes. A large-scale GWAS has identified numerous loci (95 loci) that harbor common 
SNPs which have relatively small effects on lipid traits, 22 of which are associated with LDL-
C levels and CHD events, including SNPs at the LDLR, PCSK9, APOB and APOE loci (160). 
However, the majority of common variants that have been discovered in GWAS are in non-
coding regions and their functional implications are unknown (367). Interpretation of the 
molecular mechanisms of non-coding variants is a huge challenge because of linkage 
disequilibrium (LD), and the diversity of non-coding functions, including transcription, 
mRNA splicing and control of translation (368, 369).   
 
The T allele of the LDLR SNP rs6511720 (G>T) [MAF = 0.10 in the European population, 
(1000 Genomes Project Phase 3)] has been identified as being associated with lower plasma 
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levels of LDL-C and a lower risk of CAD in several studies. Teslovich et al. (2010) study 
showed that the LDLR SNP rs6511720 (G>T) is associated with LDL-C (p = 5 x10
-9
) and 
CAD in people with European ethnicity (>100,000 individuals). The study also found this 
applied to Non-Europeans including East Asian and African American populations (total p = 4 
x10
-117
) for LDL-C when combined with the European population. This finding supports 
previous GWAS results, which are summarized in Table 5-1. The LDLR SNP rs6511720 
(G>T) minor allele frequency is 10-13% in the general population. The SNP has been 
identified as being associated with lower LDL-C levels (effect size estimates differ between    
-0.15 and -0.26 mmol/l), and lower risk of CHD. More recently, data from a large meta-
analysis, the global lipids genetics consortium, confirmed this finding, where the SNP was 
associated with LDL-C [β (SE) = -0.227 (0.008), p= 2.79x10-151, N = 83,042] (161). Anand et 
al. (2009) also found that LDLR rs6511720 is associated with myocardial infarction (MI); the 
minor allele is associated with a lower ApoB and ApoB/A1 as well as a lower risk of MI (OR 
(95% CI) = 0.86 (0.77-0.95); p= 0.011). Furthermore, it is significantly associated with lower 
risk of Abdominal Aortic Aneurysm (AAA) (OR (95% CI) = 0.76 (0.70-0.83); p= 2.08 x10
-10
) 
(370). Between-study similarities have provided confidence that the LDLR SNP rs6511720 is 
either functional or may be a marker for a functional variant elsewhere in the gene. 
 
 
  
 
 
212 
 
Table  5-1: Summary of genome-wide association study results identifying LDLR SNP rs6511720 
Publication Population Sample size MAF Effect size 
LDL-C 
p- value 
CHD 
 
Bradley et al. (2013) 
(370) 
European 
cases (AAA)=5,138 
controls=39,273  
Cases=0.062 
Controls=0.088 
- 2.08 x10
-10
 
YES 
(AAA) 
Trompet et al. (2011) 
(371) 
European 5244 0.13 -0.19 mmol/l 5.2 x10
-15
 NA 
Teslovich et al. (2010) 
(160) 
European, East Asian and 
African- American 
>100,000 European 
>15,000 East Asians 
>9,000 South Asians and 
>8,000 African Americans 
0.11 
-6.99 mg/dl 
(-0.18 mmol/l) 
4 x10
-117
 YES 
Kathiresan et al. (2009) 
(372) 
European 19,648 0.10 -0.26 mmol/l 2 x10
-26
 NA 
Anand et al. (2009)   
(373) 
5 ethnic groups (South 
Asian, European, Arab, 
Irani, and Nepalese) 
6.9% South Asian (n=2346), 
9.4% European (n=3666), 
14.1% Arab (n=1498), 
11.2% Irani (n=402), and 
2.1% Nepalese (n=122) 
Total=8,795 
0.096 NA 
ApoB/AI= 
1.0 x10
-10
 
 
YES 
 
(MI) 
Kathiresan et al. (2008) 
(374) 
European 8,816 0.10 -0.26 mmol/l 2 x10
-51
 NA 
Willer et al. (2008)  
(375) 
European 8,816 0.10 
-8.03 mg/dl 
(-0.20mmol/l) 
6.8 x10
-10
 YES 
Aulchenko et al. (2008) 
(376) 
European 17,797 0.122 -0.15 mmol/l 6.84 x10
-18
 YES 
Miljkovic et al. (2010) 
(377) 
African 1,750 NA NA 0.0014 NA 
MI: Myocardial Infarction, and AAA: Abdominal Aortic Aneurysm  
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The rs6511720 SNP is located in intron-1 of the LDLR gene, where cis-acting gene regulatory 
sites are commonly found (378). Cis-regulatory elements physically interact with the 
promoter region of a gene to initiate DNA transcription (Figure 5-1) (253, 365, 379, 380). It 
was hypothesized that rs6511720 could be a part of an enhancer element which modifies a 
transcription factor-binding site (TFBS) that in turn recruits co-activators and chromatin 
regulators to facilitate the transcription of the LDLR gene (252). However, analysis of the 
genetic function of such variants is complex because of the LD between SNPs, which are co-
inherited with a causal variant. Thus, all SNPs in LD with the functional variant may be 
responsible for some or all the associations with the trait of interest, although they may not 
have any relevant function. Studying all SNPs in an LD block is time and resource costly, thus 
several bioinformatics databases were used in order to select and prioritize the LD SNPs with 
the strongest regulatory signs. The selected LD SNPs, in addition to the GWAS hit SNP 
rs6511720, were functionally analyzed. 
 
Figure  5-1: The role of The cis-regulatory elements in transcriptional regulation 
The cis-regulatory elements including promoter and enhancer sequences interact with each 
other by “DNA looping”. DNA looping brings promoters, enhancers, transcription factors and 
RNA processing factors (RNA polymerase II transcription complex) together to regulate gene 
expression, and the DNA loop is stabilized by a complex of proteins. Adapted from 
http://bio1151.nicerweb.com/Locked/media/ch18/activat or.html   
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5.2. Results  
5.2.1. Association of LDLR rs6511720 with LDL-C and CHD 
5.2.1.1. The rs6511720 genotype-phenotype association 
The UCL-LSHTM-Edinburgh-Bristol (UCLEB) consortium replicated an association between 
LDLR SNP rs6511720 (G>T) and cholesterol levels. The UCLEB consortium baseline 
characteristics and CHD incident rates of the subjects in the individual studies are presented in 
Table 5-2. Of the 12,395 subjects (range of follow-up 4-20 years, median 10 years), 2,131 
(17.19%) developed CHD, but the incidence rate differed among studies due to variations in 
mean age and duration of follow-up. Genotype was obtained for 12,165 samples and 
association analyses of LDLR SNP rs6511720 with lipid traits were performed. As shown in 
Figure 5-2, the minor T allele was significantly associated with lower levels of TC (≈7%) and 
LDL-C (≈10%) in both genders (p = <2.2x10-16), TC [Effect size (95%CI) = -0.239 mmol/l 
(±0.0437), p < 2.2x10
-16
) and LDL-C [Effect size (95%CI) = -0.193 mmol/l (±0.037), p < 
2.2x10
-16
). The minor allele was also associated significantly with a lower risk of CHD [OR 
(95% CI) = 0.883 (0.794 – 0.982); p = 0.02]. This suggests that individuals carrying one or 
more copies of the minor LDL-C lowering T allele of rs6511720 would have a lower lifetime 
risk of CHD. 
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Table  5-2: The baseline characteristics of seven studies in UCL-LSHTM-Edinburgh-
Bristol (UCLEB) consortium.  
 Studies 
 BRHS BWHHS CaPS EAS ELSA ET2DS WHII 
Number included in 
analysis 
2342 1980 1341 764 1883 1007 3078 
Number with incident 
CHD (%) 
608 328 345 165 297 214 174 
Length of follow-up 
(years) 
20 7 15.5  4 4 10 
Age, years 
69 
(5.65) 
71.5  
(5.3) 
61.9 
(5.0) 
69.9 
(5.6) 
73.6 
(9.5) 
67.9 
(4.2) 
60.8 
(5.98) 
Sex, % male 100% 0% 100% 48.4% 52.7% 51.1% 76.7% 
BMI, kg/m2 
26.8 
(3.6) 
27.7 
 (5.0) 
26.9 
(3.7) 
26.2 
(4.2) 
27.5 
(4.5) 
31.4 
(5.7) 
26.8 
(4.2) 
TC, mmol/l 
6.4  
(1.1) 
6.6 
 (1.2) 
6.2 
 (1.1) 
- 
5.7 
(1.3) 
4.3 
 (0.9) 
5.7 
 (1.0) 
HDL-C, mmol/l 
1.15 
(0.2) 
1.6 
 (0.4) 
- - 1.5 (0.4) 
1.3 
 (0.4) 
1.6 
 (0.4) 
LDL-C, mmol/l 
3.9 
 (1.0) 
4.1 
 (1.1) 
- - 
3.4 
 (1.1) 
3.0 
 (0.9) 
3.5 
(0.918) 
TG, mmol/l 
2.1  
(1.2) 
1.9 
 (1.0) 
1.9 
 (1.1) 
- 
1.8 
 (1.1) 
- 
1.4 
 (0.9) 
SBP, mmHg 
81.8 
 (12.8) 
80.1 
(11.8) 
81.7 
(12.0) 
82.3 
(12.1) 
73.0 
(11.5) 
69.1 
(9.0) 
74.5 
(10.4) 
DBP, mmHg 
144.1 
(20.0) 
150.0 
(25.4) 
145.0 
(22.3) 
148.2 
(24.6) 
139.0 
(19.6) 
133.3 
(16.5) 
127.9 
(16.4) 
 The seven studies are the British Regional Heart Study (BRHS), British Women’s Heart and Health Study 
(BWHHS), the Caerphilly Prospective Study (CaPS), the Edinburgh Artery Study (EAS), the English 
Longitudinal Study of Aging (ELSA), the Edinburgh Type 2 Diabetes Study (ET2DS), and the Whitehall II 
study (WHII).  
 Body mass index (BMI), total cholesterol (TC) high density lipoproteins-cholesterol (HDL-C), low density 
lipoproteins-cholesterol (LDL-C), Triglycerides (TG), systolic blood pressure (SBP), and diastolic blood 
pressure (DBP).  
 Mean and standard deviation (SD), where appropriate, are shown. 
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Figure  5-2: The UCLEB consortium: the LDLR rs6511720 genotype and cholesterol 
levels for men and women 
 
 
 
5.2.1.2. Meta-analysis of GWAS  
The published GWAS data were also used to identify the association between rs6511720 and 
LDL-C and CHD. The summary estimates for the log odds Ratio [log(OR)] and its standard 
error for the relationship between  rs6511720 and CHD were taken from CARDIoGRAM  
(381) and C4D (382) (http://www.cardiogramplus c4d.org/data-downloads/) and were 
combined by fixed effects meta-analysis. The meta-analysis showed that the rs6511720 minor 
allele was associated with lower risk of CHD [log (OR) = −0.1155; SE = 0.0217; p = 1.04 
x10
-7
] (Table 5-3) (383). 
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Table  5-3: Association of rs6511720 genotype and CHD risk in CARDIoGRAM and C4D 
 
 
 
Also, the regression coefficient for rs6511720 on LDL-C  was estimated from the Global 
Lipids Genetics Consortium (GLGC) data (161)  (http://csg.sph.umich.edu/abecasis/ 
public/lipids2013/). The GLGC (N = 170,607) showed that the rs6511720 minor allele is 
associated with lower levels of LDL-C [beta = −0.2209; SE = 0.0061; p = 3.85 x10-262] (Table 
5-4). These support the earlier finding, where individuals carrying one or more copies of the T 
allele of rs6511720 have lower LDL-C levels and would have a lower lifetime risk of CHD. 
 
  
Table  5-4: Association of rs6511720 genotype and lipid traits from data from the Global 
Lipids Genetics Consortium (GLGC) 
 
 
Reference 
allele 
Beta Se p-value Sample size 
TC T -0.1851 0.0059 5.43 x 10
-202
 184764 
LDL-C T -0.2209 0.0061 3.85 x 10
-262
 170608 
HDL-C T 0.0249 0.0057 6.32 x 10
-5
 184617 
TG T -0.0084 0.0056 0.1043 175280 
 
SNP(allele) 
log(OR) 
with CHD per-allele  
SE (log(OR)0 Sample numbers 
rs6511720 (T~minor allele) 
CARDIoGRAM 
- 0.1253 0.03321 
8948 cases 
4747 controls 
rs6511720 (T~minor allele) 
C4D 
- 0.1082 0.0287 
15393 cases 
15036 controls 
fixed effects  
 meta-analysis 
- 0.1155 0.0217 
24341 cases 
19783 controls 
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5.2.2. SNP annotation  
5.2.2.1. Linkage disequilibrium (LD) 
Several SNP annotation databases were used to identify possible SNP functions. First, the 
Locuszoom (384) (http://csg.sph.umich. edu/locuszoom/), and the  HaploReg V2-V4 (290, 
385) (http://compbio.mit.edu/Haplo Reg) were used to identify LD SNPs with the LDLR 
GWAS hit SNP rs6511720. It was found that the SNP rs6511720 has strong LD (r
2≥0.8) with 
48 other SNPs: three SNPs are located in intron-1 and the others are located ≥1.5kb upstream 
of the LDLR locus (Figures 5-3 and 5-4).  
 
Figure  5-3: Linkage disequilibrium plot of the LDLR SNP rs6511720 
An LD plot was generated using Locuszoom (http://csg.sph.umich.edu/locuszoom/). SNPs are 
plotted with the meta-analysis p value of LDL-C association (as –log10 values) as a function 
of genomic position. The lead SNP (rs6511720) is represented by a diamond, while LD SNPs 
are represented by circles. The LD SNPs are color-coded to represent the r-squared (r2) 
between SNPs and the putative associated variant, where red indicates strong LD r2≥0.8 and 
dark blue indicates weak LD r2≤0.2. The blue line indicates estimated recombination rates 
and the dark blue arrows indicate gene annotations. LD and recombination rates are based on 
HapMap Phase II (the Centre d’Etude du Polymorphisme Humain collected in Utah, USA, 
with ancestry from northern and western Europe (CEU)). 
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Figure  5-4: The linkage disequilibrium predictions for LDLR intron-1 SNP rs6511720 with r
2
>0.8 
The figure shows the HaploReg reported LD SNPs, 48 SNPs have strong LD (r2≥0.8) with rs16511720, which are reported according to LD 
information from the 1000 Genomes Project. The HaploReg annotation tools also provide information that relates regulatory elements for the 
SNP of interest and LD SNPs including, promoter and enhancer markers, DNAse, predicted portion binding, predicted motif changes and their 
location within the gene. General information about the SNP is also provided; chromosome number, SNP position in the gene, LD value by 
deviation (D) and frequency (r
2
), SNP ID (variant), major allele (Ref) and minor allele (Alt), MAF in four populations: African American, 
American, Asian and European.  
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5.2.2.2. SNP prioritization and selection  
For prioritizing and selecting SNPs for functional studies, three bioinformatics resources were 
used: UCSC Genome Browser (386), MatInspector (291)  and HaploReg (290, 385). Using 
UCSC Genome Browser, genome-wide maps of the chromatin state of relevant cell types 
(HepG2, human hepatocytes) were examined. Variant position was evaluated for evidence of 
histone modification markers, H3K4me1, H3K27Ac and H3K4me3, as well as for DNase I 
hypersensitivity sites and for formaldehyde assisted isolation of regulatory elements (FAIRE). 
The post-translational chromatin markers H3K4me1, and H3K27Ac are often associated with 
enhancer regions (387), while H3K4me3 is associated with promoter regions (388, 389). DNase I 
and FAIRE are established methods for the identification of nucleosome regulatory regions 
(390). In addition, transcription factor occupancy in chromatin was assessed using genome wide 
ChIP-seq data sets (276). 
 
 It was found that the LDLR intron-1 SNP rs6511720 is located in an open chromatin zone, 
which has strong markers for histone modification markers H3K4me1, H3K27Ac and FAIRE 
and the region is occupied with transcription factors (Figure 5-5). The same criteria was applied 
to evaluate the LD SNPs which found that of the 48 variants meeting the LD threshold (r
2
<0.8), 
38 did not show a regulatory effect on a hepatic cell line. Further, seven SNPs (rs8106503, 
rs139306531, rs138175288, rs114821903, rs73015011, rs111989435, rs112736558) are located 
>3kb upstream of LDLR, while the 5’UTR functional region of the LDLR promoter starts -250bp 
upstream of the translation start site (311, 366).These seven SNPs also have a low regulatory 
markers score and are not predicted to bind to regulatory proteins. Therefore, these 45 SNPs 
were excluded from this study, However, three SNPs were found to have strong chromatin 
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signals [rs57217136 (T>C), rs141787760 (C>deletion) and rs60173709 (T>deletion] and are in 
complete LD (r
2
=1) with GWAS hit SNP rs6511720. This GWAS SNP and the further three 
selected SNPs are located in intron-1 of LDLR within ≈1200bp of each other. Figure 5-6 shows 
the LDLR selected SNPs location within intron-1 and possible haplotypes. 
 
Figure  5-5: Genome road map of chromatin state of LDLR intron-1. 
Schematic presentation of the LDLR intron-1 chromatin status (https://genome-euro.ucsc.edu). 
The intron-1 of the LDLR has a strong histone marker and FAIRE signal. It is located at DNaseI 
hypersensitivity sites and within an area that harbors transcription factor binding sites. The area 
of interest of intron-1 is highlighted in light-blue, where the four SNPs of interest (rs6511720, 
rs141787760, rs60173709, and rs57217136) are located (383).  
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Figure  5-6: LDLR intron-1 SNPs location and possible phenotypes  
The figure shows the schemes of LDLR intron-1and the four potential functional candidate SNPs, 
[rs6511720 (G>T) rs57217136 (T>C), rs141787760 (C>deletion) and rs60173709 (T>deletion)]. 
These SNPs are in complete LD (r
2
=1), thus two haplotypes are possible; all major alleles 
together or all minor alleles together.     
 
 
  
 
 
MatInspector and HaploReg tools, showed different DNA-protein binding profiles for these 
SNPs (Table 5-5); the LDLR SNP annotated results suggest that rs6511720 is a strong enhancer, 
while the other three SNPs are involved in gene expression by activating the LDLR promoter 
[Encode data (391)]. In addition, MatInspector (in silico) and HaploReg (ChIP-seq data) showed 
different DNA-protein binding profiles for these SNPs. The MatInspector software predicted a 
sequence around the minor allele of rs6511720 that would bind to GATA and the snRNA 
activating protein/ proximal sequence element (SNAP/PSE) complex, but HaploReg did not 
report any protein binding around this SNP. SNAP/PSE has a role in gene transcription initiation 
(392-394). MatInspector did not predict any binding sites for either rs141787760 or rs60173709, 
while HaploReg software showed that the minor allele of rs141787760 would bind to 
transcription factors that have roles in chromatin modulation through general transcription 
regulation (such as CHD2, CTCF, Egr-1and p300) and a known LDLR transcription regulator 
specificity protein 1 (SP1).  The rs60173709 SNP was also reported as a binding site for some 
proteins, but none of them have a role either in chromatin modulation or in LDLR gene 
Intron-1 ≈ 10kb 
Exon 1 
Promoter 
Exon 2 rs6511720  rs141787760 rs57217136 rs60173709 
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regulation. For rs57217136, HaploReg showed that the major allele would bind to TFs such as 
forkhead box protein A (FOXA1, FOXA2), which are liver transcription activators, and was also 
predicted to bind to sterol regulatory element-binding protein 1 (SREBP1), while the minor allele 
would bind to SP1.  
 
Table  5-5: Predicted regulatory element and protein binding of the LDLR selected SNPs 
SNP IDs 
Position 
(hg19) 
Regulatory 
element [30] 
Allele 
Predicted protein 
binding and motif 
change  
(Haploreg) 
Predicted protein 
binding 
(MatInspector) 
rs6511720 11202306 
Strong 
Enhancer 
G - BLMP 
T* - GATA1, SNAP/PSE 
rs141787760 11202194 
Active 
Promoter 
C CDP - 
deletion* 
CHD2, CTCF, ELF1, 
Egr-1, SP1, Zic, and 
p300 
- 
rs60173709 11201988 
Active 
Promoter 
T EBF, Myf, Pax-5 - 
deletion * GR and MAZ - 
rs57217136 11201124 
Active 
Promoter 
T 
FOXA1, FOXA2, and 
SREBP1 
- 
C* SP1 OAZF/ROAZ 
* = SNP minor allele 
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5.2.3. Allele-specific protein binding of LDLR intron-1 SNPs in Huh7 cells 
The SNP annotation analysis suggested that the LDLR intron-1 selected SNPs are sites for 
transcription factor binding. To assess whether the alleles of the SNPs differentially affect DNA-
protein binding in vitro, EMSAs for the four intron-1 SNPs were carried out. This technique is 
based on the fact that DNA-protein complexes migrate slower than non-bound DNA in 
polyacrylamide gel electrophoresis, resulting in a “shift” in migration of the labeled DNA band. 
By using a non-isotopic method to detect DNA-protein interactions, biotin end-labeled DNA 
containing the binding site of interest was incubated with a Huh7 nuclear extract. Each set of 
biotin labeled probes was run alongside an unlabeled probe that was added to the reaction before 
adding the biotin labeled probe, which led to the unlabeled probe competing with the labeled 
probe to bind to protein. Multiple conventional EMSAs were performed for both alleles of four 
LDLR intron-1 SNPs: rs6511720, rs57217136, rs60173709, and rs141787760 (Figure 5-7). The 
SREBP1 was used as a control. The alteration of binding intensity or band shifting between 
alleles are a sign of a change in DNA-protein binding that may be involved in LDLR regulation 
(383).  
 
In Figure 5-7 (A), gel A, SREBP1 was used as the control (lanes 1-3). The negative control 
contained no nuclear extract and no bands were visible (lane 1), whereas the positive control 
contained a labeled probe that showed a band indicated by arrow (lane 2). When the unlabeled 
probe was added the specific band disappeared (lane 3). For the rs6511720 SNP (lines 4-7), it 
was observed that the minor T allele of the SNP in lane 6 formed a different protein complex 
which moved slower than the major G allele complex in lane 4 (bands shift indicated by the 
arrows): also there were different binding affinities between alleles. These allele protein 
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complexes were eliminated in the presence of unlabeled probes (lanes 5 and 7), which indicate 
the protein complexes observed in lanes 4 and 6 are allele-specific (383).        
 
In Figure 5-7 (B), gel B shows the EMSA results of three LDLR intron-1 SNPs that have 
complete LD with rs6511720. Lanes 1 and 2 contained SREBP1 as the positive control while 
lanes 3 to 6 have rs141787760 allele probes: the major and minor alleles showed three non-
specific bands, but the rare allele showed a new band (lane 5), which is indicated by an arrow, 
this specific band was eliminated when an unlabeled probe was added (lane 6) (383). The 
rs60173709 alleles were loaded in lanes 7-10; the major allele (T) showed two weak bands 
where the non-specific bands are located (lane 7), while the minor allele showed three new bands 
(lane 9) that were eliminated by the unlabeled probe (lane 10). The rs57217136 (lanes 11-14) 
minor allele (C) showed two bands which were eliminated by the unlabeled probe (lanes 13-14). 
These two bands were located where unspecific bands were found, but they had 90% less 
intensity than the unspecific bands observed in other SNPs, which suggest that perhaps the C 
allele migrates alongside non-specific bands. The major allele (T) did not show any protein 
binding (lanes 11-12). 
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Figure  5-7: DNA binding properties of LDLR intron-1 SNPs 
The conventional EMSA analysis of the LDLR intron-1 SNPs (rs6511720, rs141687760, rs60173709, and rs57217136). The biotin-
labeled probes were run alongside unlabeled probes. The minor allele is labeled with (*).  (A) EMSA for the LDLR GWAS hit SNP 
rs6511720.  (B) The LDLR complete LD SNPs with GWAS hit SNP: rs141787760, rs60173709, and rs57217136. These four SNPs 
have allele-specific binding, indicated by arrows. (-) = deletion, (*) = minor allele. SREBP1 was used as a positive control.  
 
A) B) 
227 
 
5.2.4. Allele-specific enhancer activity of LDLR intron-1 SNPs in Huh7 cells 
To determine whether LDLR intron-1 SNPs have an influence on gene expression, reporter gene 
expression assays were performed, where the LDLR promoter 594bp DNA fragment (full LDLR 
promoter) was inserted into a pGL3-basic luciferase reporter vector to generate pLDLR 
promoter. The insertion was upstream of the luciferase gene (luc+) at the promoter site. Then the 
LDLR SNP sequences encompassing each SNP allele were individually added to the pLDLR 
promoter construct, and inserted into the enhancer site of the pLDLR promoter after the SV40 
polyadenylation signal (Figure 5-8).  
 
Figure  5-8: An example of LDLR SNP cloning construct map 
This cloning construct map shows where 594bp of the LDLR promoter fits into the promoter site 
of the pGL3-basic luciferase reporter vector, and the LDLR SNP (e.g., rs6511720) fits into the 
enhancer site of the vector. The map was generated by SnapGene (http://www.snapgene.com/)  
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I tried to amplify a fragment that contained all four SNPs, however, it was impossible due to 
Arthrobacter luteus repeats (Alu repeats): the LDLR intron-1 has 20 Alu repeats (395) which 
prevent DNA amplification. Therefore, this fragment was divided into three fragments to exclude 
Alu repeats; the first fragment contained rs6511720 (884bp), the second fragment (643bp) 
contained both SNPs rs60173709 and rs141787760, and the third fragment contained (814bp) 
rs57217136. The SNP variants were generated using site-directed mutagenesis (see Figure 5-9 
for base change sequence of LDLR intron-1 SNPs). Seven constructs were generated, which were 
then grown in E-coli cells, and then transfected into Huh7 cells along with the control plasmid 
pRL-TK vector that encodes the firefly luciferase gene to normalize for transfection efficiency. 
The pGL3-LDLR promoter WT was used as a normalizing factor. The luciferase assays were 
carried out in four replicates, and the statistical analysis mean relative expression difference 
between wild type and variant was determined by a t-test.   
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Figure  5-9: Base change of LDLR intron-1 SNPs by Site-Directed Mutagenesis 
 
rs57217136 WT 
sequences had  an 
extra G nucleotide 
at position 337. 
The first SDM 
was done to delete 
G, and then the T 
allele was 
substituted for the 
C allele     
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To assess the effect of the LDLR SNPs transfected construct on LDLR promoter activity, the 
relative expressions were normalized to the promoter construct alone (Figure 5-10 A & B). 
Luciferase activity measurements showed that although the rs141787760/rs60173709 transfected 
construct led to a significant reduction in LDLR promoter expression when compared to the 
promoter alone: -24% (p = 0.006) for the major allele and -29% (p = 4.0x10-8) for the minor 
allele, there was no significant difference between the alleles (p = 0.28). In contrast, both major 
and minor alleles of rs6511720 appear to function as enhancers, and increased LDLR promoter 
expression by +54% and +89% (p = 1.88x10
-6
, and p = 3.70x10
-13
), respectively. The 
rs57217136 SNP only had enhancer activity in the presence of the minor allele, which increased  
LDLR promoter expression by +28%. These data suggest that the minor alleles of rs6511720 and 
rs57217136 function as enhancers. The minor alleles of both rs6511720 and rs57217136 
increased LDLR promoter expression activity significantly by +29% and +24% (p = 0.026, and p 
= 0.002), respectively, when compared to the major alleles. Since higher expression of LDLR 
would lead to greater number of LDL-R on the surface of the liver, this would increase clearance 
of LDL-C from the blood, and would  explain the lower LDL-C levels reported in individuals 
with the T allele of rs6511720 (383).   
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Figure  5-10: LDLR luciferase constructs map and SNP luciferase activity in Huh7 cell line  
(A) Schematic presentation of LDLR-luciferase-construct (promoter only) and LDLR-luciferase-
enhancer-constructs. (B) Results of luciferase reporter assays showing relative expression of 
LDLR-luciferase-enhancer constructs of LDLR SNPs relative to the LDLR-luciferase (no 
enhancer) construct.  
 
A)  
 
 (-) = deletion and (*) = minor allele 
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B)  
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5.2.5. Multiplexed competitor electrophoretic mobility shift assay (MC-
EMSA) 
To identify the transcription factors that bind to LDLR intron-1 variants and cause differential 
expression in the luciferase assay, MC-EMSAs were carried out. Multiple MC-EMSAs were 
performed using seven sets of cocktails, with each set having 10 unlabeled dsDNA consensus 
sequences for well-characterized proteins. These proteins were multiplexed and added to the 
binding reaction comprising Huh7 nuclear extract. When a particular set of a multiplexed 
competitors eliminated the allele specific band(s), the individual competitor from this set were 
examined further using EMSA. The two SNPs, rs6511720 and rs57217136, showed a different 
DNA-protein banding in conventional EMSA and an increase in gene expression of luciferase 
reporter gene in MC-EMSA. 
 
As shown in Figure 5-11(A), both alleles of the LDLR SNP rs6511720 were run with the seven 
cocktails. For the rs6511720 G allele specific bands (Bands 1 & 4) were competed out by 
‘cocktail 4’ competitors, where the bands’ intensity reduced by ≈90%, while the rs6511720 T 
allele specific bands (Bands 3 & 6) were eliminated by ‘cocktail 4’ competitors. Further EMSAs 
were carried out on individual proteins of ‘cocktail 4’ in order to determine the transcription 
factors that mediate LDLR gene expression (see Figure 3-10(B)). It was observed that two 
proteins bind to the sequence around the rs6511720 G allele. The rs6511720 G allele specific 
band (Band 4) was eliminated by sis-inducible element (SIE) and signal transducer and activator 
of transcription 1 (STAT1) (competitors #42 and 48, respectively). However, the other G allele 
specific band (Band 1) was competed out by most competitors, which indicates none of them are 
specific to the G allele. On the other hand, the rs6511720 T allele specific band 6 was eliminated 
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by sterol response element (SRE) (competitor #47), while the T allele specific band 3 was 
eliminated by several competitors.  
 
Figure  5-11: DNA binding and expression of the transcription factors of the LDLR SNP‎
rs6511720 (G>T) 
 
MC-EMSA analysis. (A) Nuclear proteins from the Huh7 cell line were incubated with 7 
cocktails of unlabelled DNA competitors. (B) The single competitors of cocktail 4 were run 
individually in a further EMSA for both alleles of rs6511720. Bands 1 and 4 are specific for 
rs6511720 G allele, bands 2 and 5 are non-specific bands, while bands 3 and 6 are specific for 
rs6511720 T allele and migrate alongside non-specific band 5. The green arrows show G allele 
specific bands, the red arrows show T allele specific bands, and the yellow arrows indicate 
positive competitors. 
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Conventional EMSA showed that the presence of rs57217136 C allele led to creation of a protein 
binding site to the sequence around the allele, in contrast to the T allele of the SNP that had no 
specific DNA-protein interaction. Thus, when the rs57217136 C allele was run with the seven 
cocktails, it was eliminated by cocktail 4 competitors (Figure 5-12 A). In Figure 5-12 B, the 
individual competitors of ‘cocktail 4’ showed that the C allele specific bands (bands 1 and 3) 
competed with Retinoic Acid Receptor (RAR) (competitor #40) and STAT1 (competitor #48), 
respectively.  
 
Figure  5-12: DNA binding and expression of the transcription factors of the LDLR SNP‎
rs57217136 C allele  
MC-EMSA analysis. A) Nuclear proteins from the Huh7 cell line incubated with seven cocktails 
of unlabeled DNA competitors in the presence of rs57217136 C biotinylated labeled probes. The 
rs57217136 T allele specific bands 1 and 3 were eliminated by ‘cocktail 4’, while band 2 was 
non-specific.  B) EMSA of 10 individual competitors of ‘cocktail 4’. The specific band 1 was 
eliminated by competitor #40, while Band 3 competed with protein #48. The red arrows show C 
allele specific bands, and the yellow arrows indicate positive competitors. 
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5.2.6. Protein-protein network identification 
Gene transcription involves complex machinery; several proteins network together to create a 
transcription complex that interacts with the gene promoter and initiates gene transcription. The 
functional SNPs rs6511720 and rs57217136 are predicted to act as enhancer and promoter 
activator elements respectively, thus co-operate with proteins to regulate genes. For better 
understanding of how such machinery works, the STRING protein network software provides a 
visual summary of proteins that may interact with a protein of interest. STRING is a useful tool 
to identify which kind of regulatory proteins cooperate with known proteins that regulate the 
gene. 
 
Figure 5-13 shows the protein network of identified allele-specific proteins. There are three key 
proteins identified: SRE, STAT1, and RAR. SRE has a short recognition sequence commonly 
found in the 5’ of the site of transcription initiation of many genes, which is bound to serum 
response factor (SRF) in order to regulate gene transcription (396). Figure 5-13 A shows that 
SRF interacts with some transcription regulatory factors such as myocardin (MYOCD), GATA 
binding protein 4 (GATA4), and SMAD family member 2 (SMAD2).  
 
The second key protein is STAT1, which interacts with transcription regulator and co-regulator 
proteins (Figure 5-13 B) such as STAT2, STAT3, protein inhibitor of activated STAT1 (PIAS1) 
and interferon regulatory factor 1(IRF1). STAT1 also interacts with histone regulatory proteins 
CREBBP (CBP/p300), E1A binding protein p300 (EP300), and proteins linked to lipid 
metabolism – Janus kinase 2 (JAK1) and epidermal growth factor receptor (EGFR).   
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The third key protein is RAR, RARA isoform is able to interact with a wide variety of proteins 
(see Figure 5-13 C) that have a role in gene transcription regulation including nuclear receptor 
co-repressors (NCOR1and NCOR2), nuclear receptor co-activators (NCOA1, NCOA2, and 
NCOA2), nuclear receptor interacting protein 1 (NRP1), mediator complex subunit (MED1), 
histone regulatory proteins (EP300, HDAC, and STAT3), and retinoid X receptor gamma 
(RXRG) which links to lipid homeostasis.  
 
Figure  5-13: the LDLR intron-1 functional SNPs: allele-specific protein network 
These figures illustrate the rs6511720 and rs57217136 minor allele-specific protein network, 
where rs6511720 binds to SRE, which is a DNA sequence element for SRF, and rs57217136 
binds to STAT1 and RARA. A) The protein network of SRE. B) The protein network of STAT1. 
C) The protein network of RARA.    
 
A) SRE protein network 
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B) STAT1 protein network  
 
C) RARA protein network 
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5.3. Discussion 
LDL-R is the primary protein involved in clearance of cholesterol from the blood, and mutations 
or variants in the gene lead to FH (39, 40). Studies also demonstrate that the co-inheritance of 
many trait-associated SNPs can explain the disease phenotype. GWAS has reported 22 SNPs 
associated with LDL-C. The LDLR SNP rs6511720 is considered a protective SNP. Several 
studies using GWAS data have reported that the minor allele of the SNP is associated with lower 
plasma levels of LDL-C and a lower risk of CHD (160, 374, 376). I have confirmed this effect in 
the UCLEB consortium data, which demonstrated that individuals carrying one or more copies of 
the T allele of rs6511720 have lower LDL-C levels and have a lower lifetime risk of CHD.  
Furthermore, data from the GLGC consortium confirmed that the LDLR rs6511720 minor allele 
(T), which is carried by approximately 10% of the population, is strongly associated with a 
protective effect, being associated with lower levels of LDL-C. This association is thus 
consistent and of sufficient strength to suggest that common variation in LDLR has implications 
for health, and that determining the precise molecular mechanism of the effect is relevant. 
 
The GWAS hit SNP  rs6511720 is located in intron-1 where the cis-acting gene regulating sites 
may commonly be found (378). Assessing SNP functionality is complex due to the LD between 
genetic loci which creates a noise background around functional loci, because all SNPs in LD 
with functional loci may carry some or all of the association with the trait of interest, although 
they have no relevant function.  The rs6511720 has strong LD with 48 SNPs, but which of these 
SNPs has the highest likelihood of being functional? To prioritize and select candidate variants 
for functional study, several bioinformatics databases, which are useful resources to identify 
variants differentially affecting transcriptional activity, were used. It was found that four 
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promoter-proximal intron-1 variants (rs6511720, rs57217136, rs141787760 rs60173709) had 
strong chromatin signals in liver cells:  these SNPs are in complete LD (r
2
=1) with the GWAS 
‘hit’ SNP. Although bioinformatics tools were useful to nominate potential functional SNPs, 
MatInspector and HaploReg showed different DNA-protein binding profiles of these SNPs. The 
inconsistent prediction between bioinformatics tools prevented finding an interesting TF to test, 
however, the data shed light on candidate SNPs that have a strong regulatory profile, and which 
were worthy of further investigation using functional assays. 
 
EMSAs confirmed the bioinformatics finding, where the four SNPs all showed allele-specific 
protein binding. This finding suggests that these proteins may have an influence on regulating 
LDLR expression. To determine whether the different genotypes have an influence on LDLR 
expression, gene reporter assays were used. Data from the luciferase reporter assays was 
consistent with LDLR intron-1 SNPs affecting LDLR gene expression, as the minor alleles of 
rs6511720 and rs57217136 showed significantly higher expression, while rs141787760 and 
rs60173709 showed significantly lower expression but there was no difference between the 
alleles. It is important to consider the combined effect on expression of these four SNPs because 
all these four rare alleles are always present together. It is likely that the lowering expression 
effect of the minor alleles of rs141787760 and rs60173709 partially repress the elevating effect 
of the rare alleles of rs6511720 and rs57217136 SNPs. If the combined effect of the minor alleles 
of four LDLR intron-1 SNPs was estimated by summation, we would predict that the haplotype 
will show ~29% higher expression. This would lead to up-regulation of LDL-R numbers on the 
surface of hepatocytes and this in turn would explain the ≈10% lower levels of LDL-C and ≈12% 
lower risk of CHD in individuals carrying the rs6511720 minor allele haplotype. The actual 
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mechanism of this effect is only partially unraveled by this work. The data suggest that both 
minor alleles of SNPs rs6511720 and rs57217136 are likely to create enhancer-binding sites for 
transcription factors that would contribute to increased LDLR expression. MC-EMSAs showed 
the sequence around rs6511720 minor allele (T) contains the SRE, which has a CArG box 
sequence that is a target binding site for the SRF and the SRE-SRF controls gene expression of 
many genes (397). It has been reported that SRE has a role in LDLR gene expression stimulation 
in HepG2 cells through sterol-independent pathways (398). The SRF is a member of the 
MCM1, Agamous, Deficiens, and SRF (MADS) box superfamily of transcription factors and, 
SRF  has been implicated in the expression of many genes through  its association with a diverse 
set of co-activators in different tissues (399) in order to mediate transcriptional regulation of the 
target gene (see Figure 4-13). In addition, SRF could co-operate with chromatin remodeling 
proteins, which relax the chromatin structure at the target gene transcription start site and/or 
enhancer sites allowing for the initiation of gene transcription (400). It has been reported that 
there are three sets of SRF binding proteins that are involved in gene regulation  of muscle  and 
cardiac specific genes: the ternary complex factor (TCF) family proteins that include Elk1, SAP1 
and SAP2 (401, 402), the myocardin-related MKL family proteins that include Megakaryoblastic 
leukemia-1/2 (MKL1 and MKL2) (399, 403, 404), Nkx2-5 and GATA4 (405). Also, it has been 
reported that the SRF regulates expression of several genes with roles in hepatic function, but 
their molecular mechanisms are unclear (406). 
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Figure  5-14: Model for the action of MADS-domain protein complexes.  
The figure shows a model of MADS-domain protein complex formation and its gene regulation 
mechanism. MADS-domain proteins (green and blue) interact with two DNA binding sites 
(CArG boxes; black) in close proximity, resulting in DNA looping. Subsequently, MADS-
domain proteins recruit transcriptional co-factors (pink) and chromatin remodeling proteins 
(brown), which in the complex mediate transcriptional regulation. Adapted from Smaczniak et 
al. (2012). 
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The data also suggest that rs57217136 is bound to RAR and STAT1. RAR is a member of a 
family of nuclear receptor proteins actively involved in retinoic acid-mediated transcriptional 
regulation of genes that control lipid metabolism, through dimerization with other proteins to 
initiate transcription (407). RAR proteins are not active in their monomeric form, but they can be 
dimerized with another family of nuclear receptor proteins called retinoid X receptors (RXR). 
The RAR≡RXR dimer binds to hormone response elements known as retinoic acid response 
elements (RAREs) to create an apo-RAR≡RXR heterodimer complex. Transcriptional activation 
of genes occurs when the ligands, including trans retinoic acid or 9-cis retinoic acid (RA) bind to 
the  ligand binding sites on RAR≡RXR (408), however, gene expression is repressed in the 
absence of the ligand. In the absence of the ligands, the apo-RAR≡RXR heterodimer recruits co-
repressors, the nuclear receptor co-repressor (NCoR) and the silencing mediator for retinoid and 
thyroid hormone receptor (SMRT), that inhibit transcription by binding to the ligand-binding 
domains of RAR≡RXR. Then, the co-repressor recruits the heterodimer to HDACs complex 
containing Sin3, which removes the acetyl groups from nucleosomal histones, leading to 
chromatin condensation and gene repression or silencing (409-411). . However, in the presence 
of an RAR≡RXR ligand (e.g. RA), the ligand is able to recruit histone acetyltransferase (HAT) 
co-activators, such as CBP, p300 and p160 (412) (see Figure 5-15). Therefore, the chromatin 
relaxes due to histone acetylation and is able to interact with the basal transcription apparatus: 
RNA polymerase II holoenzyme, together with the TATA-binding protein (TBP) and TBP-
associated factors (TAFs), and mediator complexes (MEDs), to initiate gene transcription (409). 
Also it has been reported that the apo-RAR≡RXR heterodimer recruits co-activators NCoA/ 
SRC-1 which in turn recruit other co-activator factors such as CBP/p300, and TIF-1 to P/CIP to 
activate gene transcription (413). Binding of RAR to the sequence around the rs57217136 T 
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allele may initiate such pathways and facilitate an open chromatin structure surrounding intron-1, 
which allows further access to DNA-binding protein that facilitates gene transcription in a 
complex.  
 
Figure  5-15: Mode of action of RAR≡RXR‎heterodimers 
This figure shows the action mode of RAR≡RXR heterodimers. (A) Retinoic acid receptors 
(RARs) and retinoid X receptors (RXRs) form heterodimers that bind within the regulatory 
region of target genes through the retinoic acid response elements (RAREs). (B) In the absence 
of a ligand (e.g. RA), RAR–RXR heterodimers (apo-heterodimers) are bound to RAREs of target 
genes together with transcriptional co-repressors (N-CoR or SMRT), which then recruit HDAC 
complex and repress gene expression through chromatin condensation. However, binding of the 
ligand induces the release of the HDAC complex and results in the recruitment of histone 
acetyltransferase (HAT) co-activators, such as CBP and p160. The subsequent chromatin 
relaxing is due to this RAR tone acetylation (‘Ac’). In the last step, the RNA polymerase II 
holoenzyme, together with the TATA-binding protein (TBP) and TBP-associated factors (TAFs), 
and mediator complexes (MEDs) are recruited, which initiates the transcription machinery. 
Adapted from Clarke et al. (2004).  
 
 
 
A
B
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The rs57217136 T allele also binds to STAT1, a transcription factor that is involved in 
regulating expression (414) and regulating lipid-related genes. The transcriptional activity 
role of STAT1 is dependent on biological conditions, where it drives the expression of many 
genes, but also suppresses the transcription of others (415). Studies have shown that 
phosphorylated STAT1 is inter-nucleus and binds to a specific sequence of DNA and 
regulates gene expression (416, 417). It has been reported that STAT1 and STAT3 are 
involved in lipid metabolism via JAK/STATs through several pathways. JAK/STAT1 
proteins, for instance, bind to the promoter of peroxisome proliferator-activated receptor-
gamma 2 (PPAR-γ2) and LPL, which leads to repression of PPAR-γ2 and LPL expression, 
which promotes adipogenesis and inhibits lipolysis, respectively, in mature fat cells (418-
420).  
  
On the other hand, studies have shown that the positive function of STAT1 in transcriptional 
regulation is due to its binding to transcriptional co-activators such as CERB complex 
(CBP/p300), pCIP, MCM5, Nmi, and BRCA1 (421-424). CBP/p300 is histone acetyl 
transferase, which relaxes the chromatin near to transcription start sites or enhancer sites to 
provide a platform for several associated proteins (423). pCIP interacts with CBP/p300 to 
activate STAT1, while  MCM5 and BRCA1 co-operate with STAT1 for maximal 
transcription activity (422). Another interesting co-activator transcription factor that co-
operates with STAT1 is SP1, where the ENCODE project consortium (2011) ChIP-Seq data 
showed that SP1 binds to the rs57217136 minor allele (276). SP1 is an LDLR associated 
protein, which binds to repeats 1 and 3 in LDLR promoter and initiates gene transcription 
(60).  
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5.4. Limitations 
This study has a number of limitations. This study suggests that a cis-regulatory element near 
rs6511720 and rs57217136 SNPs acts in the liver cell line. However, I did not examine other 
LD distal SNPs that may have a role in transcription regulation and, therefore, further studies 
are needed in this area. Also, since I studied the effect of these SNPs only in liver cells I 
cannot determine whether or not they also influence LDLR gene expression in other tissues. 
However, since the major site of expression of LDLR is the liver, where clearance of LDL-C 
from the plasma occurs, this is not a major limitation. 
 
Another limitation in this study was that I could not design one luciferase construct that 
contains all SNPs of interest because of the presence of Alu repeats in the region of interest, 
and therefore I could only estimate the likely combined effect in vitro of the effects of all 
SNPs acting in concert. 
 
In this study, luciferase reporter assays and EMSAs were used, which are techniques that 
measure the difference of allelic expression and determine DNA-protein interaction in vitro. 
As such, both luciferase reporter assays and EMSA are in vitro techniques which cannot 
account for regulatory landscape elements and gene spatial organization. Therefore, more 
studies are needed to define the spatial organization of the gene, which has a fundamental 
role in controlling gene expression (425-428), by the chromatin looping that brings enhancers 
and promoters into close spatial proximity to interact and initiate transcription. In recent years 
a number of chromosome conformation capture methods have been developed such as 
chromosome conformation capture (3C) (429, 430) and chromosome conformation capture 
carbon copy (5C) (431) in order to study DNA interactions in native states.   
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The concepts of 3C are to study whether two distant genomic sequences physically interact 
(e.g. promoter – enhancer) by the looping interaction. The DNA binding proteins are 
formaldehyde cross-linked to the DNA followed by the use of appropriate restriction 
enzymes to solubilize the cross-linked DNA. The cross-linked DNA is then ligated creating 
“ligation junctions”. The cross-links are removed, the DNA purified and selected ligation 
products quantified using PCR with primers specific to the genomic loci being studied (429, 
430). Also, it is possible to use the 5C method, which is a similar protocol to 3C, except that 
the 3C library converts into a 5C library by annealing and ligating 5C oligonucleotides in a 
multiplex setting, in order to use high-throughput detection methods including microarrays 
and quantitative DNA sequencing (431).   In the case of LDLR, the proximal enhancer 
sequence of rs6511720 and rs57217136 is cross-linked to the LDLR promoter.     
 
5.5. Conclusion 
In conclusion, this study provides a partial explanation of the reason behind the protective 
effect of GWAS LDLR SNP rs6511720 minor allele on CHD. Integration of bioinformatics 
with GWAS disease-associated variants helps to elucidate gene-regulatory variants 
underlying association signals. Both rs6511720 and rs57217136 were identified as part of a 
cis-regulatory complex in a liver cell line that altered transcriptional activity and thus may 
increase LDLR expression, and consequently reduce LDL-C levels. In vitro data suggests that 
the rs57217136 binds to RARA and STAT1, which are both transcription factors requiring 
different histone acetyltransferase activities to activate transcription, which may interact with 
rs6511720 binding protein (SRE-SRF) and create a complex ‘enhancer model’ that co-
operates with the basal transcription apparatus to maximize the enhancing activity of the core 
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transcription machinery. For future work, the use of chromosome conformation capture 
methods may be helpful in order to understand the role of spatial organization of the 
identified regulatory elements in gene regulation.  
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Chapter 6 : Identification of an LDL-C associated variant in 
the coding region of the ANXA2 gene 
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6.1. Introduction  
Hypercholesterolemia is a major risk factor for atherosclerosis and CHD, most often 
caused by an individual having a greater than average number of common lipid-raising 
SNPs. The Global Lipids Genetics consortium (2013) has identified 157 novel loci 
associated with lipid levels, 15 of which are known to influence plasma levels of low 
density lipoprotein cholesterol (LDL-C) (161). By contrast, the monogenic disorder, FH 
is known to be caused by a genetic defect at one of three loci that code for proteins 
involved in LDL-C clearance: LDLR, APOB, and PCSK9. These three genes are GWAS 
hits for LDL-C.  
  
PCSK9 plays an important role in cholesterol clearance from the blood. It is highly 
expressed in the liver (93), and binds to the epidermal growth factor domain A (EGF-A) 
of the LDL-R via its catalytic domain either intracellularly or at the cell surface (432). 
Once the PCSK9≡LDL-R complex is formed, it is internalized by endocytosis and 
degraded (103, 104). Gain-of-function mutations in PCSK9 strongly promote LDL-R 
degradation and lead to FH, whereas loss-of-function mutations of PCSK9 are unable to 
enhance LDL-R down regulation and therefore result in lower levels of LDL-C (128). It 
has been proposed that PCSK9 is a viable therapeutic target to reduce LDL-C and protect 
against atherosclerosis and CAD (166, 167).  Several monoclonal antibodies have been 
developed and showed significant efficacy in reducing LDL-C levels with minimal side-
effects (234-236). In the last few years, a new protein called AnxA2 has been identified 
in animal and cellular models as an endogenous inhibitor of PCSK9, and thus influences 
LDL-R and plasma cholesterol levels (92, 101, 102).  
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AnxA2 is highly expressed in the lungs, pancreas, colon, ileum and adrenal tissues, but 
not in the spleen, testis, kidney and liver (102). AnxA2 belongs to the conserved annexin 
family of phospholipid and calcium-binding proteins. AnxA2 exists as a monomer, yet 
the majority of AnxA2 forms a heterotetramer with the S100 protein p11 (S100A10) both 
in intra- and extracellular locations (188, 433). Intracellularly, AnxA2 regulates a 
spectrum of functions related to membrane organization and trafficking (172, 188, 434). 
Extracellular, AnxA2 has several activities (435) including involvement in cholesterol 
clearance metabolism either as a monomer or complexed with p11 via the binding of its 
R1-domain to an CHRD of PCSK9 at the cell surface, which inhibits PCSK9-mediated 
degradation of LDL-R. This helps to maintain LDL-R levels at the cell surface with the 
subsequent greater clearance of LDL-C (101, 102).  An in vitro study reported that a 
mutation Q554E in the CHRD of PCSK9 increased the binding affinity between PCSK9 
and AnxA2, which in turn led to a loss-of-function of PCSK9 towards LDL-R 
degradation (101). Also, in vivo studies showed that AnxA2 knockout mice had higher 
levels of plasma PCSK9 and LDL-C, which correlated with a reduction in LDL-R protein 
levels, mostly in extrahepatic tissues (102). Moreover, adenoviral AnxA2 overexpression 
in mouse liver was significantly associated with higher hepatic LDL-R levels (102).  
Molecular network and protein interaction are responsible for cell function, thus a 
mutation in any gene involved in a diseased molecular network may lead to the observed 
phenotype of the “Guilt by Association” (GBA) mechanism (436-438).  It was 
hypothesized that a mutation in the ANXA2-R1 domain could also affect LDL-C levels. 
The ANXA2 locus is located on chromosome 15q22.2 and consists of 13 exons (170), and 
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its expression is regulated at both the transcriptional and translational levels (188). In this 
study, in the ANXA2-R1 domain, a common coding SNP (rs17845226), which changes 
Valine to Leucine at position 98, was selected to determine whether the SNP influences 
LDL-C levels. In a preliminary study including only 43 subjects, this SNP was implicated 
in the regulation of circulating PCSK9 levels (102), but a thorough analysis of its 
association with LDL-C and CHD in larger cohorts has not yet been performed. In this 
chapter I use bioinformatics and genotype-phenotype association analyses to determine 
whether the SNP is associated with differences in LDL-C levels and probably Anex2 
function.  I show that this common coding SNP appears unlikely to affect the protein’s 
functional structure, but it could be a marker for other proxy variants at the locus.      
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6.2. Results  
6.2.1. Bioinformatics  
The R1-domain of ANXA2 is encoded by Exons 4-6, which has eight reported SNPs 
(Table 6-1). The missense variant, rs17845226, was selected for further study as it has 
been validated by HapMap and the 1000 Genomes project, and is the only SNP that has a 
minor allele frequency (MAF) ≥ 0.05. The SNP is located in exon 6 of the gene and 
causes a valine/leucine amino acid change; the MAF is 12% in European populations 
(1000 Genomes Project Phase 3)]. Although the affected amino acid (valine) is highly 
conserved in vertebrate species (Figure 6-1); the change is predicted to be non-pathogenic 
by the SIFT, Polyphen-2, and Mutation Taster predicting tools (Table 6-2). Interestingly, 
rs17845226 shows modest LD (r2 >= 0.4) with 34 SNPs, all located downstream of the 
ANXA2 gene-coding region in the long intergenic region (Figure 6.2) (439) 
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Table  6-1: The R1-domain of ANXA2 reported SNPs by 1000 Genomes Project  
 
Exon SNP Ref/Alt 
Amino acid 
Position 
MAF Validated* 
Exon 4 
rs41315968 C/T p.(Lys28 Lys) NA No 
rs11553791 A/G p.(Phe33 Phe) NA No 
rs75993598 C/T p.(Glu43 Lys) NA Yes 
Exon 5 rs11553794 G/A p.(Arg63Ser) < 0.01 Yes 
Exon 6 
rs17845226 C/A p.(Val98Leu) 0.05 Yes 
rs17854749 A/G P.(Leu102Leu) NA No 
rs144035126 G/A p.(Thr97Met) < 0.01 Yes 
rs147297902 G/A p.(Ala90Val) <0.01 Yes 
*- The variant was discovered in the1000 Genomes project, and the Exome Sequencing project   
  
 
Table  6-2: Functional prediction of ANXA2 coding variant p.(Val98Leu) rs17845226 
by different prediction tools 
  
Gene_ species_ variant SIFT Polyphen-2 Mutation Taster 
ANXA2_HUMAN V98L neutral neutral neutral 
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Figure  6-1: The ANXA2 exon 6 amino acid sequence in different species.   
Schematic presentation of the ANXA2 exon 6 amino acid sequence in different species (https://genome-euro.ucsc.edu). The ANXA2 
coding SNP rs17845226 p.(Val98Leu) is highly conserved across species. 
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Figure  6-2 ANXA2 coding SNP rs17845226 LD SNP table  
The figure shows modest LD r2≥0.4 SNPs for query SNP rs17845226. The summary 
detail for each SNP is given including chromosome number (chr), variant  piston 
according to human genome 38 (pos(hg38)), LD r2 score and LD D’ score*, variant ID, 
reference allele (Ref) and alternative allele (Alt), and the minor allele frequency in four 
populations including African, American, Asian and European.   
http://archive.broadinstitute.org/mammals/haploreg/haploreg.php 
 
 
*LD D’ is the ratio of D to its maximum possible absolute value, given the allele frequencies, where D is 
the difference between the frequency of gametes carrying the pair of alleles A and B at two loci (pAB) and 
the product of the frequencies of those alleles (pA and pB ) [DAB = pAB – pApB].  LD r2 is the square of 
the correlation coefficient between two indicator variables (A and B) [r2 = D2/ pA (1 – pA) pB (1 – pB] 
(440). In literature r
2 
is mostly common used. 
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6.2.2. Sequencing 
ANXA2, located at 15q22.2, has three pseudogene sequences found on chromosomes 4 
(ANXA2P1), 9 (ANXA2P2) and 10 (ANXA2P3). There is a possibility that the off-the-
shelf genotyping commercial primers may have amplified one of these pseudogene 
sequences instead of the target sequence on chromosome 15. Therefore, unique primers 
were designed to amplify a fragment containing rs17845226 on chromosome 15. Random 
samples from each genotype were sequenced and the sequencing result compared to the 
genotype results to verify genotyping specificity. 
 
Figure 6-3A shows the reference sequence around ANAX2 SNP rs17845226 in 
chromosome 15 and the three pseudogenes on chromosomes 4, 9 and 10 aligned to the 
reference sequence. The result shows that the reference sequence and the other three 
pseudogenes share some part of the sequence, however, the sequence around the SNP of 
interest is different. The sequencing results show 100% alignment between the ANXA2 
chromosome-15 reference sequence and sample sequences (Figure 6-3 B). Sanger 
sequencing verified the TaqMan genotyping results which proved the primer’s 
specificity.  
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Figure  6-3: ANXA2 pseudogene sequences  
A) Using CLUSTALW multiple sequence alignment tool (http://www.genome.jp/tools/clustalw/) the reference sequence around 
ANAX2 SNP rs17845226 on chromosome 15 was aligned to the three pseudogenes on chromosomes 4, 9 and 10. (B) TaqMan 
sequence results of a random sample selection - an individual whose genotype is homozygous for the common allele (C allele); blue 
highlighted nucleotide is the ANXA2 SNP rs17845226 on both strands.  
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6.2.3. Genotype-phenotype association  
The association of rs17845266 with LDL-C and CHD was investigated in the NPHSII 
and WHII cohorts. NPHSII consists of 3,052 healthy middle-aged men (50–61 years) 
who were recruited from nine general medical practices in the UK (299), while WHII 
consists of 3,413 women and 6,895 men who were recruited from 20 London-based civil 
service departments in the UK; both studies’ participants were followed for 15 years. 
Baseline study characteristics are summarized in Table 6-4. TaqMan genotyping of 
rs17845266 was successful with a call rate of ≥90%. The minor allele frequency of 
rs17845266 in NPHSII was 0.13 which is similar to that seen in European populations 
(χ2=1.722, p=0.19), while in the WHII the SNP call rate was 99%, and the minor allele 
frequency was 0.138 (χ2=2.585, p=0.11). 
 
Table  6-3: The Second-Northwick-Park Heart Study (NPHSII) and Whitehall II 
(WHII) cohort baseline characteristics. Values shown are mean (+SD) 
 
 NPHSII WHII 
Sample size 2463 4414 
Age (years) 56.1 (3.4) 49.1 (6.0) 
Male (%) 2463 (100%) 3344 (75.7%) 
Current or ex-Smoker (%) 1694 (68.8) 518 (12.3%) 
Body mass index (kg/m
2
) 26.5 (3.5) 25.1 (3.6) 
Type 2 diabetes (%) - 81 (2.0) 
Systolic blood pressure (mmHg) 138.7 (19.2) 120.6 (13.1) 
Diastolic blood pressure (mmHg) 84.6 (11.2) 79.7 (9.2) 
Total Cholesterol (mmol/l) 5.75 (1.01) 6.45 (1.13) 
LDL-Cholesterol (mmol/l) 3.10 (1.00) 4.38 (1.01) 
HDL-Cholesterol (mmol/l) 0.80 (0.24) 1.42 (0.41) 
Triglycerides (mmol/l)
#
 1.80 (0.95) 1.23 (0.68) 
#: Geometric mean (approximate SD)  
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6.2.3.1. Association of ANXA2 SNP rs17845226 with lipid traits and 
CHD in NPHSII  
The ANXA2-R1 domain SNP rs17845226 (G>A) showed an association with LDL-C 
levels and CHD risk under both inheritance modes (additive and recessive).  Table 6-5 
shows that individuals who are homozygous for the minor allele (A) have significantly 
higher levels of total cholesterol (TC) ≈8.4% and LDL-C ≈18.8% (p=0.007 and 0.003, 
respectively), and have a twofold higher risk of CHD (HR (95% CI): 2.17 (1.03 - 4.60), 
p=0.04)). The most likely cause of the CHD association observed is that it is due to these 
subjects having a higher level of LDL-C, since  when the CHD association was adjusted 
for LDL-C the effect was reduced to 1.25 (0.49-3.20) and was no longer statistically 
significant (p=0.60). This suggests that the main mechanism of this SNP influencing the 
risk of CHD is via its effect on LDL-C levels.  
 
Table  6-4: An association between ANXA2 rs17845226 (Val98Leu) genotype and 
lipid risk factors and coronary heart disease risk in The Second-Northwick-Park 
Heart Study (NPHS-II). 
Values shown are mean (+ SD). #: Geometric mean (approximate SD), p-value*: recessive 
genotypic model, p-value§: additive genotypic model, Model 1: age and practice adjusted , Model 2: 
adjusted for age, practice and LDL-C. 
Genotype 
CC  
(n=1868) 
CA 
 (n=561) 
AA  
(n=34) 
P-value § P-value* 
TC (mmol/l) 5.73 (1.00) 5.80 (1.04) 6.21 (1.05) 0.014 0.007 
LDL-C (mmol/l) 3.08 (0.99) 3.16 (1.04) 3.66 (0.94) 0.006 0.003 
HDL-C (mmol/l) 0.81 (0.24) 0.80 (0.26) 0.74 (0.23) 0.456 0.201 
TG (mmol/l)
#
 1.80 (0.95) 1.79 (0.96) 1.88 (0.93)) 0.970 0.648 
CHD risk by genotype 
No. without CHD 1672 (75.8) 507 (23.0) 26 (1.2) - - 
No. with CHD 196 (76.0) 54 (20.9) 8 (3.1) - - 
HR (95% CI) 
Model 1 
1.00 
0.93 
 (0.68-1.26) 
2.17 
 (1.03-4.60) 
0.113 0.04  
HR (95% CI) 
Model 2 
1.00 
0.84  
(0.59-1.20) 
1.25  
(0.49-3.20) 
0.787 0.60 
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6.2.3.2. Association of ANXA2 SNP rs17845226 with lipid traits and 
CHD in WHII 
No association was found in the WHII between the SNP and lipid traits in either sex 
(Table 6-5). Also, a lack of trend between the rs17845226 genotype and plasma lipid 
concentrations in this cohort was noted.  On the other hand, the minor allele was 
associated with a higher risk of CHD in both genders [OR (95% CI): 2.41 (1.28 - 4.54), 
p=0.02]. Although women with the minor allele were at higher risk of CHD [OR (95% 
CI): 2.85 (0.80 - 10.10), p=0.35] than men [OR (95% CI): 2.28 (1.10 -4.74), p=0.05], the 
difference between groups was not significant (p=0.77) (439). 
 
6.2.3.3. ANXA2 SNPs rs17845226 meta-analysis for association with 
LDL-C and CHD  
Figure 6-4 shows that the minor allele of the SNP had the opposite effect in the two 
studies (NPHSII and WHII); the overall effect of the SNP in the LDL-C is non-
significant [Men: beta-coefficient β (95%CI) = 0.19 (-0.04 - 0.42), p=0.10; Men and 
women: β (95%CI) = 0.14 (-0.07 - 0.35), p=0.19]. Due to the inconsistency of the SNP 
effect on LDL-C levels, the heterogeneity of outcome data was tested using I
2
 and 
‘substantial’ heterogeneity was found between the two studies [I2 =86.2%, p=0.007]. In 
contrast, as shown in Figure 6-6, the risk of CHD in both studies was consistent [I 
squared=0.0%, p=0.85]. The minor allele of the SNP was associated with higher risk of 
CHD in both studies; the overall risk in both sexes OR (95%CI) = 2.92 (1.41 - 3.72), 
p=0.001.  
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Table  6-5: An association between ANXA2 rs17845226 (Val98Leu) genotype and lipid risk factors and CHD risk in WHII 
Values shown are mean (+SD) 
p-value*: recessive genotypic model 
#: Adjusted for sex 
Sex Men Women Men+ women 
Genotype 
CC 
(n=2474) 
CA 
(n=818) 
AA 
(n=52) 
p-value* 
(ANOVA) 
CC 
(n=793) 
CA 
(n=258) 
AA 
(n=19) 
P-value* 
(ANOVA) 
CC 
(n=3267) 
CA 
(n=1076) 
AA  
(n=71) 
p-value*# 
(ANOVA) 
TC 
(mmol/l) 
6.45 
(1.11) 
6.45 
(1.12) 
6.42 
(1.17) 
0.86 
6.44 
(1.19) 
6.53 
(1.16) 
6.27 
(1.04) 
0.49 
6.45 
(1.13) 
6.47 
(1.13) 
6.38 
(1.13) 
0.60 
LDL-C 
(mmol/l) 
4.42 
(0.98) 
4.44 
(1.00) 
4.40 
(1.11) 
0.83 
4.21 
(1.09) 
4.28 
(1.030 
4.15 
(1.07) 
0.77 
4.37 
(1.01) 
4.40 
(1.01) 
4.33 
(1.10) 
0.73 
HDL-C 
(mmol/l) 
1.29 
(0.34) 
1.29 
(0.32) 
1.23 
(0.35) 
0.28 
1.66 
(0.42) 
1.67 
(0.45) 
1.61 
(0.38) 
0.56 
1.37 
(0.39) 
1.37 
(0.38) 
1.33 
(0.39) 
0.22 
TG 
(mmol/l) 
1.32 
(0.74) 
1.29 
(0.70) 
1.39 
(0.81) 
0.48 
1.00 
(0.47) 
1.01 
(0.51) 
0.95 
(0.38) 
0.68 
1.23 
(0.683) 
1.22 
(0.66) 
1.25 
(0.70) 
0.67 
CHD risk by genotype 
No. 
without 
CHD (%) 
2266 
(74.5) 
 
734 
(24.1) 
 
43 (1.4) - 744 (74.3) 
241 
(24.1) 
16 (1.6) - 
3010 
(74.4) 
 
975 
(24.1) 
 
59 
(1.5) 
- 
No. 
with CHD 
(%) 
208 
(69.1) 
84 
(27.9) 
9 
(2.99) 
- 
49 
(71.0) 
17 
(24.6) 
3 
(4.4) 
- 
257 
(69.5) 
 
101 
(27.3) 
 
12 
(3.2) 
- 
OR 
(95% CI) 
1.00 
1.25 
(0.95-
1.63) 
 
2.15 
(1.04-
4.46) 
 
0.04 1.00 
1.07 
(0.61-
1.89) 
2.80 
(0.80-
9.85) 
0.11 
1.00 
 
1.21 
(0.95-
1.54) 
 
2.41 
(1.28-
4.54) 
 
0.01 
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Figure  6-4: Forest plot for the meta-analysis of LDL-C and carriage of the minor 
allele of rs17945226  
 
B= beta-coefficient, Subtotal= fixed effect. 
 
 
 
Figure ‎6-5: Forest plot for the meta-analysis of CHD and carriage of the minor 
allele of rs17945226 
 
MEN+Women
NPHSII
WHII
Subtotal  (I-squared = 86.2%, p = 0.007)
MEN
NPHSII
WHII
Subtotal  (I-squared = 83.7%, p = 0.013)
Study
0.57 (0.19, 0.94)
-0.05 (-0.30, 0.20)
0.14 (-0.07, 0.35)
0.57 (0.19, 0.94)
-0.03 (-0.32, 0.26)
0.19 (-0.04, 0.42)
B (95% CI)
p=0.19
p=0.10
  0-.94 .94
Men + Women
NPHSII
WHII
Subtotal  (I-squared = 0.0%, p = 0.854)
Men
NPHSII
WHII
Subtotal  (I-squared = 0.0%, p = 0.926)
Study
2.17 (1.03, 4.60)
2.38 (1.26, 4.49)
2.29 (1.41, 3.72)
2.17 (1.02, 4.60)
2.28 (1.10, 4.74)
2.23 (1.32, 3.76)
OR (95% CI)
p=0.001
p=0.003
  1.211 4.74
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6.3. Discussion 
In vivo and in vitro biological studies have demonstrated that AnxA2 prevents PCSK9-
mediated degradation of LDL-R (101, 102). AnxA2 mediates this inhibitory effect via the 
interaction of its R1-domain with the CHRD of PCSK9. It was suggested that a mutation 
in the ANXA2 R1-domain could affect LDL-C levels in humans. Out of eight reported 
SNPs in the R1-domain, the rs17845226 missense variant p.(Val98Leu)  was selected for 
further analysis because this variant had previously been associated with lower 
circulating PCSK9 levels (102) and the MAF in the European population is high at 13%. 
Genotype-phenotype analysis of NPHSII data suggested that this missense mutation had 
a recessive effect on LDL-C levels, with significantly higher levels seen only in those 
carrying two copies of the minor allele. Indeed, the activity of the leucine variant may 
depend on the fact that AnxA2 exists as a dimer with two R1-domains, and thus in an 
individual heterozygous for the variant, where one of the two alleles carried is less 
effective, the other is functional and is still able to bind to PCSK9. However, if both 
inherited alleles are less effective in their ability to interact with PCSK9, this may allow 
PCSK9 to act on LDL-R. It is important to note that the majority of AnxA2 exists as a 
heterotetramer complexed with p11, and it is as yet unclear how the rs17845226 variant 
may affect the AnxA2/p11 complex formation or the ratio of monomeric vs complexed 
AnxA2 proteins, all of which may have consequences for PCSK9-mediated LDL-R down 
regulation.  
 
Unfortunately, the identified association with LDL-C levels in the NPHSII was not 
replicated in the WHII, but in both studies the SNP was associated with CHD risk. The 
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inconstancy between NPHSII and WHII results may be due to confounding factors such 
as sampling and measurements, where sample collection and lipid measurements were 
different between studies. The NPHSII samples were collected from non-fasting subjects 
but they were under food restrictions of having only a light breakfast, also the study only 
had one set of LDL-C and HDL-C directly measured at year-6 in the majority of subjects, 
where the means were within the range expected for middle aged males. On the other 
hand, the WHII samples were collected from fasting subjects and lipid markers were 
measured in three phases of the study (3, 5, and 7), where the mean LDL-C varied 
considerably  between years (~ 4.4, 3.8 and 3.5 mmol/l respectively). In this study phase 
3 data was used for analysis, which was the most informative data (the majority of 
subjects had data).    
       
 The inconstancy between NPHSII and WHII results, together with bioinformatics results 
of non-pathogenicity of the SNP and the presence of modest proxy SNPs in the non-
coding region, prevented a definite conclusion about SNP functionality. However, it also 
suggests that the Val98Leu SNP may be acting as a marker for one or more SNPs in the 
non-coding region that affects gene expression, and further analyses will be needed to 
disentangle this. Chapter 7 investigates the likelihood of the ANXA2 coding SNP 
rs17845228 (Val98Leu) acting as a marker for a functional SNP elsewhere at the locus.   
 
 
 
266 
 
Chapter 7 : Identification of an LDL-C associated variant in 
the non-coding region of ANXA2 and determination of the 
functional role of identified variants 
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7.1. Introduction  
Recently, in vivo studies have supported in vitro studies that implicate AnxA2 in 
preventing PCSK9-mediated degradation of LDL-R (101, 102). AnxA2 mediates this 
inhibitory effect via the interaction of its R1-domain with a CHRD of PCSK9. In Chapter 
6, it was found that the ANXA2-R1 missense mutation p.(Val98Leu) was associated with 
high levels of LDL-C in the NPHSII but not in the WHII study, but was predicted to be 
non-pathogenic and had modest LD with SNPs downstream of the ANXA2 gene in the 
long intergenic region. ANXA2 expression is regulated at both the transcriptional and 
translational levels (188), and the long intergenic regions are known to have key 
regulators for transcriptional and translational machinery of genes (441).  For instance, an 
ETS-related gene (ERG) binds to the DNA sequence upstream of ANXA2 gene in the 
long intergenic region, and acts as a repressor to down-regulate  ANXA2 expression in 
prostate epithelial cells (442).   
 
It was hypothesized that the ANXA2 coding SNP, rs17845226 p.(Val98Leu) may act as a 
marker for proxy functional SNPs. The aims were a) to select the potential functional 
candidate SNPs, b) to assess the association between the candidate SNPs and cholesterol 
levels and CHD risk, and c) to elucidate the molecular mechanism behind the effect 
identified. Association analyses, and bioinformatics and in vitro functional assays were 
used in order to identify the functional SNPs at this locus. 
268 
 
7.2. Results  
7.2.1. Bioinformatics analysis  
The ANXA2-R1 rs17845226 SNP has a modest LD (r
2
 >= 0.4) with 34 SNPs (Figure 6-2). 
All of these located downstream of the ANXA2 gene-coding region in the long intergenic 
region between two genes, FOXB and ANXA2 on chromosome 15, and near the RORA 
and LIPC loci which play roles in lipid metabolism and atherosclerosis (Figure 7-1). Out 
of  the 34 SNPs, the rs17191344 SNP (r
2
=0.45, MAF= 16% in European population) has 
the strongest regulatory profile as is highly conserved and has strong enhancer signs in 13 
tissues including liver. The SNP is located in an open chromatin region, where the 
markers of DNAase hypersensitivity, FAIRE, and transcription factor binding by ChIP-
seq are strong (Figure 7-2). In addition, both ENCODE and the ElDorado in silico tool 
have shown that the G allele of the rs17191344 SNP creates a binding site for CTCF, and 
this SNP also changes a YY1 binding motif . The YY1 transcription factor can associate 
with CTCF and regulate gene expression (443).  The rs17191344 SNP has strong LD 
(r
2≥0.8) with 66 SNPs, all in the intergenic region (Figure 7-3), of which SNPs 
rs11633032 and rs12900101 (MAF= 17%) are predicted to bind to regulatory 
transcription factors as shown in the ElDorado data. AP-1 and NRSF are predicted to 
bind to rs11633032 in the presence of the minor allele of the SNP, while MAZR and 
PLAG1 are predicted to bind to the minor allele of rs12900101. These two SNPs are also 
in modest LD with the ANXA2-coding SNP rs17845226 (r
2
=0.40 and 0.41 respectively). 
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Figure  7-1: Diagram of chromosome 15 locus  
The diagram shows ANXA2 and nearby genes. Single nucleotide polymorphisms (SNPs) selected 
for the study are shown: one coding SNP rs1785226 and two intergenic SNPs, rs17191344 and 
rs11633032, showing modest LD (r
2
=0.45).   
  
 
 
 
Figure  7-2: Genome-wide maps of chromatin state of ANXA2 rs17191344 SNP.  
Schematic presentation of the rs17191344 chromatin status (https://genome-euro.ucsc.edu). The 
area of interest is highlighted in light-blue. FAIRE = formaldehyde assisted isolation of 
regulatory elements. 
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Figure  7-3: ANXA2 rs17191344 linkage disequilibrium (LD) plot.  
An LD plot was generated using SNAP V2.2 (Broad Institute; https://www.broad 
institute.org/mpg/snap/ldplot.php). The LD between the query SNP and each 
corresponding proxy SNP are represented by diamonds, the query SNP (rs17191344) is 
represented by a red diamond, while LD SNPs are represented by orange diamonds. R-
squared value is shown on the left Y-axis, where r
2≥0.8 indicates a strong LD, and  r2≤0.2 
indicates a weak LD. A blue line indicates estimated recombination rates and their values 
are presented on the right Y-axis.  LD and recombination rates are based on HapMap 
Phase II in a population of Utah residents with Northern and Western European ancestry 
(CEU). 
 
 
 
 
7.2.2. Genotype-Phenotype Association 
To determine whether the ANXA2 intergenic SNPs are associated with LDL-C or CHD, I 
looked at the ANXA2 intergenic SNPs selected (rs17191344, rs11633032 and 
rs12900101) or proxy SNPs selected in large meta-analysis studies including the Global 
Lipids Genetics Consortium (http://csg.sph.umich.edu/abecasis/public/lipids2013/) and 
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the CARDIoGRAMplusC4D consortium (http://www.cardiogramplusc4d.org/data-
downloads/). However, the SNPs were not in these published data. Therefore the  ANXA2 
SNP rs17191344 was genotyped in the NPHSII and the proxy SNPs rs11633032 and 
rs12900101were imputed in the UCLEB consortium.     
  
7.2.2.1. Association of ANXA2 SNPs rs17845226 and rs17191344 with 
lipid traits and CHD in NPHSII 
The association of rs17191344 with LDL-C and CHD was investigated in the NPHSII 
cohort. Baseline study characteristics are summarized in Table 6-3. TaqMan genotyping 
of rs17191344 was successful with a call rate of ≥90%. The minor allele frequency of 
rs17191344 in the NPHSII was 0.145 which is similar to the frequency (0.155) seen in 
European populations (χ2=0.09, p=0.77). 
 
The modest LD SNP rs17191344 (A>G) shows the same trend as the lead coding SNP 
(rs17845226) that was reported in chapter six. The rs17191344 showed an association 
with LDL-C and CHD under a recessive mode of inheritance (Table 7-1), where 
individuals who carried two copies of the minor allele had higher levels of LDL-C 
(p=0.05) and a higher risk of CHD [HR (95%CI) = 1.86 (1.02-3.41), (p=0.05)]. The data 
also showed that a rising level of LDL-C is most likely the risk factor that explains the 
higher risk of CHD (439). 
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Table  7-1: An association between rs17191144 genotype and lipid risk factors and 
CHD risk in the Second-Northwick-Park Heart Study (NPHSII). 
 
Values shown are mean (+SD), # Geometric mean (approximate SD), *P-value according to recessive 
model, § P-value according to additive model, Model 1: age and practice adjusted, Model 2: adjusted for 
age, practice and LDL-C. 
 
 
It is known that a single gene polymorphism with a modest effect on a trait will have 
minimal effects in the end-point disease phenotype. However, with a trait such as LDL-C, 
where genetic and environment factors affect the trait, the presence of multiple SNPs 
with small effect can lead to a more severe disease or trait phenotype. In order to assess 
whether the intergenic SNP rs17191344 is responsible for observed phenotypes (LDL-C 
and CHD risk), or whether both SNPs have an impact on the phenotype where the risk is 
increased per allele, the association between 9 combined genotype groups (1-9) of 
rs17191344 and rs17845226 and cholesterol levels were examined. Table 7-2 and Figure 
7-4 show that the LDL-C levels increase per minor allele of both SNPs. The individuals 
who have two copies of the minor allele of both SNPs (G and A, respectively) have 
Genotype AA (n=1956) AG (n=659) GG (n=57) 
P-value § 
(ANOVA) 
p-value* 
(ANOVA) 
TC (mmol/l) 5.72 (1.01) 5.74 (1.03) 5.96 (1.04) 0.205 0.085 
LDL-C (mmol/l) 3.09 (1.00) 3.09 (1.03) 3.38 (1.03) 0.302 0.051 
HDL-C (mmol/l) 0.81 (0.24) 0.79 (0.25) 0.81 (0.26) 0.494 0.786 
TG (mmol/l)# 1.79 (0.93) 1.84 (0.97) 1.79 (0.95) 0.465 0.604 
CHD risk by genotype 
 
No. without CHD (%) 1749 (73.5) 585 (24.6) 45 (1.9) - - 
No. with CHD (%) 207 (70.7) 74 (25.3) 12 (4.1) - - 
HR (95% CI) Model 1 1.00 1.10 (0.83-1.44) 1.86 (1.02-3.41) 0.113 0.052 
HR (95% CI) Model 2 1.00 
0.98 (0.72-1.34) 
 
1.29 (0.60-2.79) 
 
0.787 0.504 
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significantly higher levels of LDL-C (p=0.007) and a two-fold higher risk of CHD [HR 
(95% CI) = 2.75 (1.18 - 6.39), (p=0.02)] (439).  
 
Stepwise models were also applied to determine which of the combined genotype groups 
(1-9) were having an effect on lipids and CHD. Stepwise models indicated that only those 
with two copies of the minor allele of both SNPs had significantly raised levels of the 
lipids: TC [β (se) = 0.48 (0.22), p=0.03] and LDL-C [β (se) = 0.65 (0.24), p=0.008] 
(Table 7-3). This confirms the results shown in Table 7-2, where only the GG/AA group 
has significantly different levels from the other groups for these lipid traits. For CHD, the 
GG/CC group has significantly higher risk compared to the other groups [HR (95% CI) = 
6.53 (1.62-26.27), p=0.008] (439). 
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Table  7-2: The rs17191344 and rs17845226 SNPs combined genotype association 
with cholesterol traits and CHD in the Second-Northwick-Park Heart Study 
(NPHSII). 
  Lipids CHD 
rs17191344 rs17845226 N 
TC 
mmol/l 
P-
value 
LDL-C 
mmol/l 
P-
value 
N 
CHD  
% (N) 
HR (95% 
CI) 
p-
value 
AA CC 
 
 
CA 
 
 
AA 
1658 
 
 
75 
 
 
3 
5.73 
(1.00) 
 
 5.81 
(1.05) 
 
 5.57 
(0.45) 
- 
 
 
0.49 
 
 
0.78 
3.09 
(0.99) 
 
3.26 
(1.06) 
 
3.18 
(0.72) 
- 
 
 
0.21 
 
 
0.88 
1658 
 
 
75 
 
 
3 
10.7 
(177) 
 
6.7 (5) 
 
 
0 (0) 
1.00 
 
 
0.53 (0.21- 
1.33) 
 
- 
- 
 
 
0.18 
 
 
- 
AG CC 
 
 
CA 
 
 
AA 
137 
 
 
443 
 
 
9 
5.67 
(0.97) 
 
5.78 
(1.04) 
 
6.32 
(0.92) 
0.49 
 
 
0.33 
 
 
0.08 
2.97 
(1.00) 
 
3.13 
(1.04) 
 
3.63 
(1.08) 
0.21 
 
 
0.48 
 
 
0.15 
137 
 
 
443 
 
 
9 
12.4 
(17) 
 
10.6 
(47) 
 
22.2 (2) 
1.32 (0.79-
2.20) 
 
1.03 (0.74-
1.43) 
 
3.17 (0.78-
12.92) 
0.29 
 
 
0.88 
 
 
0.11 
GG CC 
 
 
CA 
 
 
AA 
4 
 
 
23 
 
 
21 
6.18 
(0.36) 
 
5.90 
(0.94) 
 
6.22 
(1.17) 
0.38 
 
 
0.43 
 
 
0.025 
3.72 
(0.77) 
 
3.22 
(1.04) 
 
3.75 
(0.96) 
0.28 
 
 
0.56 
 
 
0.007 
4 
 
 
23 
 
 
21 
50.0 (2) 
 
 
13.0 (3) 
 
 
28.6 
 (6) 
8.60 (2.09-
35.34) 
 
1.35 (0.43-
4.26) 
 
2.75 (1.18-
6.39) 
0.003 
 
 
0.604 
 
 
0.019 
Adjusted for age  
Values shown are mean (+SD) 
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Figure  7-4: The association of 9 combined genotype groups of rs17191344 and 
rs17845226 with LDL-C levels in the Second-Northwick-Park Heart Study 
(NPHSII)   
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Table  7-3: Stepwise regression analysis: Second-Northwick-Park Heart Study 
(NPHSII)   
The stepwise regression of the combined genotype groups (1-9) of the rs17191344 and 
rs17845226 SNPs for each outcome variable: TC, LDL-C and CHD. The reference group 
is the group that carries major alleles of both SNPs (AA/CC) respectively.   
 
 
Group TC 
B (se)                    
p-value LDL-C 
B (se) 
p-value CHD 
HR (95% CI) 
P-value 
Reference 
 
 
GG/AA 
 
 
 
 
 
 GG/CC 
0 
 
 
0.482 (0.221) 
R
2
=0.002 
 
 
 
 
 
 
 
 
 
0.029 
0 
 
 
0.649 (0.244) 
R
2
=0.004 
 
 
 
0.008 
1.00 
 
 
- 
 
 
 
 
 
6.53 (1.62-
26.27) 
 
 
 
 
 
 
 
 
 
0.008 
Adjusted for age and practice 
For TC and LDL-C, only those with two copies of the minor allele of both SNPs differed significantly from 
the group that carried the major alleles of both SNPs (AA/CC), and for the analysis above the reference 
group used is the combination of AA/CC and all other groups. For CHD, only those with the genotype 
GG/CC differed significantly from the group that carried the major alleles of both SNPs (AA/CC), and for 
this analysis the reference group used is the combination of AA/CC and all other groups.
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7.2.2.2. Association of ANXA2 intergenic SNPs with lipid traits and 
CHD in the UCLEB consortium  
The UCLEB consortium, comprising ~14,600 subjects from the UK general population, 
was used for replication. Study characteristics are summarized in Table 7-4. It was not 
possible to impute rs17191344, but two SNPs, rs11633032 (G>A) and rs12900101(C>G) 
[having a strong LD (r
2
=0.98) with rs17191344], had a high average value of imputation 
genotype data from the Metabochip (r
2
= 0.63) (Table 7-5).  
 
As shown in Table 7-6 and Figure 7-5, the minor alleles of rs11633032 and rs12900101 
were associated with significantly higher levels of LDL-C in men with the recessive 
inherited mode [effect size = 0.21 mmol/l, p=0.018 and 0.19 mmol/l, p=0.036, 
respectively]; but not in women, which may be due to different sample sizes between the 
sexes. To assess whether the effect is different between the sexes, we tested the estimated 
difference between sexes, and found no difference (p=0.29) (Table 7-7). Overall, the 
minor alleles of rs11633032 and rs12900101 were associated with significantly higher 
levels of LDL-C [effect size = 0.16 mmol/l, p=0.03 and 0.14 mmol/l, p=0.05 respectively 
for the recessive model] with similar effects in both genders (Table 7-7). This result 
confirms the results seen above in the NPHSII subjects, who were all men.   
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Table  7-4: The UCL-LSHTM-Edinburgh-Bristol (UCLEB) consortium baseline 
characteristics for eight studies included in this study. 
 
 BRHS BWHHS CaPS EAS ELSA ET2DS WHII MRC1946 
Number 
included in 
analysis 
2387 1922 1381 850 1934 1049 3311 2139 
Age (years) 
68.9 
(5.61) 
71.5 
(5.28) 
61.90 
(5.05) 
64.46 
(5.64) 
73.64 
(9.55) 
67.90 
(4.20) 
49.00 
(5.96) 
50 (0) 
Sex (% male) 100 0 100 49 53 52 76 50 
BMI (kg/m
2
) 
26.83 
(3.63) 
27.67 
(4.99) 
NA 
26.2  
(4.2) 
27.48 
(4.49) 
31.39 
(5.66) 
25.21 
(3.54) 
27.63 
(4.63) 
TC (mmol/l) 
6.36 
(1.03) 
6.62 
(1.22) 
6.20 
(1.10) 
7.08 
(1.33) 
5.71 
(1.28) 
4.31 
(0.90) 
6.44 
(1.12) 
6.09 
(1.07) 
HDL-C 
(mmol/l) 
1.15 
(0.24) 
1.62 
(0.45) 
NA 
1.45 
(0.38) 
1.49 
(0.39) 
1.29 
(0.36) 
1.41 
(0.40) 
1.67 
(0.52) 
LDL-C  
(mmol/l) 
3.89 
(1.00) 
4.14 
(1.10) 
NA 
5.33 
(1.22) 
3.42 
(1.06) 
NA 
4.37 
(1.00) 
3.52 
(0.97) 
TG * (mmol/l) 
2.05 
(1.22) 
1.91 
(1.05) 
1.87 
(1.10) 
1.53 
(0.90) 
1.80 
(1.11) 
NA 
1.46 
(1.15) 
2.16 
(1.51) 
SBP (mmHg) 
144.0 
(19.95) 
150.0 
(25.36) 
145.0 
(22.32) 
NA 
138.9 
(19.63) 
133.3 
(16.46) 
120.5 
(13.14) 
136.2 
(20.01) 
DBP (mmHg) 
81.8 
(12.80) 
80.1 
(11.76) 
81.7 
(11.98) 
NA 
73.0 
(11.46) 
69.1 
(9.00) 
79.8 
(9.12) 
84.6 
(12.17) 
Mean and standard deviation (SD), where appropriate, are shown. * analysis carried out 
on log transformed and median and IQR presented.   
 
British Regional Heart Study (BRHS), British Women’s Heart and Health Study (BWHHS), Caerphilly 
Prospective Study (CaPS), Edinburgh Artery Study (EAS), English Longitudinal Study of Aging (ELSA), 
Edinburgh Type 2 Diabetes Study (ET2DS), Whitehall II study (WHII), and MRC National Survey of 
Health and Development 1946 (MRC 1946).  
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Table  7-5: Imputation quality of The UCL-LSHTM-Edinburgh-Bristol (UCLEB) 
consortium 
Quality of imputation was measured as the ratio of observed (imputed) genetic variance 
to expected genetic variance (r
2
) in 8 studies  
 
SNP WHII BRHS BWHHS ET2DS EAS CAPS MRC1946 ELSA 
rs11633032 0.63 0.64 0.63 0.63 0.62 0.64 0.63 0.63 
rs12900101 0.63 0.63 0.63 0.63 0.62 0.64 0.63 0.63 
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Table  7-6: Association of ANXA2 intergenic SNPs and lipid traits in the UCL-
LSHTM-Edinburgh-Bristol (UCLEB) Consortium 
 AnxA2 SNP Lipid trait 
Effect 
Size$ 
Std. Error p-Value* Number of samples by genotype 
Men 
rs12900101 
TC 0.147 0.086 0.088 CC=5995,  CG=2824, GG=161 
LDL-C 0.188 0.090 0.036 CC=4626,  CG=2190, GG=124 
HDL-C 0.010 0.031 0.734 CC=4998,  CG=2361, GG=131 
Log TG -0.007 0.047 0.876 CC=5084,  CG=2419, GG=134 
rs11633032 
TC 0.171 0.087 0.049 GG=5992, AG=2824, AA =158 
LDL-C 0.215 0.091 0.018 GG=4626,  AG=2193, AA =121 
HDL-C 0.009 0.031 0.774 GG=5000, AG=2362, AA =128 
Log TG -0.002 0.048 0.968 GG=5086,  AG=2420, AA =131 
Women 
rs12900101 
TC 0.092 0.126 0.461 CC=3714,  CG=1773, GG=90 
LDL-C 0.104 0.119 0.383 CC=3302,  CG= 1588, GG=84 
HDL-C 0.020 0.045 0.668 CC=3682,  CG=1760, GG=90 
Log TG 0.410 0.052 0.427 CC= 3374,  CG= 1626, GG=85 
rs11633032 
TC 0.105 0.127 0.410 GG=3718,  GA=1771, AA=88 
LDL-C 0.104 1.120 0.390 GG=3306,  GA= 1586, AA=82 
HDL-C 0.029 1.046 0.532 GG=3686,  GA=1758, AA=88 
Log TG 0.044 1.052 0.401 GG= 3378,  GA= 1624 , AA=83 
Men & 
Women 
rs12900101 
TC 0.117 0.072 0.104 CC=9709,  CG=4597, GG=251 
LDL-C 0.143 0.072 0.048 CC=7928,  CG=3778 , GG=208 
HDL-C 0.016 0.026 0.536 CC=8680,  CG=4121, GG=221 
Log TG 0.007 0.035 0.836 CC=8458,  CG=4045, GG=219 
rs11633032 
TC 0.139 0.073 0.056 GG=9716,  AG=4595, AA =246 
LDL-C 0.160 0.073 0.029 GG=7932,  AG=3779, AA =203 
HDL-C 0.019 0.026 0.468 GG=8686,  AG=4120, AA =216 
Log TG 0.013 0.036 0.726 GG=8464,  AG=4044, AA =214 
 
$= Effect size is the main effect of the homozygous minor allele genotype on lipid concentration estimated 
in a linear model containing age and study ID as covariates. 
*= Recessive genotypic model 
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Figure  7-5: Average of the phenotype by genotype class for ANXA2 intergenic SNPs in the UCL-LSHTM-Edinburgh-Bristol 
(UCLEB) Consortium.  
The Genotype is presented as a binary character: class 0 (homozygous major allele) dose 0 - 0.5, class 2 (homozygous minor allele) 
dose 1.5 – 2, and class 1 (heterozygotes) dose 0.5-1.5. The error bars represent the 95% confidence interval for the mean.  
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Table  7-7: Estimated difference between sexes of ANXA2 intergenic SNPs and lipid 
traits in The UCL-LSHTM-Edinburgh-Bristol (UCLEB) Consortium 
 
SNP ID Lipid trait Mean 
Standard 
error 
P- value 
rs12900101 
LDL-C 0.084 0.102 0.819 
TC 0.054 0.103 0.521 
rs11633032 
LDL-C 0.11 0.104 0.288 
TC 0.066 0.104 
0.524 
 
To assess whether there the effect of the SNP on TC and LDL-C was different between the sexes. The 
estimated difference between sexes was tested using a t-test.  
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7.2.3. Allele-specific protein binding of ANXA2 intergenic SNPs in 
Huh7 Cells 
 
7.2.3.1. Conventional EMSA of ANXA2 intergenic SNPs 
Conventional EMSAs were performed to determine whether the three ANXA2-intergenic 
SNPs, rs12900101, rs11633032 and rs17191344, are within potential regulatory elements 
and able to affect DNA-protein interactions. NFKβ was used as a control. Each set of 
biotin labeled probes was run alongside an unlabeled probe in order to identify allele 
specific band(s). The band shifting between alleles is a sign of a change in DNA-protein 
binding that may be involved in ANXA2 regulation.  
 
In Figure 7-6, NFKβ control lanes 1-3 comprised: the negative control (lane 1) that did 
not contain nuclear extract and no bands were visible, the positive control (lane 2) that 
contained a labeled probe that showed a NFKβ specific band indicated by arrows, and 
lane 3 that showed when the unlabeled probe was added the specific band disappeared. 
The rs12900101 SNP did not show protein binding in either alleles of the SNP (lanes 4-5 
and 10-11). However, two SNPs, rs11633032 and rs17191344, demonstrated differential 
protein binding by allele. The rs11633032 major G allele was bound to proteins, whereas 
the risk A allele did not show allele-specific protein binding (lanes 6-7), and the G allele 
specific band was eliminated by an unlabeled probe (lanes 12-13). In contrast, the risk G 
allele of the rs17191344 SNP bound strongly to proteins or complexes of proteins where 
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two specific bands indicated by arrows (lanes 8-9) appeared; but when the unlabeled 
probe was added the G allele specific bands disappeared (lanes 14-15) (439).  
 
Figure  7-6: DNA binding properties of  ANXA2- intergenic SNPs.  
Conventional EMSA analysis of the ANXA2-intergenic SNPs (rs12900101, rs11633032 and 
rs17191344). The major allele of rs11633032 has allele-specific binding that is competed out by 
the allele competitor probe. The minor allele of rs17191344 has allele-specific binding at two 
positions which are competed out by the allele competitor probe. Allele specific bands are 
indicated by arrows and (*) indicates minor allele. 
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7.2.3.2. Multiplex competitor EMSAs (MC-EMSA) of ANXA2 
intergenic SNP rs11633032  
MC-EMSA was performed to characterize the DNA-protein interaction of the major G 
allele of the rs11633032 SNP. Nuclear extract of Huh7 cells was incubated with seven 
sets of cocktails (0-6) with each set having 10 unlabeled dsDNA consensus sequences for 
well-characterized proteins (Table 2-18), before adding the rs11633032 G allele labeled 
probe. The results showed that the G allele specific-bands indicated by arrows, were 
competed out by cocktail 1 (Figure 7-7 A). Then, when each competitor of cocktail 1 was 
run individually, the G allele specific-bands were competed out by addition of the GATA 
and Egr1 consensus sequences (Figure 7-7 B) (439).  
 
 
Figure  7-7: DNA binding and expression of the transcription factors of the ANXA2- 
intergenic SNP rs11633032. 
MC-EMSA analysis. Nuclear proteins from the Huh7 cell line were incubated with 7 
cocktails (0-6) of unlabeled DNA competitors (70 well-characterized DNA-binding 
proteins) for 15 minutes, then a 5’ end-biotinylated allele-specific probe was added. The 
multiplex competitors competed out any specific interactions with a labeled probe, 
eliminating or reducing any positive shift result. A) ANXA2- intergenic SNP rs11633032 
MC-EMSA for G allele of the SNP, allele specific bands indicated by arrows, were 
eliminated by cocktail 1. B) The single competitors from cocktail 1 were run individually 
in a further EMSA, showing Egr1 and GATA that resulted in competition (eliminated 
bands indicated by dotted arrows). G+ indicates that the unlabeled G probe was added to 
the reaction mixture. 
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A) 
  
B)  
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7.2.3.3. CCCTC-binding factor (CTCF) specific protein binding to 
ANXA2 rs17191344 
The bioinformatics analysis of the rs17191344 SNP suggests that the risk allele of the 
SNP is a site for CTCF protein binding. As CTCF has thousands of binding sites genome-
wide, rs17191344 SNP was tested with 11 CTCF consensus sequence competitors, that 
are most common CTCF binding sites genome-wide (444). Comparing the CTCF-binding 
motif to the genomic sequence around the rs17191344 revealed that they matched up 
well, and the presence of the SNP risk G allele strengthened the binding motif (Figure 7-8 
A). In the EMSA experiments, the rs17191344 G allele specific bands were competed out 
by at least three isoforms of CTCF indicated by arrows (Figure 7-8 B), suggesting that 
CTCF is the protein that binds to the sequence around the G allele of the SNP (439).     
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Figure  7-8: CTCF-specific protein binding to the ANXA2 intergenic SNP rs17191344 
in Huh7 Cells. 
A) CTCF consensus sequences used in EMSAs were compared with genomic sequence 
around rs17191344. The single nucleotide polymorphism G allele matches more closely 
with the consensus sequence, which may increase the binding affinity to CTCF, 
suggesting CTCF may be responsible for protein binding here. B) EMSA analysis of the 
ANXA2-intergenic SNP rs17191344 G allele which is competed out by 11 isoforms of 
CTCF. The G allele specific bands, indicated by arrows, were eliminated by at least 3 
isoforms of CTCF (eliminated bands indicated by arrows). 
     
 
289 
 
7.2.3.4. Supershift EMSA for confirmation of protein binding 
MC-EMSAs and EMSAs implicated the CTCF protein as binding to rs17191344, while a 
portion of the GATA family and Egr1 bound to rs11633032. The supershift EMSA is a 
technique used to verify specific protein binding, where an antibody specific to putative 
DNA binding protein is incubated with nuclear extract before and after addition of 
labeled probed. If the antibody recognizes the target protein two results are possible. One 
possibility is that the antibody binds to the protein which then binds to the labeled probe, 
creating a larger molecular weight complex antibody-protein-DNA, which moves slower 
through the gel and will be observed as a band shift on the gel. A successful shift 
confirms the identity of the protein. Alternatively, the antibody may prevent DNA/ 
protein interaction because it binds to an essential site on the protein required for DNA 
binding, resulting in a loss of the specific complex and no band shift on the gel.     
 
Results of in-silico and EMSA implicated the CTCF protein as binding to rs17191344 in 
the presence of the G allele; supershift EMSA was performed to verify protein binding. 
Figure 7-9 shows that the G allele probe produced a band as expected and was competed 
out by the unlabeled probe (lanes 4-5), however, a band shift or band absence was not 
observed with the addition of antibody (lanes 6-7). However, the specific bands in lanes 
6-7 had higher intensity.      
 
MC-EMSA implicated the rs11633032, which binds to Egr1 and a portion of the GATA 
family. The proteins in the GATA family share very similar consensus sequences, thus 
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MC-EMSA could not identify which proteins were binding. Three GATA proteins were 
examined (GATA1 and GATA2+3); these isoforms have emerged as candidate regulators 
of gene expression for either ANXA2 or liver associated genes (445). Supershift EMSA 
was performed on the rs11633032 G probe. Again the rs11633032 G allele probes 
produced a band as expected that was competed out by an unlabeled probe (Figure 7-9, 
lanes 7-8). When the GATA1 antibody was added, no differences were seen in lanes 8, 9 
and 10. However, with the addition of GATA2+3 (lanes 11-12) and Egr1 (lanes 13-14) 
antibodies, the G allele specific band was eliminated, which indicates that the antibodies 
interfered with the interaction of nucleoprotein complexes, because the antibodies 
interact with essential sites on the protein required for DNA binding and prevent shift 
complex forming.  
 
The consensus sequences of protein binding motifs were compared to the DNA sequence 
around rs11633032 (Figure 7-10), and the binding sites of three proteins, GATA2, 
GATA3 and Egr1 were found to overlap with the SNP of interest. Thus, nucleotide 
substitution may affect protein–DNA binding affinity. This may explain the absence of 
specific bands of the G allele with addition of the three antibodies. If these antibodies 
bound to core (A/T) GATA(A/G) nucleotide motif, then the rs11633032 G probe would 
be unable to bind to protein.  However, it is important to note that Egr1 is most likely to 
be allele specific binding protein as the presence of the G allele of the SNP may increase 
the binding affinity to Egr1. In contrast, GATA1 binding motif binds to the sequence 
beside the SNP but does not overlap with the SNP itself. 
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Figure  7-9: Supershift EMSA of ANXA2 intergenic SNPs: rs17191344 and 
rs11633032 
Supershift EMSA shows the effect of adding CTCF to rs17191344, and GATA and Egr1 
to rs11633032. The probe specific bands are indicated by arrows. The SNP labeled 
probes produced a band which was eliminated following addition of an unlabeled probe. 
Addition of the antibodies did not produce a band shift or band absence. * indicating the 
antibodies that were added after the complex formed. 
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Figure  7-10: Nucleotide sequence overlap between rs11633032 G allele and 
suggested the specific allele protein binding 
   
GATA protein family including GATA1, GATA2, and GATA3 and Egr1 consensus 
sequences of binding motif were compared with genomic sequence around rs11633032. 
The SNP G allele matches more closely with the consensus sequence of Egr1, which may 
increase the likelihood of this protein being the allele specific binding protein. The 
ANXA2 rs11633032 G allele is indicated in red, while the overlap sequences are 
indicated in blue and by stars.     
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7.2.4. Effect of rs17191344 and rs11633032 on reporter gene 
expression  
Luciferase reporter assays were performed to assess whether the rs17191344 and 
rs11633032 SNPs genotypes affect gene expression.  
 
7.2.4.1. ANXA2 promoter  
To determine the effect of identified intergenic SNPs on gene expression of ANXA2, it is 
ideal to use the pGL3-basic luciferase reporter vector and insert an ANXA2 promoter 
DNA fragment (1520bp) upstream of the Luciferase gene (luc+) at the promoter site. 
However, amplifying a 1520bp fragment of ANXA2 promoter was impossible due to the 
presence of a sequence of short tandem repeats (STRs) including one ALU repeat, and 
three LINE repeats, which were interspersed in 823bp (54.14%) of the promoter (Figure 
7-8). These were identified using RepeatMasker software (446). In PCR amplification, 
primers bind to the DNA at specific loci and are extended by PCR to produce full length 
PCR product. However, the PCR product length is fragmented in the presence of STRs. 
The length of the PCR product depends on the number of repeats. In-silico results have 
suggested that the ANXA2 promoter amplification could produce four bands: 123bp, 
405bp, 250bp and 45bp (Figure 7-12), which was confirmed by PCR. The PCR product 
of the ANXA2 promoter had three fragment sizes similar to what was predicted by the in 
silico tool (Figure 7-11). Thus due to the difficulty in amplifying ANXA2 promoter, the 
pGL3-promoter luciferase reporter vector was used for further reporter gene expression. 
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Figure  7-11: Presence of a sequence of short tandem repeats (STRs) in the ANXA2 
promoter  
RepeatMasker tool predicted that the ANXA2 promoter contains two type of STRs: SINEs 
(ALUs) and LINEs (LINE1, LINE2, and L3/CR1). This suggested that DNA 
amplification could generate four DNA fragments (123bp, 405bp, 250bp and 45bp) 
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Figure  7-12: PCR products of ANXA2 promoter  
PCR amplification of ANXA2 promoter (1520bp) shows that three short tandem repeats 
(STRs) were present in the sequence, which led to fragmentation of the PCR product into 
three fragments (bands indicated by arrows). 1kb plus a DNA ladder was used as 
molecular size markers.  
 
 
296 
 
7.2.4.2. The impact of ANXA2 SNPs rs11633032 and rs17191344 on 
reporter gene expression  
The ANXA2 SNPs rs11633032 (593bp) and rs17191344 (776bp) fragments containing 
either allele of the SNP were inserted downstream of the luciferase gene in the pGL3-
promoter luciferase reporter vector (Figure 7-13 A). The inserted fragment in the pGL3-
promoter vector resulted in a decrease of expression compared to the control vector 
(pGL3-promoter) for both alleles (Figure 7-13 B). However, the presence of minor alleles 
caused approximately 18% further significant decrease of gene expression in rs11633032 
(p=0.91x10
-3
) and rs17191344 (p=0.27x10
-3
). This suggests that the sequences around 
rs11633032 and rs17191344 are sites for repressor protein binding (439).  
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Figure  7-13: ANXA2- intergenic SNPs luciferase activity in Huh7 cell line.  
A) A map of the pGL3-promoter constructs showing the location of the added SNP 
fragments of rs11633032 (585bp) and rs17191344 (767bp). B) The luciferase reporter 
assays show relative expression of ANXA2- intergenic SNPs-luciferase-enhancer-
constructs (sequence has SNP of interest inserted into enhancer site of the vector) relative 
to the control (pGL3-promoter vector).  
 
A)  
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B)  
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7.2.5. Expression Quantitative Trait Loci (eQTL) analysis  
To assess genotype-gene expression level associations, three expression quantitative trait 
loci (eQTL) catalogues were used. The first was the Genotype–Tissue Expression 
(GTEx) portal (285, 286) which calculated the association between rs11633032 genotype 
and expression of the four closest genes to the SNP in different tissues. The second was 
the Advanced Study of Aortic Pathology (ASAP) study  (310). The third catalogue was 
the eQTL meta-analysis of blood for lipid-regulatory and immune-mediated disease 
variants (447).  
 
7.2.5.1. The Genotype–Tissue Expression (GTEx) 
To determine whether ANXA2 intergenic SNPs were associated with altered gene 
expression in human, the publicly available gene expression data set, GTEx, was used. 
The four genes (Forkhead box B (FOXB), ANXA2, RAR-related orphan receptor alpha 
(RORA) and Lipase C (LIPC)) near the SNPs were tested in GTEx, but no significant 
association was found between the SNPs’ genotype and gene expression in the liver, 
whole blood and arteries (Table 7-8). However, subjects with one copy of the risk allele 
for rs11633032 had lower expression of ANXA2 in all tissues including liver, whole blood 
and coronary artery (Effect size = -0.062, -0.039 and -0.20, respectively) (Figure 7-14), 
but this effect was not statistically significant (p>0.05) due to the small sample size, with 
only three to-six subjects being homozygous for the minor allele. However this effect was 
confirmed in the latest unpublished GTEx data, which showed that the rs11633032 minor 
allele was associated with significantly reduced ANXA2 expression in a tibial artery 
sample (effect size -0.177, p=2.9x10
-06
, N=285) under additive model (439).  
300 
 
Table  7-8: The influence of ANXA2 rs11633032 on nearby gene expression 
Using the GTEx public database, five genes close to rs11633032 SNP were analyzed 
(NARG2, ANXA2, RORA, LIPC and FOXB (no data found) in five different tissues 
including liver, whole blood and arteries (aortic artery, coronary artery, and tibial artery) 
 
Gene Symbol p-value Effect Size Tissue 
NARG2 0.069 -0.12 Artery - Aorta 
0.35 -0.097 Artery - Heart 
0.81 -0.013 Artery - Tibia 
0.4 -0.14 Liver 
0.094 0.080 Whole blood 
ANXA2 0.17 -0.094 Artery - Aorta 
0.20 -0. 2 Artery - Heart 
0.33 -0.047 Artery - Tibia 
0.53 -0.062 Liver 
0.36 -0.039 Whole blood 
LIPC 0.33 -0.12 Artery - Aorta 
0.46 -0.091 Artery - Heart 
0.57 0.051 Artery - Tibia 
0.75 0.039 Liver 
0.70 0.038 Whole blood 
RORA 0.51 0.048 Artery - Aorta 
0.83 -0.023 Artery - Heart 
0.64 0.024 Artery - Tibia 
0.58 0.072 Liver 
0.042 0.056 Whole blood 
NMDA receptor regulated 2 (NARG2), Annexin A2 (ANXA2), Lipase C (LIPC), 
and RAR-related orphan receptor alpha (RORA)
301 
 
Figure  7-14: ANXA2 expression by rs11633032 genotype in human tissues. 
Data and graphs from the Genotype–Tissue Expression (GTEx) Portal. The tissue-specific association between rs11633032 and 
genotype and expression level of ANXA2 in three different tissues (liver, whole blood, and coronary artery) was investigated. 
Although no significant association was found due to sample size, the SNP genotype showed the same expression trend in all three 
tissues, where carriers of the minor alleles had lower gene expression.  
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7.2.5.2. The advanced study of aortic pathology (ASAP) study 
To examine further the effect of rs11633032 on ANXA2 expression in different human 
tissues, the ASAP study was used, where all genes within 628 kb were analyzed in 
cardiovascular and metabolic relevant tissues, including liver, aorta (medial and 
adventitial portions), mammary artery, and carotid plaque. This showed that the 
rs11633032 SNP genotype affected ANXA2 expression mostly in the heart and to a 
moderate level in the liver (Figure 7-15 A). In liver, again the rs11633032 SNP risk allele 
(A) was associated with a reduced expression level of ANXA2 (p=0.075) in the additive 
model (Figure 7-15 B) (439). Applying the recessive model to our study was unsuitable 
because of the small number of cases carrying two copies of the risk allele and the 
modest effect of SNP on expression. Although there was a lack of a significant 
association, the ASAP result was consistent with results found in other data. 
 
Figure  7-15: Gene expression by rs11633032 genotype in the Advanced Study of 
Aortic Pathology (ASAP) study 
A) Tissue-specific association between the rs11633032 genotype and expression level of 
all genes within 628 kb of the locus. In the plot, the y-axis shows the log10 (P) calculated 
for the association between genotype and expression level using an additive model. The 
x-axis shows the five different tissues examined: Mammary-Artery, Liver, Aorta-intima, 
Media Aorta-adventitia, and Heart. Each colored line shows the association level for one 
gene across different tissue types (ANXA2 represented by a green line). The relative 
expression level of a gene in the tissue type is indicated by the dot size. B) Additive 
linear models used to detect the association between SNP and ANXA2 expression levels 
in liver tissue. Gene expression measurement in a patient with rs11633032 genotype, 
which can be AA, AG and GG. Expression data is shown for the whole sample, men and 
women. 
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B)  
 
 
304 
 
7.2.5.3. The eQTL meta-analysis for lipid-regulation 
To further verify these findings, the publicly available eQTL meta-analysis for lipid-
regulation (http://genenetwork.nl/bloodeqtlbrowser/) was used which found that the 
proxy SNP rs9920796 (r
2
=0.736) was significantly associated with lower ANXA2-mRNA 
expression levels (Z-score= -4.35, p=1.36 x10
-05
). The Z-score is the number of standard 
deviations away from the mean. In other words, the Z-score shows the relationship to the 
mean in a group of values. For example, a Z-score of 0 shows that the score is identical to 
the mean score, but if the Z-score has a negative value (-0.0 to -4.0), it indicates a score 
below the mean.    
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7.3. Discussion 
The two studies that investigated the ANXA2-R1 missense variant p.(Val98Leu)  in 
chapter six showed the substantial heterogeneity of the association of the SNP with LDL-
C. In addition, the SNP was predicted to be non-pathogenic and in modest LD in the non-
coding region. These results suggested that the ANXA2 coding SNP may be a marker for 
SNPs in non-coding region which may have an influence on gene expression. Using 
bioinformatics, genotype-phenotype analysis, and evidence from differential protein 
binding and allele-specific gene expression assays, two candidate SNPs were identified in 
the ANXA2 cis-regulatory region (rs17191344 and rs11633032). Both cis-regulatory 
SNPs were associated with LDL-C and the risk of CHD, and showed that these SNPs 
affect ANXA2 gene expression via alterations in transcription factors that bind to alleles 
of the SNPs. Using data from population studies, this work has confirmed  for the first 
time the observations in cell culture and AnxA2 knockout mice, where changes in the 
levels of AnxA2 directly influence plasma LDL-C levels in human, and thus implicate 
this protein as a potential therapeutic target for LDL-C lowering.  
 
The effect of rs17191344 and rs11633032 on cholesterol levels was determined in the 
NPHSII and UCLEB consortium. These SNPs were associated with LDL-C level and 
CHD risk with a recessive mode of inheritance, where two copies of the minor allele led 
to significantly higher levels of LDL-C and higher risk of CHD (439).  This finding is 
similar to the effect seen by Val98Leu SNP. This raised the question as to whether the 
observed phenotype was the result of the effect of a non-coding SNP (rs17191344) or 
was due to the combined effect of coding SNP and non-coding SNP.  This was assessed 
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by examining cholesterol levels and risk of CHD for these individuals with different 
combinations of genotypes. It was found that individuals carrying two copies of the 
minor allele for both SNPs had the highest LDL-C levels and the highest risk of CHD. 
However, only a small number of individuals carry the minor alleles, and they had 
modestly elevated cholesterol levels and CHD risk, suggesting that both the amino-acid 
change and the intronic SNPs are functional. Although we reported that the intergenic 
SNPs did not display a significant difference in cholesterol levels between sexes, women 
appeared to be less affected by these variants. It has been reported that sex and age have 
an influence on PCSK9 concentration and consequently LDL-C levels (448), where 
women have higher levels of PCSK9 and postmenopausal women exhibit even higher 
concentrations than premenopausal women (449, 450).   
 
Although the GWAS reveals many novel loci associated with lipid levels (161), it is 
unclear why the ANXA2 locus has not been previously identified as a GWAS hit for 
LDL-C (161), but there are several possibilities to consider. First, GWAS need to set 
stringent cut-off values for association (p < 10
-8
) to reduce the possibility of false positive 
associations, although this could lead to false negative results and some of the disease-
associated variants of modest effect could be missed. In addition, most of the GWAS 
published data used an additive inherited model in their statistical analyses, which may 
miss trait-associated variants that have recessive inheritance modes. It may also have 
been that this variant (or the ANXA2 locus) was not well covered in the GWAS 
genotyping chips. 
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Bioinformatics databases are particularly powerful tools to select candidate SNPs for 
functional studies. The Val98Leu SNP has a modest LD with 34 SNPs, all located 
downstream of the ANXA2 gene-coding region in the long intergenic region. Such regions 
often comprise cis-regulatory sequences that have a role in chromatin organization and 
transcription regulation (451). Cis-regulatory sequences could be a hit for enhancer 
elements that have an important role in gene transcription. Enhancers contain multiple 
short binding site sequences for activators and repressors that regulate gene transcription 
(452). One gene can have multiple enhancers in order to facilitate gene activation; an 
enhancer can be located anywhere within a span of 100kb upstream or downstream of a 
gene whose expression it regulates.  
 
Data from ENCODE and RoadMap Epigenomics were used to evaluate whether the 34 
SNPs were located in the cis-regulatory element regions and whether they had regulatory 
potential. A shortlist of three potentially functional variants identified SNPs rs17191344, 
rs11633032 and rs12900101. The regulatory markers showed a number of characteristics: 
a) chromatin immunoprecipitation sequencing demonstrated peaks of transcription factor 
binding sites at these SNPs, which suggested that an allele of the variants might affect 
transcription factor binding and actions; b) histone methylation and acetylation marks 
showed areas consistent with enhancers; c) FAIRE and DNase hypersensitivity showed 
regions of open chromatin, which are more likely to be involved in regulating expression; 
and d) the ENCODE data and ElDorado tool showed that the variants might either 
facilitate or block transcription factor binding. 
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The in silico predictions of protein binding to the selected SNPs were confirmed by in 
vitro assays. Using EMSA, both rs11633032 and rs17191344 showed strong allele-
specific protein binding and several potential transcriptional factors involved in the 
regulation of ANXA2 expression levels were identified. MC-EMSA suggested that the 
Egr1 and GATA proteins were implicated in binding to the sequence around the G allele 
of rs11633032 (439). Egr1 is a nuclear factor that regulates gene expression in a tissue‐
restricted manner through its binding to other regulatory transcription factors (453). The 
protein family GATA comprises six members (GATA1 to GATA6) all of which have a 
highly conserved double zinc finger domain that mediates binding to DNA and co-factors 
to regulate gene expression in a highly tissue-restricted fashion. GATA recruits 
chromatin remodeling complex and mediates either repression or activation of target 
genes (454, 455). 
 
EMSA also showed that CTCF binds to the DNA sequence around rs17191344 in the 
presence of the G allele (439). CTCF is considered to be an insulator element and plays a 
critical role in transcriptional regulation. There are two possible functions of an insulator 
in gene regulation. First, it binds to DNA-regulatory sequences in the promoter-proximal 
regions where it competes for enhancer-bound activators and prevents the activation of 
downstream promoters (444, 456). In addition, insulators may be involved in gene 
regulation by facilitating the formation of separate loop domain structures, which prevent 
an enhancer on one loop from contacting with a promoter on a different loop (457, 
458). Despite the identification of above mentioned transcription factors GATA, Egr1 
and CTCF binding AnxA2 mRNA in vitro, future work will need to validate their 
309 
 
contribution to the regulation of AnxA2 expression levels in hepatic cell lines. In 
particular, overexpression or silencing of the transcription factor CTCF could provide 
further insight of whether rs11633032 and rs17191344 can modulate the deduced 
repressor functions of this transcription factor. 
 
A supershift assay was performed to investigate which DNA binding proteins are 
involved. The order of addition of reaction components (extract, oligos, and antibodies) is 
critical in these assays. An antibody may interfere with the interaction of nucleoprotein 
complexes and can lead to band elimination, thus the antibody is added after 
nucleoprotein complexes are formed. In this study, the antibody was added either before 
or after complexes were formed, but unfortunately none of the candidate proteins were 
successfully identified, that is, no band shift was seen following addition of antibody. 
However, the addition of the CTCF antibody to the rs17191344 G probe showed 50% 
higher band intensity than the rs17191344 G probe alone. A possible explanation is that 
the larger molecular weight of the complex (antibody-protein-DNA) (459) may have 
affected the complex’s mobility in the gel and the shift band may have been hidden in the 
binding band, suggesting that a lower gel concentration or softer gel may help band 
mobility.    
 
The supershift assay with rs11633032 G probe was performed with 3 different antibodies 
(GATA1, GATA2+3, and Egr1). GATA1, GATA 2 and GATA 3 are members of the 
GATA family proteins, that bind to the (A/T)GATA(A/G) nucleotide motif with a high 
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degree of amino acid sequence identity (455). These GATA antibodies were chosen as 
they have been implicated in ANXA2 expression and in liver associated gene expression. 
It has been reported that GATA 2 is a proximal co-regulator transcription factor of the 
ANXA2 gene (http://encodenets.gersteinlab. org/index.html#; (445). GATA 2 and GATA 
3 regulate liver and cholesterol associated genes (460), while GATA1 is expressed in 
fetal liver (461). The GATA2+3 and Egr1 antibodies eliminated the specific band which 
suggests that the antibodies interact with essential sites on the protein required for DNA 
binding, while GATA1 antibody showed no band shift. Overall, as the antibody is 
expected to bind to its corresponding protein, the lack of shift suggests that the antibodies 
used did not bind to the protein under EMSA conditions. 
 
The luciferase reporter assay was used to assess the mechanism and action of the SNPs 
and evaluate how different protein binding may affect gene expression. It was found that 
the minor allele of both SNPs rs11633032 and rs17191344 reduced gene expression 
(439). Such lower gene expression in carriers of the risk A allele of rs11633032 was 
confirmed using in human expression data from GTEx, ASAP and from the large eQTL 
meta-analysis.  
 
Overall these findings suggest that the sequence around the minor alleles of ANXA2-
intergenic SNPs rs11633032 and rs17191344 are sites for transcriptional repressor 
proteins that lead to reduced ANXA2-mRNA expression and protein levels (439). 
However, it is as yet unknown whether  with such low levels of expression  and in the 
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presence of high-affinity AnxA2 binding partners in plasma, such as plasminogen or tPA 
(433), AnxA2 is still able to interact with PCSK9 and inhibit PCSK9 acting on LDL-R, 
leading to higher levels of LDL-R receptors in the liver and consequently, reduced 
plasma LDL-C levels.  
 
7.4. Limitations 
This study had limitations. The first limitation was that although the ANXA2 coding SNP 
was thought to be functional, no data addressed directly whether or not the Val98Leu 
change affects AnxA2 structure and function. I am unaware of any data that has 
addressed the functional consequences of this particular mutation. One study (102) has 
presented preliminary evidence that V98L does not affect the binding affinity of AnxA2 
for PCSK9, but it is associated with lower circulating PCSK9 and may be causing lower 
LDL-C levels. The authors suggest that further studies are needed to examine whether 
this mutation modifies the function of PCSK9 or has downstream consequences on LDL-
R activity. In addition to the possibility that the coding SNP may affect protein structure, 
it also may be a site for a cis-regulatory element (462, 463). The sequence around the 
coding SNP rs17845226 is located in a DNAse I hypersensitive domain, thus it may be a 
site for positive-acting regulatory sequences which could interact with intergenic 
functional SNPs and ANXA2 promoter to initiate gene transcription. A second limitation 
is that it was not possible to impute the genotype in UCLEB for rs17845226, and that the 
examined SNPs were imputed with a relatively low degree of precision. Since they were 
associated with LDL-C levels in the UCLEB cohort, it is possible that examining these 
SNPs with wet-lab genotyping may help to see larger mean effect on LDL-C levels.  
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The third limitation is in vitro data. These data showed a regulatory element near to 
rs11633032 and rs17191344 SNPs which acted as a repressor of ANXA2 expression in the 
liver cell line studied, chosen because liver is the major site for LDL-C clearance from 
the plasma (464). However, the impact of these SNPs on gene expression in other tissues 
was not examined. AnxA2 levels in liver are generally considered low (102), but in line 
with this study using Huh7 as a model system, stable knockdown of AnxA2 expression in 
Huh7 resulted in PCSK9 upregulation and a marked reduction in LDL-R levels (192). I 
am aware that Huh7 may not be representative of all human hepatocellular carcinoma cell 
lines as AnxA2 depletion in HepG2 cells, which expresses approximately 5-fold less 
AnxA2 mRNA compared to Huh7, did not alter PCSK9 or LDL-R protein expression. 
However, this study elucidates a potentially new mechanism, suggesting a role for 
AnxA2 in the translational control of PCSK9 protein levels (192). The overall 
contribution of transcriptional and translational regulation of AnxA2 expression, which 
affects PCSK9 maturation and protein levels in the extracellular space and during PCSK9 
synthesis and secretion, has yet to be determined in vivo. Another unavoidable limitation 
is that in vitro EMSA and luciferase assays were used to demonstrate the functional role 
of SNPs using the hepatoma cell line Huh7. These two in vitro assays can only 
approximate the actual gene expression occurring in vivo, where environment and open 
chromatin modification and interaction play essential roles in mediating gene expression.  
 
The fourth limitation is linked to SNP selection. The ANXA2 cis-regulatory SNPs, 
rs11633032, rs17191344 and rs12900101, which were studied, have strong LD with 64 
SNPs, all in the intergenic region. Here the ENCODE data, a summary tool, HaploReg 
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V4 and in silico ElDorado data were used to select potential functional candidate SNPs. 
However, the other LD SNPs not examined may have a role in transcriptional regulation. 
This kind of limitation is unavoidable because there is no conclusive tool to rank 
likelihood functionality of non-coding variants. There are some annotation programs such 
as combined annotation dependent depletion (CADD) (465) and RegulomeDB (466) that 
provide their own ranking-score using growing genomic annotation data from the 
ENCODE and Roadmap projects, but the ranking varies between programs with no 
definite assumptions.    
 
The fifth limitation was associated with the supershift assay. It is an important assay that 
provides another level of certainty of protein-DNA binding. However; in this study some 
difficulties were faced with antibodies, complex size, and EMSA conditions.  Addressing 
these issues needs more time and resources, which were very limited during this study.    
       
7.5. Conclusion   
In summary, AnxA2 has been previously linked to cholesterol homeostasis and CHD risk 
via its interaction with PCSK9. Integration of bioinformatics with disease-association 
analysis and in vitro studies is a powerful tool, and has led to identification of functional 
SNPs in ANXA2 and its cis-regulatory domain. Although there was a lack of consistency 
in the association analysis data of the ANXA2 coding SNP in the previous chapter, further 
analysis of the coding SNP with a proxy SNP has shown that coding SNPs may be 
functional and the negative prediction of SNP functionality may be incorrect. As in many 
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bioinformatics prediction tools, they have a proportion of false negative results. 
Therefore, further biological functional studies need to verify whether the coding SNP 
has a role in protein structure or function.          
 
Despite the unknown functional role of the ANXA2 coding SNP, the SNP has LD with 
SNPs in the cis-regulatory region. This study used bioinformatics and functional assays 
to identify a potential cis-regulatory variant associated with the chromosome 15 locus and 
in turn with LDL-C levels and CHD risk.  However, identifying the functional SNPs was 
another challenge due to LD. The selected SNPs of modest LD showed that these SNPs 
are sites for transcription protein binding and caused expression alteration, suggesting 
ANXA2 is a potential therapeutic target. The risk allele reduced the expression levels of 
ANXA2, lowered ANXA2-mRNA expression and is thus predicted to result in less protein. 
Low levels of AnxA2 allow PCSK9 to increase LDL-R degradation and thus increase 
LDL-C levels and the risk of CHD.         
 315 
 
Chapter 8 : Identification of functional variants in the ANXA2-
3’UTR 
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8.1. Introduction  
MicroRNAs (miRNAs) are small non-coding single strands of RNA about 22 nucleotides in 
length, which regulate gene expression through the post-transcription regulation machinery 
(261). MiRNA genes are transcribed via RNA polymerase II to generate pri-miRNAs that have 
multiple hairpin loop structures (Figure 1-28). Pri-miRNAs are processed by the Drosha complex 
to produce smaller precursor molecules called pre-miRNAs. Then, pre-miRNAs are exported 
from the nucleus via exportin-5 to the cytoplasm (467). In the cytoplasm, pre-miRNAs are 
processed via Dicer to generate short double-stranded miRNAs, which are then converted to 
mature, single-stranded miRNAs via RISC, the mature miRNAs interact with 3’UTR of the 
targeted mRNA (259, 260). Complementarity  between the miRNA and a seeding site within the  
3’UTR of a target mRNA regulates the post-transcriptional fate of the mRNA, where perfect 
complementarity leads to the degradation of the target mRNA, while imperfect complementarity 
leads to repressed translation (261). The seeding site is a target sequence in 3’UTR-mRNA 
where miRNAs are able to recognize and hybridize, using 6–8 nucleotides either at the 5' or 3’ 
region of the miRNA. 
 
A variant such as a SNP within  a miRNA, or at a miRNA seed site on the targeted mRNA,  may 
create or destroy miRNA/mRNA binding sites and thus affect the translation of the mRNA, the 
production of the encoded protein and ultimately a disease trait (e.g. LDL-C) or a disease 
phenotype endpoint (e.g. CHD) (268).  It has been reported that SNPs at miRNA target sites 
have been associated with an increased risk of various complex diseases including cancer, and 
cardiac and other diseases (468). Identifying and selecting miRNA/mRNA potential candidates 
for experimental validation is challenging due to the nature of miRNA/mRNA target interaction 
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prediction tools, that usually provide a very large number of potential target sites that then need 
to be validated (469). miRNAs have a tissue-specific expression signature and their actions are 
controlled by physiological and pathological environments (470). 
 
 ANXA2 expression is regulated at both the transcriptional and translational level (188). For 
instance, ERG binds to a DNA sequence upstream of the ANXA2 gene, and  acts as a repressor to 
down-regulate ANXA2 expression in prostate epithelial cells (442). Also, in chapter seven I 
showed that CTCF binds to a DNA sequence downstream of the ANXA2 gene in the long 
intergenic region, and represses ANXA2 expression. In addition, the 3’UTR of ANXA2 plays an 
important role in ANXA2-mRNA transport and translation via binding to itself (471), to other 
mRNAs (472) and to miRNAs (473). It has been reported that miRNAs regulate ANXA2 
expression and mediate several disease-related processes. For instance, miR-21 down-regulated 
ANXA2 expression and mediated endothelial dysfunction in patients with diabetes (473), while 
miR-206 down-regulated ANXA2 expression and controlled the phenotypic modulation of 
pulmonary artery smooth muscle cells in hepatopulmonary syndrome (474). Also miR-206 (475), 
miR-9 (476) and miR-1 (477) have been linked to carcinogenesis in different cancer types.  
 
AnxA2 also has been linked to the cholesterol clearance process because it influences the 
PCSK9-mediated degradation of LDL-R (101, 102). Previous chapters have shown variants 
either in the coding or regulatory element regions that could mediate ANXA2 expression. In this 
chapter, I examine the hypothesis that the 3’UTR of ANXA2-mRNA may be a site for miRNAs 
that could regulate gene expression, and consequently affect cholesterol levels in plasma. My 
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aim was to identify common variants in the 3’UTR of ANXA2 that may create binding sites for 
miRNAs and may have a differential influence on ANXA2 expression and LDL-C levels.  
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8.2. Results  
8.2.1. Computational prediction of miRNA targets 
To identify a possible interaction between miRNAs and mRNA of the ANXA2, the 
3’UTR of human ANXA2 was analyzed using a computational prediction method. Three 
commonly used miRNA prediction algorithms were used: miRWalk (292), mirSNP (293)  
and miRanda (478),  
 
8.2.1.1. The miRWalk algorithm 
The miRWalk database provides predicted and validated information on miRNA-target 
interactions (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/). Also, this 
prediction tool provides a compression option which compares its output with two other 
popular miRSearch databases, miRanda and Targetscan. The miRWalk algorithm selects 
only the miRNAs that have 7 nucleotides seed length which increases the possibility of 
interactions with its possible target sequence (ANXA2), and miRNAs that have 
probability for random matches  lower than 0.05 [Poisson distribution is used to calculate 
p-value in Sadygov et al., 2003 and Havilio et al., 2003]. The miRWalk algorithm 
showed that a total of 71 miRNAs fitted the criteria and were predicted to bind to the 
ANXA2-3’UTR (Table 8-1). In addition, 53 of these miRNAs were also predicted by two 
other algorithms: TargetScan (479) and miRanda.  
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Table  8-1: The miRWalk algorithm: ANXA2-3’UTR‎predicted‎miRNA target sites  
The table shows miRNAs that could bind to the ANXA2-3’UTR and information about 
miRNA-target interactions including seeding length, starting position of miRNA seeding, 
and end position, and p-value as predicted by miRWalk. Also, the table shows the 
comparative platform of miRNA binding site predictions using different algorithms 
(miRWalk, miRanda and TargetScan). When a specific miRNA is predicted by one 
algorithm, it was counted as 1, and the SUM column shows how many algorithms 
predicted a specific miRNA. * indicated to MiRNA different isoform. 
 
MicroRNA Seed 
length 
Start End P-value miRanda miRWalk Targetscan SUM 
hsa-miR-29b 10 1191 1182 0.0005 1 1 1 3 
hsa-miR-29c 10 1191 1182 0.0005 1 1 1 3 
hsa-miR-513a-5p 9 1261 1253 0.0019 1 1 1 3 
hsa-miR-613 9 1360 1352 0.0019 1 1 1 3 
hsa-miR-155 9 1278 1270 0.0019 1 1 1 3 
hsa-miR-376b 8 1386 1379 0.0074 1 1 1 3 
hsa-miR-376a 8 1386 1379 0.0074 1 1 1 3 
hsa-miR-650 8 1405 1398 0.0074 1 1 1 3 
hsa-miR-376a 8 1386 1379 0.0074 1 1 1 3 
hsa-miR-29a 8 1191 1184 0.0074 1 1 1 3 
hsa-let-7g* 8 1567 1560 0.0074 1 1 0 2 
hsa-miR-92a-1* 8 1288 1281 0.0074 1 1 0 2 
hsa-miR-206 8 1361 1354 0.0074 1 1 1 3 
hsa-miR-1 8 1361 1354 0.0074 1 1 1 3 
hsa-miR-1226 8 1524 1517 0.0074 1 1 1 3 
hsa-miR-29b-1* 8 1227 1220 0.0074 1 1 0 2 
hsa-miR-548k 7 1449 1443 0.0293 1 1 1 3 
hsa-miR-9 7 1348 1342 0.0293 1 1 1 3 
hsa-miR-488 7 1480 1474 0.0293 1 1 1 3 
hsa-miR-29b-2* 7 1226 1220 0.0293 1 1 0 2 
hsa-miR-1299 7 1183 1177 0.0293 1 1 1 3 
hsa-miR-559 7 1450 1444 0.0293 1 1 1 3 
hsa-miR-302a* 7 1602 1596 0.0293 1 1 0 2 
hsa-miR-650 7 1404 1398 0.0293 1 1 1 3 
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hsa-miR-519d 7 1399 1393 0.0293 1 1 1 3 
hsa-miR-664 7 1432 1426 0.0293 1 1 1 3 
hsa-miR-574-3p 7 1177 1171 0.0293 1 1 1 3 
hsa-miR-101 7 1414 1408 0.0293 1 1 1 3 
hsa-miR-17 7 1399 1393 0.0293 1 1 1 3 
hsa-miR-767-5p 7 1190 1184 0.0293 1 1 1 3 
hsa-miR-520g 7 1466 1460 0.0293 1 1 1 3 
hsa-miR-10a* 7 1443 1437 0.0293 1 1 0 2 
hsa-miR-138 7 1228 1222 0.0293 1 1 0 2 
hsa-miR-579 7 1616 1610 0.0293 1 1 1 3 
hsa-miR-890 7 1588 1582 0.0293 1 1 1 3 
hsa-miR-520g 7 1399 1393 0.0293 1 1 1 3 
hsa-miR-185 7 1335 1329 0.0293 1 1 1 3 
hsa-miR-579 7 1354 1348 0.0293 1 1 1 3 
hsa-miR-377* 7 1289 1283 0.0293 1 1 0 2 
hsa-miR-220c 7 1409 1403 0.0293 1 1 1 3 
hsa-miR-520h 7 1466 1460 0.0293 1 1 1 3 
hsa-let-7g* 7 1566 1560 0.0293 1 1 0 2 
hsa-miR-588 7 1252 1246 0.0293 1 1 1 3 
hsa-miR-425 7 1419 1413 0.0293 1 1 1 3 
hsa-miR-92a-1* 7 1287 1281 0.0293 1 1 0 2 
hsa-miR-220c 7 1260 1254 0.0293 1 1 1 3 
hsa-miR-520h 7 1399 1393 0.0293 1 1 1 3 
hsa-miR-206 7 1360 1354 0.0293 1 1 1 3 
hsa-miR-590-3p 7 1499 1493 0.0293 1 1 1 3 
hsa-miR-20b 7 1399 1393 0.0293 1 1 1 3 
hsa-miR-93 7 1399 1393 0.0293 1 1 1 3 
hsa-miR-1 7 1360 1354 0.0293 1 1 1 3 
hsa-miR-600 7 1341 1335 0.0293 1 1 1 3 
hsa-miR-452* 7 1429 1423 0.0293 1 1 1 3 
hsa-miR-101 7 1414 1408 0.0293 1 1 1 3 
hsa-miR-1226 7 1523 1517 0.0293 1 1 1 3 
hsa-miR-513a-3p 7 1610 1604 0.0293 1 1 1 3 
hsa-miR-27b* 7 1550 1544 0.0293 1 1 0 2 
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hsa-miR-1 7 1360 1354 0.0293 1 1 1 3 
hsa-miR-409-3p 7 1359 1353 0.0293 1 1 0 2 
hsa-miR-1206 7 1356 1350 0.0293 1 1 1 3 
hsa-miR-130a* 7 1391 1385 0.0293 1 1 0 2 
hsa-miR-617 7 1381 1375 0.0293 1 1 0 2 
hsa-miR-412 7 1379 1373 0.0293 1 1 1 3 
hsa-miR-29b-1* 7 1226 1220 0.0293 1 1 0 2 
hsa-miR-548k 7 1464 1458 0.0293 1 1 1 3 
hsa-miR-138 7 1228 1222 0.0293 1 1 0 2 
hsa-miR-513a-3p 7 1610 1604 0.0293 1 1 1 3 
hsa-miR-155* 7 1540 1534 0.0293 1 1 1 3 
hsa-miR-631 7 1216 1210 0.0293 1 1 0 2 
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8.2.1.2. The mirSNP algorithm 
The mirSNP database (293) was used to identify which of these miRNAs will bind to 
ANXA2-3’UTR once a SNP is present. MirSNP used GWAS and eQTLs research to 
identify the putative miRNA-related SNPs. The mirSNP database provides information 
including miRNA support vector regression (mirSVR), the effect of the presence of the 
SNP on miRNA binding, miRanda imperfect 7 nucleotides seed site pairing score (cutoff 
of ≥140), alleles of the SNP, free energy that is released due to the interaction between 
miRNA and mRNA, and the conservation score. The mirSVR is a method that takes in to 
account local and global contextual features and is used to rank microRNA target sites by 
a down-regulation score. The local contextual features include the A:U content and the 
predicted secondary structure accessibility at positions flanking the site, while global 
contextual features include the relative position in the 3'UTR length, and conservation 
(293). 
 
The mirSNP database showed that 51 SNPs in the 3’UTR could create sites, disrupt 
potential binding sites, and alter miRNA binding stability (by enhancing or decreasing 
binding) (Table 8-2).  To narrow down the potential target sites for experimental 
validation, only SNPs that created the binding sites and had known mirSVR scores were 
selected. This criteria allowed nomination of the strongest candidates: only seven 
(highlighted in bold in Table 8-2) out of 51 SNPs were nominated to bind 9 miRNAs 
with different isoforms (hsa-miR-155-3p:rs116928563, hsa-miR-185-5p:rs11553799, 
hsa-miR-4306:rs11553799, hsa-miR-376a-3p:rs41315062, hsa-miR-376b: rs41315062, 
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hsa-miR-376a-3p:rs150128007, hsa-miR-376b:rs150128007, hsa-miR-520g: 
rs140887396, and hsa-miR-520h:rs140887396). 
 
From the five SNPs, miR-155:rs116928563 was selected for experimental study because 
the rs116928563 A allele created a binding site for miR-155-3p (miR-155*), reduced the 
free energy by 21 kcal/mol and produced a conserved seed match score of 0.52. In 
addition, the literature showed that miR-155 binds to ANXA2-mRNA (480, 481), and is 
associated with atherosclerosis and LDL-C (482). 
 
 325 
 
Table  8-2: The mirSNP algorithm: SNP-associated miRNAs  
The table shows that 51 SNPs were predicted to bind to miRNA. Details of 
SNP-associated miRNAs are given including support vector regression 
(mirSVR), the effect of interaction, SNP alleles, miRanda imperfect 7 
nucleotides seed site pairing score (cutoff‎≥140), free energy, and conservation 
in different mammalian species. The five nominated SNPs are highlighted in 
bold.  
 
           miRNA SNP mirSVR Effect Allele Score Free energy 
kcal/mol 
Conservation 
hsa-miR-101-3p rs140887396 -0.777 decrease 
G 145 -17.19 0.176 
C 140 -10.26 0.176 
hsa-miR-155-3p rs116928563 -0.256 create 
T 
   
A 146 -15.34 0.52 
hsa-miR-185-5p rs11553799 -0.736 create 
T 
   
C 154 -21 0.404 
hsa-miR-185-5p rs184828726 -0.736 decrease 
G 154 -21 0.91 
C 146 -17.67 0.91 
hsa-miR-29b-1-5p rs1803910 -0.242 decrease 
A 156 -19.72 0 
C 152 -16.75 0 
hsa-miR-29b-1-5p rs11553796 -0.242 decrease 
T 154 -18.07 0 
G 152 -16.75 0 
hsa-miR-3125 rs184828726 
 
 
create 
G 
   
C 150 -15.39 0.001 
hsa-miR-3160-5p rs116928563 
 
 
enhance 
T 144 -13.93 0.001 
A 145 -15.97 0.001 
hsa-miR-3612 rs140887396 
 
 
decrease 
G 145 -18.75 1 
C 141 -16.05 1 
hsa-miR-3673 rs138873688 
 
 
enhance 
G 149 -11.41 0.961 
A 153 -11.7 0.961 
hsa-miR-3684 rs11553796 
 
 
create 
T 
   
G 144 -12.55 0.253 
hsa-miR-3685 rs116928563 
 
 
create 
T 
   
A 140 -13.12 0 
hsa-miR-376a-3p rs41315062 -0.501 create 
G 
   
A 141 -12.44 1 
hsa-miR-376a-3p rs150128007 -0.501 create 
G 
   
A 141 -12.44 0.431 
hsa-miR-376b rs41315062 -0.501 create 
G 
   
A 141 -12.22 1 
hsa-miR-376b rs150128007 -0.501 create 
G 
   
A 141 -12.22 0.431 
hsa-miR-3916 rs184828726 
 
 
create 
G 
   
C 153 -19.56 0.001 
hsa-miR-4305 rs11553796 
 
 
break 
T 140 -10 0.304 
G 
   
hsa-miR-4305 rs184828726 -0.249 break 
G 140 -12.52 0.287 
C 
   
hsa-miR-4306 rs11553799 -0.732 create 
T 
   
C 154 -21 0.404 
hsa-miR-4306 rs184828726 -0.732 decrease 
G 154 -21 0.91 
C 146 -15.45 0.91 
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hsa-miR-4459 rs140887396 
 
 
enhance 
G 152 -19.27 0.999 
C 157 -23.78 0.999 
hsa-miR-4470 rs140887396 
 
 
break 
 
G 141 -12.57 1 
C 
   
hsa-miR-4476 rs3582 
 
 
break 
 
C 146 -22.94 0.875 
T 
   
hsa-miR-4493 rs3582 
 
 
break 
C 144 -13.09 0.764 
T 
   
hsa-miR-4503 rs11553798 
 
 
break 
T 151 -11.86 0 
C 
   
hsa-miR-452-5p rs140887396 
 
 
break 
G 151 -12.45 0.999 
C 
   
hsa-miR-4524b-3p rs184828726 
 
 
break 
G 140 -14.73 0.079 
C 
   
hsa-miR-4644 rs3582 
 
 
decrease 
C 152 -22.05 0.001 
T 151 -21.23 0.001 
hsa-miR-4644 rs11553799 
 
 
create 
T 
   
C 152 -22.05 0.404 
hsa-miR-4644 rs184828726 
 
 
enhance 
G 152 -22.05 0.91 
C 160 -21.05 0.91 
hsa-miR-4672 rs140887396 
 
 
enhance 
G 151 -15.69 0.546 
C 156 -19.02 0.546 
hsa-miR-4676-3p rs140887396 
 
 
break 
G 162 -18.28 0.999 
C 
   
hsa-miR-4695-5p rs140887396 
 
 
enhance 
G 146 -22.73 1 
C 150 -23.28 1 
hsa-miR-4720-3p rs11553798 
 
 
break 
T 143 -11.42 0.002 
C 
   
hsa-miR-4742-5p rs11553798 
 
 
enhance 
T 142 -12.76 0 
C 144 -14.8 0 
hsa-miR-4753-5p rs3582 
 
 
break 
C 142 -12.25 0.644 
T 
   
hsa-miR-4755-3p rs11553798 
 
 
enhance 
T 148 -18.26 0 
C 150 -21.2 0 
hsa-miR-4768-3p rs11553799 
 
 
create 
T 
   
C 152 -16.54 0.277 
hsa-miR-4768-3p rs184828726 
 
 
enhance 
G 152 -16.54 0.952 
C 160 -21.05 0.952 
hsa-miR-499a-3p rs150128007 
 
 
break 
G 150 -15.88 0.176 
A 
   
hsa-miR-499b-3p rs150128007 
 
 
break 
G 143 -11.52 0.176 
A 
   
hsa-miR-499b-5p rs150128007 
 
 
break 
G 142 -15.53 0.794 
A 
   
hsa-miR-520g rs41315062 -0.868 enhance 
G 165 -15.9 0.603 
A 169 -13.74 0.603 
hsa-miR-520g rs140887396 -0.868 create 
G 
   
C 169 -13.74 1 
hsa-miR-520h rs41315062 -0.868 enhance 
G 162 -15.9 0.603 
A 164 -12.93 0.603 
hsa-miR-520h rs140887396 -0.868 create 
G 
   
C 164 -12.93 1 
hsa-miR-548g-3p rs140887396 
 
 
break 
G 147 -7.46 1 
C 
   
hsa-miR-548u rs11553799 
 
 
break 
T 143 -8.65 0.449 
C 
   
hsa-miR-600 rs11553799 -0.405 decrease 
T 154 -12.88 0.006 
C 153 -15 0.006 
hsa-miR-613 rs138873688 -1.186 decrease G 181 -25.16 0.996 
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A 173 -19.72 0.996 
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8.2.1.3. The miRanda algorithm 
The miRanda algorithm was used to identify SNP-miRNA binding positions within 
ANXA2-3’UTR. Figure 8-1 A shows the ANXA2-3’UTR: miRNAs genome wide road 
map, where 16 miRNAs had good mirSVR scores (mirSVR≤ -0.1) and were conserved 
(dark blue), while 77 miRNAs had good mirSVR scores, but were less conserved 
(purple). Some of these miRNAs are predicted to target mRNA with more than one 
isoform.   
 
The selected miR-155 binds to the ANXA2-3’UTR mRNA at two positions (Figure 8-1 
B): the first, the miR-155 isoform, has been validated (481) to bind to ANXA2-3’UTR at 
position 96, with a mirSVR score of -0.2098 and a PhastCons score of 0.5084. The other 
isoform, miR-155*, has been predicted to bind to ANXA2-3’UTR mRNA at position 363, 
but only in the presence of the minor allele of rs116928563 (T>A), where the A allele of 
the SNP leads to a 7nt imperfect match to the 3’UTR of ANXA2.  It is predicted that the 
miR-155* binds to the sequence around the A allele of the SNP; this binding creates free 
energy of -15.34 kcal/mol, the mirSVR score is -0.256, and the PhastCons score is 0.55, 
which suggests that rs116928563 may be a site for miRNA binding that has an influence 
on gene expression.    
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Figure  8-1: The miRanda algorithm: miRNAs binding position in the human ANXA2- 3’UTR 
The ANXA2-3’UTR associated miRNAs genome wide road map. A) MiRNAs that are conserved and had a good mirSVR (mirSVR ≤ -
0.1) are shown in dark blue, while miRNAs that are less conserved and had a good mirSVR are shown in purple. ANXA2: miR-155 is 
highlighted in orange and rs116928563 (A allele): miR-155* is highlighted in yellow. B) Sequence identity flanking conserved seed 
matches and miRNA seeds.  Two isoforms of miR-155 bind to the ANXA2-3’UTR: miR-155 and the ANXA2 rs116928563 (A allele): 
miR-155*. The road map was generated using miRanda (478). The gray dashes indicate the same analysis for conserved matches to 
control sequences. The colons indicate the G:U wobble pair.  
A)   
 
 330 
 
B)  
 
 
 
 
  
 
 
 
 
 
 
 
 
rs116928563 A allele 
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8.2.2. Allele and genotype frequencies by population  
The minor allele frequency (MAF) of the ANXA2 SNP rs116928563 is variable between 
populations. The 1000 Genomes Project Phase 3 (Ensembl database) shows that the MAF 
is 4.6% in the East Asian population, although it varies between subpopulations (Table 8-
3). In Hispanic and South Asian people where the SNP is rare, the MAF is 0.4% and 
0.2%, respectively. In contrast, people with European and African ancestries do not carry 
the minor allele of the SNP.  
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Table  8-3: The ANXA2 SNP rs116928563 genotype frequency by population.  
Minor allele frequency (MAF) and genotype frequency in each population and 
subpopulation of the 1000 Genomes Project Phase 3. The data were adopted from the 
Ensembl database (http://www.ensembl.org/Homo_sapiens/Variation/Population?db 
=core; r=15:60346749-60347749;v=rs116928563;vdb= variation;vf=124358705)   
Population MAF Genotype frequency 
East Asian 0.046 TT:0.911, AA:0.002, AT:0.087 
Chinese Dai in Xishuangbanna, China 0.091 TT:0.828, AA:0.01, AT:0.161 
Han Chinese in Beijing, China 0.039 TT:0.922, AT:0.078 
Southern Han Chinese, China 0.010 TT:0.981, AT:0.019 
Japanese in Tokyo, Japan 0.010 TT:0.981, AT:0.019 
Kinh in Ho Chi Minh City, Vietnam 0.086 TT:0.828, AT:0.172 
American 0.004 TT:0.991, AT:0.009 
Colombian in Medellin, Colombia  0.005 TT:0.989, AT:0.011 
Mexican Ancestry in Los Angeles, 
California  
0.016 TT:0.969, AT:0.031 
Peruvian in Lima, Peru 0 TT:1.000 
Puerto Rican in Puerto Rico 0 TT:1.000 
South Asian 0.002 TT:0.996, AT:0.004 
Bengali in Bangladesh 0 TT: 1.000 
Gujarati in Indians in Houston, TX 0.005 TT:0.990, AT:0.010 
Indian Telugu in the UK 0 TT: 1.000 
Punjabi in Lahore, Pakistan 0 TT: 1.000 
Sri Lankan Tamil in the UK 0.005 TT:0.990, AT:0.010 
European 0 TT: 1.000 
Utah resident with Northern and 
Western European ancestry 
0 TT: 1.000 
Finnish in Finland 0 TT: 1.000 
British in England and Scotland 0 TT: 1.000 
Iberian populations in Spain  0 TT: 1.000 
Toscani in Italy 0 TT: 1.000 
African 0 TT: 1.000 
African Caribbean in Barbados 0 TT: 1.000 
African Ancestry in Southwest US 0 TT: 1.000 
Esan in Nigeria  0 TT: 1.000 
Luhya in Webuye, Kenya 0 TT: 1.000 
Mandinka in The Gambia 0 TT: 1.000 
Mende in Sierra Leone 0 TT: 1.000 
Yoruba in Ibadan, Nigeria 0 TT: 1.000 
 333 
 
8.2.3. ANXA2 and miR-155 expressions in human hepatic cell lines 
The mRNA expression of ANAX2 and both isoforms of miR-155 were determined in two 
different human hepatic cell lines (Huh7 and HepG2) using TaqMan gene expression 
assays. Relative expression was calculated using the comparative threshold (Ct) values. 
GAPDH or UBC was used as the inner reference gene for ANXA2, while U6 was used as 
the inner reference gene for miR-155. Relative expression was calculated using 2^ΔCT, Δ 
CT = CT target - CT reference gene. Relative quantification of expression of the gene of interest 
was calculated using 2^ΔΔ CT method, ΔΔ CT = Δ CT target group – Δ CT control.  
 
It was found that the mRNA of both the target gene (ANXA2) and the reference gene 
GAPDH were expressed in both cell lines (Figures 8-2 A and B). The expression level of 
ANXA2-mRNA was 4-fold higher in Huh7 cells than in HepG2 cells (see Figure 8-2 C), 
but it was not statistically significant (p=0.196), which may be due to the wide variability 
in levels recorded in the replicates. In contrast, miR-155 and miR-155* were not 
expressed in either cell line (see Figures 8-3 A and B), while U6 was expressed in both 
cell lines (Figure 8-3 C). Thus, no relative expression could be examined between miR-
155 and U6. 
 
Also to determine  the genotype of rs116928563 in Huh7 cells, DNA was extracted from 
a Huh7 cell line, purified and the ANXA2-3’UTR sequence was checked. The sequencing 
data showed that Huh7 cells have the WT form of the SNP (Figure 8-4). 
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Figure  8-2: ANXA2 and GAPDH mRNAs expression in liver cell lines 
The figure illustrates the TaqMan gene expression plot of ANXA2 and GAPDH, and the calculated relative expression.  A) ANXA2- 
mRNA expression in two hepatic cell lines – Huh7 and HepG2.  B) GAPDH-mRNA expression in Huh7 and HepG2 cell lines. The 
PCR was run for 40 cycles. The point at which the curve intersects the threshold (horizontal green line) is the CT.  C) The relative 
expression of ANXA2 to GAPDH in both cell lines – Huh7 and HepG2.    
A) ANXA2- mRNA expression                            B) GAPDH- mRNA expression                 C) Relative expression of  ANXA2/ 
                                                                                                                                                                  GAPDH 
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Figure  8-3: MiR-155, miR-155* and U6 expression in hepatic cell lines 
The figure illustrates plots of miR-155, miR-155* and U6 TaqMan gene expressions in Huh7 and HepG2 cell lines. 
A&B) miR-155 TaqMan gene expression plot shows that (A) miR-155-mRNA was not expressed in either cell line, and 
(B) miR-155* was not expressed in either cell line. C) U6 TaqMan gene expression plot shows that U6 was expressed in 
both cell lines. 
 
A) miR-155 expression                              B) miR-155* expression                           C) U6 expression     
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Figure  8-4: The ANXA2 SNP rs116928563 sequencing result for the Huh7 cell line  
The highlighted nucleotide is the ANXA2 SNP rs116928563, which showed the WT 
genotype (T allele) in both strands.  
 
 
 
Forward 
strand  
 
 
 
Reverse 
strand  
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8.2.4. The influence of miR-155* on ANXA2 expression 
To find out the effect of miR-155* on ANXA2-mRNA expression, the 409bp 3’UTR of 
human ANXA2, containing the SNP rs116928563, was amplified and then inserted into 
the enhancer site of the pGL3-basic luciferase reporter vector, after the SV40 
polyadenylation signal between Sal I and BamH I (Figure 8-6 A). An ANXA2 
rs116928563 variant was then generated by using a quickchange site-directed method. 
All constructs were confirmed by sequencing (Figure 8-6 B). 
 
The Huh7 cell line was selected as I aimed to study the potential of miR-155 for 
ANXA2 in hepatic cell lines. This cell line was ideal for such study because there was 
no endogenous miR155 competitor that could interfere with the experimental 
approach. Both alleles of the SNP constructs were first transfected into Huh7 cells, 
and then the cells were transfected with a synthetic miR-155* mimic after 24 hours, 
and gene expression quantified by real time-PCR after a further 24 hours. The efficacy 
of the first transfection was tested by β-gal, and when the transfection efficiency ≥ 
30% the second transfection was performed. The efficacy of the second transfection 
was examined by assessing miR-155* expression in transfected cells with miR-155*. 
Figure 8-6 C only shows samples that were transfected with the miR-155* mimic and 
consequently expressed miR-155*, which indicates that the second transfections 
succeeded and no contamination occurred.            
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Relative expression of ANXA2 in control samples evaluated experimental quality. No 
differences in relative expression of ANXA2-mRNA were noted between the control 
samples (A allele-negative control (NC), T allele-Opti-MEM medium, and T allele-
siPORT transfection agent (p= 0.12, p= 0.52, p=0.14, respectively)), which were 
calculated relative to the T allele-NC. Also, no difference was found between the two 
alleles using transfected and the non-transfected miR-155* (T allele: p=0.30, A allele: 
p=0.78) (see Figure 8-6 D). It was noticed that miR-155* reduced the ANXA2 
expression by 2-fold in a presence of the A allele of the SNP, however no difference 
was found between the SNP alleles that were transfected with miR-155* (p=0.47), 
which may be due to lack of power that was caused by large variability.    
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Figure  8-5: ANXA2 rs116928563 cloning construct map and the expression effect of 
miR-155* on rs116928563 alleles.  
A) The ANXA2 rs116928563 cloning construct map. 409bp of 3’UTR of human ANXA2 
containing rs116928563 was inserted after the SV40 polyadenylation signal between the Sal I 
and BamH I sites. B)  Sequencing of the ANXA2 rs116928563 WT and Mutant fragments.  C) 
The assessment of miR-155* transfection efficiency. D) Effect of miR-155*-3p on the 
ANXA2-mRNA expression in the presence of the SNP rs116928563.  
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8.3. Discussion 
In silico miRNA prediction tools were useful in this study, making it possible to use three 
different tools to identify the miRNA of greatest potential interest (miRNA-155). The in 
silico tools predicted 71 miRNAs to bind to ANXA2-3’UTR; 53 of these miRNAs were 
predicted by more than one algorithm, of which only 9 were predicted to bind to ANXA2-
3’UTR due to the presence of SNPs. The rs116928563: miRNA-155* was selected for 
experimental study. Studying the function of miRNAs and their role in gene regulation is 
complex because they are strongly cell type and context-dependent. This study failed to result 
in any definite conclusions about the influence of miRNA-155 in ANXA2 expression and 
LDL-C levels. However, it was of note that rs116928563 was a site for miRNA-155* binding 
and miRNA-155* reduced ANXA2 expression 2-fold (not significantly due to variation) under 
the conditions used. Other transfection conditions such as lipid stress and statins are 
suggested for future work.        
 
It is well-known that the 3’UTR of genes, which are a target for miRNAs, have an essential 
role in post-transcriptional regulation. MiRNA-regulated gene expression has various 
biological roles including cell proliferation, cell differentiation, apoptosis, signal 
transduction, immune response, stress resistance, lipid metabolism, insulin secretion and 
hematopoiesis (467). ANXA2 expression is regulated by miRNAs, which bind to partially 
complementary sites within the 3’UTR of the target ANXA2-mRNA and consequently lead to 
translational blockage or mRNA degradation (259, 260). It has been reported that miRNAs 
regulate ANXA2 expression and mediate several disease-related processes (473-477). It has 
been suggested that lipid associated miRNAs could bind to ANXA2-mRNA and regulate its 
expression, which consequently affects LDL-C levels. 
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The main challenge in miRNA research is to detect the specific sequences on target genes 
that are fully or partially complementary to miRNAs. Both miRNA size and partial 
complementarity of miRNA to target sequences cause insufficient information of interaction 
specificity (483). A computational method is commonly used to predict miRNA/mRNA 
interaction. Computational methods are based on algorithms that are created by the physical 
properties of miRNA regulation; Watson–Crick complementarity between 2-7 nucleotides of 
the miRNA and the 3’UTR of mRNA. In time, other features have been added to improve 
prediction specificity including evolutionary conservation, free energy of RNA-miRNA 
duplexes, and secondary structure of 3’UTRs based on adenine–uracil (AU) contact (484). 
However, as with many computational methods these algorithms generate many false positive 
predictions (469). In order to overcome the complexity of predicting the seeding region and 
false positive predictions, several algorithms were used. Using these algorithms, 71 miRNAs 
were predicted to bind to the ANXA2-3’UTR, and of these 53 were predicted by more than 
one algorithm. The resulting lists of candidate target miRNAs overlapped between different 
algorithm predictions, which indicate the accuracy and efficacy of the prediction algorithms 
that were used. Five of the predicted target miRNAs have been experimentally validated, 
using a proteomics approach to measure changes in synthesis of proteins in response to 
miRNA transfection or endogenous miRNA knockdown as well as using microarrays to 
quantify mRNA levels, including hsa-miR-155-5p (481), hsa-miR-218-5p (485), hsa-miR-
769-3p (486), hsa-miR-132-3p (486), and has-miR-133a-3p (487) which have added other 
level of confidence to the accuracy of these algorithms.     
 
 343 
 
 MiR-155 was selected for further functional study for several reasons. First, miR-155 has 
been experimentally validated to bind to ANXA2-mRNA, where miR-155 overexpression in 
the hCMEC/D3 cells decreased luciferase activity of ANXA2 by ∼30–40% (481). Second, it 
has been associated with lipid metabolism and chronic inflammatory diseases such as 
atherosclerosis. Miller et al. (2013) showed that miR-155 has a regulatory role in cholesterol 
and lipid metabolism in the liver via liver X receptor alpha (LXRα), which is a transcriptional 
regulator of many genes in liver metabolism. They also showed that an absence of miR-155 
in mice fed a high fat diet was associated with significantly higher levels of VLDL/LDL 
cholesterol, and hepatic steatosis (482). It has been reported that circulating miR-155 has 
been significantly correlated with high levels of LDL-C (R= 0.32, p =0.021) (488). Also 
miR-155 has been considered as an inflammation-associated miRNA, which has influence in 
the pro-inflammatory environment and thus may affect atherosclerotic lesion formation (482, 
489-492). Nazari-Jahantigh et al. (2012) found that miR-155 promotes atherosclerosis via its 
expression in pro-inflammatory macrophages and in atherosclerotic plaques and represses 
expression of BCL6, a transcription factor that reduces pro-inflammatory NF-κB signaling. 
Wagner et al. (2013) suggested that miR-155 highly bound to LDL-C may transfer to 
macrophages and atherosclerotic plaques.  
 
Another important reason for selecting miR-155 was that it not only binds to the 3’UTR of 
WT ANXA2-mRNA, but also it is predicted that miR-155* isoforms bind in the presence of 
the minor allele of the SNP rs116928563 (T>A). It has been reported that the miRNA-
associated SNPs have important roles in regulation of gene expression (468). Based on all of 
these, miR-155 appears to be a strong candidate for study. It was suggested that rs116928563 
creates a seeding site for miR-155*, which may thus reduce ANXA2 expression and increase 
LDL-C levels. Although the SNP rs116928563 is absent from the European population, the 
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minor allele has a frequency of 4.6% in the Asian population. Studying such a variant may 
give insight into the effect of miR-155 on ANXA2 expression and LDL-C levels in this 
population.   
 
AnxA2 levels in the liver are generally considered low (102), but in line with this study using 
Huh7 cells as a model system, stable knockdown of AnxA2 expression in Huh7 calls resulted 
in PCSK9 upregulation and a marked reduction in LDL-R levels (192). As the functions of 
miRNAs are strongly cell type- and context-dependent (470), two human hepatocellular 
carcinoma cell lines, Huh7 and HepG2, were selected to determine the expression of 
ANXA2 and both isoforms of miR-155 (miR-155, miR-155*). ANXA2-mRNA expression was 
higher in Huh7 cells than in HepG2 cells. This finding is consistent with another study which 
reported that Huh7 cells showed 5-fold higher levels of ANXA2-mRNA than HepG2 cells 
(192). However, it was found that miR-155* and miR-155 were not expressed in either cell 
line under cell culture conditions. The expressions and functions of miRNAs are cell 
environment-dependent (470); they may be expressed or active under certain conditions but 
not expressed or are inactive in other conditions. Interestingly, it has been reported that the 
expression levels of miR-155 are affected by a high fat diet (482, 492), glucose (493), and 
statins (488).   
 
8.4. Limitations  
The two aims of this study were to identify miRNA-associated SNPs in the ANXA2-3’UTR 
and to determine the functionality of the selected SNPs. The first limitation of this study is 
that the miR-associated SNPs were selected in 2015 and the selection method of some 
miRNA algorithms has been updated since then. Therefore, there may be new potentially 
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useful miR-associated SNPs that could have been used in the analyses besides the SNP that 
was studied in this chapter. 
 
The selected ANXA2 SNP rs116928563 is located in a seeding region for lipid and 
inflammatory associated miRNA (miR-155*). However, this SNP is not present in the 
European population and therefore it has no local clinical advantage, although it can be 
studied in the Asian population. In addition, since miR-155 was not expressed in liver cell 
lines under the conditions that were used; it appears that miR-155 is less likely to have an 
influence on ANXA2 expression. However, using alternative conditions such as lipid stress or 
statins may affect miR-155 expression in liver cells, which in turn may affect ANXA2 
expression.  Due to time limitation it was not possible to carry out such complex experiments 
at this stage.  
 
8.5. Conclusion 
Bioinformatics tools such as miRNAs computational prediction algorithms are effective tools 
to identify miRNA associated genes. The complexity of studying miRNAs and their role in 
gene regulation comes from their functions, which are strongly cell type and context-
dependent. Therefore, to determine their role in gene regulation, it is important to test 
miRNA expression under several conditions, such as in the presence of lipids or statins that 
are related to a trait and a disease of interest. In my opinion, although ANXA2 rs116928563 
does not exist in the European population and thus cannot bind to miR-155* and affect gene 
regulation, the miR-155 seems to be a good candidate for further study, especially as it also 
binds to WT ANXA2, and may affect its expression under specific circumstances. Further 
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investigations are required to elucidate whether miR-155 has a role in ANXA2 expression and 
function. 
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Chapter 9 : General discussion  
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9.1. Overview  
CHD is one of a number of common complex diseases that has been intensively studied. 
Genetic studies of monogenic causes of CHD aim to identify functional variants in genes that 
explain the phenotype, in addition to identifying therapeutic targets. For example, genetic 
studies of FH led to the  identification of the FH-causing gain-of-function mutation in the 
PCSK9 gene, and  animal models and human subjects were used to successfully develop a 
PCSK9 monoclonal inhibitor, which was able to  reduce LDL-C significantly even in subjects 
on maximal tolerated statin therapy (494), and have recently been shown to also reduce CHD 
events (495). Studies have also shown that both the affected gene and the type of mutation in 
the gene have roles in therapy outcomes. For example, Humphries et al. (2006) found that 
LDLR mutation positive FH patients have an 84% higher risk of early CHD than those who 
are mutation negative, and patients who are carriers of the PCSK9 p.(Asp374Tyr) mutation 
also have a higher risk of CHD, while carriers of the APOB mutation are less likely to have 
CHD (496). Patients benefit greatly from genetic screening in terms of disease management 
and treatment plans. Genetic screening helps to identify pathogenic variants, the mutation 
spectrum and mutation classes that then contribute to disease management and prevention.     
 
In general, CHD is more often caused by the co-inheritance of many common variants which 
lead to the observed phenotype, i.e. a “polygenic” cause of CHD. In the last 10 years GWASs 
have been successful in identifying a huge number of risk loci that are associated with 
common and complex diseases (suggest http://www.ebi.ac.uk/gwas/). The results from 
GWASs have been important in two ways: one by improving risk prediction assessment and 
the other by improving the understanding of human genetics. Detailed molecular analyses of 
the GWAS hit variants have allowed the identification of the precise functional variant at the 
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locus and the molecular mechanism involved, and thereby the understanding of the role of 
gene expression in the disease phenotype. For example, GWAS identified a new locus 
containing three novel genes on chromosome 1 (SORT1, CELSR2 and PSRC1) that was 
associated with LDL-C and CHD (497). Molecular genetic studies showed that the SORT1 
SNP rs12740374 creates a new enhancer-binding protein for transcription factors, which in 
turn increase gene expression of SORT1 and reduce LDL-C levels (256). 
 
9.2.  Relevance of studied variants in this thesis by allele frequency 
and strength of genetic affect 
Common complex diseases have different genetic architecture to rare disorders. Cystic 
fibrosis (CF), for instance, is caused by genetic variants in a single gene (CFTR) (498), and 
genetic screening and linkage analysis of affected families are successful tools for identifying 
pathogenic genetic variants. However, applying the linkage approach to more common 
disorders, such as CHD and hypercholesterolemia, often does not result in clear-cut patterns 
of inheritance. This suggests that the common diseases have different genetic mechanisms to 
the rare disorders, and thus allele frequency and the disease-risk relationship hypothesis were 
developed and are often conceptualized in two dimensions: allele frequency and effect size 
(Figure 9-1). Highly penetrant alleles for Mendelian disorders (e.g. FH and CF) are rare with 
large effect sizes (Figure 9-1, upper left), while most GWAS findings are associations of 
common SNPs with small effect sizes (Figure 9-1, lower right), and both contribute to the 
disease phenotype.  
 
There are many different technologies, study designs and analytical tools for studing genetic 
risk. Genetic effects of rare variants are more amenable to smaller family-based studies and 
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linkage analysis. On the other hand, effects of common variants are typical of findings from 
GWAS, requiring large sample sizes and a large panel of genetic markers to obtain 
statistically robust results. Within hypercholesterolemia, I have focused my study on rare 
variants with high effect size by performing cascade genetic tests for FH patients (Chapters 3 
and 4), and on common variants with modest effect size by studying the GWAS common 
variant rs6511720 in the LDLR gene (Chapter 5). In addition, I studied the ANXA2 gene, 
where biological studies have shown its involvement in the LDL-C clearance pathway. 
Common SNPs were selected for genetic association analyses in order to identify the LDL-C 
associated variant (Chapters 6 and 7). This study found a (low frequency) ANXA2 coding 
SNP rs17845226 and a more common intergenic SNP rs11633032, which are associated with 
higher levels of LDL-C and a higher risk of CHD.  
 
 351 
 
Figure  9-1: The relationship between effect size and allele frequency  
Spectrum of allele frequency and effect size in the genetics of hypercholesterolemia. 
Identifying genetic variants by risk allele frequency (x-axis) and strength of genetic effect 
(odds ratio; effect size; y-axis). The hypercholesterolemia-associated genes are indicated in 
boxes corresponding to two categories of variants. Box A shows four genes (LDLR, APOB 
PCSK9 and LDLRAP1) that are related  to the Mendelian form of the disease (familial 
hypercholesterolemia). Box B shows a list of common variants identified by GWAS (160). 
Box C shows common variants identified in this thesis and not shown in GWAS. Genes 
indicated in red were studied in this thesis.   
 
 
 
   
 
   
 
BOX B: Common variant 
with low effect genes 
implicated in LDL-C 
levels by GWAS 
PCSK9, CELSR, APOB, 
ABCG8, SLC22A1, HFE 
MYLIP, ST3Gal4 
NYNRIN, LDLR, APOE 
 
BOX A: Rare alleles causing 
Mendelian form of 
hypercholesterolemia 
LDLR 
APOB 
PCSK9 
LDLRAP1 
BOX C: Common 
variant with low effect 
implicated in LDL-C 
levels but NOT shown 
in GWAS (in this 
thesis) 
ANXA2 
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Although both SNPs studied, LDLR (rs6511720) and ANXA2 (rs17191344), are common, the 
ANXA2 SNP is more common (MAF=0.17) than the LDLR SNP (MAF=0.10), thus the latter 
has a higher genetic effect (modest effect size) while ANXA2 has a lower genetic effect (low 
effect size) (Figure 9-2).  From a scientific point of view, the LDLR SNP is more important 
than the ANXA2 SNP because it has a dominant effect (one copy of the variant causing 
phenotype), a lower allele frequency and a modest effect on LDL-C levels, whereas the 
ANXA2 SNP has a recessive effect (two copies of the variant required to observe phenotype), 
a higher allele frequency and a lower effect size.  
 
Figure  9-2: Feasibility of studied genetic variants in this thesis by risk-allele frequency 
and strength of genetic effect  
 
 353 
 
9.3. Common variant and functional analysis  
Common alleles show heritability with low genetic effect, and multiple common alleles are 
required to influence disease susceptibility. Indeed, identifying common variants that are 
statistically associated with a disorder is not enough to allow definite conclusions of variant 
functionality due to the fact of chromosomal linkage, recombination events through 
generations (in other words the phenomenon of LD) and pattern differences between 
populations. It has been postulated that statistically associated variants are either functional or 
a marker of a functional variant somewhere in the locus. Therefore, it is important to map the 
precise location of the possible effective variants. The HapMap project and the 1000 
Genomes project were successful in mapping 99% of human variation and identifying their 
haplotypes. The availability of the variant (common allele) haplotype map (270), in addition 
to the ENCODE project results,  has provided insight about variant location and possible 
genetic impact (275, 276, 499). The genomic data help molecular genetics researchers to 
define functional variant(s) and their genetic mechanism and effect. In fact, a wide array of 
biomedical disciplines is cooperating in order to translate genetic findings into direct health 
benefits. 
 
This thesis studied the molecular genetic mechanism of common variants associated with 
LDL-C and CHD that had been either identified by GWAS (LDLR) or identified in this study 
(ANXA2). The strategy used  focused on identifying a functional SNP candidate and possible 
target genes using large genetic datasets combined with in vitro functional assays in order to 
identify causal variant(s). In this thesis, eight SNPs were selected for functional analysis, four 
LDLR variants and four ANXA2 variants. This study identified that the GWAS LDLR “hit” 
SNP rs6511720 and LD SNP rs57217136 (383), and ANXA2 common SNPs rs17191344 and 
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rs11633032 (439), are functional and act as cis-regulatory elements, where the sequence 
around the SNPs is a target for proteins that regulate gene transcription. Further study is 
required, especially in analyzing the interactions between DNA elements using chromatin 
capture techniques (429, 430) or genome editing (500) which may better elucidate the 
molecular mechanisms involved. Such studies build on available knowledge and can provide 
a fuller picture of the pathogenesis of hypercholesterolemia and the risk of CHD.      
 
One identified ANXA2 LDL-C associated variant, rs17845226, is located in the coding region 
of the gene. Therefore, a different strategy was employed to identify its functional role. 
However, time and resources were unavailable to carry out such analysis during the thesis’s 
time frame. Further studies are needed to examine whether this mutation modifies the 
function of PCSK9 or has downstream consequences on LDL-R activity. Also, they should 
investigate whether AnxA2/p11 complex formation or the ratio of monomeric vs complexed 
AnxA2 proteins are in play, both of which may have consequences for PCSK9-mediated 
LDL-R down-regulation (102, 192). 
 
9.4. Relation of LDL-C concentration to CHD risk 
Elevated plasma cholesterol levels are a major risk factor for atherosclerosis and CHD (2). 
Studies have shown a positive association between LDL-C concentration and the rate of CHD 
events (501, 502) in different populations (Figure 9-3). In addition, large-scale evidence from 
randomized trials has shown that LDL-C lowering drug “statins” reduce the risk of major 
vascular events by about one-quarter for each mmol/l reduction in LDL-C during each year 
(502).  
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Figure  9-3: Association of LDL-C concentration to CHD risk 
A logarithmic scale shows a linear relationship between LDL-C levels and CHD risk. The 
data suggest that for every 1 mmol/l change in LDL-C, the relative risk for CHD risk is 
changed proportionally by about 50%. The relative risk (RR) is set at 1.0 for LDL-C= 
5mmol/l. (Adapted from (502)) 
 
 
 
Studies have shown that both monogenic and polygenic hypercholesterolemia have an 
association with CHD.  It is well known that patients who have inherited an abnormal LDLR 
genetic variant from both parents (HoFH) and who have an LDL-C concentration greater than 
13 mmol/l are likely to develop a CHD event before the age of 20 years (200), while those 
who only inherited one copy of an abnormal genetic variant from one parent (HeFH) have a 
LDL-C concentration greater than 8 mmol/l and are likely to have a CHD event in early 
middle-age (503). Moreover, several studies have provided evidence that the presence of 
several LDL-C common associated variants cause similar increases in LDL-C concentration 
as are observed in HeFH, thus smaller increases in the risk of CHD may occur (504).    
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Identifying individuals with moderate and high risk of CHD is important to reduce the 
mortality rate. The current genetic technologies provide a great opportunity to identify 
genetically affected individuals, which results in early diagnosis and thus allows early 
treatment, as well as an opportunity to identify new genetic markers such as ANXA2 that was 
studied in this thesis.    
 
9.5. FH children  
A recent study that screened children for FH at the 12 month routine immunization GP 
appointment has shown that the FH prevalence in children in the UK is 1 in 273 (505). This 
high prevalence illustrates the importance of genetic screening in childhood not only to 
identify FH subjects, but as a means of preventative action prior to development of 
cardiovascular disease. In this thesis, FH genetic screening was performed in two population 
groups of different ethnicity (UK and Iran), using the target-NGS method. Children 
accounted for 70.6% (60/85) of the subjects studied, and mutations were found in 50% of 
children. Although the other 50% of children were FH-mutation negative, they are still at an 
elevated risk of CHD.  FH-mutation negative children are likely to carry several common 
variants with low effect that may lead to the FH phenotype (506). The other possibility is that 
these children may carry a genetic defect in an undiscovered gene, in which case whole 
genome sequencing may be helpful.   
 
The specificity and sensitivity of the screening method used in this thesis led to the 
identification of several novel mutations. The results showed novel LDLR variants (5 
variants) in addition to one novel variant in PSCK9, all of which are predicted to be 
pathogenic. Three of the novel identified variants were found in children while the other three 
 357 
 
were found in young adults <40 years. Family screening is highly recommended for all 
affected families, to identify members who are at high risk of CHD.  
 
The findings from this thesis will benefit and enable researchers to build on the available 
knowledge of hypercholesterolemia and CHD. The results from this thesis indicate that both 
the rare and common variants investigated influence LDL-C levels and CHD risk, but at 
different levels depending on allele frequency and the affected gene. This study also showed 
how the use of multiple complementary tools can be used to identify novel pathways for 
complex diseases such as CHD from GWAS and wet lab findings. Such studies could 
ultimately identify novel therapeutic targets.   
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